0001571049-15-006546.txt : 20150810 0001571049-15-006546.hdr.sgml : 20150810 20150810160532 ACCESSION NUMBER: 0001571049-15-006546 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150810 DATE AS OF CHANGE: 20150810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: APPLIED DNA SCIENCES INC CENTRAL INDEX KEY: 0000744452 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISCELLANEOUS BUSINESS SERVICES [7380] IRS NUMBER: 592262718 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36745 FILM NUMBER: 151040739 BUSINESS ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 BUSINESS PHONE: 631-240-8800 MAIL ADDRESS: STREET 1: 50 HEALTH SCIENCES DRIVE CITY: STONY BROOK STATE: NY ZIP: 11790 FORMER COMPANY: FORMER CONFORMED NAME: PROHEALTH MEDICAL TECHNOLOGIES INC DATE OF NAME CHANGE: 20010504 FORMER COMPANY: FORMER CONFORMED NAME: DCC ACQUISITION CORP DATE OF NAME CHANGE: 19990211 FORMER COMPANY: FORMER CONFORMED NAME: DATALINK CAPITAL CORP/TX/ DATE OF NAME CHANGE: 19980306 10-Q 1 t82897_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36745

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware	59-2262718
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

50 Health Sciences Drive
Stony Brook, New York	11790
(Address of principal executive offices)	(Zip Code)

631-240- 8800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer ☐	Accelerated filer ☒
Non-accelerated filer ☐	Smaller reporting company ☐
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

At August 6, 2015, the registrant had 21,487,202 shares of common stock outstanding.

Applied DNA Sciences, Inc.

Form 10-Q for the Quarter Ended June 30, 2015

Table of Contents


		Page
PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements (unaudited)		1

Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 3 - Quantitative and Qualitative Disclosures About Market Risk		22

Item 4 - Controls and Procedures		23

PART II - OTHER INFORMATION

Item 1 – Legal Proceedings		24

Item 1A – Risk Factors		24

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds		24

Item 3 – Defaults Under Senior Securities		24

Item 4 – Mine Safety Disclosures		24

Item 5 – Other Information		24

Item 6 - Exhibits		25

Part I

Item 1 - Financial Statements.

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	June 30, 2015			September 30, 2014
	(unaudited)

ASSETS
Current assets:
Cash and cash equivalents	$	10,730,144		$	1,393,132
Accounts receivable, net of allowance of $30,228 and $9,634 at June 30, 2015 and September 30, 2014, respectively		2,077,756			834,818
Prepaid expenses and other current assets		209,831			135,365
Total current assets		13,017,731			2,363,315

Property, plant and equipment, net of accumulated depreciation of $743,914 at June 30, 2015 and $759,087 at September 30, 2014		526,816			576,128

Other assets:
Deposits		52,988			57,638
Deferred offering costs		0			181,104
Intangible assets, net of accumulated amortization and impairment of $325,555 and $256,208 at June 30, 2015 and September 30, 2014, respectively		525,902			327,872

Total Assets	$	14,123,437		$	3,506,057

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities:
Accounts payable and accrued liabilities, including related party accrued interest of $6,597 at September 30, 2014	$	1,418,615		$	1,494,759
Promissory notes payable, including $1,000,000 with a related party at September 30, 2014		—			1,800,000
Deferred revenue		204,863			583,362
Total current liabilities		1,623,478			3,878,121

Warrant liability		—			1,096,412

Total liabilities		1,623,478			4,974,533

Commitments and contingencies (Note I)

Stockholders’ Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014		—			—
Series A Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2015 and September 30, 2014		—			—
Series B Preferred stock, par value $0.001 per share, 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2015 and September 30, 2014		—			—
Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized at June 30, 2015 and September 30, 2014, respectively; 21,482,202 and 13,935,954 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively		21,483			13,937
Additional paid in capital		223,623,850			198,277,859
Accumulated deficit		(211,145,374	)		(199,760,272	)
Total stockholders’ equity (deficit)		12,499,959			(1,468,476	)

Total Liabilities and Stockholders’ Equity (Deficit)	$	14,123,437		$	3,506,057

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended June 30,						Nine Months Ended June 30,
	2015			2014			2015			2014

Revenues	$	2,267,671		$	841,197		$	5,028,234		$	2,075,698

Operating expenses:
Selling, general and administrative		3,508,455			2,948,452			11,078,405			10,093,631
Research and development		310,093			266,331			961,745			1,085,416
Depreciation and amortization		121,339			113,424			354,144			325,448

Total operating expenses		3,939,887			3,328,207			12,394,294			11,504,495

LOSS FROM OPERATIONS		(1,672,216	)		(2,487,010	)		(7,366,060	)		(9,428,797	)

Other income (expense):
Interest income (expense), net		5,052			111			(26,807	)		784
Other (expense) income, net		(3,718	)		52,299			(16,853	)		130,186
Loss on conversion of promissory notes		—			—			(980,842	)		—
Gain (loss) on change in fair value of warrant liability		—			515,543			(2,994,540	)		(1,663,316	)

Net loss before provision for income taxes		(1,670,882	)		(1,919,057	)		(11,385,102	)		(10,961,143	)

Provision for income taxes		—			—			—			—

NET LOSS	$	(1,670,882	)	$	(1,919,057	)	$	(11,385,102	)	$	(10,961,143	)

Net loss per share-basic and diluted	$	(0.08	)	$	(0.14	)	$	(0.63	)	$	(0.82	)

Weighted average shares outstanding-
Basic and diluted		21,444,335			13,569,262			18,075,506			13,400,540

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended June 30,
	2015			2014

Cash flows from operating activities:
Net loss	$	(11,385,102	)	$	(10,961,143	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		354,144			325,448
Stock based compensation expense		3,531,205			1,717,837
Change in fair value of warrant liability		2,994,540			1,663,316
Loss on conversion of promissory notes		980,842			—
Common stock issued for consulting services		64,426			337,500
Bad debt expense		21,750			16,878
Change in operating assets and liabilities:
Accounts receivable		(1,275,189	)		137,486
Prepaid expenses and other current assets and deposits		(59,315	)		(924	)
Accounts payable and accrued liabilities		(75,515	)		292,462
Deferred revenue		(378,499	)		200,121
Net cash used in operating activities		(5,226,713	)		(6,271,019	)

Cash flows used in investing activities:
Purchase of property plant and equipment		(221,659	)		(209,522	)
Purchase of intangible assets		(238,082	)		—
Net cash used in investing activities		(459,741	)		(209,522	)

Cash flows from financing activities:

Net proceeds from sale of common stock and warrants		19,114,418			2,145,956
Purchase and cancelation of previously issued warrants		(4,090,952	)		—

Net cash provided by financing activities		15,023,466			2,145,956

Net increase (decrease) in cash and cash equivalents		9,337,012			(4,334,585	)
Cash and cash equivalents at beginning of period		1,393,132			6,360,301
Cash and cash equivalents at end of period	$	10,730,144		$	2,025,716

Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	$	—		$	—
Cash paid during period for taxes	$	—		$	—

Non-cash investing and financing activities:
Common stock issued for cashless exercise of options and warrants	$	—		$	19,570
Reclassification of deferred offering costs to additional paid in capital	$	181,104		$	—
Reclassification of warrants from liability to equity upon exercise	$	—		$	2,455,042
Offering costs incurred, and included in accounts payable and accrued liabilities	$	68,489		$	—
Property, plant and equipment acquired, and included in accounts payable	$	13,825		$	—
Intangible assets acquired, and included in accounts payable	$	29,296		$	—
Common stock issued upon conversion of promissory notes payable	$	1,843,750		$	—

See the accompanying notes to the unaudited condensed consolidated financial statements

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying condensed consolidated financial statements as of June 30, 2015 and for the three and nine month periods ended June 30, 2015 and 2014 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2015. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2014 and footnotes thereto included in the Annual Report on Form 10-K, as amended, of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC.

The condensed consolidated balance sheet as of September 30, 2014 contained herein has been derived from the audited consolidated financial statements as of September 30, 2014, but does not include all disclosures required by GAAP.

All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split of the Company’s common stock, par value $.001 per share, that was effected on October 29, 2014. See Note G.

Business and Basis of Presentation

On September 16, 2002, the Company was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through June 30, 2015, the Company has accumulated losses of $211,145,374.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.

Revenue Recognition

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At June 30, 2015 and September 30, 2014, the Company recorded deferred revenue of $204,863 and $583,362, respectively.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Revenue Recognition, continued

Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $657,708 and $1,919,031 from these contract awards during the three and nine month periods ended June 30, 2015 and $0 and $50,000 for the three and nine month periods ended June 30, 2014, respectively.

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three and nine month periods ended June 30, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Net Loss Per Share, continued

Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three and nine month periods ended June 30, 2015 and 2014 are as follows:


	2015	2014
Warrants	6,062,487	240,439
Employee options	3,456,989	2,073,043
	9,519,476	2,313,482

Stock Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three and nine month periods ended June 30, 2015 included an aggregate of 87% and 73%, respectively, from two customers of the Company’s total revenues. These two customers accounted for approximately 89% of the Company’s total accounts receivable at June 30, 2015.

The Company’s revenues earned from sale of products and services for the three month period ended June 30, 2014 included an aggregate of 10% from one customer of the Company’s total revenues. During the nine month period ended June 30, 2014 no customers represented 10% or greater of the Company’s total revenues.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.

In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN

The Company has recurring net losses, which have resulted in an accumulated deficit of $211,145,374 as of June 30, 2015. The Company incurred a net loss of $11,385,102 and generated negative operating cash flow of $5,226,713 for the nine month period ended June 30, 2015. However, the Company also has attained positive working capital of $11,394,253 as of June 30, 2015. At June 30, 2015 the Company had cash and cash equivalents of $10,730,144. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note G, on April 1, 2015, the Company closed its underwritten public offering of common stock and warrants for gross proceeds of approximately $12.0 million, before deducting underwriting discounts and offering expenses. Subsequently on April 30, 2015,the Company closed on the over-allotment option of the underwritten public offering for additional gross proceeds of $263,950. In addition, on November 20, 2014 the Company closed its underwritten public offering of common stock and warrants for gross proceeds of $9.3 million before deducting underwriting discounts and offering expenses. The Company utilized approximately $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The Company raised $2,156,264 in a private placement of common stock and warrants and $1,800,000 in promissory notes during the fiscal year ended September 30, 2014, including $1,000,000 from a related party. See Notes D and G.

The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses.

NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at June 30, 2015 and September 30, 2014 are as follows:


	June 30, 2015 (unaudited)		September 30, 2014
Accounts payable	$	770,395	$	1,059,623
Accrued consulting fees		110,500		102,500
Accrued salaries payable		428,098		245,761
Accrued interest payable		-		11,875
Other accrued expenses		109,622		75,000
Total	$	1,418,615	$	1,494,759

NOTE D – PROMISSORY NOTES PAYABLE

On September 11, 2014, the Company issued and sold promissory notes (the “Notes”) in the aggregate principal amount of $1,800,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer, in the amount of $1,000,000, and to another individual, in the amount of $800,000, both of whom are “accredited investors” as defined in regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

The Notes had a ten month maturity. Interest was payable in cash or in shares of common stock at the option of the holders of the Notes. Interest to be paid in shares was to be paid in shares of common stock equal to (i) the amount of interest payable, divided by (ii) the average of the closing prices for the five consecutive trading days immediately preceding the applicable interest date. The Notes were permitted to be prepaid in whole or in part, at any time, subject to certain prepayment penalties. Upon an event of default, the Notes and all accrued interest thereon were to automatically convert into common stock at the closing price of the common stock on the date of issuance of the Notes. In the event of a consolidation or merger with another corporation in which the Company does not survive, the Notes were to be paid in full. On November 11, 2014, Dr. Hayward and the other individual agreed to exchange for cancellation their respective Notes (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, in the case of Dr. Hayward, and 252,137 shares of common stock and warrants to purchase 252,137 shares of common stock, in the case of the other individual, at $3.25 ($3.24 for one share of common stock and $0.01 for one warrant) (“combined price”) , the aggregate public offering per share price of common stock and warrants issued in the Company’s underwritten public offering, which closed on November 20, 2014. The conversion of the Notes resulted in a loss on conversion of approximately $981,000, which was recorded on the condensed consolidated statement of operations for the nine month period ended June 30, 2015. The loss was calculated as the difference between the carrying amount of the promissory note and accrued interest on the conversion date compared to the fair value of the common stock and warrant issued as settlement of the Notes.

Interest expense for these Notes was $31,875 for the nine month period ended June 30, 2015.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE E – WARRANT LIABILITY

On December 16, 2013, Crede CG III, Ltd (“Crede”) effected the cashless exercise of 178,253 Series A Warrants and 116,667 Series B Warrants. At December 16, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $2,455,042 using the Binomial Lattice model with the following assumptions: fair value of the Company’s common stock $10.80 per share; dividend yield 0%; expected term: 4.55 years; risk free interest rate: 1.55%; expected volatility of: 118.89%; and an exercise price of $14.59. The change in fair value of the warrant liability on the day of exercise amounted to a loss of $1,288,752 and was included in the other income (expense). Upon exercise, the fair value of the Series A Warrants and 116,667 of the Series B Warrants were reclassified to equity.

The Series A and Series B Warrants were classified as liabilities on the issuance date due to certain provisions contained in the warrant agreements, which may cause an adjustment to the conversion rate or the number of warrants outstanding.

The change in fair value of the warrant liability resulted in a gain of $515,543 and a loss of $1,663,316 for the three and nine month periods ended June 30, 2014, respectively.

On October 28, 2014, the Company entered into a warrant repurchase option agreement with Crede, pursuant to which it had the option to purchase between 50% and 100% of Crede’s Series B Warrant (then exercisable for 387,621 shares of common stock) at a purchase price of $10.55 per share underlying such Series B Warrant (up to an aggregate purchase price of $4,091,000 for all of the Series B Warrant). On November 21, 2014, the Company exercised its option and repurchased 100% of Crede’s Series B Warrant for an aggregate purchase price of approximately $4,091,000. The change in fair value of the warrant liability on the day of repurchase amounted to a loss of $2,994,540 and was included in other income (expense) for the nine month period ended June 30, 2015.

NOTE F – RELATED PARTY TRANSACTIONS

As discussed in Note D, on September 11, 2014, the Company issued and sold a promissory note in the aggregate principal amount of $1,000,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer. On November 11, 2014, Dr. Hayward agreed to exchange for cancellation of his Note (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, at a combined price of $3.25, the aggregate public offering price of common stock and warrants issued in the Company’s underwritten public offering which closed on November 20, 2014.

As discussed in Note G, the Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in the Company’s November 20, 2014 underwritten public offering.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE G - CAPITAL STOCK

On October 24, 2014, the Company filed a Third Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-60 (1:60) reverse stock split of its common stock, par value $.001 per share, and a decrease in its authorized common stock, from 1,350,000,000 to 500,000,000 shares, effective October 29, 2014. All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split that was effected on October 29, 2014. In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of June 30, 2015 and September 30, 2014, there were 21,482,202 and 13,935,954 shares of common stock issued and outstanding, respectively.

On November 20, 2014, the Company closed its underwritten public offering of 2,800,000 shares of common stock and warrants to purchase up to an aggregate of 2,800,000 shares of common stock for gross proceeds of $9.1 million before deducting underwriting discounts and offering expenses. The Company utilized $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The combined price for each share of common stock and warrant was $3.25. The warrants may be exercised for a period of five years and have an exercise price of $3.50 per share. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 420,000 additional shares of common stock at $3.24 per share and/or up to 420,000 additional warrants at $0.01 per share to cover over-allotments, if any. The Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in this underwritten public offering. The Company’s common stock and warrants are listed on the Nasdaq Capital Market under the symbols “APDN” and “APDNW”, respectively. On December 19, 2014, the Company closed on the underwriters’ exercise of its over-allotment option of 416,850 warrants for gross proceeds of $4,169 and on December 30, 2014, the Company closed on the underwriters’ additional exercise of its over-allotment option of 52,000 shares of common stock for gross proceeds of $168,400. The total number of common stock and warrants issued under this offering, including the exercise of the over-allotment option was 2,852,000 and 3,216,850, respectively. The gross proceeds to the Company was $9.3 million and net proceeds after deducting underwriting discounts, offering expenses and the repurchase of the remaining Series B Warrants from Crede was approximately $3.69 million.

In connection with the closing of this underwritten public offering, on November 20, 2014, the Company granted 128,800 warrants to purchase common stock to its underwriters as partial compensation. These warrants have an exercise price of $3.73 (115% of the public offering price) and expire on November 14, 2019.

During the three and nine month periods ended June 30, 2015, the Company granted 15,000 and 22,500 shares of common stock to a consultant for a total expense of approximately $47,750 and $64,426, respectively.

On April 1, 2015, the Company closed its underwritten public offering of 4,011,000 shares of common stock and warrants to purchase up to an aggregate of 1,604,400 shares of common stock, at $3.00 ($2.99 for one share of common stock and $0.01 for one warrant) (“combined offering price”), including 191,000 shares and 76,400 warrants sold pursuant to the partial exercise of the underwriters’ over-allotment option. The warrants have a per share exercise price of $3.50, are exercisable immediately, and expire on November 20, 2019. The gross proceeds to the Company from this offering, including the partial exercise of the over-allotment option but before deducting the underwriting discount and offering expenses, is $12.0 million. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 573,000 additional shares of common stock and up to 229,200 additional warrants to cover over-allotments, if any. On April 30, 2015, the Company closed on the underwriters’ exercise of its over-allotment option of 87,000 shares of common stock and 152,800 warrants for gross proceeds of $263,950 .

In connection with the closing of this underwritten public offering, as partial compensation, on April 1, 2015, the Company granted up to 163,720 warrants to purchase common stock to its underwriters. These warrants have an exercise price of $3.44 (115% of the public offering price) and expire on March 27, 2020.

See Note D for the common stock and warrants issued in connection with the conversion of the promissory notes.

NOTE H - STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.

Transactions involving warrants (see Notes D, E and G) are summarized as follows:


	Number of Shares			Weighted Average Exercise Price Per Share
Balance at October 1, 2014		945,166		$	9.59
Granted		5,833,878			3.50
Exercised		(—	)		(—	)
Cancelled or expired		(716,557	)		(11.30	)
Balance at June 30, 2015		6,062,487		$	3.53

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE H - STOCK OPTIONS AND WARRANTS (continued)

Employee Stock Options

In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 5,833,334 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. On January 21, 2015, the Board of Directors approved an amendment to the Incentive Plan, which was approved by shareholders on June 16, 2015. The amendment increases the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,333,333. The amendment also extends the Incentive Plan’s expiration date to January 25, 2025.

The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to our success with an award of options to purchase shares of common stock and an award of shares of common stock. As of June 30, 2015 a total of 233,752 shares have been issued and options to purchase 4,132,475 shares have been granted under the 2005 Incentive Stock Plan.

Transactions involving stock options issued to employees are summarized as follows:


	Number of Shares		Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding at October 1, 2014		2,909,046	$	4.74
Granted		950,094		2.85
Exercised		—		—
Cancelled or expired		(402,151)		(3.01)
Outstanding at June 30, 2015		3,456,989	$	4.42
Vested at June 30, 2015		2,494,098	$	4.13	$	0.18
Non-vested at June 30, 2015		962,891			$	0.12

For the three and nine-month periods ended June 30, 2015, the Company issued 49,585 and 950,094, options to employees, consultants and non-employee board of director members, respectively. Included in these grants for the nine month period was 450,000 options granted to executives.

APPLIED DNA SCIENCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE H - STOCK OPTIONS AND WARRANTS (continued)

Employee Stock Options, continued

The fair value of options granted during the three and nine month periods ended June 30, 2015 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:


	Three Months Ended June 30, 2015			Nine Months Ended June 30, 2015
Stock price	$	2.60		$	2.85
Exercise price	$	2.60		$	2.85
Expected term, years		3.75			4.85
Dividend yield		—	%		—	%
Volatility		118	%		132	%
Risk free rate		1.13	%		1.56	%

The Company recorded $1,015,361(including $544,113 for stock option modifications) and $404,507 as stock compensation expense for the three month periods ended June 30, 2015 and 2014, respectively, and $3,531,205 (including $673,176 for stock option modifications) and $1,717,837 for the nine month periods ended June 30, 2015 and 2014, respectively for the vesting portion of all options. As of June 30, 2015, unrecorded compensation cost related to non-vested awards was $2,749,586 which is expected to be recognized over a weighted average period of approximately 2.21 years. The weighted average grant date fair value for options granted during the three and nine month periods ended June 30, 2015 was $69,430 and $1,076,502, respectively.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE I - COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. The Company also has operating leases for a laboratory in Huddersfield, England, which is currently inactive and Calverton, New York. The Huddersfield lease was terminated effective July 31, 2015. The Calverton lease was from February 1, 2014 through October 31, 2014, with the option to renew for additional one year periods. The Calverton lease is currently on a month to month basis. Total rent expense for the three and nine month periods ended June 30, 2015 was $124,504 and $373,772, respectively. Total rent expense for the three and nine month periods ended June 30, 2014 were $125,268 and $380,251, respectively.

Employment Agreement

The Company has an employment agreement with the Chief Executive Officer. Effective June 21, 2014, the Chief Executive Officer’s annual salary was voluntarily reduced by $50,000. This salary reduction will be accrued and repaid when the Company reaches $3,000,000 in sales for two consecutive quarters or the Company has net income at the end of any fiscal year. Effective January 1, 2015, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2015

(unaudited)

NOTE J - FAIR VALUE

The carrying value of cash, accounts receivable, accounts payable and accrued liabilities approximate estimated fair values because of their short maturities.

The carrying value of the warrant liability is determined using the Binomial Lattice option pricing model as described in Note A. Certain assumptions used in the calculation of the warrant liability represent Level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1, 2 or 3 as of June 30, 2015.

The following table summarizes the activity of Level 3 inputs measured on a recurring basis:


Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Nine Months Ended June 30,
	2015			2014
Balance at October 1, 2014 and 2013	$	1,096,412		$	2,643,449
Adjustment resulting from change in fair value (a)		2,994,540			1,663,316
Removal of warrant upon repurchase		(4,090,952	)		—
Reclassification to equity upon exercise		—			(2,455,042	)
Balance at June 30,	$	—		$	1,851,723

(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our Unaudited Condensed Consolidated Financial Statements and Notes thereto, included elsewhere within this report. The Quarterly Report contains forward-looking statements, including statements using terminology such as “can”, “may”, “believe”, “designed to”, “will”, “expect”, “plan”, “anticipate”, “estimate”, “potential” or “continue”, or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

●	discuss our future expectations;

●	contain projections of our future results of operations or of our financial condition; and

●	state other “forward-looking” information.

We believe it is important to communicate our expectations. However, forward looking statements involve risks and uncertainties and our actual results and the timing of certain events could differ materially from those discussed in forward-looking statements as a result of certain factors, including those set forth under “Risk Factors,” “Business” and elsewhere in our Annual Report on Form 10-K, as amended, for the fiscal year ended September 30, 2014. All forward-looking statements and risk factors included in this document are made as of the date hereof, based on information available to us as of the date thereof, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law.

Introduction

Using biotechnology as a forensic foundation, we provide botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud, and diversion. Whether working in supply chain security, brand protection or law enforcement applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success. With secure taggants, high-resolution DNA authentication, and comprehensive reporting, our botanical DNA-based technologies are designed to deliver what we believe to be the greatest levels of security, deterrence and legal recourse strength.

SigNature® DNA. SigNature DNA is our platform ingredient, at the core of all our security solutions. From application to application, the vehicle which carries SigNature DNA is custom designed to suit the application. Exhaustive development efforts have yielded a flexible and durable marker with all the accuracy provided by nature. SigNature DNA is based on full, double stranded plant DNA, and provides forensic power and protection for a wide array of applications. Highly secure, robust, and durable, SigNature DNA markers are an ingredient that can be used to fortify brand protection efforts; mark, track and convict criminals; and strengthen supply chain security. Custom DNA sequences can be embedded into a wide range of host carriers including ink, varnish, thread, laminates and metal coatings. These items can then be tested for the presence of SigNature DNA markers through optical screening or a forensic level authentication. Hundreds of millions of SigNature DNA marks now exist in the public domain on items ranging from consumer product packaging to microcircuits to guitars. We believe that no marks have ever been copied.

SigNature DNA, SigNature® T DNA, fiberTyping®, DNAnet®, Sentry, digitalDNA®, and SmokeCloak® DNA, our principal anti-counterfeiting and product authentication solutions and our Counterfeit Prevention Authentication Program can be used in numerous industries, including, but not limited to microcircuits and other electronics, cyber security, cash-in-transit (transport and storage of banknotes), textiles and apparel, automotive, printing and packaging, homeland security, law enforcement and home asset marking, identity cards and other secure documents, industrial materials, agrochemicals, pharmaceuticals, consumer products, food and beverage, sports memorabilia, fine wine, and art and collectibles.

SigNature T DNA and fiberTyping. There is one common thread that runs through the global textile industry: success breeds counterfeiting and diversion. SigNature T botanical DNA markers are used for brand protection efforts and raw material source compliance programs. In situations where natural fibers like cotton or wool are utilized, we can isolate and type inherent DNA, making it possible to verify the presence of specified materials. This fiberTyping process provides DNA verification to help manufacturers, retailers and brand owners ensure quality, safety and compliance of their products.

DNAnet. Recognizing that DNA-based evidence is the cornerstone of the modern era of law enforcement, we have created what we believe to be an effective crime fighting tool: DNAnet, a botanical DNA marker that can be used to definitively link evidence and offenders to specific crime scenes and help return stolen or lost property to its rightful owner. As the crime is investigated, the fluorescing DNA mark can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict.

Sentry. Sentry intruder tagging systems help to expand and strengthen any security effort by providing a means of directly linking criminals to crimes. Each unit is designed to be unique to each store, warehouse, or sting operation, allowing the police and prosecutors to link criminals to the crimes. In the event of a crime, the fleeing offender is sprayed with an indelible, fluorescing DNA taggant. As the crime is investigated, the fluorescing DNA mark can assist police in linking the offender and stolen items to a specific crime scene, creating a greater ability to identify and convict. Whether deployed as an offender spray or fog in a retail location or a degradation dye in cash handling boxes, DNA markers facilitate conviction, and establish a heightened level of deterrence. While any commercial/retail establishment could benefit from the addition of a Sentry system, ideal areas of use include: banks, ATMs, pharmacies, jewelry stores, convenience stores, pawn brokers and gun shops.

digitalDNA. digitalDNA is a security solution that utilizes the flexibility of mobile communications, the instant accessibility of secure, cloud-based data, and the certainty of DNA to make item tracking and authentication fast, easy and definitive, while providing the opportunity to create a new customer interface. digitalDNA begins with a DNA-secured form of the QR (“quick read”) code or other two dimensional code. A unique identification code is created for each article, and represented in an easy-to-read QR style barcode. The product uses forensic authentication of a botanical DNA marker, embedded within a secure QR code, and physically included within the ink used to digitally print the code. Should there ever be a question about the validity of a digitalDNA code, a laboratory-based analysis can be conducted to determine authenticity. Scanning bar code item numbers on marked goods enables individuals to post or access information about a product such as its geo-location, original image or associated documentation. Consumers may take advantage of marketing information supplied by brand owners.

The secure cloud application also offers back-end features including DNA custody management, forensic sample submission, CODA (certificate of DNA authentication) issuance, customer account administration, order placement, status tracking and reporting, and online training. The cloud-based platform is designed to be customizable for the particular attributes of each customer’s business and conforms to strict security standards for ISO, PCI, and Federal Information Processing Standards. This digitalDNA platform is designed as the data management and reporting hub for devices for DNA on-site authentication and optical mark in-field validation. Market-specific configurations have been demonstrated to businesses in textiles supply chain, printing/publishing, art and collectibles and law enforcement.

SmokeCloak DNA. When deployed in pharmacies, banks, commercial or retail locations, SmokeCloak DNA helps protect staff, customers and assets. A thick and disorienting fog wards off offenders and deposits a unique, location-specific DNA marker on skin, clothing and stolen items. The combination of fog and DNA technologies has no negative side effects and provides a strong crime fighting and loss prevention tool.

Counterfeit Prevention Authentication Program. Our turnkey program for electronics, military, commercial, and aerospace contractors called the Counterfeit Prevention Authentication Program (“CPA” Program) empowers end-users to verify the originality or provenance of parts which have been marked by their suppliers with our SigNature DNA Markers.

Plan of Operations

General

To date, the substantial portion of our revenues have been generated from sales of our SigNature DNA platform and fiberTyping, our principal anti-counterfeiting and product authentication solutions. We expect to continue to grow revenues from sales of our SigNature DNA platform ingredient, including our Signature T DNA, fibertyping, DNAnet, Sentry, digitalDNA, and SmokeCloakDNA offerings and the Counterfeit Prevention Authentication Program. We have limited sources of liquidity. We have developed or are currently attempting to develop business in the following target markets: microcircuits and other electronics, cash-in-transit (transport and storage of banknotes), textiles and apparel, automotive, printing and packaging, homeland security, law enforcement and home asset marking, identity cards and other secure documents, industrial materials, agrochemical, pharmaceuticals, consumer products, food and beverage, sports memorabilia, fine wine, and art and collectibles. Our developments in the textile and apparel authentication, semiconductor authentication, and cash-in-transit have contributed to the increase in our revenues. We intend to pursue both domestic and international sales opportunities in each of these vertical markets.

Critical Accounting Policies

Financial Reporting Release No. 60, published by the SEC, recommends that all companies include a discussion of critical accounting policies used in the preparation of their financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our consolidated financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates.

We believe that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our condensed consolidated results of operations, financial position or liquidity for the periods presented in this report.

The accounting policies identified as critical are as follows:

●	Revenue recognition;

●	Equity based compensation; and

●	Fair value of financial instruments

Revenue Recognition

We recognize revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. We defer any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that we and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At June 30, 2015 and September 30, 2014, we recorded deferred revenue of $204,863 and $583,362, respectively.

Revenue for government contract awards, which supports our development efforts on specific projects, is recognized as milestones are achieved as per the contract. We recognized revenue of approximately $657,708 and $1,919,031 from these contract awards during the three and nine month periods ended June 30, 2015, respectively, and $0 and $50,000 for the three and nine month periods ended June 30, 2014, respectively.

Equity Based Compensation

We follow ASC subtopic 718, Compensation (“ASC 718”) which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.

We account for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Fair Value of Financial Instruments

The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.

Use of Estimates

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.

Comparison of Results of Operations for the Three Month Periods Ended June 30, 2015 and 2014

Revenues

For the three month periods ended June 30, 2015 and 2014, we generated $2,267,671 and $841,197, respectively, in revenues. The increase in revenues in the three month period ended June 30, 2015 of $1,426,474 or 170% was primarily from an increase in revenue related to sales to the textile industry for protecting cotton supply chains of $1,200,000 and revenue from government contract awards of approximately $658,000. These increases were offset by a decrease in revenue from suppliers of the United States Defense Logistics Agency (“DLA”) due to the consolidation of these individual contracts to one contract with DLA.

Costs and Expenses

Selling, General and Administrative

Selling, general and administrative expenses for the three month period ended June 30, 2015 increased by $560,003 or 19% from $2,948,452 for the three month period ended June 30, 2014 to $3,508,455 for the three month period ended June 30, 2015. The increase is attributable to an increase in stock based compensation expense of $610,855, primarily associated with stock option modifications resulting from the extension of certain stock options offset by a decrease of approximately $210,000 in legal fees as a result of the court’s dismissal of the SmartWater Limited litigation against us.

Research and Development

Research and development expenses increased to $310,093 for the three month period ended June 30, 2015 from $266,331 for the three month period ended June 30, 2014, an increase of $43,762 or 16%. This increase is due to development costs incurred in relation to the two government contracts offset by capitalized costs for the development of infield readers.

Depreciation and Amortization

In the three month period ended June 30, 2015, depreciation and amortization increased by $7,915 from $113,424 for the three month period ended June 30, 2014 to $121,339 for the three month period ended June 30, 2014.

Gain on Change in Fair Value of Warrant Liability

Gain from change in fair value of warrant liability during the three month period ended June 30, 2014 was $515,543. This change in fair value related to warrants containing certain reset provisions which required us to classify them as liabilities and mark the warrants to market and record the change in fair value at each reporting period, and upon exercise as a non cash adjustment to our current period operations. As discussed in Note E of the accompanying condensed consolidated financial statements, on November 21, 2014, we repurchased the remaining outstanding Series B Warrants.

Comparison of Results of Operations for the Nine Month Periods Ended June 30, 2015 and 2014

Revenues

For the nine month periods ended June, 30, 2015 and 2014, we generated $5,028,234 and $2,075,698, respectively, in revenues. The increase in revenues of $2,952,536 or 142% was primarily due to an increase in sales from two government contract awards of approximately $1.9 million as well as revenues related to the set up, marking, and authentication of cotton of $1,372,500. These increases were offset by a decrease in revenue from suppliers of the United States Defense Logistics Agency (“DLA”) due to the consolidation of these individual contracts to one contract with DLA.

Costs and Expenses

Selling, General and Administrative

Selling, general and administrative expenses for the nine month period ended June 30, 2015 increased by $984,774 or 10% from $10,093,631 for the nine month period ended June 30, 2014 to $11,078,405 for the nine month period ended June 30, 2015. The increase is primarily attributable to an increase in stock based compensation expense of approximately $1,813,000, attributable to grants to employees that vested immediately, as well as stock based compensation expense associated with stock option modifications resulting from the extension of certain stock options, and to a lesser extent, the acceleration of vesting terms. This increase was primarily offset by decreases in legal and consulting expenses. Legal expenses decreased by $783,000 due to the court’s dismissal of the SmartWater Limited litigation against us. Consulting fees decreased by $238,000 primarily due to shares of common stock issued to a business strategy consultant in settlement of their fees during the nine month period ended June 30, 2014. The remaining variance is due to increases in payroll offset by decreases in filing fees during the nine month period ended June 30, 2015.

Research and Development

Research and development expenses decreased to $961,745 for the nine month period ended June 30, 2015 from $1,085,416 for the nine month period ended June 30, 2014. The decrease of $123,671 or 11% is attributable to purchases for laboratory equipment associated with the corporate headquarters in the prior year as well as components purchased relating to a pilot program for the marking of cotton during the prior period, which we did not incur during the nine month period ended June 30, 2015. Also, during the nine month period ended June 30, 2015, we started capitalizing the costs for the development of infield readers, which were being expensed during the same period in the prior year.

Depreciation and Amortization

Depreciation and amortization increased by $28,696 from $325,448 for the nine month period ended June 30, 2014 to $354,144 for the nine month period ended June 30, 2015. This increase is related to the depreciation incurred on the fixed asset additions during the period.

Loss from Change in Fair Value of Warrant Liability

Loss from change in fair value of warrant liability during the nine month periods ended June 30, 2015 and 2014 was $2,994,540 and $1,663,316, respectively. These losses relate to warrants containing certain reset provisions which required us to classify them as liabilities and mark the warrants to market and record the change in fair value at each reporting period as a non-cash adjustment to our current period operations. As discussed in Note E of the accompanying condensed consolidated financial statements, on November 21, 2014, we repurchased the remaining outstanding Series B Warrants.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of June 30, 2015, we had working capital of $11,394,253. For the nine month period ended June 30, 2015, we generated a net cash flow deficit from operating activities of $5,226,713 consisting primarily of our loss of $11,385,102 net with non-cash adjustments of $354,144 in depreciation and amortization charges, $3,531,205 for stock-based compensation, $2,994,540 change in fair value of warrant liability, $980,842 in loss on the conversion of promissory notes, $64,426 in common stock issued for consulting services and $21,750 of bad debt expense. Additionally, we had a net increase in operating assets of $1,334,504 and a net decrease in operating liabilities of $454,014. Cash used in investing activities was $459,471 for the purchase of property, plant and equipment and intangible assets. Cash provided by financing activities was $15,023,466 in net proceeds from the sale of common stock and warrants related to the underwritten public offering offset by the repurchase and cancellation of the remaining Series B Warrants.

The Company has recurring net losses, which have resulted in an accumulated deficit of $211,145,374 as of June 30, 2015. At June 30, 2015 the Company had cash and cash equivalents of $10,730,144. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses. Historically, the Company has financed its operations principally from the sale of equity securities. On April 1, 2015, the Company closed on an underwritten public offering of common stock and warrants for gross proceeds of $12.0 million, before deducting underwriting discounts and offering expenses. Subsequently on April 30, 2015,the Company closed on the over-allotment option of the underwritten public offering for additional gross proceeds of $263,950. In addition, on November 20, 2014 the Company closed its underwritten public offering of common stock and warrants for gross proceeds of $9.3 million before deducting underwriting discounts and offering expenses. The Company utilized approximately $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The Company also raised $2,156,264 in a private placement of common stock and warrants and $1,800,000 in promissory notes during the fiscal year ended September 30, 2014, including $1,000,000 from a related party.

The Company expects to finance operations primarily through cash flows provided by operating activities provided that it will achieve a sufficient level of future revenues. The Company estimates that its cash and cash equivalents are sufficient to fund operations for the next twelve months. The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses.

We expect capital expenditures to be less than $980,000 in fiscal 2015. Our primary investments will be in laboratory equipment to support prototyping, manufacturing, our authentication services, and outside services for our detector and reader development.

All of the real property used in our business is leased under operating lease agreements.

Subsequent Events

None.

Product Research and Development

We anticipate spending approximately $1,500,000 for product research and development activities during the next twelve months.

Acquisition of Plant and Equipment and Other Assets

We do not anticipate the sale of any material property, plant or equipment during the next twelve months.

Number of Employees

We currently have forty-nine full-time employees and nine part-time employees, including four in management, eleven in research and development, one in Life Sciences, two in forensics, six in quality assurance/compliance, four in finance and accounting, five in operations, thirteen in sales and marketing, one in human resources, five in shared services, three in information services, one in investor relations, one legal (Intellectual Property) and one in product development. We expect to increase our staffing dedicated to sales, production and formulation. Marketing, salaries, and general overhead will be increased as necessary. However, cost containment measures have been put in place to monitor expenses. In order for us to attract and retain quality personnel, we anticipate we will continue to offer competitive salaries and benefits to future employees. We anticipate that it may become desirable to add additional full and or part time employees to discharge certain critical functions during the next twelve months. This projected increase in personnel is dependent upon our ability to generate revenues and obtain sources of financing. There is no guarantee that we will be successful in raising the funds required or generating revenues sufficient to fund the projected increase in the number of employees. As we continue to expand, we will incur additional costs for personnel. We continue to work with Insperity Inc. to help us manage many of our back-end administrative human resources and payroll responsibilities.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Item 3. - Quantitative and Qualitative Disclosures About Market Risk.

There have been no material changes in our market risk as previously disclosed under Part I, Item 3 of our Annual Report on Form 10-K, for the fiscal year ended September 30, 2014. Please refer to the Company’s Annual Report on Form 10-K (filed with the SEC on December 15, 2014, as amended on March 6, 2015) for the fiscal year ended September 30, 2014.

Item 4. - Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2015, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended June 30, 2015, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II - Other Information

Item 1. - Legal Proceedings.

None.

Item 1A. – Risk Factors.

Before deciding to invest in us or to maintain or increase your investment, you should carefully consider the risks and uncertainties described in the first two paragraphs under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this report and our other filings with the SEC, for the period ended September 30, 2014 and thereafter. The risks and uncertainties described in this report are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect us. If any of these risks actually materialize, our business, financial position, results of operations and cash flows could be adversely impacted. In that event, the market price of our common stock could decline and you may lose all or part of your investment.

During the three month period ended June 30, 2015, there have been no material changes in our risk factors previously disclosed in our Annual Report on Form 10-K (as amended March 6, 2015) for the fiscal year ended September 30, 2014.

Item 2. - Unregistered Sales of Equity Securities and Use of Proceeds.

On February 27, 2015, we issued 2,500 shares of our common stock, and on each of March 31, 2015, April 30, 2015, May 29, 2015 and June 30, 2015 we issued 5,000 shares of our common stock, aggregating 22,500 shares, to a consultant for services provided pursuant to our 2005 Incentive Stock Plan. The shares were issued pursuant to an exemption from registration under the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) and/or Regulation D promulgated thereunder as a transaction not involving a public offering.

Item 3. – Defaults Upon Senior Securities.

None.

Item 4. – Mine Safety Disclosures.

None.

Item 5. – Other Information.

None.

Item 6. – Exhibits.


31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended

31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended

32.1**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)

32.2**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)

101 INS*	XBRL Instance Document

101 SCH*	XBRL Taxonomy Extension Schema Document

101 CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101 LAB*	XBRL Extension Label Linkbase Document

101 PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith.

Signatures

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		Applied DNA Sciences, Inc.

Dated: August 10, 2015		/s/ JAMES A. HAYWARD, Ph. D.
		James A. Hayward, Ph. D.
		Chief Executive Officer
		(Duly authorized officer and principal executive officer)

		/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		(Duly authorized officer and
		principal financial and accounting officer)

EX-31.1 2 t82897_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, James A. Hayward, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 10, 2015

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.

EX-31.2 3 t82897_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13 a -14(a) OR 15 d -14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Beth Jantzen, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: August 10, 2015

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.

EX-32.1 4 t82897_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, James A. Hayward, Chief Executive Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that


●	the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and

●	the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ JAMES A. HAYWARD
		James A. Hayward
		Chief Executive Officer
		Applied DNA Sciences, Inc.
		Dated: August 10, 2015

EX-32.2 5 t82897_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Beth Jantzen, Chief Financial Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2015 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

●	the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and

●	the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

	By:	/s/ BETH JANTZEN
		Beth Jantzen, CPA
		Chief Financial Officer
		Applied DNA Sciences, Inc.
		Dated: August 10, 2015

EX-101.INS 6 apdn-20150630.xml XBRL INSTANCE DOCUMENT 0000744452 2013-06-01 2013-06-15 0000744452 apdn:CredeCgIIILtdMember us-gaap:WarrantMember 2013-12-16 0000744452 apdn:CredeCgIIILtdMember us-gaap:WarrantMember 2013-12-01 2013-12-16 0000744452 apdn:CredeCgIIILtdMember apdn:SeriesWarrantsMember 2013-12-01 2013-12-16 0000744452 apdn:SeriesBWarrantsMember apdn:CredeCgIIILtdMember 2013-12-01 2013-12-16 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2014-06-21 0000744452 2014-04-01 2014-06-30 0000744452 2013-10-01 2014-06-30 0000744452 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2013-10-01 2014-06-30 0000744452 us-gaap:ConvertibleNotesPayableMember 2014-09-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:PresidentChairmanAndChiefExecutiveOfficerMember 2014-09-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:AnotherIndividualMember 2014-09-11 0000744452 2013-10-01 2014-09-30 0000744452 2014-09-30 0000744452 us-gaap:SeriesAPreferredStockMember 2014-09-30 0000744452 us-gaap:SeriesBPreferredStockMember 2014-09-30 0000744452 2014-10-24 0000744452 2014-10-01 2014-10-24 0000744452 apdn:CredeCgIIILtdMember apdn:SeriesBWarrantsMember apdn:WarrantRepurchaseOptionAgreementMember 2014-10-28 0000744452 apdn:CredeCgIIILtdMember apdn:SeriesBWarrantsMember apdn:WarrantRepurchaseOptionAgreementMember 2014-10-01 2014-10-28 0000744452 apdn:CredeCgIIILtdMember apdn:SeriesBWarrantsMember apdn:WarrantRepurchaseOptionAgreementMember us-gaap:MinimumMember 2014-10-01 2014-10-28 0000744452 apdn:CredeCgIIILtdMember apdn:SeriesBWarrantsMember apdn:WarrantRepurchaseOptionAgreementMember us-gaap:MaximumMember 2014-10-01 2014-10-28 0000744452 2014-11-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:PresidentChairmanAndChiefExecutiveOfficerMember 2014-11-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:AnotherIndividualMember 2014-11-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:PresidentChairmanAndChiefExecutiveOfficerMember 2014-11-01 2014-11-11 0000744452 us-gaap:ConvertibleNotesPayableMember apdn:AnotherIndividualMember 2014-11-01 2014-11-11 0000744452 2014-11-20 0000744452 2014-11-01 2014-11-20 0000744452 2014-12-01 2014-12-19 0000744452 2014-12-01 2014-12-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2015-01-21 0000744452 apdn:UnderwrittenPublicOfferingMember 2015-04-01 0000744452 apdn:UnderwrittenPublicOfferingMember apdn:UnderwritersMember 2015-04-01 0000744452 2015-03-31 2015-04-01 0000744452 apdn:UnderwrittenPublicOfferingMember 2015-03-31 2015-04-01 0000744452 apdn:UnderwrittenPublicOfferingMember apdn:UnderwritersMember 2015-03-31 2015-04-01 0000744452 2015-04-02 2015-04-30 0000744452 apdn:UnderwrittenPublicOfferingMember 2015-04-02 2015-04-30 0000744452 2015-04-02 2015-06-30 0000744452 apdn:EmployeesConsultantsAndNonEmployeeBoardOfDirectorMembersMember us-gaap:EmployeeStockOptionMember 2015-04-02 2015-06-30 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:TwoCustomersConcentrationRiskMember 2015-04-02 2015-06-30 0000744452 2014-10-01 2015-06-30 0000744452 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-10-01 2015-06-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2014-10-01 2015-06-30 0000744452 apdn:EmployeesConsultantsAndNonEmployeeBoardOfDirectorMembersMember us-gaap:EmployeeStockOptionMember 2014-10-01 2015-06-30 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesMember apdn:TwoCustomersConcentrationRiskMember 2014-10-01 2015-06-30 0000744452 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember apdn:TwoCustomersConcentrationRiskMember 2014-10-01 2015-06-30 0000744452 2015-06-30 0000744452 us-gaap:ChiefExecutiveOfficerMember apdn:EmploymentAgreementMember 2015-01-01 0000744452 us-gaap:SeriesAPreferredStockMember 2015-06-30 0000744452 us-gaap:SeriesBPreferredStockMember 2015-06-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2015-06-30 0000744452 2015-08-06 0000744452 2013-09-30 0000744452 2014-06-30 0000744452 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2013-09-30 0000744452 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-06-30 0000744452 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2014-09-30 0000744452 us-gaap:EmployeeStockOptionMember apdn:IncentiveStockPlan2005Member 2014-09-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure apdn:Customer utr:sqft APPLIED DNA SCIENCES INC 0000744452 apdn --09-30 Accelerated Filer 21487202 10-Q 2015-06-30 false 2015 Q3

1393132

10730144

6360301

2025716

834818

2077756

135365

209831

2363315

13017731

576128

526816

57638

52988

181104

327872

525902

3506057

14123437

1494759

1418615

1800000

583362

204863

3878121

1623478

1096412

4974533

1623478

13937

21483

198277859

223623850

-199760272

-211145374

-1468476

12499959

3506057

14123437

9634

30228

759087

743914

256208

325555

6597

1800000

1000000

800000

1000000

0.001

10000000

0.001

1350000000

500000000

13935954

21482202

13935954

21482202

841197

2075698

2267671

5028234

2948452

10093631

3508455

11078405

266331

1085416

310093

961745

113424

325448

121339

354144

3328207

11504495

3939887

12394294

-2487010

-9428797

-1672216

-7366060

111

784

5052

-26807

52299

130186

-3718

-16853

-980842 -1288752 515543 -1663316 -2994540

-1919057

-10961143

-1670882

-11385102

-1919057

-10961143

-1670882

-11385102

-0.14

-0.82

-0.08

-0.63

13569262

13400540

21444335

18075506

325448

354144

404507

1717837

1015361

3531205

337500 64426

16878

21750

-137486

1275189

924

59315

292462

-75515

200121

-378499

-6271019

-5226713

209522

221659

238082

-209522

-459741

2145956 3690000 19114418 4090952

2145956

15023466

-4334585

9337012

19570 181104 68489 13825 29296

1843750

<p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">NOTE A — SUMMARY OF ACCOUNTING POLICIES <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">General <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The accompanying condensed consolidated financial statements as of June 30, 2015 and for the three and nine month periods ended June 30, 2015 and 2014 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2015. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2014 and footnotes thereto included in the Annual Report on Form 10-K, as amended, of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The condensed consolidated balance sheet as of September 30, 2014 contained herein has been derived from the audited consolidated financial statements as of September 30, 2014, but does not include all disclosures required by GAAP. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split of the Company’s common stock, par value $.001 per share, that was effected on October 29, 2014. See Note G. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Business and Basis of Presentation <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On September 16, 2002, the Company was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through June 30, 2015, the Company has accumulated losses of $211,145,374. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Revenue Recognition  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">   <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At June 30, 2015 and September 30, 2014, the Company recorded deferred revenue of $204,863 and $583,362, respectively.  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $657,708 and $1,919,031 from these contract awards during the three and nine month periods ended June 30, 2015 and $0 and $50,000 for the three and nine month periods ended June 30, 2014, respectively. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Net Loss Per Share <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">For the three and nine month periods ended June 30, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.  <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three and nine month periods ended June 30, 2015 and 2014 are as follows:  <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center;">2015</td> <td style="text-align: center;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center;">2014</td> <td style="text-align: center;"> </td> </tr> <tr style="background-color: #f7ffff; vertical-align: bottom;"> <td style="width: 785px;">Warrants</td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 157px;">6,062,487</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 158px;">240,439</td> <td style="text-align: left; width: 16px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Employee options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">3,456,989</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">2,073,043</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #f7ffff; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">9,519,476</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">2,313,482</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Stock Based Compensation <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Concentrations <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company’s revenues earned from sale of products and services for the three and nine month periods ended June 30, 2015 included an aggregate of 87% and 73%, respectively, from two customers of the Company’s total revenues. These two customers accounted for approximately 89% of the Company’s total accounts receivable at June 30, 2015. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company’s revenues earned from sale of products and services for the three month period ended June 30, 2014 included an aggregate of 10% from one customer of the Company’s total revenues. During the nine month period ended June 30, 2014 no customers represented 10% or greater of the Company’s total revenues.  <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Recent Accounting Pronouncements <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

<p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">NOTE G - CAPITAL STOCK <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On October 24, 2014, the Company filed a Third Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-60 (1:60) reverse stock split of its common stock, par value $.001 per share, and a decrease in its authorized common stock, from 1,350,000,000 to 500,000,000 shares, effective October 29, 2014. All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split that was effected on October 29, 2014.   In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of June 30, 2015 and September 30, 2014, there were 21,482,202 and 13,935,954 shares of common stock issued and outstanding, respectively. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On November 20, 2014, the Company closed its underwritten public offering of 2,800,000 shares of common stock and warrants to purchase up to an aggregate of 2,800,000 shares of common stock for gross proceeds of $9.1 million before deducting underwriting discounts and offering expenses. The Company utilized $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The combined price for each share of common stock and warrant was $3.25. The warrants may be exercised for a period of five years and have an exercise price of $3.50 per share. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 420,000 additional shares of common stock at $3.24 per share and/or up to 420,000 additional warrants at $0.01 per share to cover over-allotments, if any. The Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in this underwritten public offering. The Company’s common stock and warrants are listed on the Nasdaq Capital Market under the symbols “APDN” and “APDNW”, respectively. On December 19, 2014, the Company closed on the underwriters’ exercise of its over-allotment option of 416,850 warrants for gross proceeds of $4,169 and on December 30, 2014, the Company closed on the underwriters’ additional exercise of its over-allotment option of 52,000 shares of common stock for gross proceeds of $168,400.  The total number of common stock and warrants issued under this offering, including the exercise of the over-allotment option was 2,852,000 and 3,216,850, respectively.  The gross proceeds to the Company was $9.3 million and net proceeds after deducting underwriting discounts, offering expenses and the repurchase of the remaining Series B Warrants from Crede was approximately $3.69 million. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In connection with the closing of this underwritten public offering, on November 20, 2014, the Company granted 128,800 warrants to purchase common stock to its underwriters as partial compensation. These warrants have an exercise price of $3.73 (115% of the public offering price) and expire on November 14, 2019. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">During the three and nine month periods ended June 30, 2015, the Company granted 15,000 and 22,500 shares of common stock to a consultant for a total expense of approximately $47,750 and $64,426, respectively. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 11pt calibri; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On April 1, 2015, the Company closed its underwritten public offering of 4,011,000 shares of common stock and warrants to purchase up to an aggregate of 1,604,400 shares of common stock, at $3.00 ($2.99 for one share of common stock and $0.01 for one warrant) (“combined offering price”), including 191,000 shares and 76,400 warrants sold pursuant to the partial exercise of the underwriters’ over-allotment option. The warrants have a per share exercise price of $3.50, are exercisable immediately, and expire on November 20, 2019. The gross proceeds to the Company from this offering, including the partial exercise of the over-allotment option but before deducting the underwriting discount and offering expenses, is $12.0 million. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 573,000 additional shares of common stock and up to 229,200 additional warrants to cover over-allotments, if any. On April 30, 2015, the Company closed on the underwriters’ exercise of its over-allotment option of 87,000 shares of common stock and 152,800 warrants for gross proceeds of $263,950 . <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In connection with the closing of this underwritten public offering, as partial compensation, on April 1, 2015, the Company granted up to 163,720 warrants to purchase common stock to its underwriters. These warrants have an exercise price of $3.44 (115% of the public offering price) and expire on March 27, 2020. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">See Note D for the common stock and warrants issued in connection with the conversion of the promissory notes.

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">NOTE H - STOCK OPTIONS AND WARRANTS <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Warrants <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 12pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Transactions involving warrants (see Notes D, E and G) are summarized as follows: <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 11pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 1.8pt;" colspan="2"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 1.8pt;" colspan="2"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Number of  Shares</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Weighted  Average  Exercise  Price Per  Share</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; width: 752px; padding-right: 0.8pt;">Balance at October 1, 2014</td> <td style="text-align: right; line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; width: 217px; padding-right: 0.8pt;">945,166</td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 29px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; width: 171px; padding-right: 0.8pt;">9.59</td> <td style="line-height: 16px; width: 14px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Granted</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">5,833,878</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">3.50</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Exercised</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">(—</td> <td style="line-height: 16px; padding-right: 0.8pt;">)</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">(—</td> <td style="line-height: 16px; padding-right: 0.8pt;">)</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">Cancelled or expired</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(716,557</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">)</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(11.30</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">)</td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Balance at June 30, 2015</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">6,062,487</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">3.53</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 12pt 0px 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Employee Stock Options <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 5,833,334 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares.  On January 21, 2015, the Board of Directors approved an amendment to the Incentive Plan, which was approved by shareholders on June 16, 2015.  The amendment increases the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,333,333.  The amendment also extends the Incentive Plan’s expiration date to January 25, 2025. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to our success with an award of options to purchase shares of common stock and an award of shares of common stock. As of June 30, 2015 a total of 233,752 shares have been issued and options to purchase 4,132,475 shares have been granted under the 2005 Incentive Stock Plan. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Transactions involving stock options issued to employees are summarized as follows: <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 11pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; width: 516px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 201px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 44px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 155px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 29px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 61px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 157px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 14px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Number of Shares</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid;" colspan="2"> Weighted  Average Exercise Price Per Share </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid;" colspan="2"> Aggregate Intrinsic Value </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Outstanding at October 1, 2014</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">2,909,046</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">4.74</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Granted</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">950,094</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">2.85</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Exercised</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">—</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">—</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Cancelled or expired</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(402,151)</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(3.01)</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Outstanding at June 30, 2015</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">3,456,989</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">4.42</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Vested at June 30, 2015</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">2,494,098</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">4.13</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">0.18</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Non-vested at June 30, 2015</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">962,891</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">0.12</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> For the three and nine-month periods ended June 30, 2015, the Company issued 49,585 and 950,094, options to employees, consultants and non-employee board of director members, respectively. Included in these grants for the nine month period was 450,000 options granted to executives.  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"> <p style="text-align: center; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The fair value of options granted during the three and nine month periods ended June 30, 2015 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions: <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 12pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="width: 707px;"> </td> <td style="width: 46px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: right; width: 203px;"> </td> <td style="width: 46px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: right; width: 205px;"> </td> <td style="width: 16px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-size: 10pt;" colspan="2">Three Months Ended June 30,  2015</td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-size: 10pt;" colspan="2">Nine Months Ended June 30,  2015</td> <td style="border-bottom: black 2px solid;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td>Stock price</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">2.60</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.85</td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.60</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.85</td> <td> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="font-size: 10pt;">Expected term, years</td> <td> </td> <td> </td> <td style="text-align: right; font-size: 10pt;">3.75</td> <td> </td> <td> </td> <td style="text-align: right; font-size: 10pt;">4.85</td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right;">—</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">—</td> <td style="font-size: 10pt;">%</td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: right;">118</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">132</td> <td style="font-size: 10pt;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Risk free rate</td> <td> </td> <td> </td> <td style="text-align: right;">1.13</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">1.56</td> <td style="font-size: 10pt;">%</td> </tr> </table> <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0.5in; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0px; font: 10pt 'times new roman'; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The Company recorded $1,015,361(including $544,113 for stock option modifications) and $404,507 as stock compensation expense for the three month periods ended June 30, 2015 and 2014, respectively, and $3,531,205 (including $673,176 for stock option modifications) and $1,717,837 for the nine month periods ended June 30, 2015 and 2014, respectively for the vesting portion of all options. As of June 30, 2015, unrecorded compensation cost related to non-vested awards was $2,749,586 which is expected to be recognized over a weighted average period of approximately 2.21 years.  The weighted average grant date fair value for options granted during the three and nine month periods ended June 30, 2015 was $69,430 and $1,076,502, respectively.

<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Net Loss Per Share <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the three and nine month periods ended June 30, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive. <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">  <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three and nine month periods ended June 30, 2015 and 2014 are as follows:  <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">2015</td> <td style="text-align: center;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">2014</td> <td style="text-align: center;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #f7ffff;"> <td style="width: 785px;">Warrants</td> <td style="width: 46px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 157px; text-align: right;">6,062,487</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 46px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 158px; text-align: right;">240,439</td> <td style="width: 16px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Employee options</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3,456,989</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">2,073,043</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #f7ffff;"> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">9,519,476</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,313,482</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

<p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Recent Accounting Pronouncements <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations. <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">  <p style="text-align: justify; widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> <td> </td> <td style="text-align: center;" colspan="3"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center;">2015</td> <td style="text-align: center;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center;">2014</td> <td style="text-align: center;"> </td> </tr> <tr style="background-color: #f7ffff; vertical-align: bottom;"> <td style="width: 785px;">Warrants</td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 157px;">6,062,487</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 46px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 158px;">240,439</td> <td style="text-align: left; width: 16px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Employee options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">3,456,989</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">2,073,043</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #f7ffff; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">9,519,476</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">2,313,482</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

<table align="center" style="width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 11pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 1.8pt;" colspan="2"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 1.8pt;" colspan="2"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Number of  Shares</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Weighted  Average  Exercise  Price Per  Share</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; width: 752px; padding-right: 0.8pt;">Balance at October 1, 2014</td> <td style="text-align: right; line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; width: 217px; padding-right: 0.8pt;">945,166</td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 29px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; width: 171px; padding-right: 0.8pt;">9.59</td> <td style="line-height: 16px; width: 14px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Granted</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">5,833,878</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">3.50</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Exercised</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">(—</td> <td style="line-height: 16px; padding-right: 0.8pt;">)</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">(—</td> <td style="line-height: 16px; padding-right: 0.8pt;">)</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">Cancelled or expired</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(716,557</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">)</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(11.30</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;">)</td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Balance at June 30, 2015</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">6,062,487</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">3.53</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> </table>

<table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font-family: 'times new roman', times, serif; letter-spacing: normal; font-size: 11pt; word-spacing: 0px; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; width: 516px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 201px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 44px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 155px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 13px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 29px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 61px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 157px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; width: 14px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: center; line-height: 16px; padding-right: 1.8pt;" colspan="2">Number of Shares</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid;" colspan="2"> Weighted  Average Exercise Price Per Share </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid;" colspan="2"> Aggregate Intrinsic Value </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Outstanding at October 1, 2014</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">2,909,046</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">4.74</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Granted</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">950,094</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">2.85</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Exercised</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">—</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">—</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Cancelled or expired</td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(402,151)</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 2px solid; text-align: right; line-height: 16px; padding-right: 0.8pt;">(3.01)</td> <td style="border-bottom: black 2px solid; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Outstanding at June 30, 2015</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">3,456,989</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;">$</td> <td style="text-align: right; line-height: 16px; padding-right: 0.8pt;">4.42</td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> <td style="line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Vested at June 30, 2015</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">2,494,098</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">4.13</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">0.18</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> <tr style="background-color: #f0ffff; vertical-align: bottom;"> <td style="line-height: 16px; padding-right: 0.8pt;">Non-vested at June 30, 2015</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">962,891</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;">$</td> <td style="border-bottom: black 4px double; text-align: right; line-height: 16px; padding-right: 0.8pt;">0.12</td> <td style="border-bottom: black 4px double; line-height: 16px; padding-right: 0.8pt;"> </td> </tr> </table>

<table align="center" style="width: 100%; border-collapse: collapse; font-size: 12pt;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="width: 45%;"> </td> <td style="width: 3%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: right; width: 13%;"> </td> <td style="width: 3%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: right; width: 13%;"> </td> <td style="width: 1%;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-size: 10pt;" colspan="2">Three Months Ended June 30, 2015</td> <td style="border-bottom: black 2px solid; text-align: center;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-size: 10pt;" colspan="2">Nine Months Ended June 30, 2015</td> <td style="border-bottom: black 2px solid;"> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Stock price</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right; font-size: 10pt;">2.60</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.85</td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.60</td> <td> </td> <td style="font-size: 10pt;">$</td> <td style="text-align: right;">2.85</td> <td> </td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td style="font-size: 10pt;">Expected term, years</td> <td> </td> <td> </td> <td style="text-align: right; font-size: 10pt;">3.75</td> <td> </td> <td> </td> <td style="text-align: right; font-size: 10pt;">4.85</td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right;">—</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">—</td> <td style="font-size: 10pt;">%</td> </tr> <tr style="background-color: azure; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td> </td> <td style="text-align: right;">118</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">132</td> <td style="font-size: 10pt;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Risk free rate</td> <td> </td> <td> </td> <td style="text-align: right;">1.13</td> <td style="font-size: 10pt;">%</td> <td> </td> <td style="text-align: right;">1.56</td> <td style="font-size: 10pt;">%</td> </tr> </table>

one-for-60 (1:60)

50000

657708

1919031

0.87

0.73

0.89

2 2 2 11394253 9300000 12000000 263950 4091000

2156264

1800000 1000000

1059623

770395

102500

110500

245761

428098

11875

75000

109622

0.125

P10M

P5D

315171

252137

315171 252137

3.25

3.24 0.01 178253 116667 387621

2455042

Binomial Lattice model

10.80

3.00

0.00

P4Y6M18D

0.0155

1.1889

14.59

10.55

0.50 1.00 4091000

2800000

1604400

P5Y

3.50

3.44

P45D 420000 3.24 420000 0.01 416850 4169 52000 168400 2852000 3216850 9272649 128800 3.73

1.15

15000

22500

47750 64426

4011000

2.99 0.01 191000 76400

12000000

P45D 573000 229200 87000 152800 263950 163720

945166

6062487

5833878 716557 9.59 3.53 3.50 11.30

3456989

2909046

950094

402151

2494098

962891

4.42

4.74

2.85

3.01

4.13 0.18 0.12 2.60 2.85 2.60 2.85

P3Y9M0D

P4Y10M6D

1.18

1.32

0.0113

0.0156

8333333

5833334

833334

233752

4132475

544113

673176

2749586

P2Y2M16D

69430 1076502 30000

P3Y

449142

125268

380251

124504

373772

50000 50000 3000000

2643449

1851723

1096412

1663316

2994540

4090952 2455042 2455042 Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

0000744452apdn:CustomerOneConcentrationRiskMemberus-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2014-04-012014-06-30

0.10

1 0000744452us-gaap:SalesMemberus-gaap:CustomerConcentrationRiskMember2013-10-012014-06-30

no customers represented 10% or greater

3.25

0000744452apdn:WarrantRepurchaseOptionAgreementMemberapdn:SeriesBWarrantsMemberapdn:CredeCgIIILtdMember2014-11-012014-11-21 1.00 4091000

0.125

49585

0000744452us-gaap:ExecutiveOfficerMemberus-gaap:EmployeeStockOptionMember2014-10-012015-06-30

450000

0000744452us-gaap:ConvertibleNotesPayableMember2014-10-012015-06-30 -981000

31875

0000744452us-gaap:WarrantMember 2014-10-012015-06-30

6062487

0000744452us-gaap:WarrantMember 2013-10-012014-06-30

240439

9519476

0000744452us-gaap:EmployeeStockOptionMember2014-10-012015-06-30

3456989

0000744452us-gaap:EmployeeStockOptionMember2013-10-012014-06-30

2073043

2313482

0000744452us-gaap:WarrantMember 2015-04-022015-06-30

6062487

0000744452us-gaap:EmployeeStockOptionMember 2015-04-022015-06-30

3456989

0000744452us-gaap:EmployeeStockOptionMember2014-04-012014-06-30

2073043

9519476

2313482

0000744452us-gaap:WarrantMember 2014-04-012014-06-30

240439

9100000

EX-101.SCH 7 apdn-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - PROMISSORY NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - WARRANT LIABILITY link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - CAPITAL STOCK link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - STOCK OPTIONS AND WARRANTS link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - FAIR VALUE link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - PROMISSORY NOTES PAYABLE (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - WARRANT LIABILITY (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - CAPITAL STOCK (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - CAPITAL STOCK (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - CAPITAL STOCK (Detail Textuals 2) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - CAPITAL STOCK (Detail Textuals 3) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 apdn-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 apdn-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 apdn-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Preferred Stock [Member] Series A Preferred stock Series B Preferred Stock [Member] Series B Preferred stock Statement [Line Items] Statement [Line Items] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Accounts Receivable, Net, Current Accounts receivable, net of allowance of $30,228 and $9,634 at June 30, 2015 and September 30, 2014, respectively Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property, plant and equipment, net of accumulated depreciation of $743,914 at June 30, 2015 and $759,087 at September 30, 2014 Property plant and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent [Abstract] Other assets: Deposits Assets, Noncurrent Deposits Deferred Costs, Noncurrent, Total Deferred offering costs Finite-Lived Intangible Assets, Net Amortization on intangible assets Intangible assets, net of accumulated amortization and impairment of $325,555 and $256,208 at June 30, 2015 and September 30, 2014, respectively Net Assets Total Assets Total Assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities, including related party accrued interest of $6,597 at September 30, 2014 Total Notes Payable, Related Parties, Current Promissory notes payable, including $1,000,000 with a related party at September 30, 2014 Deferred revenue Deferred revenue Deferred revenue Liabilities, Current Total current liabilities Total current liabilities Warrant Liability Noncurrent Warrant liability This element represents amount of warrant liability as on the balance sheet date. Liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Note I) Stockholders Equity Attributable To Parent [Abstract] Stockholders' Equity (Deficit) Preferred Stock, Value, Issued Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014 Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2014 and September 30, 2013 Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized at June 30, 2015 and September 30, 2014, respectively; 21,482,202 and 13,935,954 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid in Capital, Common Stock Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated losses Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Stockholders' Equity Attributable To Parent Balance Total stockholders' equity (deficit) Balance Balance Liabilities and Equity Total Liabilities and Stockholders' Equity (Deficit) Total Liabilities and Stockholders' Equity (Deficit) Allowance for Doubtful Accounts Receivable, Current Allowance on accounts receivable (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation on property, plant and equipment (in dollars) Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization and impairment on intangible assets (in dollars) Related Party Transaction, Due from (to) Related Party, Current Related party accrued interest (in dollars) Debt Instrument, Face Amount Convertible promissory note issued to related party in advance for working capital purposes Promissory note issued to related party (in dollars) Promissory note issued to related party (in dollars) Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenue, Net Revenues Sales Operating Expenses [Abstract] Operating expenses: Selling, General and Administrative Expense Selling, general and administrative Selling, general and administrative Research and Development Expense Research and development Research and development expenses Research and development Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation and amortization Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) NET LOSS FROM OPERATIONS LOSS FROM OPERATIONS Nonoperating Income (Expense) [Abstract] Other income (expense): Interest Income (Expense), Net, Total Interest income (expense), net Interest expense, net (Note C) Interest income (expense), net Other Nonoperating Income (Expense) Other (expense) income, net Other (expense) income, net Loss On Conversion Of Promissory Notes Loss on conversion of promissory notes Represent loss on conversion of promissory notes. Loss on conversion of promissory notes Loss on conversion of promissory notes Income Loss From Change In Fair Value Of Warrant Liability Gain (loss) on change in fair value of warrant liability Gain (loss) on change in fair value of warrant liability Represent income (loss) from change in fair value of warrant liability. Change in fair value of warrant liability Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income taxes Net loss before provision for income taxes Net loss before provision for income taxes Income Tax Expense (Benefit) Provision for income taxes Income taxes (benefit) Net Income (Loss) Attributable To Parent Net loss NET LOSS NET LOSS Earnings Per Share, Basic and Diluted Net Loss per share - basic and diluted Net loss per share-basic and diluted (in dollars per share) Net (loss) per share-basic and fully diluted Net loss per share-basic and diluted Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding- Weighted Average Number Of Shares Outstanding, Basic and Diluted Basic and diluted (in shares) Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Depreciation and amortization Stock based compensation expense Stock-based compensation expense Stock based compensation expense Equity based compensation Fair value of vested warrants issued for services Common Stock Issued For Consulting Services Common stock issued for consulting services This element represents amount of common stock issued for consulting services during the period. Provision for Doubtful Accounts Bad debt expense Increase (Decrease) In Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) In Accounts Receivable (Increase) decrease in accounts receivable Accounts receivable Increase (Decrease) In Prepaid Expense and Other Assets Decrease in prepaid expenses and deposits Decrease in prepaid expenses and deposits Prepaid expenses and other current assets and deposits Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities (Decrease) increase in accounts payable and accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Used In Operating Activities Operating cash flow Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows used in investing activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property plant and equipment Payments to Acquire Intangible Assets Purchase of intangible assets Net Cash Provided By (Used In) Investing Activities, Continuing Operations Cash flows from investing activities Net cash used in investing activities Net Cash Provided By (Used In) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Net Proceeds From Sale Of Common Stock And Warrants Net proceeds from sale of common stock and warrants The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity. Net proceeds from sale of common stock and warrants Purchase And Cancelation Of Previously Issued Warrants This element represents purchase and cancelation of previously issued warrants. Purchase and cancelation of previously issued warrants Net Cash Provided By (Used In) Financing Activities, Continuing Operations Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: Interest Paid Cash paid during period for interest Income Taxes Paid Cash paid during period for taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Common Stock Issued For Cashless Exercise Of Options And Warrants Common stock issued for cashless exercise of options and warrants This element represents the amount of common stock issued for cashless exercise of options and warrants. Reclassification Of Deferred Offering Costs To Additional Paid In Capital Reclassification of deferred offering costs to additional paid in capital Represents Reclassification of deferred offering costs to additional paid in capital. Reclassification Of Warrants From Liability To Equity Upon Exercise Reclassification of warrants from liability to equity upon exercise Represents reclassification of warrants from liability to equity upon exercise in noncash investing and financing activities. Deferred Offering Costs Included In Accounts Payable And Accrued Liabilities Offering costs incurred, and included in accounts payable and accrued liabilities Represents value of deferred offering costs incurred, and included in accounts payable and accrued liabilities. Property Plant And Equipment Acquired Included In Accounts Payable Property, plant and equipment acquired, and included in accounts payable It represents property, plant and equipment acquired, included in accounts payable. Intangible Assets Acquired Included In Accounts Payable Intangible assets acquired, and included in accounts payable Represents value of intangible assets acquired, and included in accounts payable. Stock Issued Common stock issued upon conversion of promissory notes payable Accounting Policies [Abstract] Accounting Policies [Abstract] Organization, Consolidation, Basis Of Presentation, Business Description and Accounting Policies [Text Block] Business and Basis of Presentation SUMMARY OF ACCOUNTING POLICIES Liquidity And Management Plan [Abstract] Liquidity And Management Plan [Text Block] LIQUIDITY AND MANAGEMENT'S PLAN The entire disclosure about liquidity and management plan. Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Convertible Notes Payable [Abstract] Debt Disclosure [Text Block] PROMISSORY NOTES PAYABLE Warrant Liability [Abstract] Warrant Liability [Abstract] Warrant Liability [Text Block] WARRANT LIABILITY The entire disclosure of fair value gain (loss) on warrant liability. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Stockholders' Equity Note [Abstract] Capital Stock [Abstract] Shareholders' Equity and Share-Based Payments [Text Block] CAPITAL STOCK Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK OPTIONS AND WARRANTS Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] FAIR VALUE Business Description and Basis of Presentation [Text Block] Business and Basis of Presentation Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock Based Compensation Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentrations New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of stock issuances under options and warrants that could have a dilutive effect on the shares outstanding Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued liabilities Schedule Of Disclosure Transactions Of Warrants [Table Text Block] Schedule of transactions involving warrants Tabular disclosure of components of transactions of warrants. Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of summary of transactions involving stock options issued to employees Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of fair value of options granted Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value measurements of common stock warrants using significant unobservable inputs (Level 3) Stockholders' Equity, Reverse Stock Split Reverse stock split Revenue Recognition, Milestone Method, Revenue Recognized Revenue for government contract awards Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Concentration Risk [Member] Customer Concentration Risk Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales [Member] Total Revenue Accounts Receivable [Member] Accounts Receivable Major Customers [Axis] Concentration Risk Type [Axis] Name Of Major Customer [Domain] Concentration Risk Type [Domain] Customer One Concentration Risk [Member] Customer One Reflects the percentage that revenues in the period from customer is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer. Two Customers Concentration Risk [Member] Two customers Reflects the percentage that revenues in the period from customer is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer. Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration Risk, Percentage Percentage of total revenue and accounts receivable Concentration Risk, Benchmark Description Concentration risk benchmark description Concentration Risk Number Of Customers Number of customers It represents number of major customers in concentration risk. Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Working Capital Surplus Deficit Working capital It represents working capital surplus deficit. Gross Proceeds From Underwritten Public Offering Of Common Stock And Warrants Gross proceeds from underwritten public offering of common stock and warrants Represents gross proceeds from underwritten public offering of common stock and warrants on closure. Gross Proceeds To Repurchase Remaining Series B Warrants Gross proceeds to repurchase remaining Series B Warrants The cash inflow from gross proceeds to repurchase the remaining Series B Warrants. Proceeds from Issuance of Private Placement Proceeds from issuance of private placement of common stock and warrants Net proceeds from sale of common stock and warrants Proceeds From Promissory Notes Proceeds from promissory notes The cash inflow from promissory notes to the entity. Proceeds From Promissory Notes From Related Party Proceeds from promissory notes from related party The cash inflow from promissory notes through related party to the entity. Accounts Payable, Current Accounts payable Accrued Professional Fees, Current Accrued consulting fees Accrued Salaries, Current Accrued salaries payable Interest Payable, Current Accrued interest payable Other Accrued Liabilities, Current Other accrued expenses Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Promissory notes Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] President, Chairman And Chief Executive Officer [Member] Chief Executive Officer James A. Hayward Represents President, Chairman and Chief Executive Officer. Another Individual [Member] Another individual Represents another individual who is also "accredited investors" as defined in regulations promulgated under the Securities Act of 1933, as amended (the "Securities Act"). Short-term Debt [Line Items] Debt Instrument, Interest Rate, Stated Percentage Convertible promissory note, Interest rate Interest rate on promissory note Debt Instrument, Term Promissory notes maturity term Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt instrument, convertible, threshold consecutive trading days Stock Issued During Period, Shares, Conversion Of Convertible Securities Common stock and warrants issued in settlement of convertible debentures and interest Number Of Shares Issued In Settlement Of Convertible Notes And Accrued Interest Number of shares issued in settlement of convertible notes and accrued interest Number of shares issued in settlement of convertible notes and accrued interest. Debt Instrument, Convertible, Conversion Price Conversion price of convertible promissory note converted (in dollars per share) Conversion price of convertible promissory note converted into common stock (in dollars per share) Debt Instrument Convertible For One Share Of Common Stock Conversion Price Conversion price of convertible promissory note converted into common stock (in dollars per share) The price per share of common stock of the conversion feature embedded in the debt instrument. EX-101.PRE 11 apdn-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) - Common Stock Warrants - USD ($)

9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at October 1, 2014 and 2013

$ 1,096,412

$ 2,643,449

Adjustment resulting from change in fair value

^[1]

2,994,540

$ 1,663,316

Removal of warrant upon repurchase

$ (4,090,952)

Reclassification to equity upon exercise

$ (2,455,042)

Balance at June 30,

$ 1,851,723

[1]

Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`&&!"D?#F.=LP@$``#@9```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%>P&N@`0O8))M8S6.+=N4\O;8*2"H"FJ! M2G/)3V>],\DZWZ47#R^.PF!IVBZ,BR9&=\Y8J!HR*I3649>4J?5&Q73K9\RI M:JYFQ,1H=,PJVT7JXC#F'L7DXG9!WNN:!I%\JY5EO=1W: MZ5175-OJR:0E94S6=)#T8G"G?+Q1)K5@RY;UPNK(RZRS_S$,SI.J0T,435N& M^-)2V.2_4MZ=KVBJGMJXD_';NRL]M7U-:+1[L[I>IBXA_38NDAJV]89>DXKND!I9:_\G[?:=4UM-6AKEPCQ]%HSS5]]&G^6[^-CX7 M["]'GFM__=W0>S&P_K1'2.R40X#DD"`Y#D%R'('D.`;)<0*2XQ0DQQE(#CY" M"8)"5(Z"5(["5(X"58Y"58Z"58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%" M5H%"5H%"5H%"5H%"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OE!5M;_ M83)Y!5!+`P04````"`!A@0I'2'4%[L4````K`@``"P```%]R96QS+RYR96QS MK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B_?N.V(#"0ZW$TJ][ MCZZ\#JFL#C2B]AQ2U\=43'X,JQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH` MA3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`88$*1Q8J%YF?`0``8A@``!H` M``!X;"]?6K#Z+VZU&'9WU]G98SMTKFP*WU5A(>F]76_>FBZJHC]97=T;;$[%T?O-,^G MKAO.R3:KG[-'V_TZZ[9[R48O17?T<9V]-=TYE-['X&XG>>@WZ)>OK?_/]LWA M<-KYQV;W6ODZ_E'AOC;(7#I(TT%*";)TD%&"QNF@,25HD@Z:4(*FZ:`I)6B6 M#II1@N;IH#DE:)$.6E"")`BM';P5Z*^E=&[UL<_16H+=R]%:@MW+T M5J"W1OI6@CR4< MO0WH;1R]#>AM'+T-Z&TAM'+T-Z&TO'W3[E-A0T#K6._DW>WX]T?';>IGR'NU^^$S0=02P,$%``` M``@`88$*1POA.(3A`@``]0H``!````!D;V-0&ULO5;;L=L]JA2:9Z(\#GA>,RX0)]+)*,S$&XW5O*64QUC01+]F*B@N`9+"ZR/F* M2ICR)RU?+)*8F7F\7K%,:L-^_ZO&7B3+YFQ^7C1.>_JDW`4719K$5"9YIKM) MS'.1+R2R7F*63K2W@(H!GB,6KWDB7_5^C6F;*DP4TY09L)>^H*E@->JOL<(8 M^:J@V:M6SYPD>Q;3@N0FE:S-VE^HO2\I9W/8=,][8ZPP/UXAS[3D&DN:/;%Y M&_M^<:?%C'%19CH87O3AUTBPL]>^&9TGV5-`$R[TR4:.-RR6.=^6:2-/K=(\ MC\NBBQF!^$0//5+!RN%U;T-Y0C/90R+Y#=-AK]ZVME;CM!"2Z_X:%3N", MCN%$!/Y4#8 M,Y&+/7Q7AD0^12B`C)2AR'V"/C"-[8#P2E1H>54D@0XA/`),")L$!O44@N*`YM@!Q3TC9]J^

5CRJI;2`''/JN:Y-2K!H,=2KUMKR#8M]B.T0S[$S5:7>73WT<.SF#;\?7 M;_#]2&W0&:&/'Z1;8>"R^'Q\#L/!"9SA"1QUZW;VQ_#R>'V'ZM8]U!_HS&22 M)O_6)EMPB@A\\]='-DU%_KAS]O>`SZJZIMV<`U=K%V>D/@?=G`/GX/!9/D>$ M'\\9J<]!)R=2UZ>38ZU.B$U]!W1>7NCLHWX^1[?P$$`SFJX9O3K: MSX4(5E7N0^JKVJ:9M1,4ET-S.IM.3P;3=E%A M#1?N-FED6F[Z3"`)07CE4%ES$2YAOHD3+.P^/D'@Y:!.F"[;%MK&>AFJ=+^& MZ/!RXLK6UK?'U(_H[%557U!+`P04````"`!A@0I'F5R<(Q`&``"<)P``$P`` M`'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYB MZ(:(E/)X8-DOV]:[MR_>X%#BVR]+4 M1B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV( M]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W.76!4!EQC?-HU+,76 M>)7`\:V@S&L%&KQMUAVC2/'K^!?F<-0HACAFNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=Y`\F MIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z>`HWEL:\4Z">P'_T=HW MPJOX@L`Y?RY]SZ7ON?0]H=W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JV ME+ZU)CA]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D^`VVZG=PZ M.)Z8D;DTU0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L/O/)8=QXCRHB'N MH8:8S\-#AWE[7YAGE<90-!1M;PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q M6\8#Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5 M'<]56_POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN M>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86 M%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEP MVSK>`U[F$RQ#I'[!?8J@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\UM: MI60K$3]+!WP?D@9CC%OT-%^/%&MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL M.8T;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L# M!!0````(`&&!"D=S-N`83`(``'H```-````>&PO>A;D6W9%NCBR7+F]-=/%U^20)8V34OS MHJ-/1]_Y='2<,63-4@%0U7$;P8(.#VWXD,1_#I[.N?1JC; M+\"-DV^3B?]T?KN+G]F%(DD02`^:( M$;IV\,P`]NXZ/T:XD#:VB[`;9^J/D6211-#O?B\/EXSL=C#'(Y1N'T\#<5@A MI;#D"ST!G;U<5_IP7'#L1%J_`]Z%1.M@=KFQP0XZ;B)DAN40.8`]%(<4YTIO MD0HS:A$9:0+I0331D90(3BBAK+?T1F:-L64/I@OY3'?XFYSX'S,'?L0&!6] MJ1/1F6,9V1ZFVR.>Y/V.%[0YD,`O1M5%5U_IZ3@##NQ#EJ(;G:(/MA#'X>H M9P6ED.19^YM"2#6`)00K+!5)-Y&_$E5+WJN@KTVWZ?PV"._IZ;39VU4HTOP MH]-S='`+W35-O^\TMZG MIDY1[==O5.9UC6&C^VSUG@$%24.H(KR7@,QKX=[(IEMM8>P[FC-KQY9C5Q5 M]$-PXHFRW".&JI^DY50=C&"H_W3R`_F@]=RH(C@:/_"&6G8M54POC;C?U!+ M`P04````"`!A@0I'JF:2#=D#``!^#0``#P```'AL+W=O[5X5K^J,=/E?KV6%7?T',A2SU6$V]KS&['KB3>PS>J)'W6H M>G=3"]DTAOVAUVM@+Z'.%5I5:[Z'Y5NAOQQN>&C--ZR6)K>+?9EWXOEX@/%H MSV@>NQ?\24-@TX'8RHCO/&>/$Z_O(5:;ZE9(P]6,&7ZGJGHGRJ^6Y:&-4-ID M3;CMDX4H12%^-NNV+;VMGOZME/A9E8;);4J*=M1S8UVD)U!_^ZQ:S1B=?2@ M88^+9B1]/X(I4W_ZQ4JV^2\;#%BY1H%I;$4 M%);[S;.I:=9@'P[7[<1J+.R%"M?^/E40-$V369!DP0S9JRR-PAG-;>.&1C29 M!@B`,`#A",`&=TRHG"_Y;A+,P?$$UF**8)O6LBRM]E:&ZS!$"7 M`'1Y"CJLP@ZC#_0F"EJ>[5PL;7Q1"$!7`'1U"IHOTCC,LM0&EZ1Y\!L("->` M<'U^$(7"YKD=E9Z$T8V-JA>'[K7/QV\")V2^9T89.26U!&IWEH=PM2C@QV M4SG84XCN['I]#,<"(WU'?G2C_$J@H/ZYAOI7 M$`45]1V.OKU+Z,67(B"KOH.65\SW`Z57/\#"QS4%3MT[
B"+2= M0-N)P_9.5`:](M!VXJKG7:B@@"AH.W'5\\X`83TGT';BL+WS)8Z5ARBH.WD^G`Z?CT0VV\"4?)U\[F@VVGL>7O5?$/8 MG_T!8#!LW@E-.[;?%1.O.?S;_?#5\^@502P,$%``` M``@`88$1_"\XB%-`@``\P<``!@```!X;"]W;W)KC%>LV01CT@;?R M4D@=@'D&!]^IK&DC2M8`3L^;8!NN]V&L)4;QNZ2=&(V!7OR!L7<]^7G:!$BO M@5;T'4HAXWNJ=5I3,I\E^7]).IC>-QG_V[5&25,+_@>!62U;TE`#7YL,^R,<_._A-'SN8W8&?`@P$G MDX;(&:+!8%\=M"LS=7TCDN099QT0+=%?.UPK.==)5&8@3#95DC#!K8[>]_9X;(^- M/;E?WUBQLXK%BL,_12W.],IBM,L9U"PGVW:+B:HKB-CF90(C\E',MGQB15>/2BBB[4#3Q,GJ6>IBJ,;=WDIU(UO97 M['#/Y_\!4$L#!!0````(`&&!"D?]73,OQ0,``!<1```8````>&PO=V]R:W-H M965T&ULE5C!CMLX#/T5(_?6(BE;TB`3H..BZ!X%#WLGCT3 M91+4CE/;,^G^?66+29-"T:@YQ+;R2#Y:U!.5Y;'KOP];:\?L9]OLA_O%=AP/ M=WD^/&UM6P_ONX/=NU\V7=_6HWOLG_/AT-MZ/1NU38Y"E'E;[_:+U7(>^]JO MEMW+V.SV]FN?#2]M6_?_/]BF.]XO8'$:^+9[WH[30+Y:YF>[]:ZU^V'7[;/> M;NX7'^"N(IH@,^+?G3T.%_?91/ZQZ[Y/#_^L[Q=BXF`;^S1.+FIW>;65;9K) MDXO\@YW^CCD97MZ?O'^:TW7T'^O!5EWSWVX];AU;L@/@]PS MF_/Z6(_U:MEWQVPXU--LPYV#]Y,3YSD;9F\NI6$>_#"-OJY0+O/7R0]#\`+R MP)#;B(H1Q1F2N_A!$G@B09VI.W5]<4U0S9^R0\!(0B`5+> M!E8,)$-`^#8A&20D/2%]':>X),00H90JRMNXRN,T20WZ;3I%D$[A8YD('88( MHPDB;`I^.P65";-=!MF4LP\2$38EAQ&@5)2/!R51)!`2`4)4\H$N?!0PHL M-<0FBV&J!$R8+!U<#-JS2:@]$\S&>'N9&,X&Z,C%5J94S4D`N(()EYV+&1 M$3:,B=1#Q1#0`$(FD($P&:]35,3(`+^;P@B,,6)?J+1F"K`,".O?!2IJ0?& M@`0D22K&B;T5HA2%2B!%P0($+X&4XB$L?^!%BV+ZQQB7EBXA,B/5&6BDDP" MI[`&@I<+B%[29(<(0377H)DBEM5UA^T`N&3&B\,-QY MH=<&6N]&(,@=60"OS=>24H#X:5![U8R)CR,`9=UX"DB]B^PU`P&I72>J# M8?7!@HLFQLMCWB$`N-)2D3VS.F'!&%43-F","Q6R`(3$RO&`$IC3!%34$:^ M`UEJJ5+JBQ8R)T4Q.I13;&Z])2?[L25ZR%)8-$LE+ MEL)=$'&'DR!=%#ZN$:9G<>/`1N$L\HLC[%^ME_J_GFW'[+';G2GX?GHNNFZ MT3H?XKTKOVMU^>'QF[&Z5:Y^]Z?V_W#V!U.?T.<_PM9_0)02P,$%`````@` M88$1^9PHST)`P``R`X``!@```!X;"]W;W)K?'R^)%UZI,=[]MJLM^ MGXACSZKM.AM$@1`FK15W<6KQ7COI5\M^$DV=<=>^DB7ZI_'9>K]->58"5O?M5; M>5"V((ZV;%>=&OGS]^860,="FYX(\;_T>8D)&\O0^HK3[TL>[&XUE_DA$S MS#X`F0'H.@#Z!V`S`-\-2+39NXOE:Q6BYZ?(W&LAK<-'Q7>#T54Y4B,U=22 MQ'CS:;C[OJ)DD;P/=0R")LBS1I";`U!KTBBYK=H(L$F4H@+4%OI\A&I-,2 M&L$`H=Q-E9HJ4DS"MBJ@K5>CL)G:IH)".X@,2-E0:C! MC$8PHO3^^=W8$/.4@3RL`VUVE!MDWNFT4ABQE+3JV3I'J2PO.6-0+!^!>> M)[/.DVE3<#M//GVT&@$/`$`W5=HHITMN="\/X-#XA;@]H]]#YEA)/KQ@FU"Q6S.UCCTN( MS+?,]UQ,IH)PQQ@48CJ[::`]/'.O-27GH9!D.0(`4^#E8:$N,"TH#,2'=I# M%.KL2S.?%9EM1?[7RAZFT0IFE'!GI0P#4>888)M:98;PZ]XC;PYZHL)@19N%,_82X?VK90Q7I-1X1@5['"(8[CLT M+PZMF-O'\>L1A?O.,#/ZSD6ZK>Q9B'"X[PSCU;E'W![V]$,DW'>&\7K<(]HC MF>PYCM6>_:CZ?=V):,VEVKZ,>XT=YYI$N!!%3RH;>7UHF$[.9QFZKS7&RU] M(?GQLF^\;EY7?P%02P,$%`````@`88$1^A7:P43!```:!$``!@```!X;"]W M;W)KKVIA4LDC5 MU"R2-6W+EQHN#M#MR=M'((%ICY#)QACY.Y?_6.A(K&]E]:,^]4$/_.LJ%\7 MYZ:YKLPWI]5GM8OY545^I=C6>5IHV^K4UA?Y4>.J,\"S%"/,S32['8K+NQ M;]5F77XTV:50WZJ@_LCSM/IWJ[+R]KJ`13_P_7(Z-^U`N%F'@]WADJNBOI1% M4GCZ^(-5@GND([XZZ)N]>A[T";_7I8_VIL_#J\+U.:@,K5O6A>IOGRJ6&59 MZTE'_L^^_=7)U^N]IK>(R^_MR:,XZ6[0(#NJ8?F3-]_+VN[(: M6.MP7V9U]QGL/^JFS'N319"G/\WU4G37F_DE0M;,;8"M`1X,ACAN`V(-R-V` M>@VH-:!S(S!KP!XBA$9[5[E=VJ2;=57>@OJ:MO,)5AJO6B?:#I`;(@(>7)XZB3Y MQVKL'U,.J0PE3`(QCSBHSB_<+'A!`60T32V M,QA#6&!"I[G$AD41XU(\E\>%BRQ']2"(/MY.V5D12/8\]^BP(#%$JV7.%@)P2 MNV&M47@T6F8)/,(8//]TW).8B@@!\NCLR8APCKB'3'I2%T1$HV5O6BDXURDP MW2J2,SQ@=ZU,)Q&>;+>689PF`XIT@P,Z8]\![K8,IO^).8NGN_>! M:3"^ZHE9E=+SZ6F%\M\;^KY>Z%8!K.8Y.37[0:9HE>D)C&XCL&=!K;W3%. MIK'DCHD93RT>VN"7YH!-DQ$SM@H8G/7!IKT(SZWM0S6.Q=B&\G:TD@>F>. MN6_9ZDG=(QA#GN:<##XI0N/5Q"@-1\?(7%6G[@!?!_ORHVC,R6@8'5X2O.'V M&/HPOH55#([Q':P2\PK@[GZSOJ8G]6=:G2Y%';R7C3[\=B?58UDV2B>-7K2$ MLTH/PTVFCDW[-6K_#?,BP-PTY;5_KS&\7-G\!U!+`P04````"`!A@0I'I=CG M7V4$``!2%```&````'AL+W=O"C(#)`1\??>GKJ+^]E`_KEI M?@X/?VX?YV+@8"O[T@\N2G?YL(6MJL&3B_PO._V,.1A>WD_>?Q_3=?2?R\X6 M3?7/?MOO'%LQGVWM:_E>]3^:TQ^6FZL;?V4O?]T? MQNO)_Y,+-@L;(!O@V>`<)VQ`;$"?!G+,U#,;\_JM[,OUJFU.L^Y8#F\;'AR\ M'9PXS[-N].92ZL;!IV'T8VW$:ODQ^&$(7D`V'@)GQ-(Y#T;`><@<1W/\.D#A M$5K48)\%<\I\3;-KINHR)P\A)4'KV$%PU!)F=]GHX-LM,\F$F:CF0T! M"A6AXW&@0>>D[_/)@WQRSR<29^,A:(Q44D3X>!QD&1%D]_F8(!\S.LDQPL=# M3"YRB??#@`C&&8>=E]AGP9A,2HS`"H81:242.A<@3(CU1\<(>0R"BQ0CQ#J5 MY3KA.P4,MAT@ESG!`X4S8C4RL8R(10U@CR"+!@)I&6>\'5!6.#`BQ(2/TV M#%HH0Q!KP`EG4"804F%"B@E!C)`'+;12<4**6Q5EEM(:8<$$KW.Q7M\P9D$Z ME[$77##0+9P`$Z8E"LFL-;=SC?7G#2_-L1,`\5(,3)#[0IO$FCEX1YAR1,) MDQ.$]0X,NXC-"`Q:($FHM6>@,XB2L4\+BB())Q:8%!BV0G!GQ`KK'K)8 MB9@2,V@AE=$RTBG%!$PN0%C\$)E4PKR8?5#UBN1Q_)BD'$+)`D19,%(!%<" ME:!_&-8_G/0O)LH,6DAAAC(F!`MK&[V04Q))I`22#+S;.,3"]!6-XP8U8Q MQ660<9.Z$ZX819"2215KA)8A14.6>%BP383B-S$1%%6'IA1)DBD[%?"BT-D M?;L5TZL-P002VH6Z73]?;0@8B053EDAH@DW)TLF),RZ%!8X8H&#A!=&8=TB MUJV41"BL,L0J`PDJ0V&5(1:06^VXJOL$,BII9QE6#F+E`!/Y%B90#I<3VM>A MPKI!+`DH8DFQ&DBE1,H^@,)J0P&&%,#!F6YS!,6"Q3N<.+FQ5B'3R#,>73 M#+876S ME^;]T/MSE//H^9CL"8>CGIOQ#3P4_K#KT\UZ=2S?[%]E^[8_=+/GIN^;>CSU M>6V:WCINXINKR?F'OCE.)WCG8\3U_U!+`P04```` M"`!A@0I'0?%A3(!``"Q`P``&````'AL+W=OVRC!<8%'&__OH`O:U61 M]L7,C,\YMC#O1SOO^R)BK.M#"/6`/)OQIT&KA0VI;YGH+ MHDXDK1C/LD>FA32T+%+MQ98%#EY)`R^6N$%K8?]>0.%XHCE="J^R[7PLL+)@ MZ^6&HR3:(B%YD3/^?&RCX@$^"5A=)N81.]7Q+>8_A/-(L60$'EHX((RPV> M0:DH%!K_F34_6D;B-E[4OZ7=!O=7X>`9U6]9^RZ8S2BIH1&#\J\X?H=Y"X'@MVBT(SA&\QEQJP(%M3OMN#T'ITG M.O^SP\7.!_2PWPKL[V]QB[DLF?_FK#-F6JP;;HZCE0X&#\= MZ5I=;^>9IYE\P,NB%RW\%+:5QI$K^C#9-(8&T4-HGST<.G"^UD3!8V/X5.( M[72EIL1COSR0]966_P!02P,$%`````@`88$1Z9:/H6B`0``L0,``!@```!X M;"]W;W)K1W=:!)L``2A<4A%\N\`!!2'?^'W6_&H9B-MX47^,N_7NS\+" M`ZJ_LGM-YM04D$M!N5><'R">0NW0;!$9>.7E(-UJ!<)5I\3OLXCI.?[)T MIETG\)G`5\)]$HU/C:+-7\)(C8TXQ9$W MN,6<9LPN^:\)VYRI!M/$JV-)B4/GIB-=J^OM//(XDR]XD?>B@3_"-+SY(S. M3S:.H49TX-LG-[>4M/[]K(F"VH7PAX_-=6FQ&&_/)#UE1:?4$L#!!0````( M`&&!"D=_SMEZH`$``+$#```8````>&PO=V]R:W-H965T&UL MC5/;;MP@$/T5Q`<$WY)6Z^EW515\A`IRD/[S-IC&P48%_`Z_?L"OL2J5FI? MS,SXG#,'!LH)S;OM`1SY4%+;(^V=&PZ,V;H'Q>T=#J#]GQ:-XLZGIF-V,,"; M2%294GRP!07FE9EK+V:JL312:'AU1`[L7-[S-(G(XTI6OA372]"P56E6SC M-4!M@(U,=`>Z2D]G(N`B(`?`B:[BTGP?D%\#\ESB^=DR$/?QJOX][M:[OW`+CRA_BL;UWFQ"20,M'Z5[P^D)EBW8JW2/"W9-0@MF&R'.2^8#<&\^LT6&;U%SR(] M^S<]7^GYWF&^./P/@6(5/8"Q>TM[C'G%9/_U83MSE2!Z>+5L:3&4;OY2+?J M=CM/69S))[PJ!][!"S>=T)9OY\MD="Z$'[QL9FO MU)PX'-8'LKW2Z@]02P,$%`````@`88$1S4>=_B`0``L0,``!@```!X;"]W M;W)K:>=0[NA1>1-NY4&!EP59>+11HU`3`\V1GG:'U'_&W7KW%V[A">6; MJ%WGS2:4U-#P0;H7''_!O(5]$Q0VO@EU6`=JH5"B>(?TRIT7,?I3_8PTVX3 MTIF0KH3')!J?&D6;/[CC96%P)+;G87:[@X>;(.5B8UJWJ&-Q5.H7LM=EA?L M&H1F3+K!G&?,BF!>_6:+E-ZBIY&>?D_/%GJV=9C-#O??"^2+0+X5R&]O<8LY M+YC[_YJPS9DJ,&V\.I94.&@W'>E:76_G8TS^871<];^,--[0E%W1^LG$, M#:(#WSZYVU/2^?>S)A(:%$''YOI2DV)PWYY(.LK+3\!4$L#!!0````(`&&! M"D>&V).-H@$``+$#```9````>&PO=V]R:W-H965TDVS9R+"5=K78?5JKZT#X3>VRC`N,%'+=_7\"76JM(?3$S MXW/.'!C(![1OK@7PY%TKXPZT];[;,^;%K1P-]B!"7]JM%KXD-J&NZ^D@2=+7^UL!\G4#@)$PN%5,HOY>P2A28,7V%.$V9!L!^M06GU^@\T?GW M].U,WZX=;B>']]\+[&:!W5I@=WV+:\QIQCS\UX2MSE2#;=+5<:3$WOCQ2)?J MA`0``L0,``!D```!X;"]W M;W)K&ULC5/;;N,@$/T5Q`<4QW&V5>182EJM=A\J M57W8?2;VV$8%Q@4Z"M<]V> M,5NVH+B]PPZT_U.C4=SYU#3,=@9X%4ELC1)?C#%A:9%'FLOILBQ=U)H>#'$ M]DIQ\W$"B<.!;NA<>!5-ZT!%3E;>)50HU`30S4!WK<[$]90$3`'P<4D M>#\COH7D=W6@2;``$DH7%+A?+O`(4@8AW_A]TOQJ&8CK>%;_&7?KW9^YA4>4 M?T7E6F\VH:2"FO?2O>+P"Z8M[()@B=+&+RE[ZU#-%$H4OXZKT'$=QC_;AXEV MFY!.A'0A/"31^-@HVGSBCA>YP8'8CH?9;?8>;H(5R8VJGF'-A:/H7HI-EF2 MLTL0FC#I"G.:,`N">?6;+5)ZBYY&>OIO^G:F;]<.MY/#_^B?S0+96B"[O<4U MYC1COKMDJS-58)IX=2PIL==N/-ENMS.8QIG\@4O\HXW\,Q-([0E9W1^LG$, M-:(#WSZYVU'2^O>S)!)J%$['YOQ2HV)PVY^(,LK+3X!4$L#!!0````(`&&! M"D&PO=V]R:W-H965T<.3!0C&A>;0?@R+N2VAYIYUQ_8,Q6'2AN[[`'[?\T:!1W/C4ML[T!7D>2 MDBQ-DA],<:%I6<3:LRD+')P4&IX-L8-2W/P_@\3Q2'=T;R(MG.AP,J"K;Q: M-!6H"8&FB,][0[G/"`BX^`T6YB$KQ?$%]#\KL^TB18``F5"PK<+U=X!"F# MD&_\-FM^M@S$;;RH_XR[]>XOW,(CRG^B=ITWFU!20\,'Z5YP_`7S%O9!L$)I MXY=4@W6H%@HEBK]/J]!Q':<_V?U,NTU(9TZ$AZ2:'QJ%&T^<V!MLYU>\9L MV8+B]@8[T/Y/C49QYU/3,-L9X%4D^M0S11%/\:5Z'C.HQ_=ME$NTY( M)TZ$.Z3:'QL%&T^+W.!`;,?#[#9[#S=!Q"L3&]6\0QN+QU"]%)OL+F>7 M(#1ATA7F-&$6!//J5UND]!H]C?3T=_IVIF_7#K>3P]WO`MDLDT%LNM;7&-. M,^;^1Q.V.E,%IHE7QY(2>^W&(UVJR^T\IG$FW_`B[W@#K]PT0EMR1N&ULA5/; M;J,P$/T5RQ]0$P)[B0A2TM6J?5BIZL/NLP,#6+4]K&U"^_>US:6HBM07/#.< M<^:,+\6(YL5V`(Z\JGMD7;.]0?&;-6!XO8.>]#^3X-&<>=3TS+;&^!U)"G) MTB3YQA07FI9%K#V9LL#!2:'AR1`[,7-VQDDCD>ZHTOA6;2="P56%FSEU4! MM@(U,=`QV M!P\W0<0K$QO5O$,;BZ=0O9:[[&?!KD%HQJ0;S'G&K`CFU6^V2.DM>AKIZ=?T M_4+?;QWNI^YY\K5`M@AD6X'L]HA;S'G&Y)^'9)L]56#:>'4LJ7#0;MK2M;K> MSE,\1/8!+XN>M_"'FU9H2R[H_,G&8V@0'?CVR5U.2>??SYI(:%P(O_O83%=J M2ASVRP-97VGY#E!+`P04````"`!A@0I'L%=BS$!``"Q`P``&0```'AL+W=O M:>=#;&# M4MQ\G$'B>0[NA1>1-NY4&!EP59>+11HU`3`\V1GG:' M+XBO(?E='VD2+("$R@4%[IU)_B;KW["[?PB/? MJ%WGS2:4U-#P0;H7''_!O(5]$Q0VO@EU6`=JH5"B>+OTRIT7,?I3Y;/M-N$ M=":D^$AB<:G1M'F3^YX61@UYF-WNX.$FB'AE8J.:=VAC\12JUWW3PMV M#4(S)MU@SC-F13"O?K-%2F_1TTA/OZ=G"SW;.LQFA]GW`ODBD&\%\MM;W&+. M"R;_KPG;GD"T\:K8TF%@W;3D:[5]7:>TCB3+WA9]+R%/]RT0EMR0>'6OG`0``J@4``!D```!X;"]W;W)K&ULC53- MCILP$'X5RP^P)B20'Q&D9NJ/51:[:$].S`$M#:FMA.V;U_;V"Q;H=`+]@S? MSXRLF:P7\DW5`!J]<]:J(ZZU[@Z$J(&3M63Z`U?RHA.=4FE%>B.@FT="3. M2!Q%>&T:7&>N=R+S#-QTZQIX44B=>.3.[U7X1XL\'W\H@C6P(P+15H.:XPS,P M9H6,\6^O^6%IB=-[4/_JNC757ZB"9\%^-:6N3;$11B54],;TJ^B_@6\AL8% M8,I]47%36O!`P8C3]^%L6G?VPY]-[&GSA-@3XI&PBUSA@Y$K\PO5-,^DZ)'J MJ'V[U<'`I14QRD@Y-5.A8,X>,R(49^UB/$)F^#O3UM,+UX!ZGRP;(+"9"FQ\B^GG%J>8<\!LETV269/$"^P>F`3,?MDD MG35)!X$T>F`2,/_Q7-M9DZT7B!^8!,QZV60W:[+S`IL')@&3+)OL9TWV7N#1 MPP?,OP]/)L/$05[=SE"H$+=6#[,T9L>U='+32S[@>=;1_R@\MJT"EV$-B/M MYJ\20H.QCYX2C&JS.,>`0:7M=6ON:2$-+?(4>[9%CKU7TL"S):[76MB_9U`X'.F&SH$7V;0^!EB1LX57 M20W&233$0GVDI\WAO(N(!/@E87`KF\3:+XBOT?E1'6D62P`%I8\(FQ7>`E MHE!(_&?2?$\9B6M[5O^6N@W57X2#)U2_9>7;4&Q&206UZ)5_P>$[3"W<1\$2 ME4LK7OG4<\42K1X&W=ITCZ,)X_91+M-X!.!?R"P,5$J\ZOPHL@M#L1U(LYN MX';/S_><"NUE@MQ;832U^^;_%->8\81ZR#TG8ZDXUV"8]'4=[(T? MKW2)+J_SQ--,WN%%WHD&?@K;2./(!7V8;!I#C>@AI,_N[BEIP_]9'`6UC^9# ML.WXI$;'8S=_D.67%O\`4$L#!!0````(`&&!"D>T?4RI0$``+$#```9```` M>&PO=V]R:W-H965TZ:EE42$YHD9:5_7Y)Z1"T,M!=Q=S4S.\M',:)YMQV`(Q]:GND MG7/]@3%;=:"XO<,>M/_3H%'<^=2TS/8&>!U)2K(L2>Z9XD+3LHBU5U,6.#@I M-+P:8@>EN/EU!HGCD:9T;R)MG.AP,J"K;Q:-!6H"8&FB,]I8?S+B`BX+N` MT6YB$KQ?$-]#\E(?:1(L@(3!07NERL\@I1!R#?^.6M^M@S$;;RH/\5IO?L+ MM_"(\H>H7>?-)I34T/!!NC<81\$Y0V?DDU6(=JH5"B^,>T"AW797[GA9&!R)[7DXN_3@X2:(>&5BHYIW:&/Q%K7 M,GU("W8-0C,FVV#.,V9%,]^LT5&;]&S2,_^3<\7>KYUF$_=\_\0V"T"NZW` M;AXQ^W/$+>:\8/_FK#-GBHP;;PZEE0X:#=MZ5I=;^P0``!D```!X;"]W;W)K&ULA53-;J,P$'X5RP]0$P(D&Q&DINJ/:Q4]=`].S#\J#:FM@G=MZ]M M#&4KU%RP9_S]S(BQTT'(-U4#:/3!6:N.N-:Z.Q"B\AHX57>B@]::7I24N]Y/Z@^O65'^A"NX%^]L4NC;%!A@54->Z1RWX1,&(TX]Q;5JW#N/)/O"T=4+H">$W`AF-7)F_J:99 ML6`5$?MO]L<#%Q:$:.,E%,S%2J7/-GL-=OLHI1IF\G^G99X79TCW:W!:))(%H1+[%^/\6EYCSA$ENF\2K)K$7V/U@ M,F'VMTV259/$"_SZP<1C]L$W$[8#@ZR[YJ$HH@$``+$#```9````>&PO=V]R:W-H965T MVRC M`N,%'+=_7\"7NE6DOL#,<,Z9&0;R`5-2VP-MG>OVC-FR!<7M#7:@ M_4F-1G'G7=,PVQG@520IR;(D^<44%YH6>8P]FB+'WDFAX=$0VRO%S?L))`X' MFM(Y\"2:UH4`WV\"JA0%N!FABH#_28[D_;@(B`9P=DDU'Y&?`W.W^I` MDU`"2"A=4.!^N\`=2!F$?.+_D^9GRD!S65W_F%NY0OHCM;[8A)( M:MY+]X3#`TPM[()@B=+&E92]=:AF"B6OXV[T'$?QI/;9)=)V03(?M&8&.B M6.8?[GB1&QR([7B87;KWW48O:UQ37F-&.^)V&K M.U5@FOAT+"FQUVZ\TB6ZO,YC%F?R"2_RCC?PCYM&:$O.Z/QDXQAJ1`<^?7S MHZ3U_V=Q)-0NF+^];<8G-3H.N_F#++^T^`!02P,$%`````@`88$1U=U9"9: M`@``1@@``!D```!X;"]W;W)K&ULC5;;DJ(P%/P5 MB@\8((2;A50INK7[L%53\[#['#4-4!8$F7V[S?/JTDICWI MWFF!,;,^ZJJA:[M@K%TY#CT6N$;TA;2XX4_.IL1X\ONXM"VP^@D277E`-<- MG1J5C9VELO;:92FYLJIL\&MGT6M=H^[O%E>D7]N>?2^\E9>"B83I<[`.Y4U M;FA)&JO#Y[6]\59[SQ40B?A5XIZ.[BUA_D#(NUC\.UM5WC`%3XR(8'XY89S M7%5"B7?^HT4?/05Q?']7_R;'Y?8/B.<5+_+$RNX6]>V3OB,KA5[(_UWK&<( MA."15%1^6LDMVB+Q>_)6'-X)$:YL4:G&0Z.RN!'56^;% M,'5N0DACP`BS59@PF8;LM,R`<+@!HPM@FSH`20?3#7%B-P9#T]%]E]$)FWZ M=YO^."Q?AQ4\%X!W`3@6@%H@_-]D(#&-RD)ADL!+8#2#RQ4.^)X/8S"-VRW4 MVYOU)@<,C`,&>L#HN4!HC#A<'G%D=!`MB%AA0C<$<.3T:\0!Z`+_60FX85R M>Z/H[<633?DA MGZ4MNN"?J+N4#;4.A/&M7>[#9T(8YI[=%SY!P0_U85'A,Q.WD?@JU#&G%HRT M]U-[^.N0_0-02P,$%`````@`88$1R6B6@B`@``\P@``!D```!X;"]W;W)K M&ULC99=\Y),"&[,/XACI1[ZLJ:S'WCU>9D$@ MMD=:$3%A)UJK7_:,5T2J6WX(Q(E3LC.BJ@P0`'%0D:+V\\S$7GB>L;,LBYJ^ M<$^Y#_TF\%H3+ M7HO:7"_V%SQULGX!<@+4"F`Z@B=(+P\@@('\V0 M.$%R(PCL[)JU61))\HRSBR=.1#^P<9PKDV4LR>,FUH688)/.OJ9PW2:!9_: MR#&HPSP[9@J&F85EXA&;E;-IB4`5V5LI\ONJ0X.%%9=`PL;1$,M+ZJ[) M^K[)QIG@^]V&3;=A=UU"VRV[QM$C4'4-8C<=-WTT66>&R:\GP3W)L%VU:/O M.5#U#:'1<`$`#A,+1ZB5@]1FSYJL^XMZ_83W_NHVVY_43TAOV37P!9TO8$U_!V=H>QU?[/#N1`_U-^&HA??.I#HF MS)Z^9TQ253"8J.4[JC>0]J:D>ZF'B1IS>RC;&\E.S2M&^YZ3_P=02P,$%``` M``@`88$1W:1`4]V`@``>0D``!D```!X;"]W;W)K&ULE5;;DIL@&'X5QP=8Q6/,&&<23:>]Z,S.7K37Q)#HK(H%$K=O7T`T-L75 MWD3Y\YWX42'N,'FG!4+,^BKAN[,@K%V:UDT+U`-Z0MN4-"J+>U&])R`8NLNA!3&F6`./2:(YB&9DAD1%@^@3>&8.@='TIUY@[1' MA/8G&19%CO^(S,9TAYC>M%FN:E:X+.`-`NY4P%,"FV4!7YO`5P)/:S'%''L, M_RPLFP1:DT`)K%C.4#O-WL53+FL:XNM[ZO]'3_6O&@B6>YJ-H&B%3ZCW"9=[F@V@ M)Q=KLJ_4B%SECDZ-'-\:UG\IQ^IX:M@[8E]ZJA_`-@6:>B9.&7(?>\@G<0NO MZ#LDU[AQ@DSOAOK>N",4,\K?W"LQ?\'#0.G1AXC84G>A/!OV`X78XZ(RG MK>0/4$L#!!0````(`&&!"D=&WUJ?\0(``.D+```9````>&PO=V]R:W-H965T MXUU:A, M@;B`M?OO-R=I;U>W,0HHT^RZ)J9I-#VQ[OXKC9'$29 M-;?R"KURT[69=:JVWH?-\=:9%LCHL8`4#C,LNKR7QJYE[J^52>VBOQ$L= M-:>RS.J_#Z0Y]D$3KJ)UWQ_:/5$/)_&%]TV+T75Y+**:K&;3>[AW3-$&C'$ MKUR]\VQY4MF`2;<4N.Q7MJSROA:N!:,.-+!KS'6U.32O+3C) MRNS37O/7,_V%Y8ZV;``.0&Z"&#B%6`GP&"Q`F24`%Q`A(JH$Y`0P7,"5BH M('6"-%3`G8"'"O2:VY4#5Y+8+KG9,(]9F\VGM3Q'S3'3CQ&\TWRM?91YU!A# MM5D:,WFO9S_F"()I_&='(-ZS$/'P'%FT3%HG'GL&#S._'#,.+&T!/,DO/K6 M9/V]R9,S(>/(+,I"F:#RI M90=RR`%AXXZK#H0X)1!X+-<="3A53<$!99+!,HG;+,23E65N"$473\F?7#M M0(H8!#!D\]#!GC+B7IZ;QG5)X@XLEI-0.Y\0& M73HO@`B[KO'+M@\U7'L,^[UX[-%B''^U&\^<#V;.7>:I)Y)E$L!A6"0(!D.9:1V+>];M M`A&:,AK'<+A8.ZO`0%?,`O!-+2'$`T'0RX8]+RN'03!4+"X=W8X9GOQ,ZOW M>=5$;[)5!Q%S9-A)V0IE!&Y5#0=U[K[<%&+7ZB%3X]J>1.U-X_=P?IRNI__ M`U!+`P04````"`!A@0I''I>4+!H"``!:!@``&0```'AL+W=O.]VL:-UL,]`&K?L(ZJ.S&P MWMPY"ME1;:;R!-0@&3TX4\NH_/O( MN!BW,8JGA9?VU&B[`H27'V'MF.]:D4?27;E13=9XJBC;_[:]NXZ^CL%#+9E M`PX&?#6@=-60!$/RP0`\F>OKB6I:E5,D1JHW6QT;^32AICD2+DTTY)RBP]V M]5)AC$MPL4%!@V>:QZ"YK:B#(KM@`%8I,`313GP,Z/$OQY0#(%I/.`)+21 MO(]'VA;,[C-RFSC9(DX6<+(5'])<0$WQ0I.B$HSDJ//6I[%>V$-B>^_R/0FAF&PO=V]R M:W-H965TUH54A^TN$(>6%1M35%=3<^ZYG4_Y M459EPYY;3QSKNFC_+5C%3S,?_/[$2[G;2WTBF$^#<]VFK%DC2MYX+=O._$=X M6)%,0PSB3\E.8K#OZ>9?.7_3![\V,S_4/;"K:6F-3F@RU956DFI?R.I%^: MNG"XW[.OS+BJ_=="L"6O_I8;N5?=AKZW8=OB6,D7?OK)<(98$ZYY)_5Q6>W+1NS/76_9"&6V0L(%I!S`="K!1$61X%%`NH:T&,!;%K08(% MR45!T"V66>JG0A;S:0JN..:W&H0Y>!K"F M#L`]=D#L79";P5LA!C+'Y($]XA#AP#`>B]49Y#2/>)`K50YXV`5!L7HO^3LN>:9"YVR<;L$@S>D0_%COTNVEW9".^52_6Z;=Z-MYQ+IEC"B6I_K[[, MS@<5VTJ]FZK]MOM6Z0XD/_2?7N?OO_E_4$L#!!0````(`&&!"D>#`4R[D0,` M`H0```9````>&PO=V]R:W-H965T@;4HZK8GN=W<-63ZOCX&076XZ#RI'LQ5%_:7DRGSI+:WY3FHKJ5.CFU0 MG@4T#&60)VGAKU?MV-=RO3W.DL+_;7TJEN>)^5_&YV9^Y-/_'[@6WJ^U,U` ML%X%0]PQS751I:;P2GUZ\I_)XPOC#:1%_)/J>S6Z]IKD7XWYWMS\=7SRPR8' MG>E#W5`D]NM-;W66-4Q6^0>0OFLV@>/KGGW?EFO3?TTJO379O^FQOMAL0]\[ MZE-RR^IOYOZGAAI$0W@P6=5^>H=;59N\#_&]//G9?:=%^WWO?HE"",,#`30 M(6#0P0,8!+#W`#X;P"&`#P%T7D%`@'!-24`=`U0$`^U1!T3[>=FUU2)^M5 M:>Y>=4V:%4L>+;QL2"RS5[5L=EJJ=O"Y&7U;4QZM@K>&"#!TA-ET&!'TY@_ M.HR,IR%[H!D0@4T2S93Z6!84,IV1V`)&S&2ZZS%DIIH.HV9H]D`SC7CYA62R M8-87S,93PR!1NDS`>P(^)N!`P)8)!$H@6H(?2Q2M9"B>U(=1!`A^`QLW\&^ MT#CF@H?3P!<`$BD9(W(Y<8DF+J%RODR@T&>OW)]]A&80`8&8KG4'&"Y$R!V$ M8E0H!B'Y46B,V?48M2Q"0E2E'6XH/O6)>%P/@$CX$#D($5P(&I(9^KI0=+! M6X3B.N!?2>9T>I##[!"&ZX"+)9O3Z4$.ZY7@7B=@=BGF='J0@[$(WA(``HU MMQ`Z$.$/HVF<5L(]3.1B]]D!Y@NA4:1Y8W`&1DM3E;0FW#Y7+1MT"R';LT48UK82;AX)Y MU$PKW0P@EX>';ZD4'9F.L(&0#R,21C.O&AL)X#32>&>I>!9Y="Z68BNQ:Z MKRN&[YJ,+$_!=@`Y3#7##>Q$[&U-KF:QWH>Q>='(>;3)_JYE+9Z[([2G&ULE59=CZ(P%/TKA!]@N7R(&B09'3>[#YM,YF'WN6H5,H6R MM,KLO]^V%(8Q=>SZ8#\XY]QS;[BE68S MUI!:/CFQML)"+MLSXDU+\%&3HK"()BC"I>UGV=Z[Z7-,W81MS)2^OQ2U7A M]N^&4-:M??"'C=?R7`BU@?(,C;QC69&:EZSV6G):^T^PVD&B(!KQJR0=G\P] M97[/V)M:_#BN_4!Y()0L\WF#U/L% MPELE(I4]KM5DT;C>?%[USQ,TPQ=E9#!A!/,QF"BX#YF:S`0W<<\&TQR'[(; M0L&(03(5:S[AD$\TS2YM>AS]ZG5@?IPZ+O>@@L M'(N^L,99F$SA4[)T)D9&XZ89DVC(&%$$"J<,A`O;F!-.=\?RK4/'_A;(W'R0. M!X$!69H<30[]!I_)3]R>RYI[>R;D]T,?]B?&!)$JP4P:>3-85Q0T7PC6#%>#\7Z2_P-02P,$%`````@`88$1PIT:PY-`@``Z@<``!D```!X M;"]W;W)K&ULC97=CJ(P',5?A?``TA90,$CB1S:[ M%YM,YF+WNF(5,D"9MLKLVV^_0,8`ZH6TY9SS_[75-FDI^^`Y(<+YJLJ:;]Q< MB&;M>3S+287Y@C:DEF_.E%58R"Z[>+QA!)^TJ2H]!,#2JW!1NVFBQ]Y8FM"K M(N:O#&'7ZLLW\[4M)VXTW&W@O+KE0`UZ:>+WO5%2DY@6M'4;.&W<+UP<( ME$0K_A2DY8.VH^"/E'ZHSJ_3Q@6@90D$RH"R\>-[$E9JB19^=.&WFLJX[#= MI?_0TY7X1\S)GI9_BY/()2UPG1,YXVLIWFG[D]@YA"HPHR77WTYVY8)6G<5U MOQEGD6MGZUY$P)K&S<@:T"]`4:S!M\:_+LAF#4$UA`\&#PS%;T0!RQPFC#: M.KS!ZN!6C=Y2M(H2[Z:"K`8--#NC@3'H-9[,'RV" MW+$`9`/@=)&]T:!IQ<$JPN<4?D?A#Z?J&XH@>!X0=`'!,""PTWB`'&IVG<9_ M7B0<+1+J@&7PO4:D);6I821@`0"<5NU?4AW&5)/$RU'BI2$.OU<)ARQ&$@+[ MF58>C!+ZX:-T$FHU"K4R4'`&RDC@;UH@/R^\_G8 MYB/)ZJ#:']U.RC[Z55=-=[G8]?W^(HZ[EYVLBVZI]K+1[VQ56Q>]/FU?XV[? MRF(SB.HJ!D+2N"[9K%>#=>^M.N5>NNKLI%?VJA[J^NB_7TEW6X7-#%>.%K M^;KKS85XO8J/NDU9RZ8K51.UCQ6OQO:U<-_+CIYK:KOY:;? MZ=&21;21V^MZK^JPX/$'K@I^**J;O@?O;QUO:I'R2JBU_VM6R&UX-])RF1@GKE!)B?SS.W(>+SN1J]DGKE'9IYX^"?Q:(G,,]PG M+))\,+&>>_<"P+@`R70!8A`&0NHD(P5V+1"@E-VU@H?F,9.V<@0\Q?@Q)Q. M#LD'B?VGT["B'Q0=WY03$OY8F)<["@FA;X@)""#E(7L#G!G!L"_'YM7"-'A M3B9DGKP>RZ6)X,0W5Y832>B3&-Q!!#9C/$]BQ%4N$?_<-835#]X']$ M$BCC@J'&]C<2LZ'=3I9#<_S\/FRAUOP-&+>H)TA)99$N+D#C=(T>DL MLD^>KD)C3@(/FV1W!$.(^+SN^<>(99E MYS?)Z7:T6,H8G&^Q>/+-;5^\RL]%^UHV7?2L>OTUHV=[+8 M'$\JN>W-8::/6_L[@#WIU7[\6>/XV\KZ#U!+`P04````"`!A@0I',KLC<[@" M``#_"@``&0```'AL+W=O>!%#J^!1%2-_F4GVIHIO6WWD3RVG&T[H[J* M"%95+.R"1>S[NRU7#>;']MY2(P/O.(;92B8 M?GSP%:\JPZ25_R#IEZ8Q'Y[]F]=N-K]-9-\):K?Y58=M+A/G M[QQC2`WA1E2R^PXV)ZE$W9N$0MECB/D\%DJ<0@F2W2U&`I93#Q)'XND3I$4TS%]3)`Y\YGY MYS-W>I`C07$_GTN+20B`5SZG3J'IXQ>WM!C(2)+X"!5.H<)&!.1:!\(>:Q M!!"G1G=L1&XRC2K+Q5$T4E1>"B!6PG+^[8LBRLA"R(3`AY"U"V$I0EC+PA! M4/C=!'#7,,0HE8Q)65">>5T%%3Q$OZCC,%=QX"%#.G(I4,04.+9F"!S MBV'1PTU0R57'SS!RC]8"[M8`V!L@'WM-%I3FL5]([N8`4Y2:CDEA"Z$%]9)R MMP?H^\-(QULA:)I[!47=38)BDZ!D1`E!D)J_P\I=Y>@V"4HW+]_P31+"[2 M6ZEH,'D9=_`-02P,$%`````@`88$1Q1G."H"`@``F08``!D```!X;"]W M;W)K&ULC57!CILP%/P5Q`?$V$!((HTH5JUATJK M/;1G)YB`UF#6=L+V[VL;0]G(6[@$^S$S;]X$V6G/^)NH")'>1T-;M(J]Z4C#=8JBV_`M%Q@@M#:BA`0;`%#:Y;/TM-[85G;M)6K?D MA7OBUC28_SD1ROJC#_VQ\%I?ZD+($O!Q"OJAK2B9JW'27GTG^`AATA##.)7 M37HQ6WO:_)FQ-[WY41S]0'L@E%RDEL#J<2\5I,0WE]9_YW8&6(M>&%4F%_OG$30:">=&T&`D M2)8%PE$@F@N$@X/=]K/+O<&T@\L!$V[BY2:1LTED73[$-6V_59)DX'R76IV1]ECMGDYW]]%;DM'>.N5\_)@R<%DQ9>X@^#QK/ M![4@N`T3%QH!=VMX(I,+2C<1-&1LC=""U_HZ<)]!@^F!TB';Z2GYA?ZU9X M9R;5>60.CY(Q291(L%$Q5>J>F#:4E%(O$[7FP\DY;"3KQHM@NHVROU!+`P04 M````"`!A@0I'791.MC8"``!9!P``&0```'AL+W=O>=$&4%";MDY MX#W#ZA)I`U@&8!04WG5Z6NO;JI!?1-AU^91Z_$(+8OQUNZ;#Q@3\6WIIS M+50AJ,I@XAT;@CO>T,YC^+3QMV"]`[&":,2?!@]\MO94^#VE[VKSZ[CQ0Y4! MM_@@E`22ERM^QFVKE3SAQ7]\E3$^7I4_Z$?5\;?(XZ?:?NW.8I:I@U][XA/ MZ-**-SK\Q/89$B5XH"W7O][AP@4E(\7W"/HTUZ;3U\',]4G\>6$LX4R)2V>-:32;DNKA5U6L5P:0,KDK(8N`,LS,8 M,"$"J>ZT@+Z+#C4=/J9'(SV:)XQLPO2Q0#PQ'.!V`IDMX^8:$QG,AI,$2<@ M7>"3.'T2ZY/?\3&8)(^B/,L?&Z5.H]0:%8\%,J=`9@2B\$Y2@WG0)HDV6.C MW&F46R-PQ\A@TC"%<;[`J'`V26&-%G09")U1==G1)L4\JP45JV3!NP?`;03< M?7)K9$&K9($/=/O`Y6T"(K=$Y&Z4VZ@&]`3`EK@Y/Y&0>SNE%NG>'PIWXV" MV>@CF)WUA.?>@5XZ82;?5)U.D2W4H_,+7I4].N/?B)V;CGM[N0`UM/R1G` M,D"XDHU;RW-NVK3X)-0RDVMF)K_9"-J/!]ETFE;_`5!+`P04````"`!A@0I' M%P8]E&L"``#R"```&0```'AL+W=OK.B?<-E6K:GV/1]8P> M35!3QPB`+&YHU8;%QJR]]L6&7V1=M>RU#\2E:6C_;\=J/FQ#&(X+;]6YE'HA M+C;Q+>Y8-:P5%6^#GIVVX3-<[V"N)4;QNV#F(P#G?R>\W<]^7G9?C)UX'0\NG\WCZO2WU/!7GC]ISK4F4+PN#(3O12 MRS<^_&#N&5)M>."U,+_!X2(D;\:0,&CHA[U6K;D.]DX.7)@_`+D`=`L@)F_+ M,5E^HY(6FYX/@>BH?G=PK=2]]E#&@3!FD%A%I_UZK5(DF037[61TZ")9FO__`DJ=?N/E[QH?S_#S%_^7TB9(\%D`;>4SZ"OFY>/#G/.GIFOVA_KEH1[+E4)Z,YQTZ<2Z9< M02ZMU0?(+=)S4Y2#U=JW-LCV4XD[\8OC-MG3O$?4$L#!!0````(`&&!"D<> M8A&Y\P$``!D&```9````>&PO=V]R:W-H965TL5N:F]\")G%TGKEKQP("Y-@_FO':&LWWJ!YPJO];F2N@"+'(Z^ M8]V05M2L!9RL3>]^';<>KY&()0#!'\-8MV;LASN9;VWS!F0-:#0$Z:(AM(9P-"`#!@DT M67R?))HEB2P)6B")'B")_H,DGB6)+4GX>9>I9N@'$:F)_`<1I@K]`X.0K[O"9?,?\ M7+<"[)E4!X+Y>D^,2:(R_%7L@4J=T^."DI/4TU3-^7!T#0O).G<0CW^#XC=0 M2P,$%`````@`88$1X#[C$GR`0``:P4``!D```!X;"]W;W)K&ULC53+CILP%/T5BP\8B`UA%!&D#%75+BJ-9M&N'7(#:&Q,;2=, M_[Y^06A%D[+`]N6\KK!=C$^JQ9`HP_.>K6/6JV'71RKN@5.U9,8H#=?SD)R MJLU2-K$:)-"3(W$6XR39QIQV?506KO8JRT)<-.MZ>)5(73BG\M<+,#'NHTTT M%=ZZIM6V$)=%//-.'8=>=:)'$L[[Z+#95;E%.,#W#D:UF".;_2C$NUU\/>VC MQ$8`!K6V"M0,5ZB`,2MDC'\&S9NE)2[GD_IGUZU)?Z0**L%^="?=FK!)A$YP MIA>FW\3X!4(+F16L!5/NC>J+TH)/E`AQ^N''KG?CZ+\\)X&V3L"!@&?"[+-. M((%`;H34=>J3N;X^44W+0HH1J8':G[W9&;BT(D89:=F6EN>+#5:TDR7,17 MQ0P>(%Y\9C-C(B-^JH%CM;HV-'O&%0XA""/+ M\?$83$B^V";_],E7??+@D]_Q\9AT0W":9W\9Q8O-S4$V[M`K5(M+K_W>GJOS MO7+`[G#YF4M_ M&?B%%L-TMK0(``)8)```9````>&PO M=V]R:W-H965T.`GUJ@G>][65IA>XC$J65T9TAU%2$`DJBF91/FQ-[:?,5 M/\NJ;-A+&XAS7=/V[Q.K^&4=PK`+O):'H]2!%]%/6]7UJP1)6^"ENW7X2-< M/D.L(0;QJV07,;@/M/DWSM_UX,=N'0+M@55L[4$59FYDJ_\\IVY&H@6W/)F/]@>Q:2 MUQTE#&KZ::]E8ZX7^R0#CN8G($=`/:'/XR?$CA!?"7B2@!T!]P0TG8$X`KG) M$-G:3><**FF^:ODE$">JYQ-<GBK191R((R::IHPP4<=_;89#$.2P$]HA(&?"Z0$O`S)T-)Y@8Q$IF/`P*_+\16349MS9C(?-BFVS M0#HO@#L!/!3`KMLWK4P-IK&]L!@(((D3.([;6!P&F`S\?($57$&R9**/?MRHH=1K'6&;B;I$%-TF'@^2>9-DCD!/#'),O=)XQA,U)RYJ9@F M!!Y.PNOG86S0^8%(/!^=B9\YW<'H=<$=.MIHL&F4[/V8+9[$6SYN9%V M&>VC_9'B$>E-ZR;^!)<;Z(D7^@AB-KFK?+XZT0/[2=M#V8C@C4NU59I];<^Y M9,HR>%`%'-4AJ1]4;"_U;:K;88\-=B#YJ3L%]4>Q_!]02P,$%`````@`88$* M1RQ.OC6(`@``5`D``!D```!X;"]W;W)K&ULC59; MLZ(@'/\JCA_@'BM,6>ZGO9A9\ZQY['M$5>(O9$3KL63/:$5XN6'CQVHACM%DJ M/>C[L5>AHG;S3-4^:)Z1,R^+&G]0AYVK"M&_,UR2Z\0%KBE\%H,U4!"%^%7@^NT'1E^0\B7O/FQF[B^S(!+O.52`HG+ M!<]Q64HEX?Q'B]X\);';-NHKU5T1?X,8GI/R=['C1Y'6=YT=WJ-SR3_)=8UU M'R(IN"4E4__.]LPXJ0S%=2KTW5R+6EVOS9/(T.P$J`FP)<#P2'0A.!&`$\) MH2:$0PF1)D1#";$FQ$,)B28D0PFI)J0/!]Y'>IE+A!'>4;)U6$G)9)T83#@2=0!.JL!.N\&`_LQ:X,)7@],8`8FZ+["0`N$ MKP5"(Q!V!4(M$-VGC!2F;D9?8WSQ>VT366TB;1/?VW0Q,X-)7IO$5I-8"SS, MYZ3;EP83AB,0PM<^B=4GT3ZC?I]Y@P$PC/RP'[8PL`@^KL(N;&D#`?MA MPU(?1@.66FKM7&HT7@N,K%-R-'Q`M\:095E!M#?UW<-BNYFY7^PM176'PC8 M`^DO9?ID\-<&Y/L6+Z_S?:XP/:C-FCE;QSH_BB-/>E'C/93,1 M;=IL^LT-)R=SAFD/4OD_4$L#!!0````(`&&!"D>-8+0]50(``#@'```9```` M>&PO=V]R:W-H965T;/M".M_'BK,%"+MG9XQTC^A)3>U!`"OP57KYIFNO;`\HQ=1 M5RUY80Z_-`UF_[:DIOW:]=VA\%J=2Z$7IYY(^]8-:3E%6T=1DYK=^.O=CY0 M$(WX4Y&>3]X=%7Y/Z9M:_#JN7:`RD)HTA5(('6G/]ZQPN7-!FH+A. M@S_,LVKULS=?$F!I\P1H"?"[A,`2@I$P!ILG($M`-P+26V-:T1NQPP+G&:.] MPSNLCH>_DG"F12RP[6:W`.NBQM5O>9!$F3>50E9#)Q@"H/Q1X0GU6A#0:F0H1>!#:X/PH"@(_6@X= MS8:.;#DP2X:S!,"4A#N.P4SSK%UBE]T)+!/$$4A@!]PRF9=4J,4_IH\PS& M3T(_AL&R4:J-1OI&K1\2?#`;39=G#L#=(1E`Z>>_KS>9%@UA9SUVN7.@EU:8 MO\E8'4?[%JII\ZE>J)$_4]^DJR=J8_G.S&`W"T&[X9X:+\O\/U!+`P04```` M"`!A@0I'9\%(RA@U```(_P``%````'AL+W-H87)E9%-T&UL[7W; M4N38M>#SX2MV=-!AB!#9>;]TVX[(`JI,NPHP4-W3X9@'D2E`W4H)2THH''[P M/\R\G(B9GYA/F$_QE\RZ[)NTMY0)57V.?88'NXO4ON]U7VNO]=NB,6G59(6 MO_OJKBSOO_WFFV)Q%ZW"HI/=1RE\N]_6_[^%NL5U%:BC!=BN.T MC,LG<9+RF'&6B@-1W(5Y5/SVF_+WO_T&^W"_F?B0I>5=`7V6T;+^]?MUVA&# M;B#ZW=ZH_G&^ONV([MC_<=-Z_CR_+LH\7)3_O=Y3-KZ(;F-L`4.$R3F_% MY=/J.DOJ7\/[95K_[7"=Y[C!MW&Q@)%_BL(<#U$V?!O>[!GQH[G$=YG"T;-ZN`9N??_LT+-C#&DL9YFX3.JF["I'!&U#/; M9_T6?G3`N=Y2+M7;]D\#YTK/3H^.3R\!K.!?EV?O3X[F5_#'F_G[.<"7N/S# M\?'5):#2Q\LCL;>[7^]^&=UK;!DV@4M8%%%9?.M\#HL[PI4%_B/ZRSI^"!-H M[ZP:P`&QOQ!YM(B@T742!2-2I'=B#!)LL?D4B/LDE-0##^,>+]7LTJX8;.XKNLR)VMW`4W42P13B3 M&_@'TI1%5KC-3E+`R]L8KD].X-U=N,KR,OXK[PXW$_@\',"<;KC_B@8C>3> M^J-QT.].O\PU\VW-O;>D8#F)P^LXBCV9:W!["TBHL"2I(LS+2[%GW.T% MW6X7_R<>XQ(PL+Z&;2;2-YY'#U&Z=LA7%?"MO=<;_ACFQ/!4DX9+:1D!F4!< M(G@P7BZ`N<,^HW0!C<7>9R#.'$)%_,NRQ91GGQ&W$,^`9;WX-MQ8NX=%H# M`9#[+9C7P%$)H%;K2.QV.]UN3P`L[CQG>AU]0&S`"+"=7F7Y?%?H^5WXJ"K MY!(!-X673<3$,"W`#;SV;<#9=Q2`-%NL<=0UB\2Q>\%@U++LE^'7=Z+?"X;3 M/F!HGVBKP0%?D@L MH`32W\2S@NP22"AWGH@:%#>W>;&JW'/G;MLZ:A?(FHK7=AJJ] M-^[&V]R_%6_3MGWXT>KR"O[SX?@44.KLK3@[/[Z87YU``['W,0V!(\/%M^#6 M8&M=U6$&)^DB6T5`:P"V"-B;]<\+9N(.:SV[1R4,";2?!V9YS)$F@0"&"X M$:J;)/,L5W%JBR297>V`I29!WD?6?K)PKKZRU)K/4/JMO(3MZF[[.B0-($DLP# M<`@IY=_79+MZKW`GWWJ?,=D+4(.=X-4#N)4S#,XR:!ZQ1$N;BC2WFVP??#^>4?Q-OW9S]NB>^D$]\`/RW$ M#=RW!=`ABCA^O4.=FBO]_+PNI&1,;`8`:A$#HTO5,<.O^&]2P-<%<;+MIB0) M1L#=1"APKQ"F&4\E?#O[>BDTVE18L4R$+MAL4YHF464/\0+%\C>A$A>KLO- M:[VS"(`@L!6FIZ1;.`5!=0MT@FTLHF@INQ5A0HMF4?26B00#_Q?73]XM^#H"^\CF[C-,5%X(;(X/BL_A'B0E//R_7]?4(B"W#TH[A8 M`E:$^F^$33J6[A0V[+NMRP2]BW79([BB21;8J[]G#Y^'I:E![0W"Q!A6UN! M6"-5@_&2"`AS]"G%S&C1G:/FRQ:`>XB6B2`-S%HD!K0EGZK'!+]<&N]V#>P M6@0CAR;=.+#4A]?WQ`IX#XXD5%T.`"K2PV7`RAG9J1C#PQ<2OU:+@P`_]QJ MOHWVR\\8RPD[<0Y2R>')L2-F M2:Z"=W">)3$9RIJU@].SJV,Q%__X^_\4[=.(=U('N+J+Z`!`T4Z?^9!?4E9 M6$@+F'))"J_$%;J2"VE:+3]$"+"P.5='C$H``&Q`KU(XFL!1(6&-?MC`J2 M`#%.K)40UL%5%M8/SUKD'4B50`4C-%(`G\_-I>=+,H6P:=6<\SU`_"(&NE8H M32DA^P$:M@O;NUC2@LAE:T0>__X^_]Z-Y^?_^/O_WO?DYX9:THMMR+A!PD MK\.VTM_(IPECPAH>2-PU!=K`.C+@_^&_\;OEQ$@I#%6'7^2J@096@N"S#UL M!\N[/#ZDU1%I4N/'0#2>L%$"VC"6UBB0.]:1\QI.7`>"2`GM'T"01X!6Z$. MNG/D&-6-W619R0@@5T^\T'.2_B-GB7$%_RXC[X5V@)_0Q-D]:Z,>ZLP!;V! MO3"XKM`2I_<01&F^M`TQ<4F`T"6/:#U2S&;40M/@,3`#SPM-5"8I1!0!5:D)ZN[E]-4]X!IUZ% M3[`@DF(7962P\(:=C4_HEHS8:.L89T>$8R_$L.(N6R=+G!OC`HA#9>G/ZY3@ MR@";-?16=,6F)&KQD<^P7`,[%-PC`&:;QN,8\S2%>Q87(+_G9$]4T/['`&<, M5S1^@%//0:R)H2?Y[X'F`E(6`<#=HJ/QZ9!))F,\:&H65@&J\7$V'.)UF!": M4P2%WQG5^@="0%:E@(W%"/(%0QQ`,`!$MFZB\Y6I]Q_GI=`HK#^=61?&G) M=39(\$#.@$MI)012/E'FN"8TVJUOT(HY)4\!\IN8KAP8!K/L`NZR5!BCK^W?BXJ.4/'!5%TP`:/7(QP=SXAR M6BK.%F6&)]B?\0EVX%0C03ZL=QWQ9EW`U15,E]%80>=^;E.0L]2ZAQY%JG3[ M@;UFA.-,SF`+)W,&LZ+,2()'PO-!O"4\(_3Z"%`U0M1'5&>N?CT!+@EN/&,[5:+!)2(NS9+L]DD4S,[@'UFR9J;D9;?$Z]8H.L+\,#C\6-T68LH=D(0 M9,\5]31]1WP`A#2&#H1[R45#42,3);;X=1$X4&J6ZX7),3R0(9Q2'^JEVQ MLS)O,.!3S[+X#C[1@I3T7+4SX)<"F!5C.IIZ(F!QA[``0#6`%62_M84A,A7K MZY\E\"M&G,?%+S@+4HNT5"<'^@Y(H7%QI[SR8>W0I>S707)(/90V1;MD5DC MM`('R]:W=U4VY9ZZ'1[`FR''>+_7"WK#43"8##^'TRBR5$JI=2WE(GL5)-[# MSX]W&0#A0?:(YPK'!:P]#G/RZ<_/CT[%WIO.#YV3SCZ3=>SEH_H2SL1[OOX` MAHT7=\HNE#PQE29?3\H,;!"":=Z&=^FI)+1E8!4>"`/7!$NC,8H^8(M MLD8(=FDH141S0-"G(Z0O`/Z[R&`2NJ:K"G+3[W\ELLE-/7FI6%+CN`N7[IM8-L(&V!`8`_^A6(844FZR=2[84+P`5`=0"\4 MP!^EAU54DNV6B\<&\L5;Q]!M%C#(,@$T-PB@XJ@,7$B%@4!SP#5 M`?_V^OM`@!)HG3.09@N)B;#=;^"V)-X:!@OC(Z_"(("]P3Z!5\'>$R1P"_0( M`H!^DN[P)8BJ.5X3:'O?T2][0Y0FDP0P5&G<,5Y"6&38Z@F54N"G(#(>J;Y M8]>G@A.KL1#CV8(+C8RP2USLY_7REK$CCVY#$MFEV(?K@X%A(H4CE4UHS%&4 M2AT23I,;8J9-6K@:YMJ5G=$H&5K05H20':&]"RP`Z\`OV[)JB^BA\ETL(V7Y MX>6"3;($8N[3%C0R,>]$##RI501->"3.04G>]`A,RZEH[I@M'<4=57+W M004@]'>UP@!/)RYL$IQ'-\"9!:(1TLUSAC0P4AODZ;Z`1AZ]D3N'G+"8J MHD#(ZF.OL;X^OLLZT-KK2_6B'F/@#]=:EX2CFF\;(5+6B`F>M+%5J:,E^MX= M!M/Q@".]1M-!,!CWJ_$>AEQ9%HP"5JA>P`T/N)%(,E9FQD@$#$$?I'R MH!1^U4Q=T9%D9&6'0NXS()`?:%B&20BMBY<8S6T!!73G%@-5QG`JT0(83H M`=AP8)Q=#P8'O011&,=",BXR@E2;7!0_'!Y=AS@V84/89QP]%EY%^K.2X!=.L5XV651HR'<5TWM0Y)?G"C(['I0;B[87(@!=D/U3` ME5LLIGS,&['5C"I(.0!(T.V@`=$EM`O0JM9P(EV&6A6'JQOD?% ML'#4!,OOC0H`M4&U01TNX!V>+L8%A:G0MER!8HA`$TJJ14L,8X>^-.]!$.U MFHZ?=5?0#+:;9Y_HL(%F[(Y'DV#2E3&TO6#6FP7=04\+\454WZJRE[_8-K?; ME1C.P60RSI$]&(_BL>[+3M=$5"V7 ME./EN^N.5#@XM7GZMH%F#/BCZC15T= M^T5N1U+UN0#$Y(!6/I1&X/NC<"-UDNUW<;S8W<>"T@A:2)"2IVT`VE1L>>N M!8.0`HX$=#.C"KGDS8.@6R729$\$(]=,(%<',MQ4HI?\_X";"3\M;KW)B MZ;FDI>XSWW17UV3H,Q0OCRS1!AES9#3>L4C?VM,\`\9!A.@EA1(818.Z?#16L-$+XH,B&I)"0J%4&/D<0W M-3.;MA\UWN_UD[4A]!4B4SI(B#R`!(P,YJ0%38`PH^FR##\!L;134S99C0 MY6IB;3,7>R52UL#S50YI:;[8(L1#7B>36IZSP@Z0P^ M1-4=0,,8Q1M4[VS!PT>I#:Q99!("DB?T3(NVUWR//:BBK.#_27/6SPYH2 M"XY14.[AZM6BA!$E?/'2T<#N2>FU`ZF!I4`0)8%H62H_F>Y]'$!1"YOR"QH M[Y_,L$K-M#4A7W,`UZ5<<'6]FM')R"CTS!A2A#]7%[0//:C\1?9=+!VK@ MY`NCD^!N8L13H!>&.=U8IA3R,^&TH,EQ.TZ1A4:=1O03U;R#2C,BUL:=4<'HRYIR@MZW,I(]=9RAYLE(W`KC`&> ML-(JF2VF:6N+=4%PV(OJ!&1`(SQ%^AIH(1GH]XJ=J-@"Z%#@"79"RIN'R\@ M%2RJ$'$/O`$%;12_5=`4+!C=)_F3L$,+./&'=!>M:B_@)9"QD#8?5RRBX/L M,6@N@FW3+=DC2)\NWR;29`D;X].#G&4=4[DFYP3E:5-BL]%("CJ2+=D). M6_UP$QJT7BQ4:D$8C;"WMTB8V%4TG7Q-XTP&7U?UOD"RDL=,FU;JQGS:14GQ MXFHOABDVDVBJC0?5O7DZ>SKYF%]CV#J+ZA^A8.US].G(39RG\>R'-@""- MS->WZ`$^+?SRS?DG)"T;W[YD88Y0`<5?#>!B;C6CZFT M%'+8S#6QU%1F`:#5STV0W"&]4%Q'["A\E^$2B;E;)?5B'T;$J-T#\HFVQ! MU%(]OH9\!$GD$PI1P'@.I)]]E9:?#J/I-49[09(%<4R6U^7:@OD4=C6G%^ MB\H6;C,9Y(5;8-F=NBOZJ\(H;\_VP/(P)93\(01R0-K,XZEF=0DWDI4VP@) MAUG_)X\9@@KI(%Y-4B^K([15,L=6IC"714BSQ,O:7^,(E&1@Y=EW2U"]T/M)$='30"=P''DBB5F9]=/YJ#4U?(B=;@( MWA)Z_4O+?Z$71!JI&8Y603:-4""%SO'(I14'E\^FK7:7,$7@T]BYCH&JZ,VD MWQ`YL^@)D`E-(GP4Y>,][9$7VB?28;4CY;# M"Z7+(0=VT9S]S%PGZUO4/%[A6M6Y!VD!K;+FJ+TA0"KO/&LURE9$:$`?BP M-Y5N2M8'X/BOB:,;IYIO=$VXU+:JEA-ERK##W+3:HNT;(!H#3^&X$/^>$1EC MBQ.H6:M4PXK6\2>C?LN(9%$C>V&U&/?BO?WTY?1,PA&K.-OZ)$%BY\6;4L9AL<0Y%&CU;XK`39 M&W(@EM$][`!8UF.6_\(XH.-)0+58&X<9.DP>OYD/(9Z)6C<4(^@S.DEZ(FC MT`*E^UN'$'CW9OLGD863SU^N6Y$7!(4XLKQHE<"55$88**V.90YIR5E4?+)Q M0UHA:0T"'MEPC))73H<' MMJS%2]HA&1R,$S@@Q%^SY.P+6\8O=4$(%;%_)M)P<\!XBM#OM1J.]UKVE`?#"6 MJK041P$!B_4-8C$E:,)H%-RW]I%8=C&S6.G8M2(10O\^&ISVYQ23D!!M=.>#OK>WZETWG$6LBLF MDRX0[!'\JQ=T1[-@W!_LS.72K(P"-^ACZ0'U'76[`G@2_E>W`S)&$=]ZV&%_ M&G1G4]$')C@9]W1#[8)5#0]@S&`Z&>W()'NRG?:\]KJXHKZ8C#`0:H=3FN!2 MA[UI,.[QLH?`;R:CF7#N^^+LP\GEY=G%3P)O3=^3^_`4WY>6](KUE)XV24AY M$6P<$6PTS5U[C=+SA8!:&Y1WQ/:@YA9@#%PR?."ZACL#X M]@8=\"!W']YA5JF0[9^'0&1OQ/$GX'$D/)PA+4!A0ZW=7J=,NZ:I3YBR4Q&? MY@$%!\3U]9NJ7M?0FART=T"4$%G@L!"V(GXP9Z?+,>S0SQ2%HT8?<>WZT3S MF@RDN]O:@R`KTFF^H'E[L\'`?MIFWH)6FK+5&LDX`QD_G$'NS)+9"K46>LN@ MT^C@NR3+'TPDJ-IHZD]D2Q@4FR2+=QWN;V03O$Q'$-+'TMS!E()JE13+)$ MHPT-%XL8L2XS?.1'8JA\(E]R!+L[+V3-F(8O M6AR]?F?\5'T`LGIOTFO$7%L"AV7=JWPI[?TT&5S(K#'6[IEZ]D?]H#>8/'O> M]G[.O+Y3)D39'73Z()/@?X9T$.@;XM!,WUHP,6=/MY,KVR?['[2]9@44@9CX M7E!G>S4]QX2!:L!OWKT)Z:CSM#9=2C]58]4KLV"RWU5/5J]8#+?26!CPKA@5 MI/Y?3WI14[YF4V:13P< M>M)P'8$>$RE8R7-?F%XA+1<5=)`>G');$L="U$JLF7F.A;-$\W3=-]:S,+W MI&69Z%/Q\4CEFY#'5&C2!+UW!R3"/O<(G>QL\XN+^>F55AQ^:LH+_%YGE]E@ M!CLF2=09%\FFL3=RYGZ07P[A%`'JWXF3DY-`O"_9YT^_$JKI-]D2Z]VL/+W) ME.P^.CNKCFZF3+N@L2>XH3J2GVJURCK%;-ES\CQ95 M`]:QVP^&(U`CAGT["#5.`?8P'VU8ED@@M@L\?488[&ZOVYEV[43#.D#U8Y` MNN]^_9W1JW%+WXIA9S1B2_%W3?&KWXH>-+[FAA86!-\[DT[T]G7_$XR-F' M#"'BQV4=W-O?Z@W;LC5Y>41: MBB)@7O(C-R,E:HN]R4$ACT0=.LDIS91,K''4#5^T8"E7[=J5_/&0+)JIPD M2OIYC&9WULN8EP!!E6W=XH;(^`SBRFC(+Q0K0#`>#X)!;_S%'C.=6:DAICXU M.B)\D:\:0[T#$,UUDCU6D_092\MTOQ<)"`EVH`Q'IB1K`24HF>G^`]4X)P\M(=OZ=TJ^?S M"V#R5\#T+^>'WFR^F7W.;T/O;+S(VP0=Z22-$\D]]M<41NB^>:O4)',-S6 MRM7]I[-R;:6K;J&2PI+1.TVG^D^FAX8R8M!2T>@Z4/W;J;]6LK9-KI9DZ>M M/D_#U2H!X0_$W[VHC/D'UD%2G.6Q_PFB)KZ?6B>E2'YB49X>?=J[/\UMT[ M).)P?GYR-7\O+J_.#O^X5?T/.HP-1.&=.!"5D2N\>>C#=<[D%6L!1S!(5K? M0T`8&I#25]5+7O)ZEM3C+IP#"I:XD/!"-SJ!$7^KIE&20CM)H0CNIU5[O MVW%WORFW%8=-;IG/BF4@E6P6[Y/>1YD:(M61R(56+3L""&C7)6'<"ZQ@%#<[ MUK]HK`MDWV=>7#VQ3[OOG:`/)?Z>42E;<;SN])W9YV>\IU_2=QV)QZ.6Q\K"5:'^.F]&L[5/"5IL1P%.P0/I M]"Y%I70R&DBS3M5\@MP&!9G#GB(&K3=06=DJ>%DR0883Z-:]D1CUK-AC-[` M&BN3OB)Z$R.&HP,2#%VE@,%FV)?RB/&:-_MOV%!JO<#GW$F-(^FSPKYD/#5] MM9<=_^\`DZ:44I>D-WY/;@S-?PZ3B]M1UQ/JTXBTN.T$@Q:U)?0T+);A7\2A MC`KZ$.:_17ET"NHV&-!8>CG1Z?D$X01Y9\_PM\>U=/8JV8M-$FNP`876'[% M:$9:4.5V+._=L#<.I@"V&T)S`-U[XQE3"&MI_@1#[4NS`&OK58[Z+R"!O?$T M&"I=C-\QN2D\&L7`M7D':Q#6SO#@YN3P+Q\)#U!QN06<:A#T^=3KMW[E):/V MT1(5FW4&FK:3=`2>NW)LLT7-\^@W+2XFD8\Z`#4R+4V$D3E M.:39-B!JX!6Q_:2TUY\B]_2SVPH`8"BQS=R)Z$HR@B7UK%?"ZM6B'K25(4P& M(.WU1OK9HEQP<`\8:V5OK\>2[:SRY.^Y[SD;SF:DP;%/H39-R$5&!QFF MHZTB$IUT:@C7$C())B.98F@\#(;]L8?"?9DH0Q!$>KTO''U@G%WB(2C30^% MJX4&>[O]SFSVA5R.59A`AXA-;WJSRA[I&>Z85JFWQI$\EDV1`$Z"<)U6U:FR MEW;51"7YU,LP_P89!#61PZ,,-$301.P2UR>;4,&97AK"VUNVK>?1F/&9$= MKAR333W]@C(E#:L$K8K_4!%PA`E[MA,!\94"]>F#%M1O$/8V2W8:A?VDY@M) M-/))N3NC?I5.M\@$/3'@V`&5.D+,:(&!K$I@%K=,M]`#]8TZ;^01SV/%PV' M+^!%'ZAH7)]23O>[5F;L(VU+WL:BYCUM)UJA'H;H6)>D[>=<6H)/CY3OV3%` M6R_%SVZJV:4;?H04R?)"N8'G,SJ7+T$W6"/^H,X$,UK,<+15<7!6Q(M+-8K MC"__JWQ7R798>GWC\YM94IFL5UF-6FM`BZ8<)E7UR8$?T5D0J'.`K$,9W) MNWT9\"U/((Z!F0<4EHWBA]^$CK MPPJ(K#A-?++]J:J"U>0\R'@)G1$LIOO5Z4"NBQU,J.M5\Q)\Y M.I67E/8JP1V_=:5?[%5/P"D9.M"J#)=^LV;T0N;I&!ZU<@IKVH'AY>9LE ME[7$4^04D7JDV_9BB$5SOM_#=(U6[GZ%@?EN1YTLO>A4-G4IOU1OWXXDT]U@U32MOF'Y MU%^&Z(QJJ1JLB_O/NK4IG!6>UZ"^-'K$%GT"28&3.H@Z\/][P32`F1`GJ\C, M4=.K3&6=K/9%P7(9%?%M&LG2Q13E=0ZT2H.=X#A/K[5<''FWN6=4PZ`V`GDY&;D\MEFFK72-]:V18 M54`R/-BZA>U9UHYF68J_&)[%37;F&C)/\+Y2S'OZ`SJ=LYL"<+E:_U@UIT% MW2%RMF%G,M2<;8:>H1DTZ$Q'%E]#?@;_:^!HPVX_Z(UZP-!`^[MUR>OWJ+) M,8I3#_L[/T1D2G4:]NG5#;[QP8:]`?RGV^E-=[`$X$-#GQEPR^FLQTW[#M09G162[.42D,E?DVZQT^)\/T(SUYT=&332DY67PAL,8&'YHB(YU4 MS':HY,X5K>X49MIA'&6E9Q>`>-RE_UBPW/#1"HX,I+-GT`$R,<3/1]5P2D2& MK_G_=WXP(9&]WA1^!OH"/U_HD$H`^DA^'Z-\91C^(_M3],QU1A3`H`W&/>L MH(O=T1`HEGQE;1,7#"+553TUMEVA]UA,.I.#(NK)#>LQ1<+-WO9ICS0U8QO M-.4@&`UZ01_HI+WJ\600]";C[5;="R:]"8A"DV:X?L["]"@ZX2SF2I`A[AA8 M=J]2];D-`PWP\F1"7&IROL.)NZ^F"R;82 MNK!M/(]5FVJ_T^\Q:$JS7+VC2?AK8S89';\P:N^.9\%PT%47V)V`1M.M5XEP M2W=_^'!RQ46Z45L^/-"EL>GOF9AUCV4-44P:`G>F!\&Z54-M-2[CKW)L^R70)Q&C^(G MS-="=5`HJD.6YQ)W4;C\"\A]VHBCAI!E5O"XR>B%C2)Y2:NUW%B(FF14BD5 MB/NB`!517@`M18]DH+LQZ11LTWD2@Y[46:,DMJRR&L-38AU6,E7RX!S@$I M$1)<>&&8&490D@0+RF+,'(,ON6DT6CL:2X>`+;UAWT3'U;VJKP0M9-6AY2$ MUWB<:"Z"L__#>HDZQ`W2Z$`DJ3W%A%7J4QE-0I`5)OBN#>UVZL)X M%?9X0KQ=E<6R.'-.9=RI')#6UJE'W M2QQ26$F8K(_L/?QRR_SG+?D[J!!1)M^$VEOB&!;:#BLC+#4J MX:&;-$#T$Q:_DXF"I/Z>Q+]$27R79?KH.;B95`LB[Y0MSISD\NQ`_S]Q^=E`MO400B9;A2SGZ#O/`]R`MF3`XY4T\ MM:;$6:<]Z7RL'S?FX3"RG04\5E$(756$`3E&GRM6NY5O^'6"?7=YY9WO>4'< MI)'5WZ=),:!:)X'T.9555,7DS3L4-XNV$LA@[%-9+%ZN&DY>7SO?&1&8A#! M0'0\&`"L9M?H:I"OZN_792T.$7/:XUMNZ?!Z4G4#`&SM4\9XWMM,VUIH>"+@ MV+`A?=06/AM5$Q)[\Y@#N4I3A0-CV)BG`()J M'5G!1WMH_>D&LU%?[)/UZ4_I9/E+/5[.NZKO9ZHF^^9QYA^!\LN-<-M3D>@ MA/8'M-;G;<_Q3W[\\&%^\9,X>ZM2]X"B(<[/WI^0KK%WGB68G:C8KW?<7&1X MJ_0PK[67VL5O]8J?JU5_&O6G:?^CDEA+=H\EK>^+6\>/7 M\L:OY8U?RQO_Y0W=DQ&3K7C[9)XOA9)UF'ZKT627XLD_]OQ95?BRN_%E=^+:[\6ES9.M?7XLK_\L65/>4"K%+([5]?S&_5F)^ MK<3\_U\E9M?'TEZ8^;GM7PLYOQ9R?BWD_%K(.7LMY/Q:R/FUD/-K(>?70LZO MA9Q?"SF_%G+^\@3BN5&T5V1%<&)H+Q=WT7=6$951M#9DWR>O]L-BI%(.UR MJN[:]61NY>W]C_4R;5TQ=)M3W/8UPU;G\%I!U%=!M"6+U#8W5+9G3MHN'.&_ M:ZD5OI`#SJ>6HYP8RZ/%YWM:U/ST[JT7:MK1DMZAW_Q?)&-#]]VXI26$>S MJKT\JOA]-5]DGT9A!9)[7F69ET=;HT>8T2H!8?=`2EF.6`.#:[',"G(ZKL14'5:CD4"I3NF%LXFS^_-[ M!)`3=(@Y#T`K80IX9JBLY>ZK+><\5?/BQQ%7TJL;P\'MK'RR.Q MM^O@?Z^""O6O9QC+J8JG^)YLU.IIU)LX%4V<`W5>Y30]#&D/?/W,`Q(]/")E M(Q`5]ZD@BFN^.CR"A#FYS%9'+(_4!E_5YA38:#'R_&K&H<47U MY>O[.TN=J7M=WR1:D;@P;L@-QS"=^09Z?_GCR='6-<4Y?,/\]/YNV-,)_,; MT++>ST^?@Y'S^[PCNC%A/>C$GN<(\L>.CK?O8,1T;WN.7#P7#]"U)%%#JG* MF!5XP^#5NC$ME0<<$XLSRXN#J+;`]4$PT@# M%3RX]?JJX]93%#^O-?^J4_GBZX(7_`5_KMUW@&;U3;!:&TLSW>?YMW4KYX M-[6KZ]T.&'NU;R_9<"[EXNS#R>7E&?`,S/)@SO89F$OXI\KJ>?&O\2/F;3B@ MI$='T779RB/.ZP`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`Z>%2!8N?%'P=\-Q><._$7@J'Q2V_VU MAS-M:-UZJ@W11ZY%KC'HJ%F;KP5E!6++R5I&>,8Z6J_=\@%?.'5A.:1\3K M#?J^GZOQ7X9KS=P1^J,QLZ/K=?>@)8^@\B+,-A_C]]C';1^DR=;`_NO4:/O M>?+URZHEHK[-4?E;.B8<>M5<%&^+$G._!@"T6K4NFWD-+B-+AOK.KEBR`MK MC7R2K=2DEN/J2&VJB\)0%\;XOT$P)EKZ^)#MGR7\[?]V]N&!<,V"^>$FZ M0)PC\;364')(C4,LD#VHL?>PX: M;8Z3=GML%R7=LELE@7_>[O`E'CVZ-_6("(%NPYC3\A$]>JYH^1F85-]'&E9.$U@2AVY-<=OD&0;Z[-R\.E2J;6.[LLI2Y4M3Y M\:M#;S:JJRRN
9GP$``&(8```:``````````````"``>$"``!X;"]?&UL4$L!`A0#%`````@`88$ M1WWDO+@^`0``:0,``!$``````````````(`!QP<``&1O8U!R;W!S+V-O&UL4$L!`A0#%`````@`88$1YE&POJ9I(-V0,``'X-```/``````````````"``>P1``!X;"]W;W)K M8F]O:RYX;6Q02P$"%`,4````"`!A@0I'\+SB(4T"``#S!P``&``````````` M````@`'R%0``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M88$1_U=,R_%`P``%Q$``!@``````````````(`!=1@``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`88$1Z78YU]E!```4A0` M`!@``````````````(`!^",``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`88$1W_.V7J@`0``L0,``!@``````````````(`! M0RP``'AL+W=O&PO=V]R:W-H965T?-C.WH0$``+$#```9``````````````"``&UL4$L!`A0#%`````@`88$1S?"ZW.A`0``L0,``!D` M`````````````(`!HC,``'AL+W=O&PO M=V]R:W-H965T+%K;\H@$` M`+$#```9``````````````"``5(W``!X;"]W;W)K&UL4$L!`A0#%`````@`88$1[!78LRA`0``L0,``!D``````````````(`! MSD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`88$1[1\I3E`0``L0,``!D``````````````(`!_3X``'AL+W=O&PO=V]R:W-H965T[YJ$HH@$``+$#```9``````````````"``<]"``!X M;"]W;W)K&UL4$L!`A0#%`````@`88$1U=U9"9: M`@``1@@``!D``````````````(`!J$0``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`88$1T;?6I_Q`@``Z0L``!D````` M`````````(`!ITP``'AL+W=O4+!H"``!:!@``&0``````````````@`'/3P``>&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`88$1X,!3+N1`P``JA```!D``````````````(`!654` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M88$1S0^S62D`P``9Q$``!D``````````````(`!)UX``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`88$1UV43K8V`@`` M60<``!D``````````````(`!F<``'AL+W=O&PO=V]R:W-H965T M8A&Y\P$``!D&```9``````````````"``3EL``!X;"]W;W)K&UL4$L!`A0#%`````@`88$1X#[C$GR`0``:P4``!D````````` M`````(`!8VX``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`88$1XU@M#U5`@``.`<``!D``````````````(`!+W8``'AL M+W=O```>&PO XML 14 R33.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) - $ / shares
9 Months Ended

Jun. 30, 2015

Number of Shares

Balance at October 1, 2014 945,166

Granted 5,833,878

Exercised

Cancelled or expired (716,557)

Balance, June 30, 2015 6,062,487

Weighted Average Exercise Price Per Share

Balance at October 1, 2014 $ 9.59

Granted $ 3.50

Exercised

Cancelled or expired $ (11.30)

Balance, June 30, 2015 $ 3.53

X

- Definition
Represents the number of warrants exercised by participants.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightExercised

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the number of warrants that were either cancelled or expired.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightForfeituresAndExpirations

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of warrants granted to participants.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightGranted

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightNumberOfSharesRollForward

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightWeightedAveragePricePerShareRollForward

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents weighted average exercise price per share or per unit of warrants or rights Cancelled or expired.
+ References
No definition available.
+ Details

Name: apdn_WeightedAveragePricePerShareWarrantCancelledOrExpired

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents weighted average exercise price per share or per unit of warrants or rights exercised.
+ References
No definition available.
+ Details

Name: apdn_WeightedAveragePricePerShareWarrantExercised

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents weighted average exercise price per share or per unit of warrants or rights granted.
+ References
No definition available.
+ Details

Name: apdn_WeightedAveragePricePerShareWarrantGranted

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents weighted average exercise price per share or per unit of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: apdn_WeightedAveragePricePerShareWarrantOutstanding

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 15 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 16 0001571049-15-006546-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-15-006546-xbrl.zip M4$L#!!0````(`+.`"D>56,>JE8,``#L5!@`1`!P`87!D;BTR,#$U,#8S,"YX M;6Q55`D``Q$$R541!,E5=7@+``$$)0X```0Y`0``[%WK;^LVLO]>H/^#-@MT MO]2QJ+=R3K)PG3K;EZ;Y'1;W'L1!)M\U:67$KHQ?8O_V2>MB2+2F61'P-?SZ]]>)S3U#["'7.3X`A_P!!QW3M9`S.C[X]G#1T0[^ M?O+]=U__TNEP/T$'8L.'%A=X))\[_[/SZ^G=95<4P_%0_Y0X?Z+U[J\W!5X M('.\?@3$(U[F;J_^A^MTDJI.#8]40\J$%0B'8)X7IIRY9C"!CL]=$2A#1+Y] M0?Z8MGAN(=_%W"]QFR!L4Z)5W1M^@"WC[4>N%XP"S^=X[42?P1D+C> M5=S.ZQ.VT1']?XXPP/&.CE%Z!_[_O2HVWUY>3DT+,?P#DUW$M+!R+A3/2I MC9S?,Y_2:@Y=/")?\F79C\1\I+/::Z%9@72'RO='/VZ5+5+V+X+=!UO1OF MSC[U4-Z'I%+0_?7J\MXF&S@^?LM^ZT'S M<.0^=^-,VLEBAP<=$Y/\4%WY.;IDP)Z?0JUTBO[]>II0J\''AIWJ7Y!Y0VT'5 M\,@+%>P.#KE0+8\,;&+7AN7VYUB=PJQCPC.E)D(Z#HCP\\-)G:L[0QAL/C M`VJ:.HD1.GSUK(-N8D;[KN/#5Y^[AZ9/K6'&NIEQ)K.#^(/'_O$+KJ31QX\ M_APXCU1,'GC^,?K?P\TCD)?3#^8U$H.,_+?Y;V31%&>,1?R(TM^TOW]P3\/ M3GCRGRI)DBQ\[2X6IA5V\UL@W$N-?]-S!/VS\@81)(B(5=(9\_+I_-GHV% M`D!.-YCD)BGS)KL9/I8SMN<]W@P?@?)X!LTD??8Q]"" M_=%@,+CTK2LX>8+X\=XGX.A`>/Y'0+[KNY.IZY"?7ECBWP;&AN-'W[;33S&; MX8B"2A(LTN3KU$8FBK%P%B+YD4]!K-[1`JD')U2FCW((_MK-K6^EAFS<53* MLX.3Y+,,\TK:[2Z1O**L1H.IGP@>$#I`F9>>Y]83O+E&[R5O+WD%5I+(7C4K MN2"LKQD4\+:MPW/NQG&C+W!=V@T]L.O[PE.Z,49WEY>,_):R+:XV3SF[>7U M'7E]3Q9/L_Q<1;ZW56"KR='IRH+4FJ9\/(F-_%!AYM]+&8'-3T>^#6^&`\=" MS\@##L2PS&"P_-7:`8^>B;90V1"'(ML;X1A.,Z%7YZ38O[%OY,TG=#;',) MGP_3)1RH([NAF&8X&(MN(1\;=TXE.BL24N++RCD5K\ZI\>Q-\;(LBORR+&[S M7),P2:JDXR%719Z]CNL15V],?WE(VC6N$D/([R97'R\,A'\Q[`">OETBXPG9 MU.6G(V%H%<\(B&>#6HX+Y!B.B0Q[0+0A\O:7E`#(N[82M+B9W;S(I4MS,T M;XF`Q4M$@/B!TV5SF)M^/W:Q_P#QY`P^^0]O4Q@-S:[S3%<1GVQX[?K0NS7> M#/+W;@A2+DFI0;>,MC8&0KT#&A@(V^G[QSMHT_VY6R+A;P_$U_:,<%W8.WU+ MYX05W6+HA7W:'Q/5GAA.S[%/)Y/E8KM[\ZYV-OKR+_]Z+/3O1[CNN/(9[[ M_7L1;T3$"_B\NZ)\\5NIB[@DR!_-\=8;](OR^+<3?%T6O323V%K1DR:[^#$ MRW/WOFO^GEJ([)$A:`@QAE:8LR-&L(BHN2$LH:X=T[,C_7_ZH?L_E[I=[W]! M2@:?A77=G/1M-I)DZ!$D]DR:;]?L)I>65APK#]$+C&6\JZ`5\#4OG<6V[>)6 M67;?([K&&/=X8SBE:TKI"#)L%DKWD?5?-6IGDF$_-I3$8X]MJ] M@]IMO.ZU>Z_=!=J=%HZ/I]TKS"8!>+QVGW-WA);2MVJ6OCB)`,UNFZW,I/V. M<;65Q%W;3MN^'>-/(_K['>./OF/6]&?_T9GS9-P15?<.LNK"? M^6V-NNQ-_X?:F$2?#1R3\N@Y^HYFT3!#N^$(9`B>.P"%E+,8_-/, MBX?W,A8V/KT+`P(U<;\Q$L#Y#<>L`.:FWP=/Q/U'!GZ[-^CMT_FIO&^.!?$+ M1KX/G=O@B7""3`0(+&>T&Y)62%DL`N_1UX889&]P[J08+&UUS0I`O".7"1N4 ME'R'=VR&1VUT86PB>A(F.;F,RNP=C]R++AD65+1"<,LU,L M-W'HDH^KD,W$ZZCU8)`6LEBT?J]0;NO=>S[&N7:>39)VZ!K9NAF<(0]-W MXXV_V2G$U5:LMEVA"X)MI2)?Y;%H%0ZQ6+%BN$JV2?.R)8I`"M+5/FQ0AMTA M[_?3M_G&;#C,0;ST37)(=[GL73,\<3`\>55,AXDNG%E_^+DQJCN$L/+^XL MH:"-;5>5$O:E=G#+^UG0Q][ M-K37S'S-[)GAVW+>'30A\83GA\_W:KH=:EK407N=;5%G9W'MU!?ZK'.YCK3QH1NJJ.4^W.@&PDTV;'&8 M]O\^W.C'[O_]"N7G6%LU>51'GO!.>L9$[Z5ON%&N%3Q'IM_0QYX4' MZ;@WSN'H;A:3BNTTG2O_]N\!_PWQ>_W/X#OL(S M65&UW^[@'^CD"MO>VPL:_(?F9*LFZ1W35F6S8?_&Y^<7VB2>O3E"U`460/: MS[H&CL^/_P'4KYIR_/6GXPOI^"AN)$(3T.:IZ'MC`T/"U#A]`@TOP/`D9E.8 MF5"0Y"6_:1TY-7Z[/UNJ#GFN)`#UB.15K^V1\/+QGD9U1NNOL3U,?7Q!AA MPW?QFDTOE:>)9]!Q)\3DY52[H,R572SZ,LIGP8I@K/-TJR?$RV?Y9JC+N MQKD5_7^&/I+%08^/J(9[]5%I?W<#I>Y,HKPE5Z".P_5\0Z.$!EGB&91[>=B M%;J#PSIG47NWMY>#\S/N[+K'W?<'Y]?]\WMN<-W_VBUJF**=Y_7#S3,R`EKP M]9_PC1&JM,$N;"L!\H`-"SFC^[?)DVLS`D#E(&HZ4WO29#_`F("Y0)YIV+]! M`Y]'6W&,6N]$%C4"4-16MA\ND`UQGR2/7,RJ%WJF"6UJ!Z#%A?6G.R/3X(), MN).)ZX1#46BHO)O`IR,"Y6,NM#46FCBJ.&$EL#ZXN#$P%( MFBKP60$J`9:0<.::H2='!W5&?`1\YU\1C'3EBPW>AF,D6T&:KPYFV\^TE0#I MD1R+YE[81GX_5057G&T05HJ+1&7T:("B_2[>9M)&5Y(;>, M%&?914H-4A9/D!T#?UXR&Q#1S11(E.,.0%E>-C@9J,0`J^JJJQ4!WZ+X=1` MUOGKE,Q+(>FK&QHRM.=YT/=:Y#L095&1Y_!7@,64"E:]H&LB6)NUKDNB(HH M@A3;64!C9.&)2535-#-+.M\EDVC_C:Z3^(3)U-),Z;!,)+X-+LJJ`@0MW>O% M>-C@9L-B65"TM+%>%?<9G+H>(F8\[)!KUS';DUC":S'%ZB(H]>&R8K&N588; MG7GINYZ?[Z^R-KT:`+R4!ID"D$9V@4@E\!(]0VO@D&G6B(:ZCDEI1]-$0263 MP#G4);;"7YE7>%E=M+E5P3`:`20@B))8CB;V1;[#CY#)X`M4B!KHJ@(RZ8[BZ0N5E:^L:0I8A6LF]%A M45,U(3\SG9WI!&L0TJMI[(--O\LWVP-MUV`"O\20?^V^@Z6`IVU`E'15 MDD4QEYEKP6J^CS.K/^YD@OSPM`)=:B%@D#."CMD<]UX]=.0@^_C`)S;_H,L$ MS-H\P&3/3_>Y#KK1D"L>3UD)Z#GWVQH$/I6R%_3-X-V`GK=KD_M"K:ZM9: MJ"Q"6!\>(]\+2)JX&KR>92%Z6L&P;PU$9J9]8XI\PTX5:86?NB:HJI:92KT+ MC"49C/@N$/=FO-GJC`W1= M57@AO?3R/C6=+#ICHX``""NGBJM2T?806/7MB#VZ/HGW\V@SG_)463U-12 M[3..B@9^:N"I.MZ6F7+4:;<6>(J;H:S2PM>[X%B1T!3BV15.C9MOMB.":\ MWCALD?="5NXF(?_1FF%^[HM-&7JJSSFII9-&2"O7U^L)$!51)U(#7+CY)-A51S MZ6I;V6:6%8'75MKZ$#9)(V,-%R0R7^L:"QXZO4L@!?8G3RXZ?P6S;,BZVK: M=:H,,KL4_>3/;]I<&"8DW`A"0$@GY#<]#4>,:ZV75!$P)83V>3#YN4KP9^/ M?T4O79<>06N'30Q7^-<`G%WC(0R[P>&ZD!4N2-Q"'![H;@1^ZL9-BA#QX(0_ MY/GLX:T5(&Z,!9+@)^%%2LL6XW];T43X(41]?U%M=/6^+%=&=G%[@DS$6 M_0DM]M:\XY0/"+Q1:0L`FN=A-H"_6$)?T]\MXSP=>SRKI+PT82V/9O;$N$# MSPM:M++OX([0M(JY0G=04K7%,G6&5H.+FQ65F7I1+@RZ[>6J`9 MLIL>IA6$]%7.=4!OPCE=@=WO#PF;\UI68'P!_/#UL/BB6=%U7S&`A2_R%T4 M!6C5,"(2`.FC$@L`JF++1BBJ':1%E15=8P:NZE/F[YR85E1%!0UQ;H783J77 M+7E!$]('%,O`0=LF4O@3="`V;'J6RYH@)XR[1X]-Q"%!FI=$09>T,.Y>-6", M2&$JN(#G=5%)AP1IE1:F!LQ3_4Y0TPO:LZPI0)7D- MW.D3O@L'>YL7;P!$2"D$4P9(F1K=G51 MU[0F65C7EQ!$72(N:U6$`\=T)_#2]5J0PXX@:2H/^!R,XP,"`D//CW)CR6UEX0&`E!M; M!&-MJ$PEE$P:&H35$QE/CV#;IBM=8554+3T+DVC`LZ;7KN%FQ;FW^)0N" MGO;RN'4!,YVR!=YH"DM(6=K>44U'>>X19;7E6^@:+)8!7D8>8J:Z!NG'U[L MH>_OW`QOL3M!GN?BM_".3PO(=8W7I"04UKN`9M#G8PR]5].QQG4('#@OB.=6U2B51WZK`JOFCǋM& MN%%=#DM@D&EFJRMS2^-4!D`U9$V/!36@-6QOF3&-O4TKA):$;TN.&)X:'C+I MKARR`[_@<%@]V7#?-%S3XHN MI$/7KP>V(7)K%4!N1+/AS/)K22WAOKEDBL`29)$4=Y2DM,[.?DXUD3=AM$ M!:HFK@U!EN9G=(A7XH:(6OM257!$+F9&4AU.BE\_EY^.@*PH6+"3`OL.G& MR#W$S\ALXR2,**HRGZR;K@:/0TU>:](DJ!4)B'IJ%OL/B.ZK9,3X;4%?50T M-?L@82$8AJ!K,EP`JLQ7!TWF@Q@2C3B#T;\#9SF2;AL3?%&5TCO!J\!J@(S: MYZ]4&6@Z2S+B-U"3YYYRWT)MOG]T02HC:A60K9!9]X:GGG.M0E"5WG[K85+ M31#%6$5.2W#V0JEM0^?R7)YG]:G=.$MMC;NH/&9-];>A<0:?]U.$55-TDOM M9`D!]"5NPQN'(YP%K=.W;QZ-$CT[5-@S??066LVO3PF"F""KQDO7,NFL- MQW27K=G97H%$8A-T$X4-'P9[<'MF7\$",-J\>@9:Z!.$VY6RMC:XRBNOZC M`)3TZR.,%J,WMX"(:+&:V5=LPAI!?T:.,_0VPK;LBAX]0"W2GI=TR+)NBH! MEJ2'LU-2#:G"A-`=_KII>2;86K2D0]/IK4AF,&")5R,G&N`(T9.?.#CM?N M\WW"?QR>C%%'>G@1%3T+K&QDAB.\?3`9`D>OAW;7IN`VR.C7#>T?/V-BA M1-(3K/`9N8%GOT7+).T1)?$ZM2LQ357QK6!%+I!#:MH"`SI3,#:`6R6]KN3 MO"!2B.TTVI"M7DFU!)E]XKG:@S;T4!(S6V;IYC-7 M]O#(<.##73;TK61%?Z@!U"\T"WV2!]&28&''&KSJ!G8C1-CD9$-!,IOR6% M32Z#X2<4[OH'>7=)[\8/M?IISGO]GP^.`%6>Z+=\2!+QRMKN/35[:&+IX< M<8[KP#@5.?1ELB..G[Y^X28&'B&'_O"CA%+\P#]_3^.9Y5?/##R/]"V4!S M$TY4H:\UB?ZQ_7-PSG7XWXP)M,O?]4$('SA[K]=7?7N?N-N+KA>OW_S[?IA M@/SN]IR>Y34D>7-C'[,:5_??_=ON>:[+FPIX#"[_F_,'W9%'T+<_]_>MSZWC>3Z?KY;M?\#;VZFJFB%5B7C.[J7)L9X[/ M26+?V)F]\VFEEHV9RA2RX<3[U]_`?2#38G4RWI0,O=LG74DJHE&HP$T&OC! M];U[8.B?:9QXHR>89[TH&UV4VP=FN.`AC"=N\"0088>85T`'1.%NP#]&/"P# M9Y18%HW'AAL;X<@`CX`9+#B,C@8&3AX@Q^B0`Q\2`PU7R8$PH M0!`;#-XS+/@Q.AT&(F&G@9O"N8,-&P90&6L?K$3D@_O(C#O&`F.""13@#QI> M0'..AAA@!)$"JESE)<%C'@PR@5.?<<\UA_^$W[-)PG^+4_L6$"%401\;;Z15 M;EJ__'IZ>JW^:?_REKCA8=S!&VL4>@%*+4]&Q&GCC"?8M4(PD-.!"/0>1._F_#."7R@%_^DXG//AG#$"0K@=^0MVT`V\08 M^8F.PC`)"+5!S&9HW#T5<;IX29";**ZP!UGA@C=J[5(9[5K_`HNRB778.'$ M"W!/@NJ`W[OWM'M,VK;N$)G/MW6GBHWP@V+J@:#!R@KLT2N%8^Y94 ML3=DN$#-H!SJ!L]T79UC9'K15[<4V0:66A+T#+J[0,&![S<^-G&!+0IJB, M)"$>!:0$`ITP8N%NI2O21[$#/O'@`,WYB;H2O0O)N M4$%A78AZ(9FH-0U4_!"F_A#?'3&75#_\YL\T(+6;Z6)MZ7,LFZ()?%HL:9I M=Z:T,B83,M#U"ACHZYB@:E#EH3E`00M98NFGV; M:=RE";B,.-LIIW$("M@$7!_PI3=`3E5;#0"SPF/B>1>!NP$7G#2 ML>`AQ,D#_8-W'$8,OD$B/;`I\V]W?\&;0+R&Y4^;!IS8C4<$Z3)>8[.J;`(F M=]N^@X;A;P9X6=7@R1$1=/L) MI#/HJA%WK'[9N&HTO5Z_>E.]S$6Y"C3_U^Z@6;:IF[^R(B!"QQ&<+8FDYL" M=_G1W7>_QRJ\B^87__&%/;I#MV%UX94C/S6B M--[JXW,&[P=CR^,;8MP+OA\'AP_RT$3RX`X-U_"],?U2 M00D;#QYX$-$3=WLP0"'"/:;A8?`\RWVE4-0D"H?I``:0`V41KHA7@<6<:_CC M6%:RDT=%OTSB7^`K(@@8DV)R$862J/<"/H;?Q+#%^`D+SC?P1! M<1OZ!8^?B5D%&'1'5S!YB,+T_B$?3YOENCL8I./4)VGBD\%WOF[:MFD[;;/5 M=6IGJSHJJ+8+%5R4]2/&,EJ2B,O;5%P'ZIL4=0[JD^\/(>CHD_`[JAW0)K$W M]%SL2VT:I]?G7XPW'QJ_-2X;;WEX%G]5%+T5:MCXQ+6CB8LS>#!(T:'NXDHT M"'7UA9%_GL,/2N<&9(D234ECX1(?620&+GBCA'?+$5^LTM0ZT"H7RG%23O9$G8>+8)AFXTC&&(H:J]R40G=[DVTF.GP M9^.-_1;/#W$@V#H%TOX<+)T[VQ0_)DG%,`A",YA<#AZTWP+IT,?GH[X"2(< MB&,2L.,=^`KB4)7=.L'X**-L"#]NO27G)N;=:?'T"4_",73D_>`CP-@P#W02 M[GP0:/SDC8,Y";X/QR?9=\+#17+C$)\"%RG&2Z9A`TZYXK>)2(A07,$7R['P M.':'^&T89LY2)GQZS_3X3WWT2)V[U)^E$@B0#KA!?!"Z:GE)J/\-WF4H9F_F!$-]+RDTD3M>K)^3(S9`PRA)!YXS2F^!?8UE_QI#YDX M2$7GP(4_0X]\62EVF]T&J?IXVLY+;PZ?8$BZKL'A_@[E<@'K#I-"G(@B^Y+ MDRFE@YSFS(TH7,%92X=PRS%[G1:-]+K=:YFM3M/$Z,>$!XO\I]FS^?X=P-IR M5=`KKQ=E!XLB+;MF-F/N-HP1I7)"=72R-1=IVJ''U3/HJQ#&G[@8UJ5Z,Y[Z ME7D;'A@S%F'4,3-J.`8>5/$$?"Q[P^,#`$JF3@34P"Y(8T(9A#)C,GL#,A>@&$21G$NXI&FO;O)C4W>,4#[ MPEQ0_#@POET-!HP>AB@U;("NEQ&2U=!=&%+8O]U<79C(._?1]7QT5#_>M$0 MKZ/!RBI_!Q[!9_$=:)JTQY$$V"]C;B/S?LL(Q,0C?M./`PK(9J,CN^1`?'HN MAF0&5%$I%7VDN8&YE85Q`_X#'I(G1@CG@AA=!V:KL_5K?5S!1?FJN:GW(:C" M0&@12XX@7@C-HQE##1.)Y@1&Y?FLX@[,7X:&HWH6^-8)K"%7^["3/?;(OYH(;2VIRCO=VC":9PA:(0I_D$X"-_=UI]TU MNU:/^XFVV;?[IM6RU>5@S:G;`S32)YHUJKM>6T)I]0R01C63>]V%CFS]=:I M]5F]+.A8&QB3?V?KD%Y$!Y]G<53Q?6J-U'U%D6WKJ2:;,!RVE-DT\W_L/ M546!J73]?,D3&&`> MGFNP#/C+$(5B.+(8THOCE`XMBAHF8)3FY?_RD7GN,@]2BH3F^N12H?U0ZD M+LK'YQ;>FV7;6VYI5$?LAZ@,5&F$&"A,S5'4:1"!83W\F32=\ MNX!1,6/([TJ5_\8O@5.Z_N5E2TQ4J$^764^I4JE&<=PI57K'!FX:,RVSV]^ MXXQBKEVS/+J[X%0V)S\,RM\5VW%J&6OZ%T)!HNXEJDO0'9??,U5B=BW-+XM^ M39J=8Y'F$L-R!YR^C\(T&)Y(%WC4'<%_?C&6L3F:;X^.0;?71M<`GY`0Y',8 M)7[D=.1O5C:P/ALEF7?57GN<"".1VD!=.5+'M#I-T^EU=T!0==G1DR,U'.'3XS)4.]:IF$9IJ^B]XCF[0S-UYO& M;IE.NV/V>ZNM\?.X<&P\;)I6MV5:3FOK/-RN4I^FJ-EH/VM=5_U](?L=8/\P M3"F7?M-+6S:VMK9]LVWW3:?;>=;:UIS$7=R0=OTFCO@9&Z?O/@SH@<5U" M5IFX<7T_M\M,'&KW@9?];$AWX"R(:U2=RJY:O96JMRAZ/H["0,`;#;JY/N%9 M,`-M:_&J`''FB$423L0&21C%A26;-V=&U^Z9N?TY4W$)3\Q67,'6<4EPK;0 MA8V@:2):`E-NOB1'K\6XYZW/PI'Z.I\28^(O<_68JD1/0D3@CS4DAJE:"D)C MI@J.N&%\4TA#DZQ0$#%\Y?1+^3G`IEFBF,2E2DI#5,O1#`1)\4T&H\_%IUYY;>"`/QQ M\L1)?LN3J&>I7`13F&4K14PK^T`0-9Y%]8'\M9O!0XC%DOSI$ZP&P0?&X9#Y M&=XQOT2C++(X3L=\Y)\S8.K'$'NB8K6G0J!@'D1,1NA@8P1WN9YHM$A?:%* M'=48OC>:PG128$6EZWWWI$T(]J2+7N:)3U>&+'G`)+'+.=N(_4`H;B-Q?X#P M!FSD49$LJ,G_Z)DD>H83HE(0$?^RJ9U`@S$C1^,$=XZ\D%&LG^H!!_Q9(V0 MN'[E[\SEJF"67O2HEU,BE2[O&2[K7'FQ$U"6FP$\%`X\>D`MX,P' MH258PS@91Y'=U(]]D!#>&)JO"N@)ZD4A,#[AVS(VS+`IXA;17S%\F#>V"R_ MM)@ER'R^\%/PV[SWA6CY$8)+Q%P!P^:4M-F>D0(I#@04'(\DTOE!&&"R M?%:OBMZ',1W":0IU]=AG-\&<(OSU05UD<),LWRL;]GJ.JZGISB,UC<$\GG M,$"4>I@][!_6I2-S^HI\FL.X)YM1[DC@@@1=4WZ(#%"L-EO@4?]$U$'`]Y/,UQMI"`K4K`!WY2#R[CBPN#!1)[9E MH@JYTJ+HH,SIR%`=XHB]-3'9IXEK5&ZAZB_)1:VZ7&4,\7\`DX$)K\6A7)]$1.'' M3,!2H&V-\^>D"1S2L6H):YGPY_03\"+""#M9T4=>@%$$#:'C`0[!DJA_IRY' MF8+9>PD'-B:`'\E`M/_Z"+E%/<3\'`LG(R/YY=G.$H:T3F:((EK\UT=0:^U M3P47Y;8D3J?@NYD;!3+4A!EN-L4VAKN=>7;K]UV3B7S(PC>_3T&3CB.>J_[ M$XW3;?V4!R\P1>CK>ZA@=:A?'.S2<$VN_Q.CW%QK?50=T:_U404796OZ2%=#1>@HY5K(MG[BKT,(+P5[N(V M.<_JPF.;LH#XP+^ MG>2]E5.!PYV$"(896,-Y_Z-402;0CZC2%$SG56DOI#0TC'=_E"` MJ!R/'(^:&"23^.>!P?`ZBW?(TJ[G(R9`M!$""&-RE%>X];&J^KY!:ZL^-P\$6MDFD14"H% MZ"MV5)<-?W(20%E&JO4;'?)Y<_9IUL6R8SW/54(+-8+#FTK0-5.H[[1.])RXN<0$(6Q$YK'9Z]=L M9G=/&:/D$G,B5:MH7"WL/)=H\.R($I.;SED[+'P"CM!#OW@+`X+.",K-^NI%JK`27F7J/EZ MLPG>^`E)V^/&L-/U'/R8E8SE>59T+7Y/!Y-79O/"BXF,_/[M.ZUM/JYZRG MPK;',PF>4!'>79B9,QFI7VS-K'Z!-5,'TY3>/R0P2?#UP1A3E["BUA5Q:)" M'>3I43<'>G6,2SP4[:=]%@O-/Z+.(`F;P,S@X`3+^A2_RSK5^)#ZVV#^73(176.&63@WO?$('BBIL9:@6UIIU@> MTW#_(FH[HB%P485GOC\A#R=B4JN$6U+?O=R M'Z-TK)D15<5)5%\10W7C\/,:6'!`S)LJ)_CI_J>\8YGII@&R;QT4U(54Z&T MG=F.!=4PPMUCM[/_>)?&)_>N._GYKH'8>2E,6=ZCUT$I8ZO1M<:FO4'S$J& MN9S329Z\D]-@F&FC:_CQ``3[%I3H!Q\\M/=__]L_W,DP^/F3!^(#WMP3//]9 M!7:N?3=0SY(B@']\9:-_OCKC?__1_WSQAV7_<35(_L!==VM9?_#_WE[]T;+^ M@!,&?MY6G[]ZO[E+N@46J>HVB.`(.?'90X2V].7J]L+XH`R$#=SY=/E_OUV> M7][^;IQ^.3<^GWXY_?7B\\676TT<;XSK3Z=?2(1,)MVU3OVZ!9F[P[8L7%T MNA`N0G14RF0DJJ%H-'"KGR%,5B5,^8C@6T/AY;!U["FRS:MFD[;;/5=?`T M#!_ETZ/R5B.0O4XS(%<N^2B1/Z&Z/+LM"1?MDV MF\V.V;5;RIXODY#1UKNEJ[_^_R.92CY%I-DZI%A;H)&&J,K9&&`)G2N.$6B M;D[,I.^8S7:KF!LS;2Z3W+H,LXS;FGA!3_@ZS..4MP'`1HW),61[;,/X+_+`P0G0?S-Y+IL2+&V1=8[U$FSA M^%&RL[H/D%D_H@8Y`^X%?L7D5:5QS"7Q"]Z7_&JBBW`8_F&S?F8IP"],/'N M%'W4[Q&&"@)CDM[YV.T.W`Q9OIDK7]:;+)!`W4>$-8PN#AO&!;VC[&;#PO94 M/LS.E`V#154JO$"]G;I)P$0X"NYETV9(K6C]7O=;[3D@CUSO7JC?<\0=66%Q#'M/HV=?D2')TB MB1KU3F!_PJYA4V&Y&W@A;-L/QK_4G.BX"AJ44?W>[-:X-1LN99H>.$WA4Q M[7;';'8<7H$-XO2(1QM_I?8">7,%;W2>A;O8.91I]\Q',;#Z`FOIUBN29IV M.!':NBS;W:X?4TZ_M> M6G!"V,@I\R@J>)'$RQIB;#=5#=R.^>-'\H@W?('J"@BB>R!,05`6RB.!VA MXX:;V\=FC+C%%1J$EDF?$2L@/&(Y8CS'/\&+#>T-.$%L]:W-3KEHP&8C^<[\ M1^&I[3+X76_?>ONNOWT%<@E%_G3?!T4]Y@DQ_#)1-27%[)AAKODI[#H.B<%S MW$WY%^;WI"/8SV0X>;J'W$4L49[)S^TB4QVMNY ML=)F+(8:/@P:;$Y#UE"H6?.D"C2\E'5Y1GNJ94'UJ[#@1T#CC"PN40>IN1)< MHNFO)1R+9QIZ:;Q7=YSV3;GJ=W505+])`S>%XR$;OIU+_/'NCD.@\9!V<,[9 MIA-J9+P3&\0Y+AE;H>>M7K/E8)YR=Y:[>;JLUQGP:>/7"CMAF^V&_&[7,EO]`INWK_W)`"'+:3K$%0=(;5[W=V0 M;YM6NV]VFJT-<-RIHFE9H_W=LPWFFJ:$@G68&9SZO#.L7BSTE6%_5E1/;:# MK69;9MNR7CKK:JG:K%19S<.0JIT?!G:GLV/7=RG9;2O'@'I[[7%[.:?5[ M1\>ZO_^MEJM]RE73:9O=CEU]UAVMHZV::]5^]@VU\E+9UHM3QL^N9F][G," M>573U6NYV%N_9UAG::X(TYF.LF27OHA;2/Y" MMK=+9V04LWA3MLIT[)[9'<$,TGMJ$)_.(MV\0:?UB`B"9TB MWVF!PZUDG:@4%HY$-R2$'X6I@>^Z8RZ!:A(.X$U1[/5;/1_@E1C@BV?HRE MO>=1P_AO%]?CM&'\E_N$Z,EF::DO(MEYN,2FH@R3\]>_#8R+CXP08I M(1U=8?4P(B/).>CT"J0.5:_L`D,PH@3"XSUZP]3UBW[7D[\"^TMHE-\?$.@C MRC$1@U,4L=%O]`PTGE$"@"0AG>`&Q%@"H!I!".4_^>,$,(U(7>?Z.0A8S3 M`=%A]ULM@EA+@/P\/0ZYG^2ZT91J[1:I565HXA9P`%R$%3,-1`]B8.BC1& MU$,0G4NI5+Z[6=4KHKXBLD>(&YBCRL>S4$`E'KVDEOUU["T5@) M1"P;&-]<^,7T&QDV%<9'WWAOIU3)]"VD:9#>X3@I;SSY_".+W'LFJ4/OD2!1 MHUQG08+/Q?Q!J?FP53)A0;E/L>&-QZ"-.+#3!`'2%+ZK.YGXWD`P4)"#R0< M3H4OQ'=LQJ)@R^6T!:X:S!P4(,@$=\1YL@D98\-H$$8S:PU=&@(P%C^8X+Z MAW$#U^>0:=\F(2'V49<7G"^H2#?U$S-;%E[;3-@P4S>YU.0$\>616%3F1R. MW(3#O"%G,#R$CX>%$I%CJ^U_J``'1L$X9VE8/@3$D-_4M-P=7@7@6XZYA% M]Z#6>6,`87(&881=JCD0<"#0#'4SKKJGP-'A$=97YXF6 M>0=H:86!%>T&8!)3A@^,?<1$I'6#%>0\R:#P](F_\[9<$'^"Q\J&_YFNVG:K>[[YW_ MNYGW%G&9-LKK5J/9-M[@_SC$"&P[1(,6TO+::EBV>DY0]C8'\@V_N>.`CRC, M.5?.G/;DIG#IT"7C[U8;H9P;PK7TRD&/YV'@2@KFKM_CCJ"@YCM'&,4(B\(9+(%N5IV?\C#-&\#SQ"D2\4@- M+"!@"]U>:./H8B=E,):=(SQ&\ MN6C2158&7&T#L;+5:0F'>K<$1LQ^!J^8E2FVLOM/9"J\I1Y?S)AC1B4\? MYH)@OVY1;LCZ&[YXL;88TG`4"&Q"W1-&8%\JD.^PDI7N1"BO\Z_?KU],NM M`I+ZO8XEUBJO^AR%PT+6.J-#RJIEX^Q7X_+RTC0^)?FFK/1MSL'DC3#8 M4/J^#SZVV&`_6#3PN"-L=WN$,BXP@D\SC&!T'VQX=:?3G440)@3R&0--_(\ M)E_Q-A_^'#+L($?><+$#\R_-MX<#U.NFZ;3;IN4TC53U^?C@!>!#P2GFDYLD MZ!:/PR'SLT8N'"F+7"_P>L847`"QFGU9<6,0S8-Z;5N-GI6YX;^(D`!PYLEC M_M!`7"P%J8A3^]EP&NTV;X;RBQ%Y\5_&"(YNF6N',5=89WA(_^ECB($!\@Z#;,'4,>`UN./M/@\+B`,AGC-GIBC]/PD\]I0=G)_T=1)> MOF:WW13>I`)_5P<->8H"QC'CC3#0;T7X0`YOEBSW?G+/Z3! M5],1&\X%/BRP-_+$R9A0WVL_ME;JE>7HK2[R'.ZO4+0UP88=IX,&BMVKPEVD M;X:^AZP,**(UYKP9^U!Z#0ABX:H"Q-C'!1P+G->ILRB_ M-A).=DH&`.]=Y`S"-%&5\#5>C/6F[&R'%W==.;C6?>XUZAWC-TVVTZ+&VO= M='8Z+;-E=[(6<0_H"N!C,V?3N.!PZIA:-->O+5N]F:K+43BN7`V2D,+%O:+$ M!X+ZXC%.=##EYM)ZEHA;0&691!--WJ0$GD+1^:(VRLOH2M)[?Y0OPZ0D=BV M]1-W2WX`W9E[HA$#O^T"::;>^6YTE4>! M+)!/,7B?`L,Q]L^8S[#CI^S`4=OUY\.KV].#>N3[_> M_F[:\+5NP(4%B\A?LWBWNE-\@RI,9(U>T"7`:3"D#S_@N>6:IS;& MM6>\'\_X5^/$.#N]OKP]_63TG")'%U0N=2"_??!` MA9YAN3LH9>&1GF(9B-ZE;^K[RT#/,597US=L`/2Z$>GOFT0\3-_(?YR#DOR. MD21JI:DN^%U,0#V!Q3KI6,8;^^>.]99:]T7@ZW'_Y[XGB(G[^R!RA?QE-<- MR[S<)4I@MI#I`O=1K`'^',W31["B/H4YT>B)HVV6I;RGT'K[-M9?_D#JK[TE4T133U`GPFE>@/I,K7GY(?R+JF8-J`R16/C'MZ/ M&:8@/2XGAI,E;[TTGA8QDY8`8T5J&<)@=CKYO>D5;->ISW)-KO-GYWS0".Y MT2"T4]S%59Y$#"QO1)FQ2#%/<*>$95QAM>**E]0D?;K3?$E3,I,?0OAM9=,V MG5[3;%H\2O"DZ<^9VZ0N?YIJK4 M7/4,7W!3L,QXI0WM[:TVM-]]"WN>'96/8>#DF3MXF%/3(2\3>%)QH]GF`ZDE MP$R).Z;=F=!MAXS\8R]L-"24`D;C/;B/K"2+J]5H6[H&OJ3RB(`-\FY!5J2A MR]@]DI-5`Z@EPN(YUW#:)W3Y,7LWQL7&:8KH6M8(N+QCY?#9&87IO4.)ETZ MDN(5_I99++?JL;!^/]`S_AA(A)1O!'6J>7$ITG8&_^5BXGNWPS(SM\+TZR MXI8O;CQT_VVCMTQ>R#VB@LE^L@Q[4Z?:QB- MQ-8\=;N`1$U`EZ:VW5Q#E=J=GNG,N5`N#%FB[(`L94XZC- MB'1&X8Q0IX&!$+/"5[7,)E^0:?^KA/99I:TO!.G,?J.E+`EENX`(JQ^X(UB6 MA9;%G#4KJCI2SQD8K6`GB+BI:^=6`V1,T%J[G+7+65F.EG@&LE":-L(""V46 MWI04^Q1VLX=N9+'?F5-7>`K5O5SR/H3]!"6'EABV+YW0R43&FBPV6S@Z`#& MOHN\JO-Q'5Q$.`&=@C'Q#;MH:ZT0R7%,R[8W&,FQS8[EX$%B7I8&6$IXX,WK M9J/?WS!@1=[4ZH6%^N'#[N?FC"_I=HAJ-54.=::E\)(]%Q["],&E[/16>"9 M"LUPAT(+-I3$7$Q#^Y+#[628/&:93R%<)E%V-_\@1,>.N0>VLOD7']SNTF0V MI=CEWY^@[,F7B!\-IN-BQYY)G1+0OU4J/PJ9$+`S[]7+#OII39#@-<[6YK MV0`7,(O_IMGLF\V24-;BN)52),5&>L-QE%YWD:JQV\V\$U\2KFAV6F8?['J! M^:YM^9'9\N/@Z$9.PR6G5#HFSW$(I%;B&L.&O=-MKGE07NU`[#AK'(@_NT"+ MT>SB3)I6[:#7F[JR'+UA3"2:J\:91("Q7!#"+9--!N>37.NFF%.6QQE;%X M-3K3=(O(<#P+XR3><89B+7^KI2W^EW'"TQ6-JVNJW#%.OYQ+-&ZC?6J(?` M47@HQ3_D;1CQ,JW%MA;;G/T-@?B1-T_C#@=PX3A00ZZR2NJ8D+G+0`>T>Z M.5;G%#[S_,1$\-2!Z2=L//'#)\84%+4X`:MW\,9WL%:]@RT70O^1 MRO;DCGD3,PG=>6X:%[1=?WU+05FUT0G[BN!^.>Y"\,U!"W(/U\-"&GBU3, M5(% M&E[NI0T[Q4G^FZ5^U,KUINOY:A>P5!7N=:_(M,3UW]DI`B9%AO"O]A32; M8.F58U'.UE7O&RFT5M!Z_(6(TR'06$F1_Q>]FPT/3^)/>5NB_(BH`MQG33S MFGV2?$U76]&EFVC_GY$U@O\\NXVV."5TV\W59[G.#OK@^H1+ MZR:J#E:@XRR[>+IB.^6\]HK:HXF?LE:"6F->WN;H2A[[1-N]-Y&5RMG"@V M^[M9Y:4;9:_&SJZ](R%M/LAMB37V;\5V6D89QU6_\I#Y)N5ERKLN(IJINVO M:-OLM5IFK]M[ZTS7IX4:R5]/)M)U7;8S=WQ;QU" MW]9"5PM=Q83N$&Y1UIGV&<W=M3MF MN]VM#.^W:F]J@:\%WK8;K:7/)(WM"VK`G=?K&1N]8;B8&2VU6BWJB^N.8ORCK)TLW^O"YV? M3T:G#'0+5NCXQ8`@Q%X MEV^;:W"NJ5NF#C>;/81?ZYA!A&X,`Q$4@=7C(&66W9P[DXW-XM&-O#"EKH[4 MR2"6[0(R%-8RJ#0$^1^X"(JMD.MC.3RV^N4\@\X/$O,X?$%:NLLL!._-FVU M'!TT:65B"(T&J+E[DG2,W2'C[WO`(Q!GK!?,0+0N#X+AFY$V-3X7)Z0LC7 MJ\#X;S=(L25%,P>'4;1@DMDX7]4`0Z#WY`5#=AU7DR/?"Q5G2/\!5T;+,[ MLH-F"29M]K)L>?>UMCW@'UM02UKA]C>[@$_AT7,"F'(DTQ6M[H@IJ^PZO5 MPK0)W:.TPVAMMVJ[M7>.WLZ(-Z1#5D,/.,UM]CY!C25PF`W$0:'0[W''),M M9CYOLY5YN+'&8YEC#HD8KAS!3[:F`IPQ^Y?^&^$U8B\NU3LXQ`L2(1MF`]S):K]KB#YST+;TGQ8_5M)A1M/BK+T9**XKQESNKW-051UQ0?8$VQ MH1=G4R.JJ9Y5XX@,&H5HZAR+')VF2V^%(?:[:I15+4U6Z><8JL$=2JWS=IK MU!5MEZ(#J\HXAH2-0Z"QDL7'.ZFWKPOF"VB<6=(YIS,I+MI)BPO&LK>0SSP' MJ1+UXJ)I60>^\JESW_,J+5&O/.59'?O!D5Y28J^1?;R;_A!H/"3%="HO00YO M&UQB5#B(O<'AD?X;]O`^KAU\A'FH5SHRZ9:1,>I4Q&H50C7-OM4W+>V.8,H?`_$.@L3("TFI8QR4=-0TU#4=Y>)ZZKCTFZ`7 M1-8Z]\RG7;'[/>>@PA_>'O_A5S6.LT7M:HU#4=`PZ$>L']C,58=KVL]]P+$ M=:B@=X=]WK95$[?,:W^T@TGC@,KL=HF_F"DQVG82\/FU8)S.$36THWC6`W[ M&-3B$084OH3!R6/M$=5T;R-CKM,T>WW["#9^361-Y$LFLO9BA!>S=)RNPHS M'/9UC:5632RU(,0(6#'"OC.%7#\8$IA$. M8X,!/X9Y?Y6#OYZ%XPDBR@K`-:=OMGMM&D4D\)LZ3J$"8S-S4(WT4O",Y=?@ MMPOX1`D!:8P98F+`[R(63^`C[Y'Y3P@D//!3)(UC^,:,PQS&A/5(P\P%T.? M"P'-.DB;92G2)#8BDJB0)F=1$!=S%1ZZQ#5.R6G.Q%:E)2#50-+5UJ_)94 M4C<>-T<1IG;D>I'QB)7U.@RLU!;#-!+8LE/TUBH/$D+#1E,?>PAZ&T:RY$^ MD.MR,W@(?>`?;TA@(+((/O`Y'#?X]/BLQR_$K_X+L!@#)?#OA@NZ.,QI_>% MP%LV)Y6'MQ2O[5K=>;:Z;`=-,V6.?]\II%PA)V$F:WJT98P2E)P5ZVJD9L MO;R;7-[$2NY6)'EW3[^804F>92T%N(ASGA'S\$]7'YRM^A2T8%0MI]1J\J MSGUT@:Y5[A/I9I7`XCW[IF4^L^K%7F]R7\`+KO):5V!=MW,;NKUY\782$\1$ M7+0(^V=N)@BE<9W-$_>V/^"+:W/&ZT M;VTF811JA7:`VZ'67P>V8$>EO];3MNA$%S\F/!>:AB--JDE9`$`?-787PT: MJN&AM1K=`]@PU:"A&BOF')>JX2+=NX]>D,6#(TGC_D+03SVS]UJT+`7"[\& MU-$.-^=/];H=X[H=6@#MM]!W$\_WDJ=#D,KM716 M<776Z[`\L:]>_)VR;6.+0Z]AN/:@PPR_9UVW%,VVY1=8'><-X8 MAT-O!`:7$F[?4B+P:\=RS+;5Q4;S_-D!O(0%,3V$6/P-U.%"CR#>''B,`Z- MO:+RE1`F?V7+;+=LLVFU#9WJ3K=EVMW.-%&H)55?W,UOL^`($8&B'X3(8[FTDMRD:0WLDD"G]X M8W@K3S9:-H\6-[0]J3Z"Z5J9BS'#>&,(">6HXLVG1N^>M.WW1:EEQ3J]L! M66Q.E<^4:)!_O$OCDWO7G?Q\[L4#/XS3B%V-SK0%^,I9?P;+$%/KR`]NS(;7 M[M,8%$9\"_OT@P]R]O[O?_N''`I^/O82^OXT@%\&`TL&'@LSMZB?HGE0;C= MO[+1/U^=\;__Z'^^^,.R_[@:)'^@H-U:UA_\O[=7?[2L/X`)^'E;??[J?:T) M5[,MOBA?^G)U>V%<&B?&V=7GSY>WGR^^W-X8IU_.X=]?;B^__'KQY>SRXH8D M9L>E3;5YK\W[ZD=XA]7H#-=LD&?&@K?L>9UN);BV^5.:I[IS[)+;@B(VPT M35,`%VF(?@LX5$J\Z3&LB+U)0OC5AR@,_S-+\"#W\/H+W(WO"2&N47@C$O M\L#&;Q1#\#I:%UT++)>-\2'T5\+$N$L]']U+_CRF#J"+EC? M@K\&QGZ`CE7`_1-TZ,`^M\@GX5#[,7[YV7TR6KP#:L?,BMN$CTHEN0E>ZV5C MDT_Y/32P,@L?/0>`#?:HK3DDF^>X?L#,GY/U_I4-8F'B$=Y&F<1'< M^S!M,W-$!VF$9/GXL$L.&?'ES/4Q=A<&V8)QO3Q!.'HY_$0O#V6C$/3M@ MMZ]8VA:3D.-JOQW!EC`^LKL(5O5)]J!%3H;I_8/J3=O2FM.2L3\&R MP?1@!L2;;)U@_QJY52KSG:<)SK$,/G6%(PPOXG_`2GLEPX4)O)F$H/C4M:IO M;3?Q9.>(,Q>!(W3>]@)^%?MB]4B7'V.ZMX`.@+@=;%,F%TIS)D/<_;@L9%Q M(2%%C"ORW**&<:'9:M#T36%CS7F_4LD7W5]B\D_`OL2NC[8;K=)CZ=!XD:> MCV',88JNU]V3\9I#G:`7`"94/$_?DYW^[OD^!L+1(1`B M?HLN'@;9X(&1%P]@H_@=A&L4$\7.'0#PL MCAO&OZ:M'UA/O%NBQUQCX+O>&`W;)$Q@;3":0!^9AI<@^`[#__0A?<7\[V' M,%3FS0_C6+0;I%N/AG$YPI_!&X#B.P+D21[`++K\4;+1<,Y+_80FAZ.ZXQ"L ME0JYX&,#,%5TI>7&8ONP(SAE1O>5@WSC!3CX<4:OL)S[RC+4)U/<32$5E.& MC]8#3;0#&RAQX-;RFLIXVS`R MC8;,BM.[/\$/0.J\X('163L-P-(GK@<_P[P%?#%9\$<642"(FC`XO#B#?Z* M0+82\E10QKB,C:%D2\)/O#@1F.=H3G'0DE0+IP140`C".&8S[M)^=I,2)AE M;$I%F]`K@M_@JQ=?UUVNZ;?RWUTO>@WO(;,GLLN\.IKN/U?P_VW<6)\/+W\ M:OQV^NG;17WG5EORZG,4#\H#-XJ>4LI_+R!&S^8>-)$TQ6CY6#>(UH$[<.) M^Z0LACR32LL"RDS/P=#,499,$:.+X;D["'-SRJ#D/2"<(Q>TR?P:O"F4-S)3`2Y)A0)`F`,AY$WAWW MH[^`LV6<-HPS[C_I")(PMH+8!>K\0>J[,HFKF+2(3<"/0(?L$WMD_DD+'+/P M+F81[7<8:I(F@A"'`"WA5=A3V1%YV0HZPK@`%L^/LPHI0MF`(-3^$? M?+"%'TVGD=7[O=[OE>7H;0[&E8.QPKZ#"<.#_`!)M\.XJ4"PN;BWQ`8RQG#6 M`X=]R"]$P:"F$5URTUWH"\%]M:N/^UJ%KA6'08/-:5@&=.[%\0-+R4=3G4 M+JL8Q3$HC&-\YC:!8D%H,C`T%%(NV.`OXU_<4XN-;^0MWL!LJ`(`/BF.VB7 MW+Z\$?;F;?57+AEFPMG1%F9N"P'-KS#:2!C]M827L;$(#R8`<:Q+0^%;KAO? MJ+TY'\Z'`-E9<= MYYAD9^?=6,5AK4_=,G;@0WUP?3<84#Z2S'V6.=&BMG'I2OD"<+'R"6(GL6I8 MAV<0M`[#GX-_7$Y]TVKNAGS;M/H=TUF^26'E1`6TWVJ;-!\O_^MWEXJF;' M:9F.T]\`S]<@>OL69P70F[V>TD^'&`2G%&&>B8)G<$HT&3RXP3TE)FEUX6_< MI<_=RXE>%39O197<]A>_:?;[CMEV%F)1'SOS:KG:L!O2Z;3,EKTTM`+.D)L MG_M?V3A\Q+K&D;H%3R=A@!?@:01:/5X(?U9OM8/9:F\<@#(_%._\QOX;APK1"R"'OAWBID7I-9:`%SX`J]NA'& M]2_![9A:_;7DGT`DOVF:3KMMFDY2[LZ6^?^%ERA(SR0:+<8N6OX(S-8#@C6 M,$SO?+8GR5HZKR0_IL^4T9LXTNS2[DIY;[%RWWMMEKVV:WN?3M;H6EOL;9 MWG&IP]![W"17C[O8`2^TFF^"D9 M\HK)&P0HO3%A+$=D+-.-95Q`O^CLH@%YB%"=<_N!]@$^'=6CCZWJ%RO/O\@ MJN7/J1-JLU.@^$'+%^Y&EWS$C)Z[8&5I">+=^]TK4NU]_RLY@_D'0R#6G MS4!+C0F+S8)U8[A:NKU>T9?E'I1]K0H5X%QPR:@IRE;L8/IBHCRGT-[<6-" M6A-@OT.!&$Q`+^[W6-;PWB3"['QAC^[0U2'JSME`O!++^CE7Q"QW/`<.&5V M1&EBUAJ0-+EO+J96'TO@4>CD3OY\KG(HW`KB%6QG=_+00 MI>[!Y0@Y8_IEAOO[X,6(\ROP96JO43/Q21@Y/::Z#=Y.4U\!#1'DM?&Z:=NF[;3-5M?984EWK8(V M8Q>V>E"JEV5F5-2I:>"F0](X)3[^R`M<4+4(A)EY^P^2QT44G$$R%3@=9! MC?+](00M?1)^1\4#^B3VAIX;$?36Z?7Y%^/-A\9OC3B>_! MPZC";P8>0L3'0A$;G[A^E"CI&=XWJ=$@U!48PHJ+POA&KH[1PT0$Z&1#!(C M=R"4'KS_CL?'A6J^8RPP&.IECJ&.ARG%(/A-8YYTSQQ[5C_-Z&>AK]P6?.4M MB?"Q:Z!C\+35HT^][;9TRA&K:6C+J1UK]N!+3P?LZL6;9\KJPT[UEF>Z41\U M;HNE#XVZ&\U5-3[3T3/.7FBTK=$]#^U!KN3.MZ9[R1MUY-ZY?3FS/U+_N7 MMT;'`N>T8!]/_P@?U'_8,,2'0-J_4VIS0MB1HS"-")IE8(!Y@%7Q7&,,PHH MG6.&_P/"P=1\%)ZG;%'WL_'&?HNN=9S"(&"]V,W1`/@44-BO;=--\"P%+!+BX$<@,"X_(9YD`W_TR']]QYB=B]&PTE$A:G,T#H-X6CE9N, MV@%B@(\<,=#QR" MHXZZO+-#V3J+=2BAY^]8G>LCE,\H,P/1AQVW8TR!-8I."TV0D!3OE>X0.&H MW+/29LS1V+&A#RZ^FKV9$PSUO:301.[D(5@C-DH#C"XD'KB3;Y%H:9.NX[$ M09AZ.`8N_!EZY.0I++/L-SJ-T_3QM9P67IV^0!$E4>[%?@16G28%[2NS4(IL MO3(=Z1`Q=V)N1"=YSEHZGUJ.V>OP]D:OV[V6V>HLV7"Q/B$M,"2$Y^:FDV`M5)?PPIY_`H.]%_,)BYU4TL# MCQ^8W1P!##[II&UZOW^P,@PT#6@,D3JK3S0AXX,"`-VTN(W M??+N4BA4'OD#POA16>"L(IDQF:$!V0\P5,)(SB5<65Z.I9IILRD[RHU/WE%` M>X,M0VA@?+L:#!@]#%%JV`!=,2,DZ[-3`?[NYNC"1=^ZCZ_D<39Y\**A M`12#U57^#SR"SW,[41_'$E0,+%3?LP(Q,0C?M./`XI=9J,CN^1`?'HNQBX& M=%\L%7^DN86YE4T0/]X5P0[,)$=&"&>#&%U^CUJ?+>HH9KTL.9V,JN0>.W0' M=+K!0%CD@F/(NWW+@&&<3C#;(BX%YQ=72/R$-!K1L[!QE1X"]Q$5$0PH,BQ$ M;W!0NV,/_.T$UI"K?MC-'GOD7TV$QI94Y1UQ;1C-6\SW$G_=:7?-KM63[;K[ M=M^T6K:Z2XO9])2?U2"&.?68Z(4;`1WW\36+ MJ,_X#BBF>"^XYX6'YGMG"A;IC>?LLJB++M7+!]"]6!II,-]I"I-3YVWMI M+BT1-/W"$N,3)CC!>ANTXNF@M2KM_O56S%66B_1SI=(MT<"F#WFF81HNV+< M:$::>+[W'[0I+A@7ZIZ475A1;R27%+0S_-3>3F?C="@9[!]+BJ&U`0\A_B M<#)K@8(V$E$>^.6H'52S2#;[QNOVZ!W`=^:LG6E]L=517[0:I MRV'#T$N:Y)I=%"L_/`?P$`EOPPZ\3_TA=58-$N]D!30#I5`+4SU?C_8);KA M69R>O#H=T&Y2_0#QMHBVH7!M&["NN/![P!3NOVC8;YC(SZ,$`JG)&MJD]_G MM![<4%JGNALP@N.U?**L$.J!U^CL) M6ZKM1/$-#?^S@'FH)[[5-D=_K$>GW1GJW@8M6[J=Y-N]Y-:^#T5WHWK69? MC2XFR[!W13"VH@E[/;:\B@@NPK-X9?XD=-1QX=E_`SI4K:GCU`^&Q77Z2\8 MISL]$`>>H)$ZIM5IFDZONSN"]LV.WAQV-!W+=%K])8;IK$7.LX64XPH6BN@, M,4:I6;D83_SPBHS$>/= MPMBBMA>R4K+RP!=<>^17?MN$/-Q:KR8`TW]PU$I\8=W+J55-_1E)WFJ46(J MMFIUX63U%D5/_U$5_7C]1)?A)SSI9J!M+9ZZ+TY&L5&8`R8^2LP9R(VE9\L`&$,3)+FV4J"(;GT).)T#-N M2N=$:>&;>Q8`#_!F%7_\B$436"G!OQ4$"#1\(ODMSW>I;(HRJ7>Z&2HRF MU6:DL4S:^D!XFC>#AQ`K'/G3)UBR@0^,PR'SN=`1D^C&DY+6XC@=\Y%_)F8, M<-3'$'ZL$33%-4Z",!'S$:H&V.$5Z^$&`&4T!>J/E&-X7NC8PB!;Y3NMYW M3]J$8$^ZZ,Z=^'2_RY('S$F[G+.-V(\!`J0E[@\0WH"-/IL%;"!CE%ST?3 M1$9XLA?V=%`0%NX\8,QPBMB/HB`_T#N<2@-3Q;RB$MS_LY<^@LF!4:/>@TD M4@EO84FLBE-Y11)0EIL!/!0./'I`+>#,')1X4,TFAU4BE6,,X&4>1RL"/Q0? MPB1%UQ-3FWB(^>A)@4A\/XAPQI27@F%.$S$5ZSI=9^RTAX=?XCY?.%Q($V% M$<'85K)FE>]]OH<1#? MH9A`GGZ5PL#14HPGYD:9JL(B)D&F63ZV2E;Z\DI/H/%/9%\#@/0%!Z5G8,V MYNWFW?R@GB:S[@CFR9,L!5>0!%X%K?@A$DZQ1%S57=5>1&6\B+I$JI++,M^Y M,PJ,D[`/F.#,=37P_23S]D8:\(%)]4T1X1G=87[VDS12)[9EH@\CBB+/1:% MGQ!A'I,`5<`OO`#FD@J\4Z'AQUV!)(MD8`0`AD=5.'%T+D!O3+F.!GNT--P M`WC!9V9VA:=%/AYAZMZG'A;58@D7"^#ED8!\R@0;Y]:VVB=M:YEIC6B$7HP MXRRD![CC^16\D3,R'"1Q>L7@(2XKPY_03LUAY$9/_",OP-.U!B_Q M`(=#2=2_4U<`M8.`)1S`EM!J)`/1NHCC-TG=-RY]<1#HS"]'\\OSW"4-+S M)4'/UMYT=02]UCX57)3;DOB5@FF&LW4@0S"(P(6[34&'X5Y7'N^:!?7MK#0! M$=WN[S&@P/&R>]V?:)QNZZ=\U;TI0D+?0X4!,PW8FIL-[XXAYT3Z"T,UN9^+ MDX3`(LNC%?3Z/RT>7AU%,E6I]R2CN=;ZJ#JB7Y_N[DL6]-(NB(J`O8HUT.V M]1-_'2)012_%?3->5:@/:,3"TD)=,T4,1$GA,>0%$2&B9B;K$3#$J?[.<=S M_13_A7W/4$:OHS"`/P<[;\RE`L=6S:_[/5AOXJK5[O; MU5N4R\`X3>\1`3G#6LT"`(7@S1]"^)]<9L''TYL/.=AF$4\^O?E&PYY@BQ'M M^:PE&=J+;X'`9:37?>.[O4"XP+^G>0MRF`^DU"Q%<$LE+&6[_\&B)9"ZB M0+\+S.<_&JFAZ)A'$Z5)R+0,#(V,PK#)`@3!$E0?=]X M4QB"/\R:X7%C;VJ3F\'HI9P//B4V-2&ZV0X#?CE)K2#0KB>B5CQR\3YYS/& M<`VVX0/G!]9LZMXNE_@B-,%'36H&IVD4N!(PL=#V6PC)P&4$Z$:+]'1PA2 M\ESRK.S(]VCTLUJUJI33Y3AZ>):`-0QPY,=/#&:@CB)@W0,"[<""]>A_SZ MG=HPX:TZ)HI8&E:)WI.W+)@.@.V`?+8[%51-K.[IXQ1YY,PI@#=X:12#18W.JP MMA6U`:\713/@=%+3S#=88V6!BPSXMPFI`+Z/FSG+K#U/%\!%B8#?$5:73K&@ MG6+9^``OM7UY+K#E7T,R(PFL(A,HHCB=I#UYQE!Q9IRYV(W<^X'OYA0 M8T:&?GT+)Y.5$0FGP#ILEAEXO&T-+=\$L`'E0.))@[$C,5SIR9R(Z="??$4 M4,-HG@WO_".M]A5J/Y%HRO[+Z>5SZ:4Z8WQ M0T&JDLIYC-@87#G>6]XSFC+/,W!DF_-&]T1N"]@(-#&Q\8;W73.VF'A$W`4 M&/K%6Q@0=$90;I[;]A;3S4P!$[&Q[-UYM-1\5/4#IY<\(8?J>D]=EFJDL MS]FLS>?Q:.K:?%9P45C]G/154-IY)\(2:-'"S)S)Z.EB:V;U M"ZR9.IBF]/XAH>F!KP_&F!H1%:'AQ6+"G60IT=%<_5/67=!10EF"SIHCUXBV)8^'WX=HH[2,/M&H04D47U'#]>,P&##U&=7HU/XN82QRP#Z+@1HYD?0.V<9C-[5:+JNQ8J2@[.;6GLMDT15%UV].1(B[';RLE99EI+"RG':%M)1N( MW;:WEL1BV^5H35TOL/#5:L>#_>.>;8AI;YO%U"]CO`?@$YM?&E+1M;6]O# MQ".K(BH0O.L6O]EU4&N-YA< M4&M.!(I\UY$[]ORGGQ=[NF51+Q6\@C>B:ESC'F87(2OY+):#GSQ0FS&)9"M% M-^(?6HW>O&.DGM5(MY+'$0.@P:;TY#%R)HU3ZI`PTM9EV=$7)?U$ZNPX$=` MXXPLSLDMD!T$LCR!'URBZ:^%&0.KWMG/3%X6&LU.?5%6Q+XI5R'<@Z+Z31JX MZ=!+V/#M7./=W<<`HV'M(-OV"3A]_IB&]]%QCNQ09SCDK$5P@C6ZF&$@GG) M<'&[N?HLUUEP>>R2V';+BG-!4+1\-G:KIZ4T>Z;5[[UTUM52M5&I:CIML]NQJ\^ZHW6S50^- M6F4?V^8ZV1C3_OZW`V5;+5$;/KF9O>YS`GE5T]9KN=A;OV=89VFN"&;)%5I= M-CI:=JE63\2LQ-ZL[HW/?EF[WOD9PY_-FO65)_L0:R5'?;IK5\4BZG#^Z M\\N&NX,#-[+YQ=^B)NC<3RJ1FU2V=D%+-X4[;=.R>V2GHZJ:UH+ M<=6%>%?^E>GT';/;[E=?9E>IYEBYW@+K-MS),-`&R9!];[$JPJ6FG_'52):X M[JM@8W.0(K0<2Y=HZ(M75HJQ'"))7;!Q@#2\E,`0Z/AI:Q+7;!Q,#06Y7-O M5)#7\72^I)35'8YF9KF80SZE@?,\\,)?2"/J(G#X0K:6_GQV0C04E9@61$U? MB#@=`HV5%/E_T;O9\/`D_A34NGO/\B,J@BY^L&C@Q;.WPOLD^3I"6.AK%I40 M39OXR/;PT5>0?'!]@A1U$P,.<2'!??(N8IN-KQQ3FOZN:QN:]HZ2\?M.V[0[ MG9?!UQ5HJ$HTO&WV M6BVSUZT3BFNYVJ1A.X1;E'6F?89A&A^[V&#[UA\3[`>ZJ?A:1;=G=<."AY>0^:9K=\QVNUL9 MWF_5WM0"7PN\;3=:U?Z[D+(JNRL_.] MUZPFW\0DKG5&XJ#D=E6H_TL@4^8%-0Q)UG,`H.2D.M1^VSM M?JU5#W3YFHW>0:'_U324T?#WOU6!BOK,^>)+OUX066M%B?90EW/06[U>PB-: MPIJ&?=-PJ?)NF"N)GNS$O7&L9JFW;8W5H9V",P_!!HK(R"MAG5USI+-U([BE6M:3@"&@[U M@/T;BQ,X7:]K/?=2NWNH=?'2O=Z^51.WUFEZ?UQP"M4V\0?C/0X#7OI2OM: M<`Z'R%JZ<1RK81^#6JQ@0.'O?WONVGP)@Y/'VB>JZ=Y&UERG:?;Z]A%L_9K( MFLB73&3MQP@_9NE(784%9X6.O>OB7>70LPK'.$70K7LV9D'RX2E[Y-I]PH]. MO[O14+R!$NSCR^":15XXE'7FHJZUII82[V_M]_7VGEY?H,,4H%"](/6"[(TCVT<'V@LO M#Y"F0O2?&4N_`LK/$I.X?8@8%>JKAIB?X?ZCBV#(LQ#5)RI.D/OTV4&# M^;RHUTR$;,!SK."2[5]GS4;BW/^D$5LN#O=\ZLDM-B:(N[.(I?N0Y.(SP[.( M>$ZNQ1;(:38Z"['S:\YOA-&+ZRDKJ`V^/WC)SK2!+'2K%<(.Q;+>__7^WX@W ML,6EN_@Q80.\;P-?<6P:3\R-"A`N]R>U%3F,;X'SK4:W0F)[S)QV#E-![-1! M./<>O2$+AL:3Q_R%17XO3RXW=IY)W-8,'OX6^FWB^ESQ5 M25J.1C+MY3/0:@WP'#ZWEKXAK_#.WZD?\-6+_S)&$6-&5`A37._^YTOE"NG5 M]?9_%J/;2P/[GG_%R:^[#-51<^948^0%]T"" M%W\+PCN8_B..-U^[NC:S[V@"L-5:%BA`\Z+X4D5:'@I MZWHU;!H9PPR-(:P,6C28B,<&6`!QV%@\$MMV2/5^!8C]L0-S,8;P%+=P9N[(=\VK7['=)8O):N<"-1BND\Q7:-U]#KD-\V.TS(= MYSF(HG>`(?P>^,P0/&I0TO,$9XCG^D M<_P;=^E3=T7Q#:I`0U5CIMFO^^8;6=A7NNQ,Z^6JPT[(9U.RVS9!]#^L8P M.\_E_E2PKSVLS0&_I:FMC>=V<]?O0^!\Z,P M.NE8QAO[YX[U5BL6$R'GKJ/7P8IPXG?!Q[.^K/G,R`I8)]9\A`.\P_\APT+ M9]'BV?FGDVA>=KXV!2.%M]$0WV[.7QE#-O!`5&/,0W]O9;-9G;PM3"Y?>M!Z MWN3:%ORG8A.DU6OU6LOKJV8-\%.N]NU>A6;X=\TB_,"]9_9&ENN/F3=\>+I]FK#3'UXL]`^+9I[YS,9W+"KZ[0<6 M#![&;O07#7#CPE3%PY_=/\-(CAC3U[??0_5!R3LT9D]`3>O<;H(V:/2Z&:OG M,>M93%U50@Z=J=W6BV/JZ6``I]TDAFW(/#+ZVQ7;_M(.K]\U_O%N29>^?R=UJ"7'-W<-4$9MD];_"Z"\XPYRY M$R]Q_9LTFOAI?,Y&WJ#DD'$:_W$UF;G6@Z0W>H[S79+4#Z/'$7SKU$8Q]=1 M.&!L&'^$\^JW`(XHWR,O25AP#2=;W`U&C$\F\&4J9J+3BRGP5"5<\T_/WT) M'PO.3];LY^5S.VF_>M]O6=Q%WQ39NV)!RP8I+;``V;ELF>5%%MA-ZT!Y,,<* MKL`#$/%FI]5O;YT!M^%7E4/SE8U=+X`A;F`@%G_8G=3#=!VK;YO@'GD+(,N?C15^;#+(?7;I0\[8!\:TGR MITG3!4G:XFOW"0WQ61I%98C[-L,F6N2W^YWFMH!J9B4YQ[&6/<[5J@JE:D M-4J!X5$X8G$,WH;K?V0LWBF#FVT]"C:?HDW1OBGGQWH>[>#!NZ@]=\COIM/N M=NP9FJ2ZMF^&OT^Q9_=XJM%YB422+DSTH"KO7U;9>,2$ZJ5?)`XO$C#YY M[AU"Z.U6%+KM7/QY/D&;(GU#.\\"K=Q(E/S\YB&,DEL6C?'5V?DT#"BU`H2#S)\0E(7QI!;&D^RF)FK+ MS^A][IHJ_SLD<$-H2]>V];F,/'Q-^7)H3,'^+C%>7L%G,1NDB??(;B,7[Q3/ MW:?-!!"`U/9Y&:7+T_)^^NX/74HV/$_Q%,`1M0A\^9#HF'`LX$:_@9O(DE> MUW'P[:+/UY"Y/W3GZQ8!L-P!88-]>-_H8&N83((`9R-'8#.-Z97##DL2GHU7N]S1UD""AOZ4&FZ]_\/ZK>V% MC3'R):[LS?$1KF_T,)D.^L:FZX47Z%5C\OKRSZX='],X&7$V:G[LE:CW+V9 MP[-C9O1B<3X`AA:%(I<+46YC9K3!2W_Q,8RN`D:OS,5QIT;:D/@L/UM':;G M$KXB!T1T=Z^SMQJ6O=+LBXG6[]BQ_$D]=Q5]Q5Q%V?ZJ.'LH\_W.V6`V/&IW M"C[_Q.Y=_R)(/+&9SR(V9&?WEY>7GYAO(XL(H7?\E)\78;7ES5C=K>7WZ#/N6X(?=Z72Z.^1'<0IGK^#S38C'-,].[R-&'@H]([[, M+F\XZK-Z:&G/M-?M-.VM,_$9&7J2\!^Q]W/@^?]\!2J"O7I7C%"MX$D4>8O. M>YO=\Q2>P??SY%Q$[@X#1#'5%ZW(T,^&=-N6TRS>2Z88B$O=`Q5_$`D/0\> M`N_?Z<)C\/[8\OZ#%X1CS_6-3VZ2H$D:AT/F%[!BP0QS(0,4HH4&KFAZ>Y&& M4H-I6XV>-841KXS_2I,MRALHRR?XXR:]@T.!YT9/F`$AR>Z_\9)E-^5K^C. M6@NGI:?]IV,.^6SW MSI>;_W2\N>A9S+#Z"90#YU7=O[E[5'(/I=,NL"[&G$" M;L-K09"@\.@.(W]\181`^L%G+_#&Z7@YNZ@2]99@6LU@P6#WQ[(,MAO6.@P^ MO8>7WV-NG7B`!%S-4'4>"E@4]Y$/+1N^6%Y/WU^W?Q19>ZL4+5SGG`\P.M/,+EO:B)5I$ M\#9G7+7`1,VL@H"]^@&+9N\OYO/3<3;`S]Q5/B9L<5O]J_?(P&?1J=N@5G`P MLVSY-V>NTG!(9>.NS\UD[A)/^@:?O/%"#(D-6CJGJ:7P+T]@P9Q`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`A:D45VD2PSD/85PV#[=4,IN^T[8[G05) M#1IAFYO$.L!+)9/H6)VFDX-B7V(6Y3=D8A%W%,AI]UJM7KWY`E'?J M969KWI8VU.`5N10)7F=/62H>G9E50 M0;PLB6=X+L2KKJN(-MUN5\"V&ZT5EF"6V$V&ZC7!Y:9[0[OL#WJ)PEFY&$_\ M\(GQQD;\U<(#N?;=X(L[YH]=$JRZ]\B?PZ_@3-->NOK=:7?Z>N78QIFS+\[/ MD<)9K;X'SC?[5M]R.@?"^?S5#GGZFVEWL`?.PXG%ZCO;NO8BWAP$ZV^]!(\^ M&?Y2;@GB[,X(/:TO87`BO_H0(G6C,LVKZ]'(7U!N M4[T,Q.%;3;MN;D[@"WFPDQ44,_QN+P0WP_D=+.^; M3M_)X6)O@SN;Y/X71.!:<@$.PQ?L=YJ]_K3X;YY#6W((IXX%RQ;G5V91YAU_ MG(:.A+0CIE5KG2KCSL]?I^X&'99MK%.\DI.T\EI5RM+,SY?I32=0[H9M&UTM M.?)Q+MASO-;%G%.!XZ/DW32VV"I>[89YMR!YE8\WDO@(-U"VI?L9[DXMHFR=Q5F(+;G-=C6 MG/;(N1W)R#8Y]^P0QB+XS6)(DI5E[OUUZ_?^9^M\`T&7A13OD2]K]+!R?K>M MSYW],&9SDKDD-N\S=!4O#MQ&@/]9,WJ&#MG/C)9`@7WVDV7<$Y'N[<[IRJP M\-EB,<7"UB;"HA5@X=)HS1N400&M;+>VQ,)%F,S[8>`&)5!B4V\BAV.G#,S? MQYRFR4,8>?^96^G9M/_X;[?@,%CX^1[NKGHM^L\&5J,.?OB?&6.X26<;Q/K M-W'ML57."SS@_#NN621Y5/VXU#S)WP3[%W%H(\O`1Y5-!P\\7Z39:G7;F_!` MBKBR07;+"L?AQS"BCP^6XX[=:CK=56[N5N3,3$88GPG2B2YA4`)ME&,BK;C MY+VR0CK6I'2S$!3=EMWMK$IDA(6/2.4N'RJ4@L+4E\&R;Y(JBS,$Z^A,GO M#.@:A/#`DQ(_LPZ^LK'K!?`Y MLC1R!TGJ^AN-^31_;WZV-Q+SV?@4%X1CIX91-PCK5?UYO&\^I6-JI%.WVG- M#U6O3O5NV+!1'65;W4[;FG])]`Q&G$;,O1I=1^&$1P9\P;'#_B;D+ M02S%9::YK1G/]>-X[]'R=0L6SH\[B2="WRB<4Q8_@Q?O?^=_$G]E`?O. M-\/&9H31[VRSKT&)6@5<4?@\X9G;E\`HS_7I\8T2/!=9RNG;CA2S^?2\S[6& MF)U>(@SG%S8'$4M5-9?MCV7Q3YOM9D>+1,XEY_VSZ,[OZ];SZ&[UK:>K+U% MNC>JENVFT[:N[43%3A9G MFA8#&6>:_;RP@&5.K_:I?C?<9:-_KM#BIJVIVL+IK3UYRS[Y;S\O`M".]B.`^X=SZ[#";@=J); M'PP\W^/Y.$A7)T-KGBK@/3^H%5%I/##IG MD??H(AL_>H$+I+E^UH1<4>2QPB87,V@@3LMQBEKL;9(O%67\K.SNCO%VKVUW MFZT7P?@ETO]WR'BKWW'LHB[556-\R?B_PG'W4QC'E\'`3X<8?;QP(SP`+U-) M5J4]8'C#?[[Z&(9)$";LQ/X#KX<[G5;+[CQ_<5;F7547;(F@[MX6S,:2^+[3 M=HJ:0.]BP>-CUV&W)L4'S[W'8MU1+GO+OJM.$DOK5E6LPP[:"8?SC# M@D,8/37FUIB^`IN>02H/>_WODQ-#JGWCA@UP$./D!'GA>\%?/X_$=Y_@'\8/ M^BAYFK!_OH)L0"T]BOQ:13Z\.E#DDQ^?O?N^_?OC1]WD=\(H_MW3ICZ,08`<\,V+C!/3.\P!B!#!J/Y`I[L9$\,,.E(Z<1CHP$[XJ, M>S!AL1%&A@]V#([9(_@3GYOPFW0W22+O+DU06.$7]%4V?!I$S/4IWV1ZG(CY M%,S!'WT7D.!^MIN,!^;CZ#1@Q"9A1`\/,$C`T M8ME3/L:A0A[!@@<:_WB7$Q`E,7XXR`D+_-M-PDBQ$.$6^;_Y+R8O!C!__R1 M^_K=C#2>1OEWN-%`#@)_+I`Z\<2[D3M(3C3IXV\`Z2H@0;XMS$LYLC[ZYRN[ M86E$KLR`YGP&-/?/@.:R#'@WHX]TO_ZG//SQ]8,'@8>Q&'%:58F;E#ZLT$OFNDA>]>B_FR@B`5?X+D]$3L$DL M,N+!`VSQG,3$;-"X#Q_?G5W^#[`1_M-U'`?]L^D?R^%B=H]:@O]S""_[,?&] M@2="A\;0@V]CH.N?K^2S'+MU7L.8KF0=YR,F;>L\/)%S'_U7EVH9ZNPE=?* M9N&`]2ZEX-[42[XJ6G5L]M6J)&]&U[7N4Z!,+_FNK<=1W2GZ&VJ.=$[PJ MSW\C_RU?\BZWR6#7_:]_E')"M$]R[]F<0J$CVI5ST_2MAIWKS%+.JPR<=OHA M!4(N6?#"V"J?G$62EF"Y"SDVWT[P(\,)'!E."HX,!:Q[Z1J_5KJS2K=U8EO[ M4[J_><,6SV5`^A76-:#T!@H%0<'+3@J,LJ3LJV?\AT#R>M!%=P)2[D_=:[ M)`N9G&%"(ASFX+S(_T1IHTK:8L/%?5J[I+5DT>?+MRQOZP[NDD3.5VH67VB@ M:=8>-(L^SU\>B\A&%EWC.6!3-\E_%'=()K$`6;Q!QDA6D@<`:>/#N[O[R\ M_)0,JZGT>%Z9SASAWB['H@VHO3(>"SH.;W^:X?,^WEJF:0_/[M86_1A;7MI M=0J/-NTUU"G-O/!9-^KK"_2O`YQA[O!%A26JN2/)3B3Y8+>`^'WP/>IOJI3 M.]'R\G"FQ"M5]V2_"FW5GHEY`W&\H;9\LPW5X6-'`H_OWD(HP2S-/'5F>'. M3-"7,&'QM?N$,5;!IJ\8/<4,]"AYNH6IQ"Z%M>,/3_HW--`UT$^:^.S!]:Q M&YP&PSGI3'/DM,71;TJMYCQF[0.?>M4LRJKC4V/]QR8JD>;#4R][8BL[["[F M9TD:W9)LJIBC(E>C<[9`:EXTL]W4W)GX@'T8T>U=<$6 M&9!IE!PGRC0(7BKG9Y%]4BTMLB'>\8J)S6S$WH$/JZ"5Z$MSBVJM4`VM4+M%=(3:O;`L?I"/RFEC$4.,FZL1##P.`[)GI\%0E@N4M9+,0)8+Z\6:UJ)Z,9T1)VVP!;:.S+D9 MRK4M@?\?_OG_`5!+`P04````"`"S@`I'B3(B->H(``#(;@``%0`<`&%P9&XM M,C`Q-3`V,S!?8V%L+GAM;%54"0`#$03)51$$R55U>`L``00E#@``!#D!``#E M76USXC80_MZ9_@>7?BV!7[M7:9IAP!IF>$"`\FU_72CV`MH:B0JV23TUW=E M3(X76Y9Y,8+,S23$:7=YY%7J]7+_?+;R]AWIB`DY>RF='E1+3G`7.Y1-KPI M/3[)2'!0+R9O2J,@F%Q7L_/SQ5>M7E46!4OSDM/'2O0M%I7T6D;R;>Z2 M($(J4R\GM83ZJ[PH5E:/RI?ORE>7%R_2RD,!/>A!P,G:OXZF$W@IB3I>.(K MM:-G(P&#FQ9>RL<S^=%55TM_7._>-YGV_V<`/_4Z[U:@]-!NWM7;MOM[L M_]%L/O1+CJK]L==:,8%XC,@+EX\KZMN0345I:A+?#?T(T3:J-:PO`2`//` M6ZBLMZQS:A_<'>E&5\QPL4J,'$K$>P#(I\B[$-9'A(RJ2C`N`'P(^:_9)"'1TZ.="B4KRB5`^"7G&>AP%.!7A5-8HK(] M<`$5?_+A'@#?J<3LY\PO=4Q3^]LXJDK8$HUWR9`).`G:T3C$"8N@D3:?M9 M,$@)N_)O+FF:Z<=3KR`2DOB^)&&:,2L94-OK)GWI*K[2)^[99"EYQ#,`G(@0OEQEY:CEB5TNW2VL M-X+%OB#FG@>PT+T'B#1X72(BI7TB993RRF8U3RTGP6HN6&R,?N:C4P^FP$+( M)C!%X"2X2C/6OAAHR28S3V$`6G(']K%;29\U9,O?Q(AZS).Q$ M.--.^WQ./^#N/R/NHUY2S0Z#F::/)Q0N>O(>>XU(DZRD<5+I(W:<=@3TE>; M9MH7A=3Y>,R9$14;14^"ATT#[7N!:YY'YSIT"<4Y5)U,:$#\)=5U<7VV\$D0 M90"?8%%#P)"&7A-(AAE0XE3D'`<1F$K1D?4I;K8ST#X)@S`<&^/,U2$(!S MQUR#::H';&-UBQ-2&GK0$6#<;34RKPZ9P'V-&"N/J+729T@1UH0#,>U4[,Y MJ:3A.%!9VS;RZ[???/VWR^87SCRU**D8D-RGGO)T_0!_1M1T!IT)BA5^'U8YP0VRQ:])-P''^L<_@X,-?%5 MIM(;4T9EH/2:0JR7;M9F5L%15_53=EXHPW1L'$'30\D(#!J`U`#IN#S:"DV MFT"]W&GPEF&[C1MI&C`1X-(YJ-C1QEP$]+_H3_UZ=K4:5"EM=O&33.OEK48 MCD/0YM+(HR^5+CCG1GR0<=Y;OZJ[7O((9@&Y`T?O6Z?X8S@!$Q+>(FR75>Y MZ/G.5SONT-AYJ!^BTE]CKUL8<`'S<@_D!63S!4=0-(4R(F8MA"O:F(2B0? M01.``GKK(=L]8B]HP`P4WO9T;UJ],&.N9?Q&Z!U:JLC;(C@=.?L2S-'6 M632/KW;[+`U0_!M,9Z%XCZSTRD+L,K>#D-KXX-4G4$7K:=2Z.H7+-:M'A`W1PCM"1;10U1FLKTG<9N_HC?$]18HV[=?$8<5 MHWG1:KDCLIRH\.8(>L"N8&.H%9L1#QBWP&"@71],DS@-8A,L-9UGI2;N#YFT M5P?Z[GS^O.^8&=#K? MT9;@"?1.;Y>B\YT;>O+CYAVW`]U&SM]5X&P,=N_G$;%SSYLGT=.%3]#9LU@ MLW&]H#\B`FY)Y$C':NSHCA%X`Q)38-FOZL)-LZ5SH;'2=$FLEP>0\<'S2W M<5XG/&A&(^O7%DB57'S"J\$WT"C-HXW[RT?)^ M8G+R>BM?H:WP3?03,VA?>8.O8L@O@14E`M=FW M,UA2^#+%V:JPKS/G)'`E?9,+O`(NY>B&PAV1:#)15S=.SU%64&8 M4AY?S;/,F4QFKN>\Z(U/XP6^JODNXF[("CWUL--C7?5]QV:CW:K=MMJMAU:SOVZ@-B>5A^N# M-;YWC@^FZ9'N_2_R!M&C6IC;&#ONQ<]/4\:EJ#DO!RR<,V4<#..PEH/#=8$SX6X#!QO/W"\.2QC[S!2!4^S M,V`%WY,0+1=O,7AG")XZAUFXF)WI2HFS7_^K-?SC?U!+`P04````"`"S@`I' MMJOXL3@=``!9``(`%0`<`&%P9&XM,C`Q-3`V,S!?9&5F+GAM;%54"0`#$03) M51$$R55U>`L``00E#@``!#D!``#M75ESVSBV?K]5]S_X9E['L2TGO:0F,R7+ MGI)Q9-0A:G5(-D([5O_X"I"B3(C8N$"`WU6)(F$YYWQ8SX9_ M_.MU[9^]`(B\,/CZX>KCY8`V"Z.P!EUEZP#W[[D6KL^&?YT/7BT)X]BUMZ^SJX_7'RX^?SO#' MN1W%T+6W?S_KQ\\QBLXN?_K[6>_RZO/9Y?673Y=?KCZ=]1_.SL])/[X7_/YD M(W"&Z0K0UP^K-I\N;CX_OW[Q]45>872WZ^S MLE<7_WFXGSLKL+;/O0!%=N"\U2+-T.I=_?SSSQ?)K[@H\KZ@I/Y]Z-A1(BDA M76?,$N1_YUFQ<_+5^57O_/KJXRMR]W3A,FZT[R;?P.>+],$%VXWOIB5^;"]GW<$Z'A2[3=@\?D+?>^"#[;@7!DLEBUC^A M_#.A^6^DM8L&U.#/(""#YMP%2SOVHQ9I[?=$J7AVO8"-82F33>B,VGB?`W6 M3P"V262AW284KC`QT(F?P/F>\1;II+7>A-H@C/JM3IE=@PE-&4&BQNV-&YR3 M9?/RA^O+I)7!9'P[',^'M_C#?'(_NNTOAK#"<_WLX7,P_G!WR2&BS MW&A/_MM>W(+(]?P%>HQAW="5%?H7F".&-2)_"<.TA%,+M.(P`FMI; M^\D'Q6ZDB)9JJ&N/ MY_W!8H3'8`U")9MJ.OWLC1?9_CPG=^++??D9AJGOC+2KAN2=MUXOI,V)QMR MWD/]P-V-;3`?R/;2;X>!2^A_X+/ROFR(X1BX"["(>XDW``4KIDEX76>U4C MAJR?_,\U)D#]UG6QU0A&F>8;[[4/#Z/%PW"\F/?'9&\D.\MP7-Y7)#=9V=8: MDGUG>_";[<=@_^$!V"B&@-PVT60Y"-?K,$CDE@GS$9$YX#T'^"+JX"\>@_`) M`?A"MJ11L(DC=`]>@'^]FPE2_!Z!C$10^#;B!1[!_QY+I2`O+%`0N,#-)$;H M:GA\2V[6H5/HQB=WV1!2#[#)X75IHZ?D!!NC\V?;WEP0O"Z`'Z'LFP3!\\NK MW>7U;[NOK7ED1XG`,&]@A#^BK!???@)^TK?%+FQ=IC+20?&"H"9#;5+0NCI$ MLP^+-.,;1-;:[C)1Z7:^Q.'@&,%!Z8B!X;G#QMMP7E"`65U'`WP_W>K:7+Y6W^,O6MG[1#18&`L?]+,F0,@GW'"6-,X@PX MP$OT!F,0[=CES2E.->OGT\%+P($#>VYPY?-_CT"O`0FT0K``O<!(WVVX]:SKM1H=MH%2G4 M$-3'XX`%J<&3.`2!'M;S^C5W)NMIJ@$@1!%"FO&G`@R+@=RI#1-JB=DE"9018UNA%:NG4RM1 M"]NW)ESB,S.MS/P`H(8B'&D5[!Z.K45M2!C,V+R;EAI%[1Z.M43M5"A,]'& M6;[LE4F^L0Z]Z;DZ!T$-JZ=3Y=#@M"'!ESE+5HY/N=E@]71J'MH]!!)>S%F? MB,.P%R7>P\0F&0:1%SR#P.%#PZEE]70J'UJ`2L";.4J)6K=DCDAZ.I47+0#' M9\T<74?1;TGD_D`I;?7T:C"X8F8:8VE<&'-#RL5-"/U1#HI:/9TBEIHT%@P MYW30=UTO[7IJ>^XHV,70Y8CF2"$E:UKG7J'6GC),67.H6)&0HD"X`YM&.#- M$_4=)U['R9T:W]D\Q^/M4.+UK5.[4(M!.68,OEL4>E,85WK5";40HC.A#FG M!M$!J8%EQ+HV1,G0PNVR6"&Y&CQT`>Y(+H(B)E>XB(KN(R"XB MLHN(["(BNXA(Q:M9%Q'9142:#-`)1$3Z?OB=)+B\"^%M&#]%R]@OA]=(N)E4 M:>=TXBDKV;,`=^SJ)4NM`9U M5AH-[3%LCF:0X_2;XS?/%V=(5&],:YAH%?!KL6:.^C#G0+7-I8:[C<$=%LLB MS/\N7NUKM8UOK0T/5X,T0N>HE&`(IBDW;ZS'8`'92SP/Z-7T1M=6@4T M'@<"/:,V.S,>01.8,.DF-K\I@/.5#>5-SZP&]$:@5H%-GI\,Q!\,`S$A$/7C M:!5"[\\W_;,0O,.>F-3ZX-&XR,#ZT,9'C]K!VOG(=#C?U+HK;>D-8JN$DR\Z83 M,`F\"OL6IY;>N-::8-&8V(.D7W-3HE2X7S%JZ(U];03.&P-[8/1K2DI4RNU3 MO&JG$_DJXF/$T/5H=:;H\+3&$Y3X/G!J66`[P<;DEH"]P88S,MLX5[ M%+L?L&OI]@L1R%UV'N;Y><]@&>(TTCYJYOF/#&(4A6L`2V0+710$-?7ZD?"G M#@,Y(4/FH%8>F3<@<%9K&XI<&455U;B7''M7.V3)'^$,K$9J=77S(.JBGQ MFNQR)1QD$2QQ9O#<:Q%`^UI`T;P^\MU):W75DY@H=FR('QHB_ M[$TFQ()51:LK37U@..R8LW$]V/\-879&0H)31KFP&N<7I><**A/FNV-[368 M+`M$"G<@9AU5?B[2AP>ZL.G`<+DP9EUK&Q]#S@9M`=7F.8"1A"GKC$`.]#8")W:I^GK=BUH!D,66PG6P1,,X M)HQ.EOL%@;DG"6OJ=1RJ@D@%A@0!!&6K>KMV]2GFTT,HA-M\,M:#=[R/K;!8 MA3!:`+@F/M_W,MD1J!5T9$AP5L"-?;Q;%D@2YDO@5-.1/8$E3I;BA4_^:=O5 MBRR)+>K4\@;8TD4@,:!E<&/,+;1$H/`.RJBAVX;.E+0D,.99SEN$QA#=0%L8 MF65%P`C$O&8/P>(K>2\>EIMY)P)PCP]9_$6Q3\HT8 M8#&OMW=58M&..&62ZLVTI>3>IBY,RSD#<&R)#=3!521]!\3R%`GDOR M':UL#ZYMDIAAL/+`U0G2EU./6# MD+P@.`I<[\5S8]OGX\$HKM7L+2UW-O'F["UM9@[0FNVAHH:"PX2IX(R""."9 M',WPZ$OC#M_4\=)P\1K1G/JA$8(BOLSQ8BC231B6!H\4UISHH1%(&?WFI,@I MTI>[\"UP+XBD+\;?H=TNB8]$)/3MUM[R'^NMUZ3F9!"-@W&I3EY3FC6L.>5$565_8U[;R-;#.&]F M%K9\C/$HF(,H2FT+!:H2+<_;>Y+9GL(ZG+;1MN:4%9)0M\JN.6E]F(O8VZB= M0GPQXGE\2+>A.5`CA'>/K:+KU-S2DTVD>6S68;888J-Z'"$V"_.Y_X%?" M@DY847/^C"KX2/%B4Z@;)<>OFX`/KP3%CD['Z6TWF?BJ^YQ#`9$>8'4IC4Y M?#U6K^/5+OWYCJ@)G'G/RD'+'Y%'2E-:`0)TYHP^E(;2(2P?,3^4!@_)2#$7]EW8-GVQ\&D<>T95-&>!HQ0>@"!J=@Y8M MG;("3VE@6C0/B^ARF&+(K"S8`V)/1:J:K<,UQ7N,<"<(7#!X'HU&]Y$KB&\J M%]7BC$0;AI23(YU<8QP>J"N:`\'JXX![D155F@9?LPQ(5IE'W8BE9+MS<1 M5^P5D#+/BT@!5(;X%;6-V1&VEO0MIUWW[%P9S+)Z,V;P!SQEOV&PH%J^-U4$ M?%!8;^J+FA(N\]#&5L'RM7J&(+FU,7;FT\!=8N=IZ7(^8 M(Y0B>GD^C#GU[1-RIX^D#\+U)@SP?T4)A[CU%/D2;]3"9DRQW/L@$+A.9U: M7I6C3_7WFYD"IP/%Y,:8>=46/H93(IWUT#)CCA)J0)1SVN5J?(_D(_H@N0(^XU>LT9Z M16D;L@=4%[MYJ_P#%MTZ7@L!)33ZY)U.)+I@B\1;([([5?+Z?6RDA3Y M(<$=6G4_6;XBC1+YD:0O@K`+OCY@;?"/; MA-73&4K7&$L)[LQ1ER2^R"R?[7(AJZ-UT?T2G&V%=JV>,](-KG9GCM2U:WK M4]D5.5,](:]VB#"V?"^OQC>3ONSQ6^+67\\[P\6H\EXWF5Q[[X=UG%M\OBWF5Q5[:;=5GQ)?#T4FO"&=@;+[+]9!4JFFUZQ[?;X)EQ8R/@DE`W M?`VQ4Y0AL1X3.=YLWXI,[6T2'__=AJZXT_YK0X8EN+L+)VBQ@/`P9L,DS]=?`S1-&H",@CZ!D?\4D,?LD%C@Q!WI/P+V) MH\?`2^YS7$NG3`.:U8[J3E/2[)NCL2Z[NUO\7L-S`"?4#$3VRS,<5>PL39957K=.L7TH MA.RVH5.4047@:4\KJUOO=PPTX8G"_%8<^NXTABC&O2_"R0N`?=\/=W'[ M:52`2'M?K37=+TXJ0K.^,-H($Q7@G6V3;2%>M3W=3T\JQKR..,R)(N4F6BF& MG>S/63Q[3JWV=#]9>>03K8PXS`E%G<+0`<13RKC+RM4Q$M@DLPD&(3PV%DX-P9DHVH_O5 MS,AI2"&JVY6M6MN&/@N)L.H%B]N.WHQQQ[Q:"<6PAU>A1UPVQAIA]6( MWO1Q1[L_"66P1U6!ENH7&"4/[!EU.!;FSRLU5K1FWM.&:[5A;`'UC`'N.O. M`:YS@.LXS@&N&VW=-D`1KFWG)GH),OHBN+`T-H9$MIV%>6JN8-H:9XC[G0`RAX M9+E<4DM>!-H@Y"W9>6H5>"E+:AM_(7\#MX]('@?/]O-KG:RRD=?&._5]JRH" MPYV0C^^?\=XTE8W%89BC\9-8/$^'XCE(+ILSL.S238B4B4HZ?7\>@L>1F<"Q M6JT./2$F5>B3K`5[^VLN]0H>`G]%WS5R9=-LR`LPN%ZXX=;`%"J@,;]+Z]Y3UD19TTNE/MK:-@/639'UN;XS>6`G?JVP'1KDDD_6V_.]V: M^QVG!-%^ZQW(ZE-<1IB0]`ZI,Q+6)V=.'.G46&R:F8=S8FJU2P"]/'!DX$Q MX&;,"`X-^6+OVY;!X-@<-9?T>P3C4GJSZ4)U_JYJ6BKBUV0S:U>O(_@CED M%!"]C/>2KI.$@-[EY6>^88171VOJZ/+XI:C8!=0;,^1KW]MWJM)''(#EPO M>)Z%OG\70OC"NT/M\-WFRA&F;C,V>Q:9#$U;!UG]5]G6;R&>'@4#X8]])[ M-RMA8D1%HR#-5YVX_2L3C1GCJ:QR!"@0YNV[EQD[4 M]:'N:HE'\.LW@WDA06T!%X4DU3LNRFA`(N`6WPA0X7_!Z>Y$/2^:C$@%$C3G>8:F'([)4P5''96,'D\T@92F@/!I)(!X[\22>:.<_0&5!9]H?#6C"3JH' MJCF>CTW"B>8(;',>1Q)NKWG69@/(;8!$N:EG!3BF\ZF9T[,)N[#2+JRT M"ROMPDJ[L-(NK+0+SWAD61(!$X75MJ%E59:!.CCHPLK/>4S0Q=6VH65=F&E M75AI%U9:_=Y>]-+LQ]$JA-Z?_-B6MOOJ@DDK2,J.UT4FIP!F MIS`58T_4YVG&E:H<@Q(2.R'G$!:75MI))K2"Q:/R<:0IRT+'$9%BD57W6 MLF2J[ET(^ZH"`QA=G6B(J?KQ1I74:9H8N]2UG8VQLS%V-L;.QMC9&#L;8V=C M/.619(@ZMK,Q=C9&G39&UI]C@K[P(K(ECP+7>_% MK1YNN0VZ_OK-,,7NGRP:8+IP]T0[A#>C<1ADO]R$Q5^>>M!X.!6T[U&\#AB MLU;UQJC7F:D4BV]S$?#3W.C>R9M&9^A/N_GNHF84"\N<8P>=PSM_DN/L-70B=75TVM8/6,OOHU`9')KSG)^?:740!?/`?0Q;$/ MQ$LX1XLPCY5.PA1-`ZCWT`T`T[X'!`/E;QE2D8AH+)_J_=>TYP=37R&I>Q[ M$HOSB1O`C$]R9#XZ$7GVDWS%#NJ?`0(S_AX?!"-H.\2\N@!PS7O>V!PBK=Y) MYD>3W2.-D7$V07XX5MC[`7'[&.D[VX-)>/1="//G0:HK9ZOM6[V33$W&&6JM MBR<;)3]J7T:'K\")B4/S9+G$.P<4J^[I%4[YGB^2!7]JW7\&4P>'D:+A^%X M,>^/;P>3\6(T_F4X'HR&\[JY!!C+"Q[5:R]%-UX,21K&U[B0.!X`/%<GU9 M'B&.E7>)H1EO6>$LUH!@+P/=7#3+' MNE\>+='.@#T&$6>F<>OI"3QM85()N586GL&W-@!;G\=QD$T6KVPJ;38O6LT@;^:T[,,# MGH$QW&UI2$Q&"3>"EEL]"/9^.;><^#A.SO^XC$(GQ"`+^0N.@HV<83NP0OP MKU,SRM%S,>\9N??L)\_'8@)HQY,["6;`B2'9'?!>X:$2Z<1!`\/I>_9.NL+( M:17=:8BE;I$-44AUVUUIBQ6!#ICMRB20U:%-A;E?>LVO`E'@?+UB"F7;@`>1]"&F`7-'8GF M&11O`?1>;&(UN_,"&W-@^Z,`X8TX.;(7)"$P,E9L2:OA\2B+#GV451>3,6.E M1:D-;-^)4SOO[.U]^^.L7O2^U1AFCS\>CWL%8,K2'-L$31=!_`SFH8B:Z@H MB/TL9ST^IK0_1>;MHX].]G@1#-66A6G>FEJ1009_OV`\[T.$1H'CQR[)QCFT M(8F"D+K)JJ9!:^;P$QS%=02LT#.G939F8!V^V/YDN=,%/VY(TC M5TK.`E<`BMF-R'(&E@4XD+?>O%D[6"-['J_7-MQ.EGW'(=8_3/,T]#UB-]S_ M-`TCS#>^6R;&-I9&U\U`4K\B+[9T`MC5,Y3G-G8S@AMC[,1-]6Q:B(N6K9- MB?XGT?-$XO)=#T_<7>>DY&;S_A:WH@N,.SD80_QE$R9B?+['PP!3`)D)2Q M1;;6Q=%SZ#8C/#6IJQ/,KGU]W/;8Z>4J+<=^9N3_V:??+`A9_+IP5OIZ-AV M;-7CJFT-T0UT5#?"\,7"!+3A=737,!>F`I#"__E_4$L#!!0````(`+.`"D&UL550)``,1!,E5 M$03)575X"P`!!"4.```$.0$``.U]:Y/<-I+@]XNX_X#S3<3($25;LB2/-;L[ M%]4/>6JFU=7;7;)OPG'A8).H;JY99)ED=:O\ZP\/ODF``/A`EF)C8M>M;B"! M3.8+B43FO_^?S[L`/>$X\:/P/[YZ_OWZ%7;_[Z]M5?R0_+C^CE M2[I.X(>_W3L)1F1?8?(?7SVFZ?ZOWW[[_/S\S>?[./@FBA^^_>[5JS??Y@._ MXB/_^CGQ:Z.?W^1C7W_[?S]>W;F/>.>\],,D=4WG$7!=,U[_?[]^V_97\G0 MQ/]KPN9?1:Z3,DKU[@L)1]!_OOGZNY=O7G_S.?&^HC2(HP#?XBUB MR_\U/>[Q?WR5^+M]0+?-?O<8XVWW'H(X_I;._S;$#TZ/0K_/87_^GL_W]G MO[YR[G'P%:(C/]VNA.B\K\'BD[[]&YICASQ&4W+F2/N-6WO4YN0)06IIJ8_ M7Y'U:SO#GU,<>MC+]T9G2K0E`\RT+%/^D5L#%E!U&\5U/)V]%[ZDUN/5]V]> M,4SH;W[-#=,R)&?^NEQ%6ZC>,?4]?(^26/'37-`;.L,_\_O'G_E[=O_O[V MQW=O7_^J#NC;O^44J&TXQDETB%VLA3W_"/6=.?>_OGKW^OWW[_[Q_>HOW[_1 MV!DU;`0,-=\X?/GI[JN_%2;;"3W$)Z+3/1+/O?__3O?S'BX$IUYJK\;_K7_FZM_C!I\N%Z;6SPQU2]N'' M]^]^>/W==W_YR_?OW__SU?NW']ZN?A7.GT&X_KYZ_9=7;]Z^??_^A]>O/W[W M^ON_?_]/\8;:#)?Q6#D.T8%SR\\\6,PA(GH,TI`,/3+,(1#G1"IC)U@12_CY MG_C89W?$$^>V,S(4!-R3#41L)")#K5J11"8W4;T,EG3>CCHJE8?A,[-%QP M=]S=1ZWO(Y/M^D2;6K^)0I-3LK\C/@",FA^V;:MZO9-I>A5Z%\=,Q=;GAS@F MSIK6K?G@!S@^)ZL]1'&74]/CQ=6GV_?RF^@(_`,V#.7CP"C_ M$7$`X.%WLI:B@]_%5Q/[]]%N%X5W:>3^=O?HD^^/J3T8H$:)PUG7P;%HN38M M2P,!8:"2_AV,1FR::NVHXM=>HU&!Z],S<[%=:3J`:)[H@V;($)!R"1\()QC MP]@(6-'M4D82JG,9%TW%\DNRH$<7_1`X7;Z04);K$VWJ\"834XI_H[H`#!: M?-BVK>KQ3J;I5>1='#.U)B\/WA_(;Q(=7=Z<:E.;M]$0JL-J#(4-!J/1QT3" MJE87,%6O7N_FJ'E$@-L4D1#T>FQM(!"\]B[4^G@JLB,;L"('P]H4,J.SZ MB[A/5W2V3G+/\#LD+Q\<9T_EY]VW.$B3_#?O!# M)W1]LI\H\772E;1@S6UM-!%M,F4Q#:VWJ)B(\IE0DI9&PS+2Q')V>V7"N)T& MS(!K+8CEQKD/E"-0@MFV+)H0&3'[_<&S"Y+$V_?FK62LY/43$EYR8(@G`=. MDJRW+!J\_.SWGGCZ`5BW1!THM2Z0Z1!J>M@@HH?),&"61AF+2(Z%?4LB8C$U M\R'@K_E$I;J!BVCG^&NW>B`8-MV="+5)R5\("PKHH%(U(>(=7LB9C4EFR+D MLQGM"CESX61Y0T#B.,8>V\M'O+O'L;)ED8"P9END:+4<%S8:%:-SMN,3@-@9 M$XR6%9P2.@&.L>GG.[FYZ66ZN67H3%&&Y`ZJ!)1M$R1'4\"!9V"D:EKC#_&_A_!"IG6C_[5)&0G?I,,3&`;%&X^W?_GFGQ4AJ M!YTF%\TG`LLDP6DB"4M+E4)CMFVSTDF=4_.!EB,,`_<_MW=Y>8.G&GHYB$E M:]#)0'-S?Y9XKWLWTSW9EAD0H=(M`@N4OZ,`=MNBBD:^?8>-_RL82R#E**DQ MD+'3C!$O)WE(U<@9 M'>M]J]:0Y>]4;_'#WX84MRC+>([G`CQLC`4`+0Q^;T08>N>EY:V5HLC:ZCJ M&?TTUXT.9!^WV,5D3_FQRQEO.6#4?E^`4B,PIW#H8/ M9XA47$$JQ"QQQ@F"Z)E6]:/_^-.;5XOOOON!R>J?WB^^?_.62N@_#B%&Y"^\ M["#]VQT1)Q90RG_]=D%@)WOLIOX3#L9_YRDU4Q.1"(['JR";W7S#GTS0W M,=X[OG?Y>8_#!!--N$X?<5SSS76]7Q60MGU?-;2;;)G-0MDT)GQL(FJ<,D&Y MO<-PQ7Q:PI"-&+)N[2PSDG08&DE%T&=GRT%0'"?V]+#6'=]$RJ!9=]V2A%M M&Q(^?('8!%[7,I_"O'E@UM(0NWV!'2ZQR]UZUSWL#@$MB8L\O"=>K<^K>5(O MG[#^XOUK@6__I[^\>[]X]<-?Z%_;?CZ@`)0AW81D`Q=E&IWM%^BLB#&=.0$] M]0&+,$V`\B4KO2'"%X#OV_$%9W&7@T^GVFJ.S7A#AFUW]R(+:\R3[4FCQ: M/ZZ54Z#="YKA!>UV4(GQI#Z="M?-)T@7>$^?=27-#>GZ=T(XMGT["8MM[;9 MT`YA`N70&:`$SBSU\9V22>IANCFEB="GD=)JIR!6)]DR]PTM][FH"RIE0VH MRL14EZW!(?!M-+29F+TEKLH3OT_LO-^ MB/P2PXD"A4.LI39ZJR8ZG4$/ITH$>B[T=WO'C_-Z`7]Z\]V[Q;MW6JCI+B4'1$EQS7V'HG=Y8OG61'A=`LM$.Z1WS-, MM%/3:Q'-?5J^!]&X`)E=DY\Y]X/_)2^@SY`Z?'/"(B:51K_1H^MI"&:YM MET>#`$V6JTPMXJ7I$>J+C2&(KI9GJZO59G5YAY;7%^ANLS[_Y]_75Q>7MW=_ M1I?_^6FU^1=Z<7'Y876^VGP-S@SJ\KB20=1D<"L2;?A81`+!E@F5(B612[!O M1[00RG$(RDEPXL3]_":U>[W,-G_F[HUSI)E]1S);^(#]MI[U#6'.J!M6T0] M,@C3/[/IS#)F`%"79((RDB/AOJ_@[F2X!U7<_=`-#NPV-<;\E+UWZ(UZ/M@/ M4TQPYP?L[Q?OWL-/(AA&NLX`JW7/P4`CJ#TEU58'\VG!ZRC%^<9N.7/>$-ZD M.Z)U>_RMCSW-Y$4=D+8\##VT6]$?.CM7>0N4`4`9!%@)D<,PO2&2XR=)%!]1 MR)#>YTB7.NU/KQ>O7KVB_X>>_?01.4TMIZ+K#DT!@(@]7#TN7_^Z[Q;_(3# M`S;T;@10;#LR0N2$=V8Q'PGHR@(.#L/N\4?"PKI'(!<8Q;M\B;38C!.8QP<` MQ044XP$@++&Z9UPD^E=.$0"B\>,B`"B$81BZT!!B9^^%3#1???_F%1-,^IM? M?W9BVB(^!WW4SU/K`V/+O>CUV2<;'`1-3A"2U,S1RF7@O&OO+VLMP2[KI\. MD5F'98I%-I`X+9/U^C-7_`IVNW\=,>J?(3> M>12F?OB`0[>;K>752"2@;)];Y6BV+H?T;P84'4\"#,Y#EYN=3QZ0:,J:`7O MLEF!1]6V_0RZ)RU9S720@1%1VTF@`@FFID0%0'YWD>RS2-_?M#RFYZ-A$- M]@\:#9&\\\YGB\N\-9W_=2K.ERDXH)`Y2L42\M;52PL`N$;0O6C59'F9)J MB?1%7JENE20'/'[%-O,@K"XZ"4=G[\3HB0Y&?WKUS:M7KVEE-G+D(6KBW]#K M5\45"?L-L7&']#&_3^P]V_HY:N7^:]]1@Q>P>60)JG#'^$ZK$^(2HHU!?@ M)"CYMIN2;P!=MH\A8%!+0HZ#&_SW^6-@"?Y)OM"\J99O$MBV>0^=42BUSYU. M2FN>+4>W`X&NLU84SF.&39Q8=104#,:[5Z7%H(K^]>+-.XD-,7O]&_HN]>+ MMS]\M_CNU7=\E3>+]V_>+=Z_>SN:90=77(8IUFT1Y-@`\`"387?9NCIF]5 MCH(")3UCSK'GL5;#3G#C^-XJ/'?V/A&"RKYTSX,$&T?#Y60;B77%I,0G87\ M$&7S%JCKZ#..T,QW6>8NGP>.`=/G7W5\F)5>7<^`;W%J>.'V+MT8JK+DV7Y M,CJ+BZDZA`J0;+F(2D@VV32?A/)9Z$5E'A)%#:>-XXR'7A67($J2^2]3IL'% MXZ,`N(M@43'U&<4([C^Y+18`_4VUUK&\4H MAX`ZNYZ!K'0P&OZTF"[YQ=ZX8?(BX+`B1-X69I&@J`6PC20@EE+G)3GR[7 M!?DYP/0'6HF@4NY16`E?U0\9;3V+30_'(I@LDE6%O4`%=%X\I0)_@1J-&A;U M3@T@O**9:%9OQABO:R=BW5U-UXJ'@C(\LBB!+,%9RJ>]=U70Q6L.V_&!%% MMWQS5=RJH$!Y,J-08JE:\+BC"+1UW3(V;^OX.\:B,^<5;E%TY;B)G3!Q7;X M#O@#(>$FJOY=LQ2""6A[E[PF9&A?W)2EC8ZH`H>X+0=R&"@T(LT^KI6`^D( MJ^["N)005&ZSK11&XU>U>RQ3.9BSUM%]N@J3-&;OXS\X+EZRQ^JZSH(0CFV7 M0()@N\[.?8KL0M$1R,^'-##&PV,SJ.0J(4F>5]O499GFF;1HTZ9$1"'>^I M".(\1_%OK&$SSI"^T.\CRSD?8Q%DAM%,L@TU?#K-JWB'@'IX"L=5^M3T4I MUI>2ZB=;CQN)[E_'=RG]%"S5]@;'=S017M754H1FR[M21K;WB0^9B]8QXK-Y M\C4B\Q$#`,)_&@'7UCN-BER6CS7@.$YZO"SUE;08V9:TLCTDR^(5CZ3U`/- MMJO4BVROE/(YJ)P$RDL8@%\FF:UW4.",I1K#&KPS%'"K75'DKV_,C&4-`@P# MV4!5=P`O4DTQ7-&F8ZPY1LJL7UN73T3%L M=!4<1"-=1U>5,2NSP)MI50SKBB2:$,-Q"SJ,]!U!O(>P@;;]!Q&#E,I0MZRM MHR4@A@:S5`!!:!@A,;9OOYF''X08Q"6IQ:^T.!FV'88V.NV48?;' M!2)_!N4.&]]YE8[`S?-1H"S>PV5ZM1T1I-:N#XNF]'&X8#`?/@1AV1' M`7UCZ>W\T>[H6G1V?ZT39\:5.L6417YEN+F$QC"OJA MYYUHOW8\T5H60:C4?U"UR&3@;+MAUX1867>R%$11\?%CGQQ:C)48QTC@Q$:48B(@/`J5K?,2E5$K#`+` M>1AS^W"".&;!&WN2RV]KJ)$N\%X%PC;CD`W6F)YSN[!7M"!X]^'#S'P:IA< M7V[0U?KN#GVX77]$ZYO+V^5FM;Z^`V33U1!10<Z"9<(C9+I%DO,?()/7-JH MOHU,!^E><_0#LF7255!L"5)E3J$5LFE?0[L!,4%PG3[B&/D99ID=_1K.;8@R M7TH-JRI3SIDLPZMEU79CD`H@A&/;Y$H0;&>=9)7#F@+&T@6FZHXYQ`J;(->4 ML04)\B%,#?()CAEN#!4T(MK6G[H?$1_Z3W'<0/]+$-K"]EW>OHTR!KD>/ M^ICQX$'MD%!-\R'3`:^^?_.:0#ZFU_IF6<=\E&B1^%ZVU9UHZ:%>4H MA"(T6]Z1,KM@S"9@]8AF>A]195:O^QB0`J6`[#D#EEAA&VV9%R_$Q]"7 ME0OLO/P:'\`.;#S2HQ]@GFXK]F/44Y)98(#YI7)F@HLE4;DFXHOF M$1^V[`+5%D9L99:(5ED;Y8L#BY7/263FWMQS`A+W^\EGOCAMPQ"WF>X1!O?P7)]!"D]1E$ M8C)C-A1.S1,@ZY-M^[A-5+KL7-TS7:9I[-\?4M;,>A/1BJ93/)8R;XZE@A(U MW:#F2W?G4SJ43T[+>25Y1]LQ)?)>^&/.# M0ZI>9;(/C"VGHQ^])H?E,\HR@O$9O'7J7P>@!>I^IA1'<7.JD7-9/02W1>H M>1.A9N)@F2$7U)![V4)-L7"T!4_,#-\LI-R%\?80!,?Q/^F`-)=I/BD8%U11 MCTI=434E.I]M^!G[#X^TH3018>;UME_R3Y^E;J0W?MF-K0)`F M4^<@4`8#<2#T-J2K`47VZ2VF_<]&$".\GCAR!ZEI4IE!=_DL&R;?M[$&T5WRKJV1+YI1,0FP'5D!MC%REB9]UD MJS"J6CVQ?BZ=-6I,-\&N&3SLG1T_)=A;A<7SWJ6;^D]^ZN.DZRY,^Z'M.M9 M>XT[%K&Z3JI,"G+0Z.R(7E#H:!5^C8H%4+G"0I"(`>U][U0D8^3:,J7!4N+ M5T=.`1+0D^!1Q4S^;GA,&9M/$2V]_SHD56+R2:ZQ93(?H!KL>U-I(B8J?\P MR1YL^QT3$;8ICY5EZ`5CP7:IA&"]J&>823_);^[%R M'B@ER5D'C$:<7^9TW+$)A=Y.<<2B"F!_E<1.6Z4$RY8+IHBH:9U$$#[3"#A: MKHQH#2UK#IZ.`$K=-PWIFS%(D]TF8>\\VM$L)Z.RJP(HMATD(7+MH$7D_D8O MO(E]=2M#\Y(B@--]'!Z.2-.@X),<+^4>75^59PN?S_XZ;$#J0ENY\W:^"FC M\J'VB.L))S0\G[WERMN:LGS7!,=/O@LP75VN$-7"@#)M..#1<:6_'F\Z^B&* MR4D_.0345[W+-KG#.J`LO\6!E-6>O/K/,L(G-1.1G="=AN5F]P%"Q9#]"J M1+DEEB+A&HRE_H-98S0WCWZ"<,"O$N+\R6Q"?<0#OUQPU0F!O$-,_YT^8L3[ M?[:>S]IY3ZHGTN)'I%KR/)]W6;QQ(-NYB`[WZ?80+%V7?D'M1'8I+-N>9@^B M\KFCG3'PR4V";W(IW]-JX^40>H,!+1[MT%(E^46C'D M),'4L(9>46T!U`V;/FOWO>K2XVN;0ISKDUOL8O^)OH'2-9M,&V;3T7$%44X MGXOR:`LJB&V+_)Y7Q,#FR%.!-G)L8TGP':4FK=&V"[[T;+N2NC(J^H;=55A MM:F5;LAYS/&]"[S%<8R]O'IYZ+'"G$MF3\S=#"7H<%P.16(HZJX,6O&ZG5IE M7M650P+J@A@2X:BQ_89YGGWGS]WCY_`G0-GH2?[)(#WB<-1K:-UVH1HRU MW4-,'W57/5$1#0!YH3I:4-,CU5"!$+S3&^=(+1.]RW3=^$`XK#Q'C.>O2E>! MZ\'V$$?7I\W`\?P&#A!5()Z(HZM)E`+[?05[)\,^F!#[096TQL&]P@=^6%H. MQY`D@)UF%34RT(U6T"$V%6JN\&_Q$PX/RHTF^@'!<9?;**IH0,+P^424S03J M"??C5R`2=R,"R,41\.F-]/-C?R$D;7@1FXFFU'9C"QA"]@LCSPSC1P0`E6 MHQ.@Q-?-7[:`\M(F^>]^>J`7#48!+#NF(VC)E4+6PW7D=8-R"JD"6YS/:74 M70W84TI]8FD^I2P6^&>4@XG6>4I9:Z_(),)_2:TE#23%Y3FHG9C"E5SC%[ MT;1T?S_X,28(D%VEQQORY5-RL79Q'LZ1#O!2AVR;2=5BPBM0'0VF;Y6S:C M?/X",0@+%DTI@(!RUX;A3G;Z2,_6O!\4F\=PQ>/C.L+=\?BX[NE$.<;6'3%] M$5?+5].5;XM;16FY%/Z-%2G=9O<#\B66Z2"HE!3I:6FJ>-?B,\X);0"+N M?/HE5DXG5M8\$F76E#H;JGQYF>:D8)BJJO9]C<&$VNZLPPHWV1T.C5KP72= M7N!'DH;Q22V2I$(`ZP[,.+IE2"1)3[%8U[H?_-`)W;DB2;JK`8LDZ1-+4_L6 M"WPQD:3A)&LJXFU!HQ,(QFF4D8R4S&!CP.)OL@>W`Q]EA_JSLGP.MMY5D@ M.=]EC23UNM?KP+7:QUZ/`%TJ(9_.NR%2`Q"9_55,0&2=R2&X7F-A/H^1YT) M=T)1;[ZPI3&3YZE0-^][/PSWS2/F_I4?4N66]>`5H8V<;8IC1,3\X'(?K/'O M0^CA^#GVV3\\/^%)1PM"RRUF#Y!KR:_T-7,]_DQF/]SY_AA]E=ED<[]B- M[^T\QAZF\0`ZFA#,1B=@P(QHMX>]@0[N[V:OKX`'6)$\)D.`GA/[A0,FD.OM M38R?_.B0!$?^O%QB2MJ/W+6!6BD[88"Z,)%S40%"#4C)9B\-,5D=D2_2L,( MN(OJ-13JC8JM6Z$)B\H7-,GJ-^1R#:"[^9C\H(6[=2]ZD"80UZ@P5`.GE$W-9]SF=[H^=QW'X<5$+1(`:&]54,D-BHWH: M9C[U2_?;$/R2&^BGXBC2U]LL')-S:1RU0BH%DQ;<4Y-Q#M#SW_$3D!'E#F%6XC>(=4['&S9`4P=IV$=71;U5YK&VFP3POYK\KM:,54M9I_S\6:R==);QQ?N7]A;8Z])YFU MC;=?7_(_(_IW$%Y"SX:9;+#$EF13U[@DU56]+.I8.Q?%]?TO9LLP>O8/-@.)%`GAU.8"Y1!K21+TJ-/ M5YRPXDY!2]B9@$0$U,OL3KM&-@9.V/)4N]A<01!&KN$/]E@)/D\C..73_! MZ^UZSY.##%-VC!>QFK\S@#3C0`R<"B'1R]F,XA`4WO&ITJ[7GY.%9Q3A9PX MHXPJ0+-^1B2+Z.:)M@H-!M0)9Z5A@,3Z`CEO)6!6FB`DKW%;N`DB;_UW>R M.:]`L\[RL,ZCA+W%\3R?#G`"ZC^NPJS^LU)2R^!%K"2YC$":IOPT05=6I0X MRJ$B!I:]N"T`LP,6+0B3P;;?DV4.ZA#UX.74=("74:=-$).21UVC&-!_6FH MHY\E-`EY"GT[&J6`M'892PN)$VI&4D&C:MI#3YQ[!D<]N\C;&.%1=X'`()BWHV/-X<<&<-Y^5,-9REQ1#GHM"Z M[L+Y(:OZ[O%2.WY.I@&5C2UXQ--0JJOBU:J(D]X.!F!N,LCZBVQQSR>TAKR MQD94=B()-Z3E,P]8QJK+/(@\'8T6>=TG!HTIW`)>7E+'DRII.`[S)(19 M=%7$(FJ"0^S7H"K((&:-EF@243Y=JV M4OI0K?BX)LAW)(+5"XW!U)>3(Y\W)3)0B78]F,)$/M/)NQOS3D?@P^Z7/%6 MK3H-WOBFSAPSIJ7]W"OM?/-JW-M)_$U$&EE45?N_$&X;HK[[KJ<9V$W(O9D MV:1X-1SMR%^C^(C",5"-\QZ7E\7OZGE>[>9;3XIR10".1G>1('ODN.>;JZ> M!(M+#PI4H).6S3`D(^&EC(W(3[6TM_Z&4^:V-;+=?.)T#I^<$+_#V:FSZ,P M(?OQV#_.G,1/V&O_)#?C9X?$#W&27.#$C7V6"<)C+@UD-OAS>D;V_)NNY9IV M,[9-X=2D;D5P^NQI_?EB@O$ULPG12KDE]GZZ+PGGOPK9@TM416WY\56/> M$6AN.AEZL[K^$=VLKU;G MJ\L[<)[0+`I1R;6:0QL.B-A<^>04Y?GID2STT0F=!Y:226-'JDZ8A@K,1DE M])J\7DQBH>MR&HMG0W)D-+^@.,2@_/DFX31M3T,9GM4[%36$-9EO2F-M?$EB MB.GJ/S^M+E:;?Z'E]07ZN+Q>_GCY\?)Z\^<[='.UO`9TR6&&WR8K%AEC5I4R M>PKEW$>'%`7%5Z;NQJ[\RO2J`]BEA8;@]M].J$OMK(U0:#@GR:^>G4`[`B$# M8;'YB02MCK8G;'39XYR,AQ:%F!8EF^U.^ABPK]%)#_?-'LV3IG.4C_R,@PRF MR]@.'YB31Q!DQ/;G.[$MMH[7&CNPP1DX:=3XD,L_[4\N[IDS@7YY>VGRPMT MM5J>K:Y6&XA'UH&"HW08'28U,S[R9_]H_B"SMVZ\"&F)@"DT"T$2.P!'R5^J#V6$^Z;C`]^D( M)E0$QK:)%/7SO^^3T_"OFC='.[_KBZNUO?_@M=KS>7A1D#9ZYZF%#)',DY M<$"L7OZ4;SZT(IE"B=;B6!4&GR3C:T\AX-R/%M2D3L!%W[&$P<:NWAKA&9 MWBRLH9B-9@J0TZ!?:`9!GVWR^M-<8+Y%Z#PJ`X>W4'1:(NVCA]GZ7X/ MCA^B%^1/R=T0@;T;)R:[('MZM2 M@RZ(O7!LG:$4$&SGH[(IB,U!U4E0#.S#FC; M!S\],F@P\BD<$0D-/B[>9?:$-+8L:B]RG<\%L@E_S@NFT#G0SDV9EF-GZP( M(D#[J<:(4NNIQ(4SBM:C$^/:=I:AQWYYYB14'1SIH<8\FUD;OFTK:D"0EH!6 M0!0"2J\7V1]>,C@H!P37I(Y`B?/ES6JSO$)WF_7Y/\&94E/>5WL39,;X,UZ# M%(:=M6:E/7Y9[")S!%B9";;?^^I^=8WNP%5L&>7!Q&G=M90^-._/78!$N>?- M@"X$2@699^2/)$>>Y5R6/-51A'O2NQ"BR!5#AC.-Y#%W.MB,RG%QCZR"H MCLKXE&+^"EK?L!``2X'+A#@Q0-&DBJU"^=11&K./C=SD^YU@L]WC#T`8?N ML,XF6D#MY3KIH=[UMC^;S_MT5B%`[DUB'V^+25X&[-Z3UJ7/Z\#$V]A_T(1N MVUW0)H8YYT/U`X:38/WQXVI#'U%QHW^^9N]T+Z]!/M(U8W\E0V_$^_,)_@?' MCW^BN0Z5EJ.Z9EPPY;5[D&LR:]T.&+C:\U7@9GDJ9&R9F]5V%!J7A5XTY0 M&1M/.3#;MK(/5566A&H(M?%;KF[13\NK3_#RI)6X4LFFJ;#D?-+67:NBHZB% M3`0[M9(!9%OFSH@(PLHSS6H]G55HK`KM#$10+K]CS6J:<[[4EAJS_9QY:D\X M/.!;[$8/(6MNQ"K2Z&>:JP.T;6E54&YGHK$YJ#)IP>MM'=$OV7^A6MZ1\`5G MAI595S'73(UOYQ/-2R<.R1$WN<$Q"V#W"V:G;NL#8\O0]J/79,I\!B)3^'40 M)!D<"/,N6;L:JAZ>;3.;?64"E,_2=,R]DD M?+-&Z6::2]BVD69DZ4PZR_(BJG`66;-HYAD6L%@YK`201,]!(995>M:B$#AC M.T!.U%/3C(1DUA(6=!(4Z%^(-T2N+$4GM0_SZ)<-U4%S6.8G9YE\QJ'B&>" M#J%':!3M^F8J6DVGCTZB$0''GIT"/4=5'P(O-UB-Z75%M)'C!Z@01% MAS1)"02R+3#.S'1"+W_T-I7$6U&7"E4`F729/YH;LI9MEVH@H83"NMZVFU&+ M:G;:UVY62$3TF6DC:NO.V!CRI1;]&"Y<`ZI,E:M7$NDJS^W7VZR83;\:9?5 M,@9NI33;`%+(E$0E4[56Q8+\8<'0#_,0PZB$-(J#?SP0J>Z-$L]VH`-0? M$7$RX!`X<:,VEDL\BBADB[8/HB$&[:4-E4]-9&RB8MF^YEU2S\FXM9\?6&\DE,4)> MAL:/3`6O0G+D]2/O9^P_/;86Q).=QXP^^.%D^(BFU7/382Q26O1.LN?1O7. M'E6VA.Z/734/$-O7HM2Z?&^T?S??W0+E^T/9!OD01+>(AGM]K7T:7RKBFO M%%LE_\K5]P,%VN[@;2_6!T$1R<."`+20A0^!U![23'2\K8=WO')7[V0YQ:M@C* M5T&L9D:V#D^X7Z#J4HBMA>J+`="UEDDJT([OM(N/Z.3$_N.D(N[Q\4%#,WP M)SZS_Q#Z6]^EMNQ0I;A/MY@%U?XB=#QS=?@?.>)%(#>ZZ<1I5_\/[O%06EZ M>9Q@]H>[?>!WO0F6'W(40-I6?VIHJ]0.7:!L9G:09W-!Z24S7'.LN!9)NK"R MKA(TF%?MOS,N3:?/7WT`TR^2H@_XO0Q\NH#_L">ZBG6`+]NOD&1%!Z&57` M01P0%^?L#_:9Q(K)[I12;"-8O00D6V$[#1,9)"]FD<./1[`21XUY_V>$OR& MC&\Q@9NYOKJ66`#%MO$5(M>?P9V=`6`Y_A/@8]VTRAE0L0R.A/LLBM+9<4/6 M7'[V$^.W$!408-Y"U-!2X#PZ&OU"Q\.I":/PK?1>"[0^E$T53E:\B':.W[K8 MUQ?&$A0\95Y%4YD/^8Q3T(.MKVBH#)N?<$;./!!?9X?CUIX^XMT]CI6U8@\8 M:YJQ%[T65V8S4)>!YK-@7.N,BAHNCI MH28\<':@C;"",2BF"#P36'[^)"C",WD"UC6S>]U\:U,P\^T(?3-%5[4!!\[! MH(6@'I<7#,[!G`FY`"=@+K94_,8U,F;,]XR.0%.A-ZE/,9?F6K;QM71:-T. MT;]:\Q<';'P3T;9Q6=`3G#GJX!VURYP6X\S'[_G;&/JHVV?7P7I'^%\6T9% M@E"3FXIG9N586(>H8;B`L11]/":U$#T,-I^D?'3^XKSPUMB0M-@@5HR`>>)3P@!=:UF47':LBY+89R]`X.[S>UC:B=W01`[!E7F0HM2K& MD+'T.6)=?F`=4W3P@1@2UV0;%8O3QW0#7@7G\-8A5@]I=RH)57"V#(PZNL(X M,)D%^4(Z"K%X$71%ONXJQ;OA=[,E)-N1""F2 MNF)=#QB$V"XAG,@9CU&T<^:9G>O3;ZT&PWA49_;7SC6H4!YK:UCIA3>IR M!HC8A29&Y5]9I0YF/3.#F%=/XR'T&%X(784K]2Y:VRP)(K.A[.HT/.^H"R@X M,R=`744F)DX=E#&6<;IB6)V7I(9+YS/6!^KKK M;>$-YW`%;/>\ M]5^"P@Q';MW="C1W"WI5B`'%[5Y4]\=E44/HM/^`_W"?[]0/9X2=RNU/R9 MB1B0;?LN0[&5AE6,16RP_=LT0Z+KV+.^3V>-&_7RGKHG6RMX)D"EE^-`1)"' M8F%=@RMQE+Q"EI"=]/2TP+O[.8I_\\.'!X?D`F]]M[-H2ML\ M20%8\>AZ4&KR3#8<9>-1-@%E,^P[<8;XN'P\`-=-$X&ZT_9<1P?Q^'P@ M3IJ&(G=,P49&B#B/\91DMS$D8NQE]#^&I]HAY/GV$]3'-X<[@/?76^WF%:` M(@XAJ[O%:L4L0R\O!ZV5>S+&>E:34\8A6).M&524@T44+JH"1APRRD&SHR2O M@L:K,A'P1?UZ$+&_;N)4`D&%7`0!X3.KG:;$O]$(:41\KQSZ>$7M]]W$, M]&E2B^LDC\@/MT'TS/7B@XPF-/5%0A<@?J>Q5A`[HZ8J8;[P3%45K[^?>OM M3>P_.2EM6)_/GLE]?,^I$>('LKHW+S6N<=IP"Q,GP%J(6X\SZPF^4M!92^H'N&_5=0("661'7O+\8A-L.]B&6+#Y&A?8A-.@HV^RZ2' M3J=SU,2ND=EKC$0]T=!JL2.3K](32/O]%>W.`FX,:)TZ-6<$T'KM4@FAX! M]/0%_VT&`C$8(%R6,1'O%D+VVSA#?#\)XN;!K6&8VJAQS@Z/#S6:0!`-XTC ML#\Y!"D-FXAMO=4XUEL[42B\XN?W=.X-#XI;Y=ZIIM MT2YU(R/BNWPD.+NDAT:2C81HGR3?QPUGWRLPA23[Y[V^FU2_2&`8ML> M"9%K91]E`ZW[<>.@D\N-GZ-E46Y,^$;'WDA9;SXY6I.C:)S1_7>#[UBIE!26;5/5@ZBLH2J;\))HP1VB4\!V9E+YEFIO1OH_Y(P< M6MO"4:\_4_=D:\]&!BT^]?7&&YANVRF!FE55#LHUCD\.G<0(PUO6=$#U% M;@/[+$[^W=04G/2CS5J8@;A5J4_TKMER'QLS6Y+4B`6RY](4>MX_)V/SZXC MLQFPWLSIHG43R],8;%8XZ6>]OA(GO7PW9S?D\G)N$SMAXKCTJC4Y.U;_8E)& M7`.R;:6O183V>X?S3_$HN.38V?=MNDSL9YT^9@.VK5ZN\8Z:])N0=2/0P M(2BY"/NWYH]$S-23\=O`1<-RE+#B>_A,#U_=/QXYX3+T#M_]/'V\C-V#ZG_ M1`[66]_%L4$)4E.8H\X7H6>_^1[!R?0'DNFFOEM8`8D=:%)1^)RJ$PCM6&:/C% M4`#/`M2W7]$%3@L3]/P8T>K@3I!$Z"MZ!88]/V67S$\X(;Q-?/YD7(_1#%^ M.`1LG^R]Y>X0L!=0_&4Z2]V](P(4L_LEM'39>ZS7[]^\8<7.B\U M'_/1U5=ADL9,H>5Y'+=$1]RE[-!3E"16/7-K0+1U%M="NLFHC#O+V0M4Y"U1 M``O$04Q9EUMZSA@?X6K4O?$JI()\3."`"%0,PK6&#BW"TD#8NLDSEUMIB$-; M:&UI**HQ=4UC!P3;9K$3J5Y-0\>!.-1KH=&\WJ)];:@C>41I!S[6;;N8WY3L MNI#9;$E,17UOR"K)8Q1XY'=)=F[>Q([GAP\7SE$Y8<88/@Q[KT607IFL0"," MFL-#%8`H@X@H2(`F;H4>:48/KX,>0`RJOM!HF%=MB9GQ M+$I+D=!J'-B[.-"R:C>L-]K=HT/VR?=-GQ/18FL%#F5<0/O,.FPUVT9\,+%: M9V!6"(9#1!PDXC#)L8)!S?4-A0D:E(\P.I7.A443?4XYG_P1IVE0 M3!44LG#]^2W![(VFYN_S@#GAHPCB6JAB#'$<$"L/6^)P!?D&UF%=\4GK"W, MTHB6H9>EQ^='%:7`_"@+68GBCT0B0<.1]393+[GN686HA-W4,SSSCMZPYF]+ M5@(AFO^:8%HZ$562<#JI:!I^V,FZF-6>@@&XD#@-0@&Y8AA308GO(T;43@#. MFJ7=N(E]M[-/H\8Q7`;8MANH0P]XV3%UV,0`&2LC(%T!:T]'=/4!XV8:_XW M>A%)](@7!8$3)[1K,U!UBILQKM= M@#SSQ`+KNL$=,5\#C!"DQ;]7EI?^+'G&2,Q%M,+S(PHFDCGL>]7#K$J\=$ M@3BQ8RDJL0,[DI::7!EGY=/[%;$XT7'00E;SK0>2:)!"SJ!"]&NGH,U`;9R% M-:$HXMG()E#&.3E.2P]/I$)4G.&Q%-7\=;`N>4T7NG?5.^FNJ;:NF[O1$8: M9<,6+.\1Q/VP)@)9"1[K;HX"&TEO:<4\-.-K_\!)DD(@U_&M__!H5FE'`LEV MQ$R9,NTL%4Z^?>`_$JV`11C1VKX9]I4;,>KNEG3Z7X3"]OZ@I<@MUO'JG M;SWL4UE[2W^@(O:V(F+D5[]>X0+6$:J MJ07\,B`V$W9-<].+L;@99-IZ/0^0-:L?^1H8!>46JA M\",BXQ84`P!!7[6=5QY/^N$VBG=L`>3<1X<4M=`"$IB5"(8XUBJ6"LMG%9/J M26)`($\J`F>&>_.5,.>Z\.;AU4G21ZSSF`S1%(O8YH?4JP40.KD.DDF2'6%K3B20I,"\%V,N!`YQ+WA@Y[XML4#.I$X#5BSH! M2JTW`[P_=C[.FK,Y%B)+>PW0!Z-0<3_I_5.28Y0_4`!V`R43FOZ;)8G$#!;D MLUY);KO1W3.MG!1%2`A8_LR^](Z(`X##HNK>N^7USZ\JG)V[Q%1)A!#F,] MQ)CEH^N<]#IF6C6N321:1:3ROT,ZN\'8N;D5[=OZJARR;O,IA&B%?`I)X? M?9?VH"T$-\0/4>JSL?0%R2$Y.$%P1`&-R)/_8@K3Q:Q(.*MYE:1D&'U8>8_3 M9XQ#E#Y'U.O>13$N9KG1;H]3NA[M3J/YY0S$9^**D([J@^&-VX1#?BZ!8B#,@1,4:S M\'/SV>$Y4>A?23:?4$DPQUANL M![561@(;ALIQ4')LM+Z5O$^8PH>:C_<:FS#K%M8-Q/9-J`BU/IZ#EP^C]+&4 M;@AE7VH^ILOTL%Y#L/HD6PJMN7616P$B+JY:3BES3H91I5N[ACQGX_A)JB M#I[RUDC%1-O:LHI"RXFD?X.:.M&BO5KSJ`;A9^85/=57G6M&U1MVP(.@98! MT$%K>=^D%J'GXXN/?NCO#CN]L$3W9-NZI(EDUNRO\,)VAN'IP>[.0?)5W8 MQ3PS\KWS6:;4W?BZQ&^N"5N'V58,P$X[6#8@:XYHG(C>Y=LC+G"[XEY]Q[/H)]I2N M=7M`V'FOTX>6>H9Q,#F5``%QL:^/3 M2#<+BUJI10'K'%$/W1_Y%;3K[SLST#]2P]LU+2)/)?='A3DMR-U'["2'F-T])O07S'!LL/L8^K\?.GMA M=![(E.'9.I9K("P1Q.KD!2JFHW(^B./\`&0_XO0QHHEHQ'IOR1G%P[2]E1_2 MG#,G8!Q)_U37NH&@+LNTN5P:?1`D[WG[+KJQ%BK\&/'3-N6L89$1Y^4>]8& M.-IN,>LELP=2;%%I^[QL[S1;'M3/1K;ING&NUH\='8=]E/BT7=2LE+?N5K3% M5K';;D-F;3CJ27+8L12YA%:80SZV!;(''TJN0SY'R_E4\R@M95[4GCK)[]]B#&N=J$>8AP[X4$RC@$6^%C M,@S1<CC_S'R<`#67.K@OZ7X M^[F\Z#LIHR7M>VFA)%AV,V?HH`[MY?;`5[F1TV]+-[[B4VE6I`X)D@9LHJCO"V<6T_9920]`K M9)&WW7#RY]:T,3F._?O-F^;#-G,_)#:9M8!.39$O;LTN^`!K[=%9?3FMAG"3$\M9-`\GLX";".4S\]L2$'9P'#RC;?YP.(U0\9;8 M5IK+V(A6Y_/TNOX,M#S$+,TGA\R467%YGJLX MI0P_55B6"KJH(MHNF9+-+%4,FUM-`\RGVT^A&P//0LJGF1Y0,\%9XF16-, M$:TH'$<#9S"%7K0D5E8`1D=R3^F=;;.^R2K=Z8>=.$&#O[)@G=V4#E;,"ARX#JJ2[%GF4G_\0C5=( M1PD9<=`T?[XHJIO/F%DQSD2@D@HUG>@6=!`%;:R$I[XD_/_`<609^=MSPQ$ MDPSV#,8D>DTEFC>.[AQP[8WZ=Q:E7GJ.739LSIQZ$$-HM5XGRK2K6[/9%[F MRU;.W$GQ]BZ9\/&=<=#/%-D,SX[SY_P]ML;'KOJ^C7[5?1-;9HIC_E4+Q(%% M^;2$MS_.IR.YEKW8VHU'>[>O!_FNO:PI-#P4^NWA-6':/!=4P-%.@V M@VV`/=`A:+(Y<Y$!\FVOF.E-@#WG<=;MPC@F_OG1?\+A)BIB1(35M=PI M-8A6W2E5I`6G(>))T9GY#2J;2^]1J[/AN%,#D24:QJ/(9C>)#PS9-.)UWZ=" MUMR],L6VXEZ%ZH@#QNK(^BIHB1TX#325I.0%V6YK M+TTB2`2:YF2#U&&S8%^77D()M@P%=MT!.G6<04Y3DC/C27=RLZ9B=(8U4G+ M#Z-C>&C=L("X9R)$E7RS(A@%WR\SP+,(/8/46V,BW:VIM/`'ZW]))5G'^9) M\=B>EZKZT53,UC21IJ8W$-:ZPP5$,4V/=NEO:@P!X3682TJ#^BUP1CH7[>+W-+B M>/Q]855N_\P3=VNU?GUZ0TJV_9+6S\NJ>+(@+P`_;0SB=$;T:W3BRKI$ M:/(\FX]R`(A"@8)IT9^GR-/1:8BXD+QAJ$#IR-+10\^2"ET0DIP+&%7]@I- M=,C8CF'IF4[C(BK"A^,LA-$W6VLG!N!ZWX6L/)K30$FN3XA[7CB89#Y? MN\U,DJ`KE!%PEU]2?`D:15L`E7T8J0"/>2R\.NAYPW,#QB2$X?LU0DVB, M%+Y!5.A.YFL2)$$"@@!S`(>H#IU$OCG+$Y6KUM[N#R]>-Q"ZY;<4^L20(!& MR0^@G%:8>$-B'&<-)TZTD<8M@N?40 M:DP%T>M7#M4],WKGE8G<M%,(;UDH%!U.519CXIN=5RV M)F++IH5Z-Z6&!LL5!.,Y6:-RP/4^$LTBT8#[%T\J^.K]D>4^IE5Z5D_ MF=-5'B]F.1''ID->96^/A]WHE5M5;\;G7@3J,5UWFWKQ^S(2QJWU_CE(K^ MARC>8C\]Q!/4OC156KAN M$F$=<`+OWL\ZLUR;Z+SX:EIA2`VP5H./6NAWA1TUE8H^7Q:YNY@%SB]>C81=J-()&LIR`PVZXNAX'TE4O<+_<+6 M^7\P_J3)YL]KVML(94[7"-+Z(S['"?^)[OQ$=^)\UOHS_[^BW)A("LA\4D M+:D(DL4X8DQO]!15GC:D-1:(9&>#S8C#Y;K7SL[\N.&2$OBN%1R+B:1)L M?LA63.!DCVL",?!TC)G\XN?94_6H#CJ#5_GHW+':^Y(?,8TM:!T\>X%9 M/6XJH"KM/LCGE.?+7_BTV5VBZ3!LA,X!'2@-,L<(P\2)(&=&57EL?^DJ"B, M)Q"@O_)#O$KQ3KEKX@@KG5P@ODJDT8/OZ!<'C'X0(Z`IT>GTXNTMP1OFNAZ M4^IF[']57EOR^GG4^7=C_QY[9X?T4^AKO=72A&K[_>,O#^1I:-D-7I+">C M^T.\ND@G.Q,.:W:\QS`-A\68^9E<["6IP\]",I1)\B.+HDJ9IL+)5A)) M):AT7V'Q)!\RN);E8S\%5`.1=2W7AE>4J4@,@1-#62I"L')02G(&NIV\** M#RD3VNE;AJJY']-^)^SC$P@9=]8B;.J.R1L;%$/\O'U+_M;@P?Z_=1JE/ M_+.1("RF#AX=TO\\$2H#;Z3[<9$)?_[D&[K<:XJWM5SMZ"-6V7E+@IH?F%R M(`MLHC7AWV7^/'R]Y:DX2HZ!(6@H]5G4R!8O(4"0SDTFAI#X:$"(!V_GJ8T MP1CU70:1HI4=1TFQSTF11D!-$Q(B/Z",+TTV8(O]:A-;3JPBKC!&+Q`S0 M@^I5+"!I1/7:&:/HQN+-'7#M."=9J@_S0&O68@B+W=S"EIS`D6@["L.5#7S M18"KU2=H51Z'D'0=\YOWR]\/?GI4O712@&3K4DD)R?91J%HI)I^&R$$HS[[@ M4T%WR1IU!I9VYY&8++^]L30%@656OVF M`7HCYC3H=$TR`'4\]!4$>H.AYY^&$'92?MZ:X6IY)"L1J7ZD!2KK\Y.L[`N MN@8B66^MD#V];,17``63=+'LZR71C3"P,)&2D/9'A50D=%25DA^?Z+LNPM>U M(Y.9_Z0&X3_I$X()054!'W8RU!Z5^'>0"Z3X,I4!?6(G[!GDU2Y.L1"XC> MDSD)^E17+S6`.D^:^D'=>=)3#N->^N4U759A/3`TZ+I/#A315\?ZHI7?$55 MG%78BE_#O=HS1+YY@5743/-#(%'J2;#OO\GK)00PUTQ7!6C=W:G(_XBW=KHZ M3#U";UV1J8?ZS;59X9^!TV238U^]6XGRJ9#7W[+!E.7C26UQI=I$VNU5E7V M?+WUUM0UTP0)HZU$']HJ?24348S""!HLLGPKE^CP>N`,P'B/3W_>FD`Q!,S MDW>-K@XJPC[&$W8<)T,>K9?383Q3KZ(C?+9-VT8"?HBNB@,@ET9I[UV/RVV5 MUM9B;66G0R@6(YZ7?N0%I?)C1.GOA-4WXUJA7R4`%H-]RBBK'`XRB"@)?$U M.(S:6V7[#L4X%?/`7DA4X>8V`QE=TJ4S4,[ACC+CT$]Z`-Q(TR$NS^8HR'9 M`Q139V_WHA<+N^N[C8+@0Q33]^I:[H4F:NNAS896N^D8"MBI:FBRJ?:'X MC?$O%!38`'R7083H51@$R5EF?LV@W%;HIA^M2T?@/P$.2C&5%?X@9^79F7O MWYCVX`Y\M$$V+%%=5= M2IR1J3$[.\0:^JF$<7R]0(1H7T[$5:7H3<33@OTCT.(T9M7#)]WUOU8 M7=4GS;A7U'MC>ZV9HSS<1\T!P?-(2Q25_<_\U#ROFAX-KU[=:=;3F:%QO6B MQ0A.]7E&=I7%"B=X&FJ/CV_NO[>@9=?IJ)/#-W:NC(96^=5^OXL0^_R\]Z/ MV0=7ZU2J"=)&%$;;77-6('".I97X-B/)0['F_H9K%UF%-.^7Y'Y38+\<+! M>%7T#3U!=^B<])%XC,\X)L=KGPR)D=M!BI8&,J?%>TZ+$#\X1-!?6([(5$S M924.BAIIJK&5[<^8_G_L+8DP.P^$-`-CEG`8M0@J>I"\!Q4=1)I!%!SH"B# MFE4.(W!YG/&T`JKF)&K1H=%CNR`(=&?2G`3_'84UTT6&SJN>(AJ@;V4+Y5M2 M#\":@+3BW&JCW:L2FJJQT:`0H+CH`XV.C@J>CV!0@L._&#,@[\<\Z^3L:^ MN-7?.BM#21Q<^H]#Z?U4'>,8M;`OAKT!I(78;4Q$ZPD4:;5BF;Q%PUP%IU M<+70-U;,4\7_C)W606C#BV8.0F[H?!).#]:;'',6U%NK+^7)I>2-SLHJ@@WAG%EI]DJTLV>;66W<1 M[`J"#A"T!9_5.1YMU]9R#SM919IHV,4G@+JZ)JVC^6^0^^&?!W:XUK8UES> M^'V/=ANSS@18662(.BC;L67@D<&ZPT>IQ0UI7:0$\K9?`KK_74RD M9#8[.&A^UA=ZUMU=1V;WA;N[EO2Y;16FL>2\3K5O>PUGI/ZA"KJ#P^PKLNLP M]9^XY:#0"5;O#&H[20%9#9KWH-CDEV)XYNDP_J$S`!9_&@LU0,%N4Y02Y-"# M#W_YA3-WB#=OV6&F?45KK+DCTXJHUV95#Y/4LEQ+AD]/^]`=O'\"E(VJWE M[N5:[C[7J6BZOQ`6@$L0A9HJZ;+HQ?$"^/E%;X&X4S/29YL M:!>CV'XT8Y\V%1Z!\,P&&D&LU_"9V?B,>F-F:/I.QWM@B>W)KQA;,UJ@\]U M/NI:^E0/1]UDG-)GX"O2UAM\3?H;LBJ`&$Y:%F>B')GP51)8LTF.HATSY M?!H#`HBR\F<_V1.Q1"-/>AP6J^,9K1GU_E=)Q2$F5I5OAL<\O?4B>R- ME-S?T%_!^FG6A"A3FIY\G8KU@71<'8-8ZPG0M?:I'F&XR3GFY4RUMN)K,DMAPW]5H M.>T3,H/GK/#0/UDO7J4)O7BQ1II9H5^WX_#O0"'GW!".+;>:L'H4FOL/5@_ M"4Q#V"G/"GS)XK)BNJXK`^^WIJ=J.W+QQ";".D?,0PL^[$1N)R;29.H7%-.H ML=.Q!]=1^1F$L2F?(+EK3KZDY!S2D-0K#J#+3!V^6>AAGY\JE3`=HN"@F) M%G#:S4RLOOJ/`Y/IKM.)\50NVALE)?X%2LM0?/XMGH%SBWN$,1Q8NZ/,E.V M<$=!]D8APLO.:3;.=70OSJY9;F& M9T7W@J(LN+UF$/.G+9D3\5)41XW>-GM$C)TX7\[^\4S,&KU\10Y5G:D2X]. MM#]P')T(Q3JSQWO(:+W_`@"R`4LLATT>P&?W^1R1N=ZK7@A@)P]8=FISLQ# M38=OHI)<^EL#?YH?]3.8A(H3\]SVN:W5A_E)OT,0E?2?IX\8K9RJ,'3)(/ MCA^C)R;$/QC:.&AX;W6:?DM4I-X;>DMF M3OXNP(;)1N;^)/Z2!V/,("Y24`_0N4]1[.#P2G'VZ:F&YPV-7:5Z;`C_A2: M]3,5]'^'.1Q7W=_)W_FU_\@)O?WB>H%?F4[Y8N0^K;>>V5A3LOB"^V"M/8#Q/?_8F&[57/3C/LQ&HE]ZF);&)UM(P. M6QK1M5&Q.&K@SCW6"'R\N$A9N>/)DGR!Z?V30\<8FT>,;_S?>E1BOD%Q9K7 M>YE=01XK%()2,B_&^RAFA?!Y>APFO>S:-#^HOESJ$^+=J9X11N:@S(%=UAD#O8&1%0J>8"=W'!R?5NKF."SD M$YI%MJ#>AQ_]QC$P0^TP.SMNGB/]\UDQT_YYJH)$MWGB3S'("&!G%-G&66+` M-'EM`P\+DET7;UX7R(D3'B'Z]$TI M4?3!&R)BPV>FB9-,7RR3Y+"KW^I+9']$C:JT@]/REA6).KZKS-)@V?N/54\U/VY0P)L"0^+_9>'O:$H7B$GC8.I#X:_NP^TD6IFJ7_/H0> MCH,C>RF5)#@E3ES@,!\NC=B`I)+PM\\8D+4F/'7O3D<;3N#:::C"$RB'U8W- M'KO$:=W@>/?:%]JFIV`R(R:BL@3U,GJ-C0L(XHMC>C:()QIQ0NR)"2`0MT MQ$X,]$7%I((];3N'APP1T%CSB\W+2''TX#Q_T- M)>XC02G)WXM0-Y^Z[;O(P\&)MUT:C7+6CRBS6XMIRCQHFHH3M\(_1?0('/CI M46"'IRGQIK$E$$>8R2W?O+;AQC36W),Q">U=ISNW,@7<9P6D'A&DTUW M@.@64+Z'+_(\K4AH@9V.9&VE$@VS#08ZMP69/!S7IF$'O:/R=H$Z:+#EW%, MEEF!^8[)$A-P`M:UWIMA>4@?H]C_PZ"W\>@;.-DCL(2D$S0@R!K:K/.&-JA< M\,LXM&F0LTP%KF2?<:J0G]QHMR.DY4V5TT4'HD_`:7YT?GL[PZ[.B(W.+[<[8/HB<_BO1NX.2. M(`HDG>#HD:W:Z@K&F@/D2Y^V4VU`V)(:-969:=JYG0C@@LAZ%RIC1WCH=I M9ID3'M'>B5/?]??T?0^-D^T[FRR?GB^JO[3^"LG\":I1OG3>(EW1/G\8& M=BY^LCZG@)03J,Q,0?EROJ/7X:OJ4C&ZZ9WR3W(+\=!E$GFM,ZA1"Q/1J/= M$%Y_I'_Z$,7LUY/[@Z)U3\X-%!-P.E56K,9RZ-G?3MOE4R=B_AJ;.&S[;'BN MTMB[`?9`@&#Q#JV(%@IIY!/QMVHW!,[I>W(]\CJ-`R<35OZ_.74=K?_@AP\7 MT<[Q6V]=1`2O3[E99I;[ZH$1J_@?^$C6GTVK?%K)\VES-8FN/Q_7""Y6=?N4%Z]V1;'"5"I?6.GHZC_E\Y$OU"Q\[>RW40&A=XBV-Z M?C^+P@,/>-[$T=9/F6FDHD/5/+6BZ@A;$RHI&TJ%2\:#%L7H9S]]O&6/]8B) M?O3WF^B26.#T%35TK.`+GC;1V%]=C1+-E'J!-6_GT=)>AVE_\+I+7:CAY#>7U;PZW)_I4IOGDW9MNES MD;[U@C=;%V4+(U'P:%&I2\>77]2#2V1A=,0II=>9`&1;'507H4M>G\8S(T M]@@5W2KUW"C)ZD_0U]01+3)6U&=CBX-S1F95%DHNS)R:X@3J4M2JF"Y#KW@S M'M%?B=L6WV+JX)'?GT=A&CMN2IQ!41T+<USGT MRG=D1'W17R]Z.ML76T:5/5LIJ'%ZG_#G9E,"GD!"#[DMRY%GQ,-QE"%15O$V M`\9V)ZJ?UUB_J+19Y'1_B.)J%U?U'.AQ%[5?87,A7QG3`+61+L5+G[[=:P3"D` M(&4J5;E37&E2D37G.Y2?/_IX>_D9NP>:^+/>;GT7QQ]9TP'=^8,E.VHI!S- MEMS1T:@8CK+QZ!<^`]:UXBBH@;&`&GRI%$KK9\H!UHK'Z=@QB=;JI3$1:>M M3<2SK=@G&3+=P78>1\D'6Y..\5$!8%)U4C84EQBX^3S@!C/7F$16\T^29G& MX;SR0[Q\4[YHD\=H-7SOR+FLXHG8K8W/D]TM%Q5?9.`XJU3Z$`.T3J\'7_ M`5&#J0?(XC+&SGI[$T=['?'3S0Y?4U^9)7LK[#3G^JB",6>55!KO76G_PU6<+VL=B,+$UN MYU!0!J9Z^9HLFLJUOSBP.!U'!B'&I>?4QS2M)B&>//N+<\1 M:_G165GG4&XN@.\"QK?)@#3"];KA3:"39=B M%QT(LE2GW.N@#L3)4!-&L8>A)(GSN1=MO95FJ<_7.-5U).3`;+L,?:BVGQ]W MV/\TS]U?(#(+E!.@BQ_+N\Q$C0HA^0?FX^%ENBJQJ9(%5^'1`;;Z%GL'%WM+ MIN36VSLG<.CDHGNGFG%,HN0:&MV-@[Q@:S'QMJWPKK8I`9)=X/=@H,].VL M.@J%>8T%V``QG5+9$%M,F6`,D-0-^6OR&`55P%@O8BX`835&+D2KW6T]&U@7 MW[;RMV+43'&IL3Y.BJ,K8=8DOSG^_>#$MPVH&B_,J8U9[H;:6#Q?+F<]4?P MI4(VGZ-?PN@^P?$3S8M9 MA?L#>\<2NF06XPRE?+#)UK7U'F,"`G96H6=K+%!E%90O@Z(0%0LAMM("5==" M;#%47TV4KF8M>7\J5I2FX$_$AQ8$^.R8HW`\#YPD$12$D9Y'Y,!LGW3[4&V% MP?-!B(VR6#ME`-%U#H$JG^\D34L3'[W"6=-OY`LP/D(2BZT1?>3[@L<^T\./7A\\$.';,$5F&2QNRDD-30-,E=U@5OVS;IDZ-= M%RR'@`H0J`C[ON!S'P>3H1S7ON<5W?XV:$WD2F\LTA[RO9<#/&/TFK?B7) MYYQ:EU_-F?HYM4FXDF1.3G5XO!GEWX)MK[%FW.9]R9CGJ1DGSN!>^`%WFZC M(/@0Q8**W&H'H\DV9-MKF(/D\RB$!:IL`/U"MX"R/<#R4>R2/G?\0LFIT8=KQ`1+TX@H_$6J^^1J<@S2;M$+BTRL1RRHZ@H[T:J: MK=TG]>TG=62+@R2#I>V%C;JX=3=L9%+U&YE5XNMDNZ&\LMVDJYC+TPN./W M767)L'>I$Z=**0ISD_3,(?]T,7)2M';3B':'>;U`1&3>LH=!Y(<3Z&SU+SS"106?)TO0.)'QP^OHB19A6YP\&C?GTLGIJ6A MS"^-)M\8&'=]AD\PLOV0F8\%HCLA[B39R]-O-5;O(L(IZRW MV77SKLCWF[TZPD/5_5SL2 M`:&7+E/922VW8F[$>LV;`TD8^W2?(NB/\@FNOS]0'Y/MWWY&<>NWVFRQ2G$ M-O9G-8G?S@=1/4DIVG/Y2:JY)[2)$-\5-^WYOD"FF?%4 M=#-_W`"%<%W/D(EABQ4I2L=NBX0CO\@U0?ET^O(J00X"K]UEU\5'M@]U:$J M,SZ7F?31H4?D;8#=E&T,LQ9??TY0]!P2>,EAQSLN.??1@8\H?YF@G1/_AE.T M=^+4=_T]NQ1[C@X!79(=LO,>R:K)7]Y2RB#06V%SY1&`0J3RL39VV.`571":F(W8BX MZ+@VHIY6":IL@17?NZ:V/>]XQ;9!3_7Y1E"V$[.T37MT:!I'(3T6["5B3A!Z M^T:;A>"<(/>,(,30>#E!=GQ+>OK;'B$:WM7H=+"ACD^X3J7P![AAF;.]DJ<,6-?-_<1>P?:[J@[PG?+C_SBY$/!%W:7^+`]?MZF]^3W."8=:`0O>B=:"%S"9H&XR&2 ME^^(OOJGE"Y93OBE\@5O9%)^4[0V1KO%^:S0>[TQZ4>3\-5\\C=PTV?' M;@""![USK&HNF3/08HB8BD33WE/A&0G7%+OI.(+J,U?>YNE10X\_6A['-9,H"`O+?2UMBMU9??YVE2T M'5FE-]GG9$2+%U6:3JXR^-:$JHX?`(E:9.76AL859J=+3QBB1IZD)`^ND8>- M(/\(<8J"$E8>5_6&/.$E4N=EB-KEIH`#;C?^#$FY+Z)(Q=C+Z&KLN8&SV0W M0YO#O>![ZZW6TRO8=9;_MB.O;5;AE[^VF[S'(GN.<:!_JMRM_AF@'M<[(:H M";83E&\%T;V@ZF80WPWMT-O/VIO&^DE2?&^D6QJ4.!_?KK0PHI")<&)L\^) MPU3"H4JX;"9) MVG@8DW?HVVV7&!#7,WR))S$?R;NW&]_(S^3_]`:]>1/_Q]02P,$%`````@` MLX`1XLW3?W,P``C:4#`!4`'`!A<&1N+3(P,34P-C,P7W!R92YX;6Q55`D` M`Q$$R541!,E5=7@+``$$)0X```0Y`0``[%UMD]HZLOY^J^Y_F#O[=2VK%X`P=)TOUZT/=]=7P#%="SK++]=/\X>;WZ[_^8___9^_ M_]_-S;_OI\.KGFOZ:^!X5X_DF04$UM4K]%97_3]O^A;T7'3U+6SKJO6A\^'N MP\#ZRC.U?KS1_Z6/OZNZWOUZU[UJ_7-UU/G^\^]SZ>4]7MW=M/M_>OKZ^?GA[1O8'%RUOVW=WG=OXP>OPR<]O&!X\ M_=J)GVW=_OMQ.#-78&W<0`=[AF/NJ6@S:72M3Y\^W0:_DD][148Y;SM'AH,-,Q@DA)AA M$A<=6+3)8X-9_-Q]W>Q$2-)4'0HH(V,)_,!F1&((48"%QP&&+2%I[['Q\'\ ML4^:(JV2J8J.+_V1\.C$HR_(VH,VF'[3AD]](4;V3U&9INN3 M!82SC(U[]].$3&SD%\.>>:[Y+P)!G?B1GPW$!GM M/=P#G@$%/>WF:A.2.$;YN#-\T77%>M53>Z'+ZH5728.6ZN.KHYGIY):YU#C4-534[0['C5@VQQL M9C11U"7O#VD48J)-YS_F9":::=U@:LK!J&!3);KK.9CDD%?&F-AHR,ORIJQ M@5XTT1TVW19CC4-?&6N=@JQU"L]VM,U3%R"Y]APX+Z[]0N;;7$Y@?;/""WY M+/62@#5W^^0E[A;LQG3!^;[TMU8CAMVL]LVP?4"CF<$37^F/P'K"A+U[VS!_ MSLP5>77D)4X0<;B(-%]=Y"?/3"O<6M%%KP%1T`]V'QZ!@7VT"^"[Z[7K M!'+A1GTD!E<.G`!3?+%D^,^8X!>J`,X<#:^AX?@!=@=F:YZ!C:D!)6V^6@C M%#+K@"4-IMMQT]TZ['U:R#Z.NA\0SL=-#)?>0;R"G"=H#\3WW.7.%BY.$Y0GHG7$<@GVQW=N60$`;Y9+JG M+)%7[Y1/:4'N)4A&J0T"F(Q[P2;PD+!QP"`9^(%CT0W:\%O:0.Z4A"!EQ#4/ M7F#3)`T79&;IV`)Z0L=;V2L00K#K$?UR&](:DQ# MA[P:R(Q;)!]/U'68W!(]<;L)DAENS!6T=YI>('(3F:,8DF<]KG^L MHQ(X:&)]=)2,0@_0!JA+.%FZB#\&'3RI_U)'+:0#B17P4K?RYLP3J<_JO]59^L=08C7\[27@@W^`,NS]Z6F_=U5$''#2Q.CXI54?8)\45DGA>;]5RS2%.:1V3.A,`-%5P3? M`I"U7;@YP.$_8-Z.8IZ5-BU#8S'B\"WUMY@VDB62:,H]L163884_BOMS:3 M@'KNVH`.1XVG#RL8@GI)5V5J1CJK<,9F4T!UB8QJP&V1[!^!HC7)]E4BJ)B M?!4Q>B8715EZ?0'HV=UO?:E0[WTN]:920JWY5F0#4#KX8Q\+"`-W[XH)H'E\3Z5H[8;P1(VJ(MI% M$5;?T?.HH)LS?`T>,I[(Q1)S\=KCD7_Z?_APQ?#IOENFMZLZ`TPT4B M_M_&@%;_;4/+91#S'GLK@`Y$Q5&W`+6JJ&I.K0LB8B=GU$GYHFH^@J\VLB3; MC8]Y9^=Q2K.2^;!GKO7NAN`O"T]G!IL&9#Y:$,=3S)$<;LKFTQOJ0TXB7I= M61B:,2PG1IV1ZYC"_C273F^IC3Z)JC@31#-&WQ[8T)T.?(R4HUX6B=Y2&WC* MUEBZIGEX&N%&]R).NR[V>,&G@^?TEMK`4WYM'H%HQEC\`!WH@2%\`=:`,-9 M0EH+(10/=[KE$^HMM<$JT=$X&T5I'M4%.,.97K#>JE-TBG++SINMC\.;#A" M?+Y@KV+EV@06IOZ?MQ5PC42;T%MJHU(R06093,T8C!.(Q:/,;"]K38F):7` M3!M(`=<(+TJD#I%X;%@%;VM-FB5H5-^P%(07R,L(UGC5%E"E>^%!(?-L MRY!H16^KC7[EL@Q)?,V8>+5R!2\`,<'V5:03J"WU<;%0FOOUMMHP6"Z-IL-0&\MF'+T_+FW'C6QE4.AMM8&M`OZ9`+)F#+0)&8GU M0[VM-KY5KM--T90WJJI;8M/SG-`+RAK1+`!BZ>I3OQ()/YFI7.E/VW5DX2AK M+:S04XP9IK^V@^B-F1=#TW(FY>SB?6.ZI.! M.?0O!JNI_IB4'Z9W5)\2R&\ET)X+X5P63I\+X7P7@KAO11"??7[7@JAKJ40 M;-M]I9=8/KBHY_K/WLW3\^F"J2_R;13IT(*DK@:,5P?Q+\(WV2Q0%&0SS8( M=.58VMI%'OPS^)YY:(Z?+EG**Q17_8TE:,UU84E9.PD)[QF[&STP+,W M<+"'PHUA@E(A_`SDG+32527E9#1.0]#$Y-)B/&.42`@]B:GP`4W!`@G%_" M:D!UZ0D9I8LCFU_XX),(+P10O.]E8O@G_L-DTS5'Q.J+DN17^5I2-@7-=1= MU>%MOI)J#HE4EZ4HJN(]"O8%$'57+_^R&T%U54JBBKZ"`K[_HDZ:3N10I5C MWA:@5EW-0D;K@G#85UW45/,2TS6'2G5%BYR:3H/!N3>CUBK.G89%JK7A12 M[1["3JWU#LM)WD4G0E:GJA=9.'9:KB"N=H:<,9<\[6!:1LG!K@TM.@7MQ(/' MB_$&H.!5^,DQ?`N2G\^=-S9P"+M@QY1`JAB#0D5VF&$#'!V,YM=O.GI2<7X8 M6XLS=`3]INQ1'9O[.,BK2E(EGTBC.#9-6@](,[839L`F;2Z_`H<@M>F6 MF[6&3G`AN`=?0(2;FY0BTH#BI#N'EEIHX&K'#/25J(2E%==[9`RSW6!G M-5O[7#K%.6'1Q>1>^]$6.W=GB$FE./3#:2\SQEO)6U6G`4D[ MA17+HK(S\6P[ M@,L5/9U"N#"68.33DZ_CQND!P1[8IU2E#TD:1!V`STL5XR!/`Q<>+?`VJ MSD390#RML070#,"38>+N@Q7(>WI6HTEEBH MM&-&KJK5"9F"?"5ZZS1A8X+<%TCT<[]]PO2,Z M<#G5L]4QO;@RX'>B`$YWZI-<7"P-`VK/'**\2E,-U"L_[CX["H/3UO;+J. M"8/+[?=`YZZ@4`6&ERI>ISAYJVJCJTADJG>IRL\68E7F$$P;8I$K3A.K2OW9 MJ4<<@31BAHOC.-1K7=/0:Y:UI!,HSB\[KWTP1:!Z.+F\C5U`<[SF$5NT13? M5?\4FHL#EG2M>?DY$HKO]SZ?.8B(HGBHHQ+U)\Z2A<<$'UQ$(QJ^324P`^@% MFFP;$-6G-!X1D,0ED&2\R+/ZUID"(9A7&(Y!`@ M[E,/A/\F9!7=8B-V?%P$=5YEN>U(#FY-".YXA3S:;E35,Z)5>=WBFI5E'; M2`=:>&5;S#&IRB@F"&P,:,570<C$-_I_B/[J:7,ILCV@M( M_S"0E)0-B,MO=B^265;VH33\^PAUE0.DVXWYPAA8'S`G"5>122+U"=)EMJ M(D4.[IW%4J#!G;:`FLF7_X$($\-S"(-Z(ZC;9$]3,B15B:,2[@3R\;T" M,I9S3LZB_;\!I,F@68LUXK)LK()375%P85N=62;Y`;U_( M'2%EN%4YLN.)C"V7PE``LX$P`HR"6C)0B@_2XBF=FC5`+F'JQ$$WI;<=6" M\M29LODJ0C%"5T,@YCXR%P906RU2R]ULP/L-$`O$#7Q_8VW%C.L@K9=O3V M1>8QEV0:>:31:.=(4Z534MZ^R(SF(N;6WGB:8)S1$40]#F\H@O4%S(DT\@_ M0-"UCN.^'%N3:49O7\AME.CBS"R@[.3<.C?0;A+:D.P2IE-)6<42OMR_D MSI42S"$%6FEY9)O`U`BWR&NT-=0QN"P,K;2$L=`:^HXBIV7F;S9V("?#CN4T M0H&7M]L3AHM3;R<1__=:R4Y4X/8M-V ML8]$:B47;5KOU#'J609JU5!TX M408:RW**MJMWU`9,J[@,N2B>EX3-J78_.E^P>ZLYMREJRQO^[1QG;C/B%N1 M<)-Z1VT(]'P&)"62"]VH2^T$Q6S?8O&=7,FB)?5M-Y1&_2LRI9$DUYT=(2 M"YHS,[BBA!V+B9.YYY>[1;VC-DI:E?T4DXCJ0[K,`@^'F5RY[46Z(;VC-GQ: ME9GD$D0S3NTSOJ`V:5F`%+)@5AD^KKU`Y>WI\U8_Q@]:MSM^ M<'HZ^3\7#0'?1GYZY$&74?HIB):T-3L'`:DTA!%IQ1YT>\P[/!6V39OF]&1!2JGN+,T? MKY>)DBKJ.+R2_-JQ'#5V>"CB6TVT7YH]\.^-NJ1;Z9/_=YPH-T/AH.Y@JDN M\A!QO!@U;)&YCD.E8+(365?O_2J1:2QGBXHG+Y6&#-4?JAU[HI'!<_BE>>Y MMR#$FP>77.=D4"CN M?,6DSNB<;AU[GS?M>E4&\WC6>]'86_ON'QEEH_'>KX,S^ZX[4Q_CDF@THOC M2"C-=^-AJ+.E3NG1"V!-#$0P$828B"`X:'#F09+%A\!LD$6J8,AGL20W#4BT MHGAJ$%`!8_R7PUCGGM;5)H.Y-IS-Q]W?SW_Q#)'?RK6)\'"XRTMG;J&K9WB$ M"GI64/S[@"'B<.PK@N].V0MT+]FFE%\HDZ$5@A='F:=NUG0O\:3^6`\FFFC M7N2)G3WJL!^_@B.ONS+UT7@7[)L'2GA.D&@1Q9K6,7R1Y1AZ0YD4=Z,,$3-Z31:B.G<23I9(O#_^GBTBBR`]\R`E14&D M/\DW5L.\CEP@&W$D,JIR3^6#K!B8I`:MPXMS"MXMM)\UB""";5!TST7S? M0`X1#2WS$:R0Q/6>0:GX>M`\6L]&I/I@2(D!Q9/;!,?Q@#=P3")@^`)HF@X. MA9`54Y1K3?7=GCEL(Q_9I2,)TLTBBZL"S6%^&>7L`T]^HF?L<"B4GUW9P[] M\]&H/J515IVVUX1HD.N0CV:0L!=9M/CD(-N4ZFL[)$.H<>A%)7U;3O9N0Q)PP-X&,W$#.DEU9NMDZIC,7Q%OG_LG8 MVU?3)9NPP\_(\-R;6&(/I&QA7'9ZM"BE%,,T(\J8+0-]+CR0=[\]28_17@UD1>+Y&G3. M@1/6@OX.X')%-,13,82!#_VBIV.Y3BMJN2+\4!ZLK,7K%,PR1GS%;0XU_ MU;"U=IA5['0B1$4'\S$+V+Y;0X M90]X!K0;$N-,_JEGO)-14JJB%_WW1CE#.;,&A+/7!"B&YGZ;WH#V!GFW#%7Y M5J6G:RKIC2>E"K4V64;YLA8@YZ[-J`C;5T)4J6#3_4=3LQ>DJ\%5'KL$C M6#\#Q-'PX7.7I\Y3,SW6R1'2)L3D^NN-[6X!2$2!,A7)IJFC4CD2B(->=59P MP:&+K$3`P`/K"AV#_2O>O0!Q;;!LLV;VI:VI5U^=<47M7][`E+\'EFQ3L0:: M&>T(XQ4TK$.WV)L1ME!;/H>"4`XG"YG&QOU9`XH:YC\I00JD:XAXD[;"8& M&J/@$B4KB+/&XP\E$I0PS,N3"!J[RZIZHCC M([0!]EP'/`)OY5J'#_RY]\$SCQF-5;#(R^Y0%9X$D;I$8=#?[KU[E#+>U1' M!ZBR]O#2"6KH-C.!E.4IVY=QO!^.R?OS-A,XU`I=HG9:A)4ZP&2ANF6(LO< MRN)079X,W0EVF^3<&JN8)_,XVN`3C!F;H)D4"IV>S-TQE!T)J2&Q#1..L$] M<,S5VD`_Y4?M`U+%WFT)0_(`6>:,RJ316W=* M%9JNH'1E#G4G`4EU93.&)N>O[LX^ M)54I0JWU(:4F`-$OC"7@ MW03.(]-;%Q:!.E2;HZ/`#5BA<-9%^P+[N8+3.SI]=:%A:)RJ9^%3/7`SOW MCOD?^70J&B]VDQ73W\JDU%L7%F_B50"4ZW/R7-N^KNSN\B?QJ4DU:O MV\5EA-((;W@$O(%#.B`8NICG`!\^5TN='D%M0$XA0=0U\&J"W!=(AMG[[1,& MUL`9;P"=)9QE5'\(`AQ>A^.3[Z(?Z<6D7&T7:;BNYE%(F$J3&5D7#+OH)V&S M:VR@9]@S'VUL'[-']6R:6FE60`2"VPSU/85D1&&()@(7IB:.@B,@K@A[Q MIR;^LPW-\8)P1RUPDCT;^H6=M M7@P;T/I?9.A#:$O@!^ME(?I:68BD:HKME[:D#%WIV#C(W-E8#`%-/)+ MV/__]JZMMW$;"_^C%N-V=]M'QW$&QF;BP/:TV"=#L6E'N[4ZI9]-J/D3LE`2$WDE+"[,NLL]7\YO?CK%K`$ MJ"(MJ+"NIZ3%2-%G@+/Z)2=P2B-4F7/6A-_L6O_UK\<_G_PDB>\KS5SI?.& M."5!,0/.,OO=&9F17YTA.Y^].4U2E>8E`R;3.HXZ/F4Z9=P79;/1:L' M`A8<0G>%_:**S7I`USLB,"D9!"1PO,JP9;D@)(D__X'A!(I`7,&`A<8=14T MGZ)A>+?/9Z]P"/G>6E)7PT`+C/J(^$V)=`I67HDNPA3A612AMI^@#@NJ). MDF52,HSDG67ZBN+V@48L8?Y`X%JB3I(64@3MOS9RX**>9Y5/8;Q9@&N-=!S- M!.1I\UF4>H%-[T75WTSO3"`H_-HA"OD-3''_(8A4=L?T_UCSOS')T@[_V'KVD\ICI[6'`5Z1^_&>L4P&]CI<"-D@2PS)0 MGP>^+XD$Q!`K@Y!R5-8=,08`7Q#8DI'4IA#@5^X&+2Z(1.#+_#&`5^1.+)B MA'$%Q`S"E55W?==['MY]U/\BL,[RDP!?GKJ9;"7R'`=FJ%,DM.'MAX$O1&J2 M$DL;''B!&?!#B;_'#)F]>GY\\D2;O+JH\/\.]KE@-/+P\'?H9A?@J@X#3`< M`UTPU&B?EG`IIPAY6D8$;_-(MS[[_X>7U?YTF0\#HRV("TU]N M)4I%Z0.`,18T7'KJI#B.MD#(683X)I^11(0';R?NF\`:`HVUP!817:0\.@9Q M,FX26,95MB8%<#BEQ)8:6GS)H'&;>@G?Q%EPS#A39H)LZ1%3QZ&AG/H)^2 M@F&$?9NTU:[Z&_R6A#21P+]+SL=%?)78^^'QWOO@[===IX0&?NBG%FIT#B.R M7#7F1?O[C-1Z%,W(\Q832<$0D@I#D`JYEPZ`/&.?+TFAH:64%6D_M1"AZT9 M%[>RH+Z@I!P$:Y1F@9YQFJ#HMRW>(G"ECLIZY:G8VYH$`I91=%,'2]C>%] MZ[)>GF-_QX6GD9X#&MM"V\Y$(TQ;&9[..ELF!0\1`4C+UT"CL/",I;5Z#OO M]A.L[T_)8N@@%KI.JY=^GO-M.H&?<[M)UCOH@&]8!.JK6)+I\4@&!3+L'Y: MDJS:$@[W$+7\C@P2WJ[7.MJ;,O/S0#$YU/;T(DHKU/$0[IL##"[HTQLMXY1]?A2F" M[$%`"8(BKK(R3WATV)!9E#=3\?H_><]\HE(?R4_$$G^6I,D_M7V$=O)8!ZF M/C.%A/(4=)\E+O.;`J-_/5-"9IE=?`,S:>/Z$:!,.P;+VGR]^E8-3&6A0^(5 M@V;'Q6+QF.X%\-OM1X&RVF@ABZ84]'^;2I@$Y#8"7Z'6.4QS(8VU?[(>A..PK[%?7CP?^1!)@[CT MQZ!RMN@LY;'=VE8X9Q6Z(1&0Z56,45`D90\)8,XO./$-**"2Z M<)G$V.##ZR[3LX(+JP$;ST$G)[%E09==Z^,'87=77G@4U5I7ST"G"76QIXV/ MUY8>!E2+1V@1KK+:4]#Y.DWF$7/_1/V4DHH\9ST+DTUQ@RZGU MR8.P?U^\[W("JS\'G>0B;#K3X9V=ACT!3_=%KD#H1.;M'F\6]0I"W'5=/M MGOK%\^\HWOG))4NB%67CCH).7)&0`BT0)Z1I$/;UP?/CO+W!=/_?+$F+_&Q. MIP"I<=L),+R3JL2EJ1J&B:[(_(\)(OSFW)"?I$+:H-VKZ'_5\8M?)&=8CNQ MT,6CI`H2!`ZCPBY/IV4E'K[DC; M0@+/@,(]?65LNC\;83X'[(_8V[F$#H.C7S6B$HAA8-W4XL=#7UU82L&%4 MGM$H)=V#'V$ZN7_BEI`FV([L3!?IZLVL`@<1ALXGO[_$058T9QD M.[$P5:BOG6B3"%U]9E(WBBNOZ&`H'+N=6)B4U%T3KBBSM#G8I>TQ:9LT>R6. MR458452QHZIU8+EXE"?:3BSTUPF]/IW(U-9D3&>9X07.9WDH4E,VT?,Y5>5, M!$O6$D.WO[CHTY,DS&2)6K^,0:S6FX/F6PEB)BE^ M$67#R`ZT%BS;RGX+3-7I3RUT6J&S8-E6=FUH8I6@H>1QGACL&R+G'S>Y&` M,&T)C-;&9/JXWR]F_8:-:N0DG_3$P#XIR9+(")6):_($0$:W6 M!ZT0T1F4_V']%OAJY+1&`\>WA`SG;=)"R@9QTJ_!IS][\3(N#K!Y6@L^F>3[ M#]>E+AP-'0?KJ`)RE`WC:%^CM3AP3+,4[T+^W]3:/HE1T'&R_CG4`1][M8C MZ^?R4U7%S1\('3[K'$A4<,X0#?)[&#GY2:`CI]I40(.<<,H_VE9N>)ZJ6+I MBQ'`X31M5KZB9A@%/BWZEEF:I%Y(^O>I"+DV##BVIDW239(,5NY`7H<_C?=A M(S[N)_0M_U-G7W8U@5 M`6WD9W;U/MV;:FWW+YWU-)_C$F>XVB'T#XO#OJC7C\#1.#S?ES]A+XN^4! M?QM>+8U6==-PSX%3T36U8_=PC61?E,6N%F#NDUTP0E>(9(SA(FZPCR7T@Z9 MB1R[H7+[[C[(JGUG+JN1'_T2-M"O.`)U$VT6\ M2M1I@U0P)>,R6-!+S!3@"?,]A.U)(76(BZT=+;<8SHN:.IP\,Q6/E:EO'3/(J,5N6KTP].LX"_(+],JR?+40`LH3@6>8=A%Z M)RHKV4.E3\AZ;;O(76D2Z+8Y>ERQ(@HK>4,YWU36^L6,:5OUKA8J M-97,H,!,!3(K#Z!R`FL^#=T9J)>TVJ14HK+,%]:R&&N/E-+W#(OS)H%N#Z3' ML(HHK.1MF5_L":5]I:TP!71#H6Z+6(V^JW!6I])KQ2ISG-!MQ;JZ4=1([12 M`LL\A=Z&A$X'9J@."%T>Z&>ZM"!VDHGW"Y4R;V)+QZ^/)`.ORA,SI+">(V MR?X^[@\\NQ]D%]-OWGQ_@K?MQY5+`X>$F[QEXW0RI)V3)GDX9$Y\VWR&#V.)G=.=W0Q55==;\`0"G> MFY]Z04Y5LS)L,E:&Z<#^%^Q#"6LC4FD4T.L=KM:7::3?;83S=?:2^'O?BS\* MAU!AH01-"%ACH`O&=$J5H3@-XW2T\#&`=['_@O9W6?HU])6!8@30)XCBFGWD^J8ISX.70AB0 MH)!@:'A!&9DV@+3G@6O<+B)+&O$0H-.R.>SKJ.`1&F3#'_Y)EKB]TV#($H+ M4/DB5:0["HQ&WCE@RE=Z,X.2\$HKA-=>F+ZGS@]1&F-:8+0T:L"WU8%]#5 M%K>^/<@P!!810Q?,\27L2[+AO1"3&Q=^RB(0Q5$E\6#PF@Z#>B-'O:48&W6( M$'PNXSF)BJ3T:YKTD7[E>0TX$4CIK(&):240 M4F\K2$>;@"J_)YI%^%V-HY;0$A.`UZ$8]\LFY_)3\0(?]:6Z[X5]M'=/2">9CB[8YAJ2E/03=",&>;Z<2R M$\7,"J?X";%O'X$J(. M50`WK@`3J)TH@R@EH/9VT^EZ4AS[6G+L0[0?IH\>W'J>T&=5EF?)6^.`>1J M?FJI2"G-D,G\`P)U2J.2X0@'I:S^+DC1I MB3&1"`3TFU@I4`"Y5Z51^4IJLH"!ZBF&@EZ["C-@NP`[\WTVD''64.#/>D M4^LKWJHJ3>4ASD2=Q2FPC&E2:,N-7@K>H>G^%BM4I/_?CS^5W)#IS'`'GC MM0A4ACAM1\L;].H0]D+ECP)RS1L699T\*YNC4[\:$WI`?HIW,W**FG]_\^-< M'LP,3+59@%SXAD7-([>_,^KW0O0A.I+SQ/!V9ICPP6UWYG_JJT$MMN9YJP) MF;@3T3^C_93O'MXQ^+:6+:3ZWJ`EYP3N-?Q[8[S\ORP]"S`(Z`DE6LB.LP" M!(6D18H4Q5`FWMX#O@0I@N.^_`Q`&$:`6G`AW%UC(+PFJ,P!!3($J`,-V@TZ M:PVKP8Q4KQ)XI&6<'Y5[Z4-[,J@P.:!BT)D`??.PZ=0`%!&WY-A0BX0;N7[8 M%=VI/UMTW=M$\]-;$'T@5(9\/HTQG[$XQ/[B$-V7T;%XY%H;"U+P6P0%(XWG MAE\D#DI^BGW&WM\\>M7,) M,SM<.`:ZC,60@.GJQ.."+IV`!,0ZLT&P]=0?&VX)#(-:;=XNF+4OO6=<+0E8 M"+QK&?`E):ZL@4F[7X0DL=%_+\P'^5K\BG_P"W-X8X`#4VUV4QP#@N\?1):8 M[64Z8[..FS;K<%,7S_ZIFI>.'U8W^\(!]P0QQK`?VY:VN5.DS=Q&=8MW.=MG M1A:QE7YPD`+$@KL4.5F!^H!E[?ZY@Z,U@(G1^A$0RLB%[=9P3M MHZ"RR$FL1[AX217=)W.VA+BK+G;BT'B&)2RI93^7B]&@X:2\S=G:9"##R6`A M=+Z('=H,?**UW+UOF293&0B?:0]`>_%IQM-]5/24%73+VUU?#=U\QH+=4=:FJUZ/L9WMS M@:P8O7S_0387$=-OH"O&J4/<;:)F94+1YGU/XC37\RW"N4$?O4H?8JSC=XL M73_S!\##6Y=;5SM@.?RU69BN&2W3V)U;YM1N+D[;ANW_@1G6_WI5'\(ID,' M/;IJOQ03\OO:/=Z]%F$:^V'B[_[P@JR[OO=YZ7;B:-29X[R]#=>@[P&5+2* MU]Q82T7OW4X<#2>;5E09QFGKBF(5`L@Z.YV\^&-YR.E<'NKN,+3_FN!=[R[P M=O];[U[Q+$GQ9[+%D`9JT1X%?_KIZ]5.-$V2[%3,,R+$HZYH(3S;E._QFV\1 MUY"4#PT,@X-('`QB>Y]Y,'SXWQ!UI92XWPGDKVIEP(C=YC3)8,,&U"PH$L. M"YU+;VB'!;9!\8G7:LG<2X'Q0(P!$YED&/1I'=COR&/1O?_N[_%Y;(6E9\+C M/MN8'@3HVIMF&_ZSO=1XA,(@0&I]Q\1EI\?^.D'A((WWPX,X>4BKDL5I[T;&+S&"05G\$V;RYNBWF`N&@JU]FOLL%O MR+S1O3"L8Y@K",8ZPC&RE"0$8QU!&/EZH/NUX1C'4$8QW!6$XRSDJDF= M93'J!S\DG-=N%N]>R9\>HGAJ"H:'\2IG05G-:RN55]HR8MH:W$P=6QM.493 MQVCJ&$T=HZEC-'6,IH[1U#&:.D93<\;2_KNELFS\E!CV1;@GB>OXJ"K8EZC/ M@WN9S&]03+JU7#2XB4S3$06I.0VBPWF4Q26?[F+2$7[X=Z/T0[/6MC#A!\C M[C[XJ=IVIQ016LZT[D M@=74),UJRN>7MJB>C95JRNHW`(@I50W2B@\%F!A;NZ&2RRTIS0P3KH>:.F`` MV$T<#6"2;#`&!>'G0?&[OT-T7E8@5#G;DDV4>D'][\2E_Q2E_T'I"NVB8T@R M>>IA+!F?D.=O61T=";<5#;>0T^2^!%+(L7QJ&@0`[$=[`@R0BOV)C M<:X0N>#AW^,K7![API=!8^@RVC]R.W&^_8]@>[>&S4ZAHEX15J$35B7Q#U'< M1.QC^7ETS;^=.-JGAZ>IVCFDK2L;[GE.]IEY.JT/!SPGA>+0U/T`6Y["$7< M,"=J\TE2L^67+XO-E_G39CU]NI\MGS:+I\_SI]EBOH9%F,!+\.2G1@T,`E$ MTA)2B;FZGAP$%W&%]1AHH:G?#P9$(!("TY#2'@,"%J!SE,=U6T$%"J=F3D7Y MJ3+9(I0!0'`"+#8SL=5Z.A?18H-K^/G9,DBRP1#^6>8N1MSP\ MQ]$;BM./K_B&'B_QCQ[Y^D?D4:.!<@.!JMZ5A$&SC!)T#:)"_1$E"4$)$Q9 M/2>H26ZR0B'Z5GBI.4?(#K-!Y?OVT)">U$7@S-L`/$LK\@FE<7XRQ>AG_I> MD!/`$+K$**C$W+[+7TS5,&JEVXJ:GE,;GA#/:\D=!U7%K&%%"^F"SO9@K-T5 MVF<[M)^>HBQ,EX>U%WCQ!VO)4A_>?H+QZ/1=J4QBH-,4&)+:X+\FKU%0_V+$ M/"73G]Y^@G''])45FQJ#,6_S,:I+I+7\X0NV'EE\/@N0XN=3%.9I-&61?]ZV M;NT?0__@[_`OOH;12X+B=WS6(1O69H\HG<4_`+4G:XBY!(ZD2GGYPT#-:O M/N?1]UY(CPFLHF?)[)?A"NVRF.SN>_WDY8`2/X35NK`SW5$5+.O^U7`P32! M(!F;IP$FN.V&KQAR]U&RY&,6>$DB"+MQQP'7[YL0LD"=&%P8B&[TY^,U?X2Q M/N/O!HX."C7'N/UBLL5MI;U'L?_ND=#9@Q]ZF%PO6(1X6\CRDTZ#;8)8H^), MP/''FV@&72G5&34(MZ1&CO-"$29?!PP>#[!1ZV6>XUCT&KDR\X)=5B0[K(@ M>(AB`2ZA\7<#(^:;TCCC^LWDYK",=LW_03)UVMZ-)E>2)@^K#3?2T;-=;X/ MN._`391-H.>:V:E+M]_R^NMUZL6I6_K-X,]G?/![C))D$>Z";$^@>.=>3J" MI$XJIK\!N+&"@^N@"XLMC05K9L$G:)W+U@>SO[OKV_DT; M_"G0D'N#47XY5O?/(>BW!L;#_N5T"@P:9R'-D550)``,1!,E5$03)575X"P`!!"4.```$.0$``.T];6_;.)/? M#[C_P,N7ZP'K.&[:O6VPW0>X_0QSK%]MM-N/SU@)-HFDM>4DKB^_4WI$2] M4F]VTLKK`HNM8\X,YTWDS)`:Z/YXV-'@GCU'4^GO7.+\X0<4S7HL[JX]G] MXK;SV]DOCW?_O]/SJ=/Z]G(W3CFOZ&.!ZZ`Y@E)19ZHMX:#?ZO,["HYS+T M.:"%>N>7YQ?G[Q!\G&//9Q;>_8(,?^5S#UW\]@MZ>]%[CRXNK]Y=7/7>(>,. M=3IB'FZNR08C#[,5\<9X0_@6F^3CV=KSME?=[M/3TSFV',S/37?3%30N?KT4 M/-M$<'7KLLT-66+?]CZ>_>5C6[)XAD!(AU_AK>544I@:BGRW.7K0#DHM?] M\VXTEQPJFC9UOJ6@GQ^8K>`ONV+X`7.BP,6HY44(2>#WW6`P`K5+Z/XY`L)) MHK0$F#KAP8T("39W.MAQ7V/0ZY'EK8P?#`K6[A;\CS;F.XV_T1"R/=85H70#J M`!1AU(SPJI%"!+&F8<=Q/>S!JOC'[WB[I<[2%5^+Y^QL+@`!"0^W,^&!>N3 ME$2MO89C#1R/>KLA4&(;2?D,45!&40TIT66U&2'UC34"=>U!,?L6.A@`9 M$/F]FZ6@B/J<6!/G#_D9K,.!AL00"U6(%8+H,&"]>!-;)N^73Q!-Z7CX8VQ&-Q<&R-CW!_,_SD8+.:!SFO`Z37_%M0]!R614/41 M(92DA$)2**#UTP`)Q4XQK-/>FG@4V.%US9'!TAOGFEEB>(PWRR7R)4QRP.\=[$.P.(%:;%],/56>U?/:O,%_',W&(/% M)K=H,AW,C,40`-";:(?IDL8H(_Y^M9VGQI;3H.H-]S[?0S7-^;_1+>CR9=3 M-=S\_N[.F'V=W!K]_N1^O!B./TU!5_WA(-R;R@#TAOA5Q`"4F[;+?4:$50(2 M0M\Q$:2HG)"R1_0OGX+[2"XNH-8(K,L8WZ,X8&Y^DN__G'$UAHSDA;8>^-I\:7XWKT0#4`=_,[@DR1FQ1?`!\;>W6S#L<,CR1<08:+1P5_97E:SL\%(QA]38P9K\PT M/#?Z,F0\(17WC>EP88SFBTG_?\+X+_F-7I5OLZH,<9!$.B'M27DG4^DTLN$ MSZJTPH&]3J]S,5H`AV%^'+/4A1.2,']R=W=<"&3`]``I`TB4!V,XV"X#$"O MZ'RS,;H?!)J-_]3K\7U6CP(!28P34EI),C:%Y-FD MA%=F;1&@7M$-LS?T1M'[F35+A2Q$_%IMA1!,;X-<4E=E@X#:5F@3LJ6-$4# M>+U-]D[T3M$Z!<%(ZMDH!=';()?_%40.`.BNUS45#4]<#.2FVYYYK?AMR[HL+$OS>L0C[C!EU?3[9 MRA31<POF$'.Z/$;XF&JSIE>?1:]K7.I:<7N`@`!-\A=HJWB!W'!$***(^0+ MEM!CP!-R`Z9^D8?`3R%?Z$W(V4]?DE8.M+$@SYZ/:SA%!EQOW5RV7!4[!%21 M(GM2IBF.S]Z[E7&9FGY#1$]^34!]<;)Y>J5QREG/2C M4R>>SBYEJKH/]H%OF$^L$<4/U`;)2'IG?#7J>LOGB@NU8_O4WHA#1M`VX$3N M?3C@!=DQ,R>Y#>H/>G3/<2U(O2%SQ8NB`Z3?G;#,%$]'CN=$2I@].K/U2UR MQTDGK??P"$B>`"4/@'3ZKPFKMT.N5E%\^'32!DD>/NF,4#N5WRN0)$ZJOJI M:ZTN>U7+HBF+W-%BW)MGU;PW,=;ZH5E@[0ZWX;Z+@'0ZSM7.C0]]N?^A9Z MNS2]V6!OLL/OO/ZOCPE?4L]YDM?R:L90^?1M1^IL])7WPX@H+=7@T-U&$Q. MAB:Z<1K90ULDH05=5%B+=S!9FN[.Q+E>[WFIJY'5N\`N0K"/@X0U%7#^JFL MKT+VZ+F("8BSSBM#:W`B%$9X#.V?2)N^DN(3V06/<<5'IM8_/;W%P#E;!8 M/F74A($[UR+V%^JMOQ"Z6@.X\4@87A$#E+X)Z-19,KX3"WJ?R]4N2GTN4:UX M%,R#\K55@&_R!<,(\DQ"EE&`<\H9!I)KH/7=I]"OA$.&$Z'K_R-_G/,/-0V2\X1FYR>=N.QMD/+-IPZ^WJ+YVR$O8-'3VDM* M[O%IZP"UP?46R]5C2B\!GO33=HLID]MH].&.8$U]3J8N]FXCO1E]23)#79. M5PY=4A.^N'?23V96HK_P[SZ'TA5R)W+2`/X`;)-E! M27[$-AUP%#[&BBKVD;`I[B9!`R`)"[SD-ME%/4!2;HL3-R34FF!$7\U5%X'?%5I_>V<]D[ M?^96P%B#^2.)&LZO\)K-K^^L4W-FA2"F?%]CLM+^-@5SROFTB%UB>UQ]TXE) MU96ZI%],&2\:M/!S)R;1E`=="YXZ3"3QU!^'L'KZ%.+CR1B]%+JJ6&+-8!AM&WN&K&A.N,]^&CO('8_GNFI5=(<,6@97 M\DY9Q@/WF'1+D6RR/!?]<"#\%VX[N"[R"Y&WID(U?,X1#J(]G'O-%\"FA M(-RCKK60>);/PE9>#K5MD0$J6.X#,O5\,?J)N?Y634!/$B'&GK`M@@B/YZ9C%C4>PD91R[G$Z?O M.F'[RLDR<_DL(6H-V(,ECNWW:B(/'=/=$"',+;#?7V-G189.5`69++,F3:A@ M#]QC4$FBUA.<^-VZ3+0C\FUQ^WY.V",U4ZY0%^'UA+?(P\O(/B8>N+%)B"5M M.L0(`+??4$Z2,+%$TX>Q>LL]BZPLT85S5&/ M]I'`?&T3S@?/A)F4QP>=>A_9G\0Q&A&3!MS+HNN@<%OR)+`SF=-EO`O+`-] MEWM\X1J6)2MMV)YB:@V=\!I00E&'DSJ")RPOI+W6$"B#6/A#O[RX=_[K>LH M)RE550,J1Z`EK>%AU[5]BX#!Z[SID(PX7X+:$6AM&M0\=^)-'QE>@_&W,M0V MX1,3LA;(G%S'#R!R!#H:.A!KZBP,^?$XTU4LP?N$6A$_[J8,+\F>:L#W)[4 MK9A;<:1\;<.67$NV!'0@7-#L^LI3W^]ITI=/3C4FP9ICZ&R/.K,4P+3,J.( MGS6P?)$Q`?Y![DRFS@$,D,3!@+:,\J_W9'- M`V')4+D&<$H^R]U@ZOPHKUT\N8IC7BU<+>@629?C<>P+'B&_55DDIQJX.1R M0QV/K`C[?FX9_)===ESV3<2#X1L)/MO:/H=HD9HTM86@AU!>0^@.$\6F3; MC"=&/8\X4__!IJ:C6L4/5Z$VA$$1BDY%^Z,;,,2QXR(YSH<$%N<%VEHWJX M1Z"1I-&+"\2E4,BC]3RL9V3KA"B15HS7>^QF"+H.HX M=.;$\P(PL2R+XQM/Y++21>.B!R2Y!)"2^]_+D$ME&P&EO7;)EZ@N/7A#(,?D M.62"]UM7A)Y2S-3.%1]VB1<_2JT="BIT&W`9T!:"=]NM80;UJ$J2+3'G7T M(?PB_=5P.!QY5CY5T8VV:`D(P@L57>38UP^WCO_K"@%RXRV2P%@Q(O\VGFDR M/,I\_YV+,)9W95&873QRPTK6;Z0&=A13+V MQ;%/M'I.V$R\=B.=JSD^E0!>.!N_)(R38$I\5;!CH&7;CJ-#GD/QE=UH%. M[2("_(<)9ZS`F\1]0\6CW.M"9\4 M74GQPTRLPN,;O`O?:?X$.0ZX95072=?:LW2L;XR#U(`E(QK7+4$=VDZF9- MD%JT'B6N%X0A:%-Q:^$=&.F^KG75LU??M`48;;=K?4&KD5ID4>WVW[==^3IA M_AF#+`G?>$H>'%U^#@^:% M&[YWD"X6-$$Z@J>A^`]5]NJ!FU154N:23JE?($D6JVREM2"M.?$(,5COGE M'VX/^YK]?>[:%B0YXJ=-O(4[>23,L&W7"P[]@MI%>8!0BT"+UMML<'"`%IJ3 M:$>1(UG-ME"JW9]+^@NE4+LU5U+L5]:>E(VT%?`LM&W,?Z9;H+4HB)4#;9U MMQJ:H1V7O$&S!YM8$R;7J:"Z_!;I(&A?^)/@;]J<7+H**182Z8@=K45BE MKX@:PA3!^Z[\>A?#3/%.WE04RVS8H>(SX9ZXUAW M2KEKB2U7PAOL0?8E-C=.3=EFJ(E^#YOG;Z31L2O[<'X/I59/U9Y-/Y-+YY< M;B?N4/L/I/!U@>"G M-:3C%]ZU+X%I4714HO\1=:0&LJV]JL';DYT:C KE%V^)$%P`E\Q(+M$<'I M:^C5L/':!4\S_F$[P;5\K1J6"E_J5C3TQ[9D4=PF3XA4!?B":\E+-`JS?!/6 MPHUH#19SF%98LGWC0O&#Y;A];L1+-:,\+5K)WE/'2$6`1R!;+I?41&_:I;_ MC909,5U86P:M,P0EW&$5X/4A[UN)F1C?N([:@P)AJYQ:\K)53VG>=]O5VW MQ:9(M]RKZ-#W0V8_@F`H^@G)^.J5V#LA5U(CUZY(H98WE!'3<\,F`?GCJT,) ME48=Y75*BZ[HV=4INF?_0+]5-(IRTL1+'>G%]%1Z(E9O])Z7_#S+4$_<_CX M_U!+`0(>`Q0````(`+.`"D>56,>JE8,``#L5!@`1`!@```````$```"D@0`` M``!A<&1N+3(P,34P-C,P+GAM;%54!0`#$03)575X"P`!!"4.```$.0$``%!+ M`0(>`Q0````(`+.`"D>),B(UZ@@``,AN```5`!@```````$```"D@>"#``!A M<&1N+3(P,34P-C,P7V-A;"YX;6Q55`4``Q$$R55U>`L``00E#@``!#D!``!0 M2P$"'@,4````"`"S@`I'MJOXL3@=``!9``(`%0`8```````!````I($9C0`` M87!D;BTR,#$U,#8S,%]D968N>&UL550%``,1!,E5=7@+``$$)0X```0Y`0`` M4$L!`AX#%`````@`LX`1S$K0:%%80``KX%`!4`&````````0```2!HH` M`&%P9&XM,C`Q-3`V,S!?;&%B+GAM;%54!0`#$03)575X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`+.`"D>+-RDW]S,``(VE`P`5`!@```````$```"D@30, M`0!A<&1N+3(P,34P-C,P7W!R92YX;6Q55`4``Q$$R55U>`L``00E#@``!#D! M``!02P$"'@,4````"`"S@`I'J>:9R`L``00E#@``!#D!``!0 52P4&``````8`!@`:`@``CU(!```` ` end XML 17 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) - USD ($)

Jun. 30, 2015

Sep. 30, 2014

Payables and Accruals [Abstract]

Accounts payable $ 770,395 $ 1,059,623

Accrued consulting fees 110,500 102,500

Accrued salaries payable 428,098 245,761

Accrued interest payable 11,875

Other accrued expenses 109,622 75,000

Total $ 1,418,615 $ 1,494,759

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_AccruedSalariesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R37.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) - USD ($)
3 Months Ended 9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation expense $ 1,015,361 $ 404,507 $ 3,531,205 $ 1,717,837

Stock option modifications 544,113 673,176

Unrecorded compensation cost related to non-vested awards 2,749,586 $ 2,749,586

Weighted average period of non-vested awards options 2 years 2 months 16 days

Weighted average grant date fair value for options granted $ 69,430 $ 1,076,502

Employee Stock Options | Employees, consultants and non-employee board of director members

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted 49,585 950,094

Employee Stock Options | Executives

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options granted 450,000

X

- Definition
Represents share based compensation weighted average grant date fair value for options granted.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationWeightedAverageGrantDateFairValueForOptionsGranted

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unrecognized cost of unvested options awarded to employees as compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_StockOptionPlanExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=apdn_EmployeesConsultantsAndNonEmployeeBoardOfDirectorMembersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

PROMISSORY NOTES PAYABLE
9 Months Ended

Jun. 30, 2015

Convertible Notes Payable [Abstract]

PROMISSORY NOTES PAYABLE
NOTE D – PROMISSORY NOTES PAYABLE

On September 11, 2014, the Company issued and sold promissory notes (the “Notes”) in the aggregate principal amount of $1,800,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer, in the amount of $1,000,000, and to another individual, in the amount of $800,000, both of whom are “accredited investors” as defined in regulations promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

The Notes had a ten month maturity. Interest was payable in cash or in shares of common stock at the option of the holders of the Notes. Interest to be paid in shares was to be paid in shares of common stock equal to (i) the amount of interest payable, divided by (ii) the average of the closing prices for the five consecutive trading days immediately preceding the applicable interest date. The Notes were permitted to be prepaid in whole or in part, at any time, subject to certain prepayment penalties. Upon an event of default, the Notes and all accrued interest thereon were to automatically convert into common stock at the closing price of the common stock on the date of issuance of the Notes. In the event of a consolidation or merger with another corporation in which the Company does not survive, the Notes were to be paid in full. On November 11, 2014, Dr. Hayward and the other individual agreed to exchange for cancellation their respective Notes (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, in the case of Dr. Hayward, and 252,137 shares of common stock and warrants to purchase 252,137 shares of common stock, in the case of the other individual, at $3.25 ($3.24 for one share of common stock and $0.01 for one warrant) (“combined price”) , the aggregate public offering per share price of common stock and warrants issued in the Company’s underwritten public offering, which closed on November 20, 2014. The conversion of the Notes resulted in a loss on conversion of approximately $981,000, which was recorded on the condensed consolidated statement of operations for the nine month period ended June 30, 2015. The loss was calculated as the difference between the carrying amount of the promissory note and accrued interest on the conversion date compared to the fair value of the common stock and warrant issued as settlement of the Notes.

Interest expense for these Notes was $31,875 for the nine month period ended June 30, 2015.

X

- References
No definition available.
+ Details

Name: us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

CAPITAL STOCK (Detail Textuals) - $ / shares
1 Months Ended

Oct. 24, 2014

Jun. 30, 2015

Sep. 30, 2014

Stockholders' Equity Note [Abstract]

Reverse stock split one-for-60 (1:60)

Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001

Common stock, shares authorized 500,000,000 1,350,000,000

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares issued 21,482,202 13,935,954

Common stock, shares outstanding 21,482,202 13,935,954

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)

Nov. 11, 2014

Nov. 20, 2014

Sep. 30, 2014

Sep. 11, 2014

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,000,000

Conversion price of convertible promissory note converted (in dollars per share) $ 3.25 $ 3.25

Promissory notes

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,800,000

Interest rate on promissory note 12.50%

Promissory notes | James A. Hayward

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,000,000

Interest rate on promissory note 12.50%

Common stock and warrants issued in settlement of convertible debentures and interest 315,171

Number of shares issued in settlement of convertible notes and accrued interest 315,171

Conversion price of convertible promissory note converted (in dollars per share) $ 3.25

X

- Definition
Number of shares issued in settlement of convertible notes and accrued interest.
+ References
No definition available.
+ Details

Name: apdn_NumberOfSharesIssuedInSettlementOfConvertibleNotesAndAccruedInterest

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apdn_PresidentChairmanAndChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

CAPITAL STOCK (Detail Textuals 1) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Apr. 01, 2015

Apr. 30, 2015

Dec. 30, 2014

Dec. 19, 2014

Nov. 20, 2014

Jun. 30, 2015

Jun. 30, 2015

Jun. 30, 2014

Nov. 11, 2014

Stockholders' Equity Note [Abstract]

Underwritten public offering of common stock and warrants closed 2,800,000

Number of common stock called by warrants 2,800,000

Gross proceeds from underwritten public offering of common stock and warrants $ 9,100,000

Gross proceeds to repurchase remaining Series B Warrants $ 4,091,000

Conversion price of convertible promissory note converted into common stock (in dollars per share) $ 3.25 $ 3.25

Period of warrant exercised 5 years

Exercise price of warrants $ 3.50

Number of days option given to underwriters 45 days

Additional common stock purchase limit given to underwriters 420,000

Additional common stock per share purchase limit given to underwriters $ 3.24

Additional warrants purchase limit given to underwriters 420,000

Additional per share warrants purchase limit given to underwriters $ 0.01

Number of warrants for which underwriters' close exercise of its over-allotment option 416,850

Gross proceeds from closed on underwriters exercise of over-allotment option $ 4,169

Common stock closed on underwriters additional exercise of over-allotment option 52,000

Gross proceeds from closed on underwriters additional exercise of over-allotment option $ 168,400

Number of common stock including the exercise of over allotment option 2,852,000

Number of warrant issued including the exercise of over allotment option 3,216,850

Gross proceeds from sale of common stock and warrants $ 9,272,649

Gross proceeds from underwritten public offering of common stock and warrants $ 12,000,000 $ 263,950 9,300,000

Net proceeds from sale of common stock and warrants $ 3,690,000 $ 19,114,418 $ 2,145,956

Additional number of common stock called by warrants 128,800

Exercise price of warrants which company agreed to issue to the underwriters $ 3.73

Exercise price percentage of public offering price 115.00%

Number of common stock shares granted to consultant 15,000 22,500

Total expenses to consultant $ 47,750 $ 64,426

X

- Definition
Represents additional exercise price of common s tock called by warrants which company agree to issue to underwriters.
+ References
No definition available.
+ Details

Name: apdn_AdditionalExercisePriceSecuritiesCalledByWarrantsOrRights

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents additional number of commons tock called by warrants.
+ References
No definition available.
+ Details

Name: apdn_AdditionalNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents additional per shares of common stock purchase limit given to underwriters.
+ References
No definition available.
+ Details

Name: apdn_AdditionalPerSharesOfCommonStockPurchaseLimit

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents additional per share warrants purchase limit given to underwriters.
+ References
No definition available.
+ Details

Name: apdn_AdditionalPerSharesOfWarrantsPurchaseLimit

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents additional shares of common stock purchase limit given to underwriters.
+ References
No definition available.
+ Details

Name: apdn_AdditionalSharesOfCommonStockPurchaseLimit

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents additional warrants purchase limit given to underwriters.
+ References
No definition available.
+ Details

Name: apdn_AdditionalSharesOfWarrantsPurchaseLimit

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of additional common stock for closed on the underwriters exercise of its over-allotment option.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightAdditionalClosedOnUnderwritersExercise

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of warrants for closed on the underwriters exercise of its over-allotment option.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightClosedOnUnderwritersExercise

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents gross proceeds from additional closed on the underwriters exercise of its over-allotment option.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromAdditionalClosedOnUnderwritersExercise

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents gross proceeds from closed on the underwriters exercise of its over-allotment option.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromClosedOnUnderwritersExercise

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from common stock and warrants before deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromSaleOfCommonStockAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents gross proceeds from underwritten public offering of common stock and warrants on closure.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromUnderwrittenPublicOfferingOfCommonStockAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents gross proceeds from underwritten public offering of common stock and warrants on closure.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromUnderwrittenPublicOfferingOfCommonStockAndWarrantsTwo

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from gross proceeds to repurchase the remaining Series B Warrants.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsToRepurchaseRemainingSeriesBWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity.
+ References
No definition available.
+ Details

Name: apdn_NetProceedsFromSaleOfCommonStockAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents number of common stock issued under this offering, including the exercise of the over allotment option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfCommonStockIssued

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of days option given to underwriters.
+ References
No definition available.
+ Details

Name: apdn_NumberOfDaysOptionGivenToUnderwriters

Namespace Prefix: apdn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of warrants issued under this offering, including the exercise of the over allotment option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfWarrantsIssued

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents share based compensation offering to consultant.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationOfferingToConsultant

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents term period of warrants or rights exercised.
+ References
No definition available.
+ Details

Name: apdn_TermPeriodOfWarrantsOrRightsExercised

Namespace Prefix: apdn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Purchase price of common stock expressed as a percentage of its fair value.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

CAPITAL STOCK (Detail Textuals 2) - USD ($)
1 Months Ended

Apr. 01, 2015

Apr. 30, 2015

Nov. 20, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants 2,800,000

Exercise price of warrants $ 3.50

Underwritten public offering

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common stock offered 4,011,000

Number of common stock called by warrants 1,604,400

Combined offering price $ 3.00

Offering price for common stock 2.99

Offering price for warrant $ 0.01

Number of common stock sold pursuant to over allotment option 191,000

Number of warrants stock sold pursuant to over allotment option 76,400

Exercise price of warrants $ 3.50

Gross proceeds from offering $ 12,000,000

Number of days for option to purchase additional shares 45 days

Number of additional shares of common stock 573,000

Number of additional warrants to cover over allotments 229,200

Number of common stock exercise in over allotment option 87,000

Number of warrants exercise in over allotment option 152,800

Gross proceeds from exercise of over allotment option $ 263,950

X

- Definition
Represents gross proceeds from exercise of over allotment option.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromExerciseOfOverAllotmentOption

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents number of additional shares of common stock.
+ References
No definition available.
+ Details

Name: apdn_NumberOfAdditionalSharesOfCommonStock

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of additional warrants to cover over allotments.
+ References
No definition available.
+ Details

Name: apdn_NumberOfAdditionalWarrantsToCoverOverAllotments

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of common stock exercise in over allotment option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfCommonStockExerciseInOverAllotmentOption

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of common stock sold pursuant to over allotment of option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfCommonStockSoldPursuantToOverAllotmentOfOption

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of days for option to purchase additional shares.
+ References
No definition available.
+ Details

Name: apdn_NumberOfDaysForOptionToPurchaseAdditionalShares

Namespace Prefix: apdn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of warrants exercise in over allotment option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfWarrantsExerciseInOverAllotmentOption

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents number of warrants stock sold pursuant to over allotment of option.
+ References
No definition available.
+ Details

Name: apdn_NumberOfWarrantsStockSoldPursuantToOverAllotmentOfOption

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share for common stock of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: apdn_SharePriceForCommonStock

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Price of a single share for warrant of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: apdn_SharePriceForWarrant

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesSubscribedButUnissued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=apdn_UnderwrittenPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
9 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
NOTE C – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at June 30, 2015 and September 30, 2014 are as follows:

June 30,

2015

(unaudited)

September 30,
2014

Accounts payable $ 770,395 $ 1,059,623

Accrued consulting fees 110,500 102,500

Accrued salaries payable 428,098 245,761

Accrued interest payable - 11,875

Other accrued expenses 109,622 75,000

Total $ 1,418,615 $ 1,494,759

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

CAPITAL STOCK (Detail Textuals 3) - $ / shares
1 Months Ended

Apr. 01, 2015

Nov. 20, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price of warrants $ 3.50

Exercise price percentage of public offering price 115.00%

Underwritten public offering

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price of warrants $ 3.50

Underwritten public offering | Underwriters

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrants granted as partial compensation 163,720

Exercise price of warrants $ 3.44

Exercise price percentage of public offering price 115.00%

X

- Definition
Represents number of warrants granted as partial compensation.
+ References
No definition available.
+ Details

Name: apdn_NumberOfWarrantsGrantedAsPartialCompensation

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Purchase price of common stock expressed as a percentage of its fair value.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=apdn_UnderwrittenPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=apdn_UnderwritersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Jun. 30, 2015

Sep. 30, 2014

Current assets:

Cash and cash equivalents $ 10,730,144 $ 1,393,132

Accounts receivable, net of allowance of $30,228 and $9,634 at June 30, 2015 and September 30, 2014, respectively 2,077,756 834,818

Prepaid expenses and other current assets 209,831 135,365

Total current assets 13,017,731 2,363,315

Property, plant and equipment, net of accumulated depreciation of $743,914 at June 30, 2015 and $759,087 at September 30, 2014 526,816 576,128

Other assets:

Deposits 52,988 57,638

Deferred offering costs 0 181,104

Intangible assets, net of accumulated amortization and impairment of $325,555 and $256,208 at June 30, 2015 and September 30, 2014, respectively 525,902 327,872

Total Assets 14,123,437 3,506,057

Current liabilities:

Accounts payable and accrued liabilities, including related party accrued interest of $6,597 at September 30, 2014 1,418,615 1,494,759

Promissory notes payable, including $1,000,000 with a related party at September 30, 2014 1,800,000

Deferred revenue 204,863 583,362

Total current liabilities 1,623,478 3,878,121

Warrant liability 1,096,412

Total liabilities $ 1,623,478 $ 4,974,533

Commitments and contingencies (Note I)

Stockholders' Equity (Deficit)

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014

Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized at June 30, 2015 and September 30, 2014, respectively; 21,482,202 and 13,935,954 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively $ 21,483 $ 13,937

Additional paid in capital 223,623,850 198,277,859

Accumulated deficit (211,145,374) (199,760,272)

Total stockholders' equity (deficit) 12,499,959 (1,468,476)

Total Liabilities and Stockholders' Equity (Deficit) $ 14,123,437 $ 3,506,057

Series A Preferred stock

Stockholders' Equity (Deficit)

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014

Series B Preferred stock

Stockholders' Equity (Deficit)

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014

X

- Definition
This element represents amount of warrant liability as on the balance sheet date.
+ References
No definition available.
+ Details

Name: apdn_WarrantLiabilityNoncurrent

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_DeferredCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DepositsAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES
9 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES
NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying condensed consolidated financial statements as of June 30, 2015 and for the three and nine month periods ended June 30, 2015 and 2014 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2015. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2014 and footnotes thereto included in the Annual Report on Form 10-K, as amended, of Applied DNA Sciences, Inc. (the “Company”) filed with the SEC.

The condensed consolidated balance sheet as of September 30, 2014 contained herein has been derived from the audited consolidated financial statements as of September 30, 2014, but does not include all disclosures required by GAAP.

All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split of the Company’s common stock, par value $.001 per share, that was effected on October 29, 2014. See Note G.

Business and Basis of Presentation

On September 16, 2002, the Company was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through June 30, 2015, the Company has accumulated losses of $211,145,374.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.

Revenue Recognition



The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At June 30, 2015 and September 30, 2014, the Company recorded deferred revenue of $204,863 and $583,362, respectively.

Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $657,708 and $1,919,031 from these contract awards during the three and nine month periods ended June 30, 2015 and $0 and $50,000 for the three and nine month periods ended June 30, 2014, respectively.

Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three and nine month periods ended June 30, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three and nine month periods ended June 30, 2015 and 2014 are as follows:

2015 2014

Warrants 6,062,487 240,439

Employee options 3,456,989 2,073,043

9,519,476 2,313,482

Stock Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three and nine month periods ended June 30, 2015 included an aggregate of 87% and 73%, respectively, from two customers of the Company’s total revenues. These two customers accounted for approximately 89% of the Company’s total accounts receivable at June 30, 2015.

The Company’s revenues earned from sale of products and services for the three month period ended June 30, 2014 included an aggregate of 10% from one customer of the Company’s total revenues. During the nine month period ended June 30, 2014 no customers represented 10% or greater of the Company’s total revenues.

Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.

In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) - Jun. 30, 2015 - $ / shares

Total

Total

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Stock price $ 2.60 $ 2.85

Exercise price $ 2.60 $ 2.85

Expected term, years 3 years 9 months 4 years 10 months 6 days

Dividend yield

Volatility 118.00% 132.00%

Risk free rate 1.13% 1.56%

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePriceTwo

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: apdn_SharePriceTwo

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 29 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Oct. 24, 2014

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Sep. 30, 2014

Accounting Policies [Abstract]

Reverse stock split one-for-60 (1:60)

Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001 $ 0.001

Accumulated losses $ (211,145,374) $ (211,145,374) $ (199,760,272)

Deferred revenue 204,863 204,863 $ 583,362

Revenue for government contract awards $ 657,708 $ 0 $ 1,919,031 $ 50,000

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of consideration recognized during the period for the milestone or milestones.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501

+ Details

Name: us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) - Employee Stock Options - Incentive Stock Plan 2005 - shares
9 Months Ended

Jun. 30, 2015

Jan. 21, 2015

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Aggregate number of shares of common stock that can be issued as stock awards and stock option 5,833,334 8,333,333

Number of common stock shares that can be covered by awards made to any participant per period 833,334

Number of shares issued 233,752

Options to purchase shares under the 2005 Incentive Stock Plan 4,132,475

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The highest quantity of shares an employee can purchase under the plan per period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of share instruments newly issued under a share-based compensation plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares purchased on the open market during the period for issuance to employees under the plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=apdn_IncentiveStockPlan2005Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Apr. 01, 2015

Apr. 30, 2015

Nov. 20, 2014

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Liquidity And Management Plan [Abstract]

Accumulated deficit $ (211,145,374) $ (211,145,374) $ (199,760,272)

Net loss (1,670,882) $ (1,919,057) (11,385,102) $ (10,961,143)

Operating cash flow (5,226,713) (6,271,019)

Working capital 11,394,253 11,394,253

Cash and cash equivalents $ 10,730,144 $ 2,025,716 $ 10,730,144 $ 2,025,716 1,393,132 $ 6,360,301

Gross proceeds from underwritten public offering of common stock and warrants $ 12,000,000 $ 263,950 $ 9,300,000

Gross proceeds to repurchase remaining Series B Warrants $ 4,091,000

Proceeds from issuance of private placement of common stock and warrants 2,156,264

Proceeds from promissory notes 1,800,000

Proceeds from promissory notes from related party $ 1,000,000

X

- Definition
Represents gross proceeds from underwritten public offering of common stock and warrants on closure.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsFromUnderwrittenPublicOfferingOfCommonStockAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from gross proceeds to repurchase the remaining Series B Warrants.
+ References
No definition available.
+ Details

Name: apdn_GrossProceedsToRepurchaseRemainingSeriesBWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: apdn_LiquidityAndManagementPlanAbstract

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from promissory notes to the entity.
+ References
No definition available.
+ Details

Name: apdn_ProceedsFromPromissoryNotes

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from promissory notes through related party to the entity.
+ References
No definition available.
+ Details

Name: apdn_ProceedsFromPromissoryNotesFromRelatedParty

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
It represents working capital surplus deficit.
+ References
No definition available.
+ Details

Name: apdn_WorkingCapitalSurplusDeficit

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * / var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 33 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

LIQUIDITY AND MANAGEMENT'S PLAN
9 Months Ended

Jun. 30, 2015

Liquidity And Management Plan [Abstract]

LIQUIDITY AND MANAGEMENT'S PLAN
NOTE B – LIQUIDITY AND MANAGEMENT’S PLAN

The Company has recurring net losses, which have resulted in an accumulated deficit of $211,145,374 as of June 30, 2015. The Company incurred a net loss of $11,385,102 and generated negative operating cash flow of $5,226,713 for the nine month period ended June 30, 2015. However, the Company also has attained positive working capital of $11,394,253 as of June 30, 2015. At June 30, 2015 the Company had cash and cash equivalents of $10,730,144. The Company’s current capital resources include cash and cash equivalents, accounts receivable and prepaid expenses. Historically, the Company has financed its operations principally from the sale of equity securities. As discussed in Note G, on April 1, 2015, the Company closed its underwritten public offering of common stock and warrants for gross proceeds of approximately $12.0 million, before deducting underwriting discounts and offering expenses. Subsequently on April 30, 2015,the Company closed on the over-allotment option of the underwritten public offering for additional gross proceeds of $263,950. In addition, on November 20, 2014 the Company closed its underwritten public offering of common stock and warrants for gross proceeds of $9.3 million before deducting underwriting discounts and offering expenses. The Company utilized approximately $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The Company raised $2,156,264 in a private placement of common stock and warrants and $1,800,000 in promissory notes during the fiscal year ended September 30, 2014, including $1,000,000 from a related party. See Notes D and G.

The Company expects to finance operations primarily through cash flows provided by operating activities provided that it will achieve a sufficient level of future revenues. The Company estimates that its cash and cash equivalents are sufficient to fund operations for the next twelve months.

The Company will require additional funds to complete the continued development of its products, product manufacturing, and to fund expected additional losses from operations, until revenues are sufficient to cover the Company’s operating expenses.

X

- References
No definition available.
+ Details

Name: apdn_LiquidityAndManagementPlanAbstract

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure about liquidity and management plan.
+ References
No definition available.
+ Details

Name: apdn_LiquidityAndManagementPlanTextBlock

Namespace Prefix: apdn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)

Jun. 30, 2015

Sep. 30, 2014

Allowance on accounts receivable (in dollars) $ 30,228 $ 9,634

Accumulated depreciation on property, plant and equipment (in dollars) 743,914 759,087

Accumulated amortization and impairment on intangible assets (in dollars) $ 325,555 256,208

Related party accrued interest (in dollars) 6,597

Promissory note issued to related party (in dollars) $ 1,000,000

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 500,000,000 1,350,000,000

Common stock, shares issued 21,482,202 13,935,954

Common stock, shares outstanding 21,482,202 13,935,954

Series A Preferred stock

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Series B Preferred stock

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES (Tables)
9 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Schedule of stock issuances under options and warrants that could have a dilutive effect on the shares outstanding

2015 2014

Warrants 6,062,487 240,439

Employee options 3,456,989 2,073,043

9,519,476 2,313,482

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
9 Months Ended

Jun. 30, 2015

Aug. 06, 2015

Document and Entity Information [Abstract]

Entity Registrant Name APPLIED DNA SCIENCES INC

Entity Central Index Key 0000744452

Trading Symbol apdn

Current Fiscal Year End Date --09-30

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 21,487,202

Document Type 10-Q

Document Period End Date Jun. 30, 2015

Amendment Flag false

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

X

- References
No definition available.
+ Details

Name: apdn_DocumentAndEntityInformationAbstract

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
9 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

June 30,

2015

(unaudited)

September 30,
2014

Accounts payable $ 770,395 $ 1,059,623

Accrued consulting fees 110,500 102,500

Accrued salaries payable 428,098 245,761

Accrued interest payable - 11,875

Other accrued expenses 109,622 75,000

Total $ 1,418,615 $ 1,494,759

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Statement [Abstract]

Revenues $ 2,267,671 $ 841,197 $ 5,028,234 $ 2,075,698

Operating expenses:

Selling, general and administrative 3,508,455 2,948,452 11,078,405 10,093,631

Research and development 310,093 266,331 961,745 1,085,416

Depreciation and amortization 121,339 113,424 354,144 325,448

Total operating expenses 3,939,887 3,328,207 12,394,294 11,504,495

LOSS FROM OPERATIONS (1,672,216) (2,487,010) (7,366,060) (9,428,797)

Other income (expense):

Interest income (expense), net 5,052 111 (26,807) 784

Other (expense) income, net (3,718) 52,299 (16,853) 130,186

Loss on conversion of promissory notes (980,842)

Gain (loss) on change in fair value of warrant liability 515,543 (2,994,540) (1,663,316)

Net loss before provision for income taxes $ (1,670,882) $ (1,919,057) $ (11,385,102) $ (10,961,143)

Provision for income taxes

NET LOSS $ (1,670,882) $ (1,919,057) $ (11,385,102) $ (10,961,143)

Net loss per share-basic and diluted (in dollars per share) $ (0.08) $ (0.14) $ (0.63) $ (0.82)

Weighted average shares outstanding-

Basic and diluted (in shares) 21,444,335 13,569,262 18,075,506 13,400,540

X

- Definition
Represent income (loss) from change in fair value of warrant liability.
+ References
No definition available.
+ Details

Name: apdn_IncomeLossFromChangeInFairValueOfWarrantLiability

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represent loss on conversion of promissory notes.
+ References
No definition available.
+ Details

Name: apdn_LossOnConversionOfPromissoryNotes

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.10)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

CAPITAL STOCK
9 Months Ended

Jun. 30, 2015

Stockholders' Equity Note [Abstract]

CAPITAL STOCK
NOTE G - CAPITAL STOCK

On October 24, 2014, the Company filed a Third Certificate of Amendment of its Certificate of Incorporation with the Secretary of State of the State of Delaware that effected a one-for-60 (1:60) reverse stock split of its common stock, par value $.001 per share, and a decrease in its authorized common stock, from 1,350,000,000 to 500,000,000 shares, effective October 29, 2014. All warrant, option, share, and per share information in the condensed consolidated financial statements gives retroactive effect to the one-for-60 reverse stock split that was effected on October 29, 2014. In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of June 30, 2015 and September 30, 2014, there were 21,482,202 and 13,935,954 shares of common stock issued and outstanding, respectively.

On November 20, 2014, the Company closed its underwritten public offering of 2,800,000 shares of common stock and warrants to purchase up to an aggregate of 2,800,000 shares of common stock for gross proceeds of $9.1 million before deducting underwriting discounts and offering expenses. The Company utilized $4,091,000 of the gross proceeds to repurchase the remaining Series B Warrants from Crede, as discussed in Note E. The combined price for each share of common stock and warrant was $3.25. The warrants may be exercised for a period of five years and have an exercise price of $3.50 per share. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 420,000 additional shares of common stock at $3.24 per share and/or up to 420,000 additional warrants at $0.01 per share to cover over-allotments, if any. The Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in this underwritten public offering. The Company’s common stock and warrants are listed on the Nasdaq Capital Market under the symbols “APDN” and “APDNW”, respectively. On December 19, 2014, the Company closed on the underwriters’ exercise of its over-allotment option of 416,850 warrants for gross proceeds of $4,169 and on December 30, 2014, the Company closed on the underwriters’ additional exercise of its over-allotment option of 52,000 shares of common stock for gross proceeds of $168,400. The total number of common stock and warrants issued under this offering, including the exercise of the over-allotment option was 2,852,000 and 3,216,850, respectively. The gross proceeds to the Company was $9.3 million and net proceeds after deducting underwriting discounts, offering expenses and the repurchase of the remaining Series B Warrants from Crede was approximately $3.69 million.

In connection with the closing of this underwritten public offering, on November 20, 2014, the Company granted 128,800 warrants to purchase common stock to its underwriters as partial compensation. These warrants have an exercise price of $3.73 (115% of the public offering price) and expire on November 14, 2019.

During the three and nine month periods ended June 30, 2015, the Company granted 15,000 and 22,500 shares of common stock to a consultant for a total expense of approximately $47,750 and $64,426, respectively.

On April 1, 2015, the Company closed its underwritten public offering of 4,011,000 shares of common stock and warrants to purchase up to an aggregate of 1,604,400 shares of common stock, at $3.00 ($2.99 for one share of common stock and $0.01 for one warrant) (“combined offering price”), including 191,000 shares and 76,400 warrants sold pursuant to the partial exercise of the underwriters’ over-allotment option. The warrants have a per share exercise price of $3.50, are exercisable immediately, and expire on November 20, 2019. The gross proceeds to the Company from this offering, including the partial exercise of the over-allotment option but before deducting the underwriting discount and offering expenses, is $12.0 million. In connection with the offering, the Company granted to the underwriters a 45-day option to purchase up to 573,000 additional shares of common stock and up to 229,200 additional warrants to cover over-allotments, if any. On April 30, 2015, the Company closed on the underwriters’ exercise of its over-allotment option of 87,000 shares of common stock and 152,800 warrants for gross proceeds of $263,950 .

In connection with the closing of this underwritten public offering, as partial compensation, on April 1, 2015, the Company granted up to 163,720 warrants to purchase common stock to its underwriters. These warrants have an exercise price of $3.44 (115% of the public offering price) and expire on March 27, 2020.

See Note D for the common stock and warrants issued in connection with the conversion of the promissory notes.

X

- Definition
The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
+ References
No definition available.
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

RELATED PARTY TRANSACTIONS
9 Months Ended

Jun. 30, 2015

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS
NOTE F – RELATED PARTY TRANSACTIONS

As discussed in Note D, on September 11, 2014, the Company issued and sold a promissory note in the aggregate principal amount of $1,000,000 and bearing interest at a rate of 12.5% per annum to Dr. James A. Hayward, the Company’s President, Chairman and Chief Executive Officer. On November 11, 2014, Dr. Hayward agreed to exchange for cancellation of his Note (including principal and accrued interest thereon) for 315,171 shares of common stock and warrants to purchase 315,171 shares of common stock, at a combined price of $3.25, the aggregate public offering price of common stock and warrants issued in the Company’s underwritten public offering which closed on November 20, 2014.

As discussed in Note G, the Company’s Chief Executive Officer and an affiliated company of a member of the Company’s board of directors participated in the Company’s November 20, 2014 underwritten public offering.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) - Customer Concentration Risk - Customer
3 Months Ended 9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Total Revenue

Concentration Risk [Line Items]

Concentration risk benchmark description no customers represented 10% or greater

Total Revenue | Two customers

Concentration Risk [Line Items]

Percentage of total revenue and accounts receivable 87.00% 73.00%

Number of customers 2 2

Total Revenue | Customer One

Concentration Risk [Line Items]

Percentage of total revenue and accounts receivable 10.00%

Number of customers 1

Accounts Receivable | Two customers

Concentration Risk [Line Items]

Percentage of total revenue and accounts receivable 89.00%

Number of customers 2

X

- Definition
It represents number of major customers in concentration risk.
+ References
No definition available.
+ Details

Name: apdn_ConcentrationRiskNumberOfCustomers

Namespace Prefix: apdn_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Identifies or describes the benchmark that serves as the denominator in the calculation of the percentage of concentration risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

+ Details

Name: us-gaap_ConcentrationRiskBenchmarkDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ConcentrationRiskLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=apdn_TwoCustomersConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=apdn_CustomerOneConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS (Tables)
9 Months Ended

Jun. 30, 2015

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of transactions involving warrants

Number of
Shares Weighted
Average
Exercise
Price Per
Share

Balance at October 1, 2014 945,166 $ 9.59

Granted 5,833,878 3.50

Exercised (— ) (— )

Cancelled or expired (716,557 ) (11.30 )

Balance at June 30, 2015 6,062,487 $ 3.53

Schedule of summary of transactions involving stock options issued to employees

Number of
Shares
Weighted
Average

Exercise

Price Per

Share

Aggregate

Intrinsic

Value

Outstanding at October 1, 2014 2,909,046 $ 4.74

Granted 950,094 2.85

Exercised — —

Cancelled or expired (402,151) (3.01)

Outstanding at June 30, 2015 3,456,989 $ 4.42

Vested at June 30, 2015 2,494,098 $ 4.13 $ 0.18

Non-vested at June 30, 2015 962,891 $ 0.12

Schedule of fair value of options granted

Three
Months
Ended
June 30,
2015 Nine
Months
Ended
June 30,
2015

Stock price $ 2.60 $ 2.85

Exercise price $ 2.60 $ 2.85

Expected term, years 3.75 4.85

Dividend yield — % — %

Volatility 118 % 132 %

Risk free rate 1.13 % 1.56 %

X

- Definition
Tabular disclosure of components of transactions of warrants.
+ References
No definition available.
+ Details

Name: apdn_ScheduleOfDisclosureTransactionsOfWarrantsTableTextBlock

Namespace Prefix: apdn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

FAIR VALUE
9 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

FAIR VALUE
NOTE J - FAIR VALUE

The carrying value of cash, accounts receivable, accounts payable and accrued liabilities approximate estimated fair values because of their short maturities.

The carrying value of the warrant liability is determined using the Binomial Lattice option pricing model as described in Note A. Certain assumptions used in the calculation of the warrant liability represent Level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1, 2 or 3 as of June 30, 2015.

The following table summarizes the activity of Level 3 inputs measured on a recurring basis:

Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)
Nine Months Ended

June 30,

2015 2014

Balance at October 1, 2014 and 2013 $ 1,096,412 $ 2,643,449

Adjustment resulting from change in fair value (a) 2,994,540 1,663,316

Removal of warrant upon repurchase (4,090,952 ) —

Reclassification to equity upon exercise — (2,455,042 )

Balance at June 30, $ — $ 1,851,723

(a) Adjustment resulting from change in fair value* is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to warrant liabilities held at the reporting date and realized gains or losses at the date of exercise. The gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS
9 Months Ended

Jun. 30, 2015

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK OPTIONS AND WARRANTS
NOTE H - STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of common stock issued to non-employees of the Company. These warrants were granted in lieu of cash for services performed or financing expenses in connection with the sale of common stock.

Transactions involving warrants (see Notes D, E and G) are summarized as follows:

Number of
Shares Weighted
Average
Exercise
Price Per
Share

Balance at October 1, 2014 945,166 $ 9.59

Granted 5,833,878 3.50

Exercised (— ) (— )

Cancelled or expired (716,557 ) (11.30 )

Balance at June 30, 2015 6,062,487 $ 3.53

Employee Stock Options

In 2005, the Board of Directors and the holders of a majority of the outstanding shares of common stock approved the 2005 Incentive Stock Plan (the “Incentive Plan”). In 2007, 2008 and 2012, the Board of Directors and holders of a majority of the outstanding shares of common stock approved various increases in the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 5,833,334 shares and the number of shares of common stock that can be covered by awards made to any participant in any calendar year to 833,334 shares. On January 21, 2015, the Board of Directors approved an amendment to the Incentive Plan, which was approved by shareholders on June 16, 2015. The amendment increases the number of shares of common stock that can be issued as stock awards and stock options thereunder to an aggregate of 8,333,333. The amendment also extends the Incentive Plan’s expiration date to January 25, 2025.

The Incentive Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to our success with an award of options to purchase shares of common stock and an award of shares of common stock. As of June 30, 2015 a total of 233,752 shares have been issued and options to purchase 4,132,475 shares have been granted under the 2005 Incentive Stock Plan.

Transactions involving stock options issued to employees are summarized as follows:

Number of
Shares
Weighted
Average

Exercise

Price Per

Share

Aggregate

Intrinsic

Value

Outstanding at October 1, 2014 2,909,046 $ 4.74

Granted 950,094 2.85

Exercised — —

Cancelled or expired (402,151) (3.01)

Outstanding at June 30, 2015 3,456,989 $ 4.42

Vested at June 30, 2015 2,494,098 $ 4.13 $ 0.18

Non-vested at June 30, 2015 962,891 $ 0.12

For the three and nine-month periods ended June 30, 2015, the Company issued 49,585 and 950,094, options to employees, consultants and non-employee board of director members, respectively. Included in these grants for the nine month period was 450,000 options granted to executives.

The fair value of options granted during the three and nine month periods ended June 30, 2015 was determined using the Black Scholes Option Pricing Model with the following weighted average assumptions:

Three
Months
Ended
June 30,
2015 Nine
Months
Ended
June 30,
2015

Stock price $ 2.60 $ 2.85

Exercise price $ 2.60 $ 2.85

Expected term, years 3.75 4.85

Dividend yield — % — %

Volatility 118 % 132 %

Risk free rate 1.13 % 1.56 %

The Company recorded $1,015,361(including $544,113 for stock option modifications) and $404,507 as stock compensation expense for the three month periods ended June 30, 2015 and 2014, respectively, and $3,531,205 (including $673,176 for stock option modifications) and $1,717,837 for the nine month periods ended June 30, 2015 and 2014, respectively for the vesting portion of all options. As of June 30, 2015, unrecorded compensation cost related to non-vested awards was $2,749,586 which is expected to be recognized over a weighted average period of approximately 2.21 years. The weighted average grant date fair value for options granted during the three and nine month periods ended June 30, 2015 was $69,430 and $1,076,502, respectively.

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

COMMITMENTS AND CONTINGENCIES
9 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE I - COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company leases office space under an operating lease in Stony Brook, New York for its corporate headquarters. The lease is for a 30,000 square foot building. The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods. The base rent during the initial lease term is $449,142 per annum. The Company also has operating leases for a laboratory in Huddersfield, England, which is currently inactive and Calverton, New York. The Huddersfield lease was terminated effective July 31, 2015. The Calverton lease was from February 1, 2014 through October 31, 2014, with the option to renew for additional one year periods. The Calverton lease is currently on a month to month basis. Total rent expense for the three and nine month periods ended June 30, 2015 was $124,504 and $373,772, respectively. Total rent expense for the three and nine month periods ended June 30, 2014 were $125,268 and $380,251, respectively.

Employment Agreement

The Company has an employment agreement with the Chief Executive Officer. Effective June 21, 2014, the Chief Executive Officer’s annual salary was voluntarily reduced by $50,000. This salary reduction will be accrued and repaid when the Company reaches $3,000,000 in sales for two consecutive quarters or the Company has net income at the end of any fiscal year. Effective January 1, 2015, the Chief Executive Officer’s annual salary was voluntarily reduced by an additional $50,000.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES (Policies)
9 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Business and Basis of Presentation
Business and Basis of Presentation

On September 16, 2002, the Company was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has had a limited operating history, and as a result, its operations have produced limited recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a biotechnology company. For the period from inception through June 30, 2015, the Company has accumulated losses of $211,145,374.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited, which currently have no operations or activity. Significant inter-company transactions and balances have been eliminated in consolidation.

Revenue Recognition
Revenue Recognition



The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and/or service has been performed; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered or services provided and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered, service has not been provided, or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered, the service has been provided, or no refund will be required. At June 30, 2015 and September 30, 2014, the Company recorded deferred revenue of $204,863 and $583,362, respectively.



Revenue arrangements with multiple components are divided into separate units of accounting if certain criteria are met, including whether the delivered component has stand-alone value to the customer. Consideration received is allocated among the separate units of accounting based on their respective selling prices. The selling price for each unit is based on vendor-specific objective evidence, or VSOE, if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party is available. The applicable revenue recognition criteria are then applied to each of the units.

Revenue for government contract awards, which supports the Company’s development efforts on specific projects, is recognized as milestones are achieved as per the contract. The Company recognized revenue of approximately $657,708 and $1,919,031 from these contract awards during the three and nine month periods ended June 30, 2015 and $0 and $50,000 for the three and nine month periods ended June 30, 2014, respectively.

Net Loss Per Share
Net Loss Per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share. Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants.

For the three and nine month periods ended June 30, 2015 and 2014, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Securities that could potentially dilute basic net income per share in the future that were not included in the computation of diluted net loss per share because including those securities would have been anti-dilutive for the three and nine month periods ended June 30, 2015 and 2014 are as follows:

2015 2014

Warrants 6,062,487 240,439

Employee options 3,456,989 2,073,043

9,519,476 2,313,482

Stock Based Compensation
Stock Based Compensation

The Company accounts for stock-based compensation for employees and directors in accordance with ASC 718, Compensation (“ASC 718”). ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values. Under the provisions of ASC 718, stock-based compensation costs are measured at the grant date, based on the fair value of the award, and are recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.

The Company accounts for stock based compensation awards issued to non-employees for services, as prescribed by ASC 718-10, at either the fair value of the services rendered or the instruments issued in exchange for such services, whichever is more readily determinable, using the measurement date guidelines enumerated in ASC 505-50.

Concentrations
Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the three and nine month periods ended June 30, 2015 included an aggregate of 87% and 73%, respectively, from two customers of the Company’s total revenues. These two customers accounted for approximately 89% of the Company’s total accounts receivable at June 30, 2015.

The Company’s revenues earned from sale of products and services for the three month period ended June 30, 2014 included an aggregate of 10% from one customer of the Company’s total revenues. During the nine month period ended June 30, 2014 no customers represented 10% or greater of the Company’s total revenues.

Recent Accounting Pronouncements
Recent Accounting Pronouncements

In August 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 provides guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. For each reporting period, management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financial statements are issued. The amendments in ASU 2014-15 are effective for annual reporting periods ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company will adopt the methodologies prescribed by ASU 2014-15 by the date required, and does not anticipate that the adoption of ASU 2014-15 will have a material effect on its condensed consolidated financial position or results of operations.

In June 2014, the FASB issued Accounting Standards Update 2014-12, “Accounting for share-based payments when the terms of an award provide that a performance target could be achieved after the requisite service period,” (“ASU 2014-12”) which requires performance-based awards with a performance target that affects vesting and that could be achieved after an employee completes the requisite service period to be accounted for as a performance condition. If performance targets are clearly defined and it is probable that the performance condition will be achieved, stock-based expense should be recognized over the remaining requisite service period. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2015. Early adoption is permitted. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

In May 2014, the FASB issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” (“ASU 2014-09”) which provides updated, comprehensive revenue recognition guidance for contracts with customers, including a new principles-based five step framework that eliminates much of the industry-specific guidance in current accounting literature. Under ASU 2014-09, revenue recognition is based on a core principle that companies recognize revenue in an amount consistent with the consideration it expects to be entitled to in exchange for the transfer of goods or services. The standards update also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of recognized revenue. This guidance will be effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2017. The Company is in the process of evaluating the provisions of the ASU and assessing the potential effect on the Company’s condensed consolidated financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 55

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6875567&loc=d3e14489-108613

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61082-112788

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28088331&loc=SL29635902-196195

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 825

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51676700&loc=d3e61044-112788

+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) - Jun. 30, 2015 - Employee Stock Options - Incentive Stock Plan 2005 - $ / shares

Total

Number of Shares

Outstanding at October 1, 2014 2,909,046

Granted 950,094

Exercised

Cancelled or expired (402,151)

Outstanding at June 30, 2015 3,456,989

Vested at June 30, 2015 2,494,098

Non-vested at June 30, 2015 962,891

Weighted Average Exercise Price Per Share

Outstanding at October 1, 2014 $ 4.74

Granted $ 2.85

Exercised

Cancelled or expired $ (3.01)

Outstanding at June 30, 2015 4.42

Vested at June 30, 2015 4.13

Aggregate Intrinsic Value, Vested at June 30, 2015 0.18

Aggregate Intrinsic Value, Non-vested at June 30, 2015 $ 0.12

X

- Definition
The grant-date intrinsic value of options nonvested during the reporting period.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateIntrinsicValue

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The grant-date intrinsic value of options vested during the reporting period.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedGrantDateIntrinsicValue

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents information about weighted average exercise price per share vested.
+ References
No definition available.
+ Details

Name: apdn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of non-vested options outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=apdn_IncentiveStockPlan2005Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) - shares
3 Months Ended 9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from diluted net loss per share 9,519,476 2,313,482 9,519,476 2,313,482

Warrants

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from diluted net loss per share 6,062,487 240,439 6,062,487 240,439

Employee options

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from diluted net loss per share 3,456,989 2,073,043 3,456,989 2,073,043

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

PROMISSORY NOTES PAYABLE (Detail Textuals) - USD ($)
9 Months Ended

Nov. 11, 2014

Jun. 30, 2015

Nov. 20, 2014

Sep. 30, 2014

Sep. 11, 2014

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,000,000

Promissory notes maturity term 10 months

Debt instrument, convertible, threshold consecutive trading days 5 days

Conversion price of convertible promissory note converted (in dollars per share) $ 3.25 $ 3.25

Conversion price of convertible promissory note converted into common stock (in dollars per share) 3.24

Conversion price of convertible promissory note converted into warrant (in dollars per share) $ 0.01

Loss on conversion of promissory notes $ 980,842

Promissory notes

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,800,000

Interest rate on promissory note 12.50%

Loss on conversion of promissory notes 981,000

Interest expense $ 31,875

Promissory notes | James A. Hayward

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 1,000,000

Interest rate on promissory note 12.50%

Common stock and warrants issued in settlement of convertible debentures and interest 315,171

Number of shares issued in settlement of convertible notes and accrued interest 315,171

Conversion price of convertible promissory note converted (in dollars per share) $ 3.25

Promissory notes | Another individual

Short-term Debt [Line Items]

Promissory note issued to related party (in dollars) $ 800,000

Common stock and warrants issued in settlement of convertible debentures and interest 252,137

Number of shares issued in settlement of convertible notes and accrued interest 252,137

Conversion price of convertible promissory note converted (in dollars per share) $ 3.25

X

- Definition
The price per share of common stock of the conversion feature embedded in the debt instrument.
+ References
No definition available.
+ Details

Name: apdn_DebtInstrumentConvertibleForOneShareOfCommonStockConversionPrice

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share of warrant of the conversion feature embedded in the debt instrument.
+ References
No definition available.
+ Details

Name: apdn_DebtInstrumentConvertibleForOneShareOfWarrantConversionPrice

Namespace Prefix: apdn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Represent loss on conversion of promissory notes.
+ References
No definition available.
+ Details

Name: apdn_LossOnConversionOfPromissoryNotes

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued in settlement of convertible notes and accrued interest.
+ References
No definition available.
+ Details

Name: apdn_NumberOfSharesIssuedInSettlementOfConvertibleNotesAndAccruedInterest

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instruments must exceed threshold percentage for a specified number of trading days to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShortTermDebtLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-30)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apdn_PresidentChairmanAndChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apdn_AnotherIndividualMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
9 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Cash flows from operating activities:

Net loss $ (11,385,102) $ (10,961,143)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 354,144 325,448

Stock based compensation expense 3,531,205 1,717,837

Change in fair value of warrant liability 2,994,540 1,663,316

Loss on conversion of promissory notes 980,842

Common stock issued for consulting services 64,426 337,500

Bad debt expense 21,750 16,878

Change in operating assets and liabilities:

Accounts receivable (1,275,189) 137,486

Prepaid expenses and other current assets and deposits (59,315) (924)

Accounts payable and accrued liabilities (75,515) 292,462

Deferred revenue (378,499) 200,121

Net cash used in operating activities (5,226,713) (6,271,019)

Cash flows used in investing activities:

Purchase of property plant and equipment (221,659) (209,522)

Purchase of intangible assets (238,082)

Net cash used in investing activities (459,741) (209,522)

Cash flows from financing activities:

Net proceeds from sale of common stock and warrants 19,114,418 2,145,956

Purchase and cancelation of previously issued warrants (4,090,952)

Net cash provided by financing activities 15,023,466 2,145,956

Net increase (decrease) in cash and cash equivalents 9,337,012 (4,334,585)

Cash and cash equivalents at beginning of period 1,393,132 6,360,301

Cash and cash equivalents at end of period $ 10,730,144 $ 2,025,716

Supplemental Disclosures of Cash Flow Information:

Cash paid during period for interest

Cash paid during period for taxes

Non-cash investing and financing activities:

Common stock issued for cashless exercise of options and warrants $ 19,570

Reclassification of deferred offering costs to additional paid in capital $ 181,104

Reclassification of warrants from liability to equity upon exercise $ 2,455,042

Offering costs incurred, and included in accounts payable and accrued liabilities 68,489

Property, plant and equipment acquired, and included in accounts payable 13,825

Intangible assets acquired, and included in accounts payable 29,296

Common stock issued upon conversion of promissory notes payable $ 1,843,750

X

- Definition
This element represents the amount of common stock issued for cashless exercise of options and warrants.
+ References
No definition available.
+ Details

Name: apdn_CommonStockIssuedForCashlessExerciseOfOptionsAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents amount of common stock issued for consulting services during the period.
+ References
No definition available.
+ Details

Name: apdn_CommonStockIssuedForConsultingServices

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents value of deferred offering costs incurred, and included in accounts payable and accrued liabilities.
+ References
No definition available.
+ Details

Name: apdn_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represent income (loss) from change in fair value of warrant liability.
+ References
No definition available.
+ Details

Name: apdn_IncomeLossFromChangeInFairValueOfWarrantLiability

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents value of intangible assets acquired, and included in accounts payable.
+ References
No definition available.
+ Details

Name: apdn_IntangibleAssetsAcquiredIncludedInAccountsPayable

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represent loss on conversion of promissory notes.
+ References
No definition available.
+ Details

Name: apdn_LossOnConversionOfPromissoryNotes

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from common stock and warrants after deducting after deducting underwriting discounts, offering expenses and the repurchase the remaining Series B Warrants from Crede to the entity.
+ References
No definition available.
+ Details

Name: apdn_NetProceedsFromSaleOfCommonStockAndWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
It represents property, plant and equipment acquired, included in accounts payable.
+ References
No definition available.
+ Details

Name: apdn_PropertyPlantAndEquipmentAcquiredIncludedInAccountsPayable

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents purchase and cancelation of previously issued warrants.
+ References
No definition available.
+ Details

Name: apdn_PurchaseAndCancelationOfPreviouslyIssuedWarrants

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents Reclassification of deferred offering costs to additional paid in capital.
+ References
No definition available.
+ Details

Name: apdn_ReclassificationOfDeferredOfferingCostsToAdditionalPaidInCapital

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents reclassification of warrants from liability to equity upon exercise in noncash investing and financing activities.
+ References
No definition available.
+ Details

Name: apdn_ReclassificationOfWarrantsFromLiabilityToEquityUponExercise

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 51 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

WARRANT LIABILITY
9 Months Ended

Jun. 30, 2015

Warrant Liability [Abstract]

WARRANT LIABILITY
NOTE E – WARRANT LIABILITY

On December 16, 2013, Crede CG III, Ltd (“Crede”) effected the cashless exercise of 178,253 Series A Warrants and 116,667 Series B Warrants. At December 16, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $2,455,042 using the Binomial Lattice model with the following assumptions: fair value of the Company’s common stock $10.80 per share; dividend yield 0%; expected term: 4.55 years; risk free interest rate: 1.55%; expected volatility of: 118.89%; and an exercise price of $14.59. The change in fair value of the warrant liability on the day of exercise amounted to a loss of $1,288,752 and was included in the other income (expense). Upon exercise, the fair value of the Series A Warrants and 116,667 of the Series B Warrants were reclassified to equity.

The Series A and Series B Warrants were classified as liabilities on the issuance date due to certain provisions contained in the warrant agreements, which may cause an adjustment to the conversion rate or the number of warrants outstanding.

The change in fair value of the warrant liability resulted in a gain of $515,543 and a loss of $1,663,316 for the three and nine month periods ended June 30, 2014, respectively.

On October 28, 2014, the Company entered into a warrant repurchase option agreement with Crede, pursuant to which it had the option to purchase between 50% and 100% of Crede’s Series B Warrant (then exercisable for 387,621 shares of common stock) at a purchase price of $10.55 per share underlying such Series B Warrant (up to an aggregate purchase price of $4,091,000 for all of the Series B Warrant). On November 21, 2014, the Company exercised its option and repurchased 100% of Crede’s Series B Warrant for an aggregate purchase price of approximately $4,091,000. The change in fair value of the warrant liability on the day of repurchase amounted to a loss of $2,994,540 and was included in other income (expense) for the nine month period ended June 30, 2015.

X

- References
No definition available.
+ Details

Name: apdn_WarrantLiabilityAbstract

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of fair value gain (loss) on warrant liability.
+ References
No definition available.
+ Details

Name: apdn_WarrantLiabilityTextBlock

Namespace Prefix: apdn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

WARRANT LIABILITY (Detail Textuals) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Nov. 21, 2014

Oct. 28, 2014

Dec. 16, 2013

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Class of Warrant or Right [Line Items]

Cashless exercise of warrant

Gain (loss) on change in fair value of warrant liability $ 515,543 $ (2,994,540) $ (1,663,316)

Crede CG III, Ltd | Warrants

Class of Warrant or Right [Line Items]

Fair value of warrants $ 2,455,042

Method used for determining allocated fair value of the Warrants Binomial Lattice model

Fair value of common stock $ 10.80

Dividend yield 0.00%

Expected terms 4 years 6 months 18 days

Risk free interest rate 1.55%

Expected volatility 118.89%

Expected price at which holders exercise warrants $ 14.59

Gain (loss) on change in fair value of warrant liability $ (1,288,752)

Crede CG III, Ltd | Series A Warrants

Class of Warrant or Right [Line Items]

Cashless exercise of warrant 178,253

Crede CG III, Ltd | Series B Warrants

Class of Warrant or Right [Line Items]

Cashless exercise of warrant 116,667

Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement

Class of Warrant or Right [Line Items]

Cashless exercise of warrant 387,621

Expected price at which holders exercise warrants $ 10.55

Percentage of option to purchase warrant 100.00%

Aggregate purchase price of warrant exercise $ 4,091,000 $ 4,091,000

Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement | Minimum

Class of Warrant or Right [Line Items]

Percentage of option to purchase warrant 50.00%

Crede CG III, Ltd | Series B Warrants | Warrant repurchase option agreement | Maximum

Class of Warrant or Right [Line Items]

Percentage of option to purchase warrant 100.00%

X

- Definition
Represents aggregate purchase price of warrant exercise.
+ References
No definition available.
+ Details

Name: apdn_AggregatePurchasePriceOfWarrantExercise

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the number of warrants exercised by participants.
+ References
No definition available.
+ Details

Name: apdn_ClassOfWarrantOrRightExercised

Namespace Prefix: apdn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represent income (loss) from change in fair value of warrant liability.
+ References
No definition available.
+ Details

Name: apdn_IncomeLossFromChangeInFairValueOfWarrantLiability

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents range of percentage of option to purchase warrant.
+ References
No definition available.
+ Details

Name: apdn_PercentageOfOptionToPurchaseWarrant

Namespace Prefix: apdn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Agreed upon price for the exchange of the underlying asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Risk-free interest rate assumption used in valuing an instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the inputs and valuation technique(s) used to measure fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementsValuationTechniques

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=apdn_CredeCgIIILtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=apdn_SeriesWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=apdn_SeriesBWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: apdn_AgreementAxis=apdn_WarrantRepurchaseOptionAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 73 224 1 true 28 0 false 6 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.adnas.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.adnas.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.adnas.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - SUMMARY OF ACCOUNTING POLICIES Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES SUMMARY OF ACCOUNTING POLICIES Notes 6 false false R7.htm 007 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN Sheet http://www.adnas.com/role/LiquidityAndManagementSPlan LIQUIDITY AND MANAGEMENT'S PLAN Notes 7 false false R8.htm 008 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 8 false false R9.htm 009 - Disclosure - PROMISSORY NOTES PAYABLE Notes http://www.adnas.com/role/PromissoryNotesPayable PROMISSORY NOTES PAYABLE Notes 9 false false R10.htm 010 - Disclosure - WARRANT LIABILITY Sheet http://www.adnas.com/role/WARRANTLIABILITY WARRANT LIABILITY Notes 10 false false R11.htm 011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.adnas.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 012 - Disclosure - CAPITAL STOCK Sheet http://www.adnas.com/role/CAPITALSTOCK CAPITAL STOCK Notes 12 false false R13.htm 013 - Disclosure - STOCK OPTIONS AND WARRANTS Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS STOCK OPTIONS AND WARRANTS Notes 13 false false R14.htm 014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 015 - Disclosure - FAIR VALUE Sheet http://www.adnas.com/role/FAIRVALUE FAIR VALUE Notes 15 false false R16.htm 016 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Policies) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESPolicies SUMMARY OF ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 017 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Tables) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables SUMMARY OF ACCOUNTING POLICIES (Tables) Tables http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIES 17 false false R18.htm 018 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIES 18 false false R19.htm 019 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables) Sheet http://www.adnas.com/role/STOCKOPTIONSANDWARRANTSTables STOCK OPTIONS AND WARRANTS (Tables) Tables http://www.adnas.com/role/STOCKOPTIONSANDWARRANTS 19 false false R20.htm 020 - Disclosure - FAIR VALUE (Tables) Sheet http://www.adnas.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.adnas.com/role/FAIRVALUE 20 false false R21.htm 021 - Disclosure - SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesSummaryOfPotentialStockIssuancesUnderVariousOptionsAndWarrantsDetails SUMMARY OF ACCOUNTING POLICIES - Summary of potential stock issuances under various options, and warrants (Details) Details 21 false false R22.htm 022 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Sheet http://www.adnas.com/role/SummaryOfAccountingPoliciesDetailTextuals SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 22 false false R23.htm 023 - Disclosure - SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Sheet http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESDetailTextuals1 SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1) Details http://www.adnas.com/role/SUMMARYOFACCOUNTINGPOLICIESTables 23 false false R24.htm 024 - Disclosure - LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Sheet http://www.adnas.com/role/LiquidityAndManagementSPlanDetailTextuals LIQUIDITY AND MANAGEMENT'S PLAN (Detail Textuals) Details http://www.adnas.com/role/LiquidityAndManagementSPlan 24 false false R25.htm 025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Sheet http://www.adnas.com/role/ACCOUNTSPAYABLEANDACCRUEDLIABILITIESSummaryOfAccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) Details 25 false false R26.htm 026 - Disclosure - PROMISSORY NOTES PAYABLE (Detail Textuals) Notes http://www.adnas.com/role/PromissoryNotesPayableDetailTextuals PROMISSORY NOTES PAYABLE (Detail Textuals) Details http://www.adnas.com/role/PromissoryNotesPayable 26 false false R27.htm 027 - Disclosure - WARRANT LIABILITY (Detail Textuals) Sheet http://www.adnas.com/role/WarrantLiabilityDetailTextuals WARRANT LIABILITY (Detail Textuals) Details http://www.adnas.com/role/WARRANTLIABILITY 27 false false R28.htm 028 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) Sheet http://www.adnas.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals RELATED PARTY TRANSACTIONS (Detail Textuals) Details http://www.adnas.com/role/RelatedPartyTransactions 28 false false R29.htm 029 - Disclosure - CAPITAL STOCK (Detail Textuals) Sheet http://www.adnas.com/role/CAPITALSTOCKDetailTextuals CAPITAL STOCK (Detail Textuals) Details http://www.adnas.com/role/CAPITALSTOCK 29 false false R30.htm 030 - Disclosure - CAPITAL STOCK (Detail Textuals 1) Sheet http://www.adnas.com/role/CAPITALSTOCKDetailTextuals1 CAPITAL STOCK (Detail Textuals 1) Details http://www.adnas.com/role/CAPITALSTOCK 30 false false R31.htm 031 - Disclosure - CAPITAL STOCK (Detail Textuals 2) Sheet http://www.adnas.com/role/CapitalStockDetailTextuals2 CAPITAL STOCK (Detail Textuals 2) Details http://www.adnas.com/role/CAPITALSTOCK 31 false false R32.htm 032 - Disclosure - CAPITAL STOCK (Detail Textuals 3) Sheet http://www.adnas.com/role/CapitalStockDetailTextuals3 CAPITAL STOCK (Detail Textuals 3) Details http://www.adnas.com/role/CAPITALSTOCK 32 false false R33.htm 033 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingWarrantsDetails STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) Details 33 false false R34.htm 034 - Disclosure - STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsTransactionsInvolvingStockOptionsIssuedToEmployeesDetails1 STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 1) Details 34 false false R35.htm 035 - Disclosure - STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsSummaryOfValueOfOptionsGrantedUsingBlackScholesOptionPricingModelWithWeightedAverageAssumptionsDetails STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) Details 35 false false R36.htm 036 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) Details 36 false false R37.htm 037 - Disclosure - STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) Sheet http://www.adnas.com/role/StockOptionsAndWarrantsEmployeeStockOptionsDetailTextuals1 STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals 1) Details 37 false false R38.htm 038 - Disclosure - COMMITMENTS AND CONTINGENCIES (Detail Textuals) Sheet http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIESDetailTextuals COMMITMENTS AND CONTINGENCIES (Detail Textuals) Details http://www.adnas.com/role/COMMITMENTSANDCONTINGENCIES 38 false false R39.htm 039 - Disclosure - FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) Sheet http://www.adnas.com/role/FairValueFairValueMeasurementsOfCommonStockWarrantsUsingSignificantUnobservableInputsLevel3Details FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) Details 39 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)'', column(s) 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2, 3 are contained in other reports, so were removed by flow through suppression. apdn-20150630.xml apdn-20150630_cal.xml apdn-20150630_def.xml apdn-20150630_lab.xml apdn-20150630_pre.xml apdn-20150630.xsd true true XML 54 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

COMMITMENTS AND CONTINGENCIES (Detail Textuals)
1 Months Ended 3 Months Ended 9 Months Ended

Jun. 15, 2013

USD ($)

ft²

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jan. 01, 2015

USD ($)

Jun. 21, 2014

USD ($)

Commitments And Contingencies [Line Items]

Area of property under operating lease | ft² 30,000

Extended operating lease for two additional period 3 years

Base rent during initial lease term per annum $ 449,142

Total lease rental expenses $ 124,504 $ 125,268 $ 373,772 $ 380,251

Chief Executive Officer | Employment Agreement

Commitments And Contingencies [Line Items]

Reduced amount of salary $ 50,000 $ 50,000

Threshold amount of sales for two consecutive quarters $ 3,000,000

X

- Definition
Represents the area of property under operating lease.
+ References
No definition available.
+ Details

Name: apdn_AreaOfPropertyUnderOperatingLease

Namespace Prefix: apdn_

Data Type: num:areaItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the amount for base rent during initial lease term per annum.
+ References
No definition available.
+ Details

Name: apdn_BaseRentDuringInitialLeaseTerm

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents commitments and contingencies line items.
+ References
No definition available.
+ Details

Name: apdn_CommitmentsAndContingenciesLineItems

Namespace Prefix: apdn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents reduced amount of salary.
+ References
No definition available.
+ Details

Name: apdn_ReducedAmountOfSalary

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Represents threshold amount of sale.
+ References
No definition available.
+ Details

Name: apdn_ThresholdAmountOfSales

Namespace Prefix: apdn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: apdn_AgreementAxis=apdn_EmploymentAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

FAIR VALUE (Tables)
9 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of fair value measurements of common stock warrants using significant unobservable inputs (Level 3)

Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)
Nine Months Ended

June 30,

2015 2014

Balance at October 1, 2014 and 2013 $ 1,096,412 $ 2,643,449

Adjustment resulting from change in fair value (a) 2,994,540 1,663,316

Removal of warrant upon repurchase (4,090,952 ) —

Reclassification to equity upon exercise — (2,455,042 )

Balance at June 30, $ — $ 1,851,723

X

- Definition
Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details) - $ / shares	9 Months Ended
	Jun. 30, 2015
Number of Shares
Balance at October 1, 2014	945,166
Granted	5,833,878
Exercised
Cancelled or expired	(716,557)
Balance, June 30, 2015	6,062,487
Weighted Average Exercise Price Per Share
Balance at October 1, 2014	$ 9.59
Granted	$ 3.50
Exercised
Cancelled or expired	$ (11.30)
Balance, June 30, 2015	$ 3.53

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Payables and Accruals [Abstract]
Accounts payable	$ 770,395	$ 1,059,623
Accrued consulting fees	110,500	102,500
Accrued salaries payable	428,098	245,761
Accrued interest payable		11,875
Other accrued expenses	109,622	75,000
Total	$ 1,418,615	$ 1,494,759

CAPITAL STOCK (Detail Textuals) - $ / shares	1 Months Ended
CAPITAL STOCK (Detail Textuals) - $ / shares	Oct. 24, 2014	Jun. 30, 2015	Sep. 30, 2014
Stockholders' Equity Note [Abstract]
Reverse stock split	one-for-60 (1:60)
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized		500,000,000	1,350,000,000
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001
Common stock, shares issued		21,482,202	13,935,954
Common stock, shares outstanding		21,482,202	13,935,954

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	Nov. 11, 2014	Nov. 20, 2014	Sep. 30, 2014	Sep. 11, 2014
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)			$ 1,000,000
Conversion price of convertible promissory note converted (in dollars per share)	$ 3.25	$ 3.25
Promissory notes
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				$ 1,800,000
Interest rate on promissory note				12.50%
Promissory notes \| James A. Hayward
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				$ 1,000,000
Interest rate on promissory note				12.50%
Common stock and warrants issued in settlement of convertible debentures and interest	315,171
Number of shares issued in settlement of convertible notes and accrued interest	315,171
Conversion price of convertible promissory note converted (in dollars per share)	$ 3.25

CAPITAL STOCK (Detail Textuals 1) - USD ($)		1 Months Ended				3 Months Ended	9 Months Ended
CAPITAL STOCK (Detail Textuals 1) - USD ($)	Apr. 01, 2015	Apr. 30, 2015	Dec. 30, 2014	Dec. 19, 2014	Nov. 20, 2014	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Nov. 11, 2014
Stockholders' Equity Note [Abstract]
Underwritten public offering of common stock and warrants closed					2,800,000
Number of common stock called by warrants					2,800,000
Gross proceeds from underwritten public offering of common stock and warrants					$ 9,100,000
Gross proceeds to repurchase remaining Series B Warrants					$ 4,091,000
Conversion price of convertible promissory note converted into common stock (in dollars per share)					$ 3.25				$ 3.25
Period of warrant exercised					5 years
Exercise price of warrants					$ 3.50
Number of days option given to underwriters					45 days
Additional common stock purchase limit given to underwriters					420,000
Additional common stock per share purchase limit given to underwriters					$ 3.24
Additional warrants purchase limit given to underwriters					420,000
Additional per share warrants purchase limit given to underwriters					$ 0.01
Number of warrants for which underwriters' close exercise of its over-allotment option				416,850
Gross proceeds from closed on underwriters exercise of over-allotment option				$ 4,169
Common stock closed on underwriters additional exercise of over-allotment option			52,000
Gross proceeds from closed on underwriters additional exercise of over-allotment option			$ 168,400
Number of common stock including the exercise of over allotment option					2,852,000
Number of warrant issued including the exercise of over allotment option					3,216,850
Gross proceeds from sale of common stock and warrants					$ 9,272,649
Gross proceeds from underwritten public offering of common stock and warrants	$ 12,000,000	$ 263,950			9,300,000
Net proceeds from sale of common stock and warrants					$ 3,690,000		$ 19,114,418	$ 2,145,956
Additional number of common stock called by warrants					128,800
Exercise price of warrants which company agreed to issue to the underwriters					$ 3.73
Exercise price percentage of public offering price					115.00%
Number of common stock shares granted to consultant						15,000	22,500
Total expenses to consultant						$ 47,750	$ 64,426

CAPITAL STOCK (Detail Textuals 2) - USD ($)		1 Months Ended
CAPITAL STOCK (Detail Textuals 2) - USD ($)	Apr. 01, 2015	Apr. 30, 2015	Nov. 20, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock called by warrants			2,800,000
Exercise price of warrants			$ 3.50
Underwritten public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock offered	4,011,000
Number of common stock called by warrants	1,604,400
Combined offering price	$ 3.00
Offering price for common stock	2.99
Offering price for warrant	$ 0.01
Number of common stock sold pursuant to over allotment option	191,000
Number of warrants stock sold pursuant to over allotment option	76,400
Exercise price of warrants	$ 3.50
Gross proceeds from offering	$ 12,000,000
Number of days for option to purchase additional shares	45 days
Number of additional shares of common stock	573,000
Number of additional warrants to cover over allotments	229,200
Number of common stock exercise in over allotment option		87,000
Number of warrants exercise in over allotment option		152,800
Gross proceeds from exercise of over allotment option		$ 263,950

CAPITAL STOCK (Detail Textuals 3) - $ / shares		1 Months Ended
CAPITAL STOCK (Detail Textuals 3) - $ / shares	Apr. 01, 2015	Nov. 20, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants		$ 3.50
Exercise price percentage of public offering price		115.00%
Underwritten public offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants	$ 3.50
Underwritten public offering \| Underwriters
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants granted as partial compensation	163,720
Exercise price of warrants	$ 3.44
Exercise price percentage of public offering price	115.00%

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Current assets:
Cash and cash equivalents	$ 10,730,144	$ 1,393,132
Accounts receivable, net of allowance of $30,228 and $9,634 at June 30, 2015 and September 30, 2014, respectively	2,077,756	834,818
Prepaid expenses and other current assets	209,831	135,365
Total current assets	13,017,731	2,363,315
Property, plant and equipment, net of accumulated depreciation of $743,914 at June 30, 2015 and $759,087 at September 30, 2014	526,816	576,128
Other assets:
Deposits	52,988	57,638
Deferred offering costs	0	181,104
Intangible assets, net of accumulated amortization and impairment of $325,555 and $256,208 at June 30, 2015 and September 30, 2014, respectively	525,902	327,872
Total Assets	14,123,437	3,506,057
Current liabilities:
Accounts payable and accrued liabilities, including related party accrued interest of $6,597 at September 30, 2014	1,418,615	1,494,759
Promissory notes payable, including $1,000,000 with a related party at September 30, 2014		1,800,000
Deferred revenue	204,863	583,362
Total current liabilities	1,623,478	3,878,121
Warrant liability		1,096,412
Total liabilities	$ 1,623,478	$ 4,974,533
Commitments and contingencies (Note I)
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014
Common stock, par value $0.001 per share; 500,000,000 and 1,350,000,000 shares authorized at June 30, 2015 and September 30, 2014, respectively; 21,482,202 and 13,935,954 shares issued and outstanding as of June 30, 2015 and September 30, 2014, respectively	$ 21,483	$ 13,937
Additional paid in capital	223,623,850	198,277,859
Accumulated deficit	(211,145,374)	(199,760,272)
Total stockholders' equity (deficit)	12,499,959	(1,468,476)
Total Liabilities and Stockholders' Equity (Deficit)	$ 14,123,437	$ 3,506,057
Series A Preferred stock
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014
Series B Preferred stock
Stockholders' Equity (Deficit)
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of June 30, 2015 and September 30, 2014

STOCK OPTIONS AND WARRANTS - Summary of value of options granted using Black Scholes Option Pricing Model with weighted average assumptions (Details) - Jun. 30, 2015 - $ / shares	Total	Total
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Stock price	$ 2.60	$ 2.85
Exercise price	$ 2.60	$ 2.85
Expected term, years	3 years 9 months	4 years 10 months 6 days
Dividend yield
Volatility	118.00%	132.00%
Risk free rate	1.13%	1.56%

STOCK OPTIONS AND WARRANTS - Employee Stock Options (Detail Textuals) - Employee Stock Options - Incentive Stock Plan 2005 - shares	9 Months Ended
	Jun. 30, 2015	Jan. 21, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of common stock that can be issued as stock awards and stock option	5,833,334	8,333,333
Number of common stock shares that can be covered by awards made to any participant per period	833,334
Number of shares issued	233,752
Options to purchase shares under the 2005 Incentive Stock Plan	4,132,475

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Allowance on accounts receivable (in dollars)	$ 30,228	$ 9,634
Accumulated depreciation on property, plant and equipment (in dollars)	743,914	759,087
Accumulated amortization and impairment on intangible assets (in dollars)	$ 325,555	256,208
Related party accrued interest (in dollars)		6,597
Promissory note issued to related party (in dollars)		$ 1,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	1,350,000,000
Common stock, shares issued	21,482,202	13,935,954
Common stock, shares outstanding	21,482,202	13,935,954
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 06, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	0000744452
Trading Symbol	apdn
Current Fiscal Year End Date	--09-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		21,487,202
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

PROMISSORY NOTES PAYABLE (Detail Textuals) - USD ($)		9 Months Ended
PROMISSORY NOTES PAYABLE (Detail Textuals) - USD ($)	Nov. 11, 2014	Jun. 30, 2015	Nov. 20, 2014	Sep. 30, 2014	Sep. 11, 2014
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)				$ 1,000,000
Promissory notes maturity term		10 months
Debt instrument, convertible, threshold consecutive trading days		5 days
Conversion price of convertible promissory note converted (in dollars per share)	$ 3.25		$ 3.25
Conversion price of convertible promissory note converted into common stock (in dollars per share)	3.24
Conversion price of convertible promissory note converted into warrant (in dollars per share)	$ 0.01
Loss on conversion of promissory notes		$ 980,842
Promissory notes
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					$ 1,800,000
Interest rate on promissory note					12.50%
Loss on conversion of promissory notes		981,000
Interest expense		$ 31,875
Promissory notes \| James A. Hayward
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					$ 1,000,000
Interest rate on promissory note					12.50%
Common stock and warrants issued in settlement of convertible debentures and interest	315,171
Number of shares issued in settlement of convertible notes and accrued interest	315,171
Conversion price of convertible promissory note converted (in dollars per share)	$ 3.25
Promissory notes \| Another individual
Short-term Debt [Line Items]
Promissory note issued to related party (in dollars)					$ 800,000
Common stock and warrants issued in settlement of convertible debentures and interest	252,137
Number of shares issued in settlement of convertible notes and accrued interest	252,137
Conversion price of convertible promissory note converted (in dollars per share)	$ 3.25

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (11,385,102)	$ (10,961,143)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	354,144	325,448
Stock based compensation expense	3,531,205	1,717,837
Change in fair value of warrant liability	2,994,540	1,663,316
Loss on conversion of promissory notes	980,842
Common stock issued for consulting services	64,426	337,500
Bad debt expense	21,750	16,878
Change in operating assets and liabilities:
Accounts receivable	(1,275,189)	137,486
Prepaid expenses and other current assets and deposits	(59,315)	(924)
Accounts payable and accrued liabilities	(75,515)	292,462
Deferred revenue	(378,499)	200,121
Net cash used in operating activities	(5,226,713)	(6,271,019)
Cash flows used in investing activities:
Purchase of property plant and equipment	(221,659)	(209,522)
Purchase of intangible assets	(238,082)
Net cash used in investing activities	(459,741)	(209,522)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	19,114,418	2,145,956
Purchase and cancelation of previously issued warrants	(4,090,952)
Net cash provided by financing activities	15,023,466	2,145,956
Net increase (decrease) in cash and cash equivalents	9,337,012	(4,334,585)
Cash and cash equivalents at beginning of period	1,393,132	6,360,301
Cash and cash equivalents at end of period	$ 10,730,144	$ 2,025,716
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest
Cash paid during period for taxes
Non-cash investing and financing activities:
Common stock issued for cashless exercise of options and warrants		$ 19,570
Reclassification of deferred offering costs to additional paid in capital	$ 181,104
Reclassification of warrants from liability to equity upon exercise		$ 2,455,042
Offering costs incurred, and included in accounts payable and accrued liabilities	68,489
Property, plant and equipment acquired, and included in accounts payable	13,825
Intangible assets acquired, and included in accounts payable	29,296
Common stock issued upon conversion of promissory notes payable	$ 1,843,750

WARRANT LIABILITY (Detail Textuals) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
WARRANT LIABILITY (Detail Textuals) - USD ($)	Nov. 21, 2014	Oct. 28, 2014	Dec. 16, 2013	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Class of Warrant or Right [Line Items]
Cashless exercise of warrant
Gain (loss) on change in fair value of warrant liability				$ 515,543	$ (2,994,540)	$ (1,663,316)
Crede CG III, Ltd \| Warrants
Class of Warrant or Right [Line Items]
Fair value of warrants			$ 2,455,042
Method used for determining allocated fair value of the Warrants			Binomial Lattice model
Fair value of common stock			$ 10.80
Dividend yield			0.00%
Expected terms			4 years 6 months 18 days
Risk free interest rate			1.55%
Expected volatility			118.89%
Expected price at which holders exercise warrants			$ 14.59
Gain (loss) on change in fair value of warrant liability			$ (1,288,752)
Crede CG III, Ltd \| Series A Warrants
Class of Warrant or Right [Line Items]
Cashless exercise of warrant			178,253
Crede CG III, Ltd \| Series B Warrants
Class of Warrant or Right [Line Items]
Cashless exercise of warrant			116,667
Crede CG III, Ltd \| Series B Warrants \| Warrant repurchase option agreement
Class of Warrant or Right [Line Items]
Cashless exercise of warrant		387,621
Expected price at which holders exercise warrants		$ 10.55
Percentage of option to purchase warrant	100.00%
Aggregate purchase price of warrant exercise	$ 4,091,000	$ 4,091,000
Crede CG III, Ltd \| Series B Warrants \| Warrant repurchase option agreement \| Minimum
Class of Warrant or Right [Line Items]
Percentage of option to purchase warrant		50.00%
Crede CG III, Ltd \| Series B Warrants \| Warrant repurchase option agreement \| Maximum
Class of Warrant or Right [Line Items]
Percentage of option to purchase warrant		100.00%

COMMITMENTS AND CONTINGENCIES (Detail Textuals)	1 Months Ended	3 Months Ended		9 Months Ended
COMMITMENTS AND CONTINGENCIES (Detail Textuals)	Jun. 15, 2013 USD ($) ft²	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jan. 01, 2015 USD ($)	Jun. 21, 2014 USD ($)
Commitments And Contingencies [Line Items]
Area of property under operating lease \| ft²	30,000
Extended operating lease for two additional period	3 years
Base rent during initial lease term per annum	$ 449,142
Total lease rental expenses		$ 124,504	$ 125,268	$ 373,772	$ 380,251
Chief Executive Officer \| Employment Agreement
Commitments And Contingencies [Line Items]
Reduced amount of salary						$ 50,000	$ 50,000
Threshold amount of sales for two consecutive quarters							$ 3,000,000